

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
24 October 2002 (24.10.2002)

PCT

(10) International Publication Number
WO 02/083872 A2(51) International Patent Classification⁷: C12N

(21) International Application Number: PCT/US02/12405

(22) International Filing Date: 17 April 2002 (17.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

09/837,306	17 April 2001 (17.04.2001)	US
10/000,516	24 October 2001 (24.10.2001)	US
10/045,674	25 October 2001 (25.10.2001)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US	10/045,674 (CON)
Filed on	25 October 2001 (25.10.2001)

(71) Applicants and

(72) Inventors: LADNER, Robert, C. [US/US]; 3827 Green

Valley Road, Ijamsville, MD 21754 (US). COHEN, Edward, H. [US/US]; 55 Hill Road Apt. 200, Belmont, MA 02478 (US). NASTRI, Horacio, G. [AR/US]; 18 Pennsylvania Avenue, Newton, MA 02464 (US). ROOKEY, Kristin, L. [US/US]; 14 Hancock Street, Revere, MA 02151 (US). HOET, Rene [NL/NL]; Churchillaan, 32, NL-6226 CZ Maastricht (NL). HOOGENBOOM, Hendricus, R., J., M. [NL/NL]; Hertogsingel 46, NL-6214 AE Maastricht (NL).


(74) Agents: HALEY, James, F. et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: NOVEL METHODS OF CONSTRUCTING LIBRARIES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES



(57) Abstract: Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens.

BEST AVAILABLE COPY

TA

DEX-0312

WO 02/083872 A2



Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*

2002-08-14

NOVEL METHODS OF CONSTRUCTING LIBRARIES
COMPRISING DISPLAYED AND/OR EXPRESSED
MEMBERS OF A DIVERSE FAMILY OF PEPTIDES,
POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES

5 This application is a continuation-in-part of
United States provisional application 60/198,069, filed
April 17, 2000, a continuation-in-part of United States
patent application 09/837,306, filed on April 17, 2001,
a continuation-in-part of PCT application
10 PCT/US01/12454, filed on April 17, 2001, a
continuation-in-part of United States application
10/000,516, filed on October 24, 2001 and a
continuation-in-part of United States application
10/045,674, filed on October 25, 2001. All of the
15 earlier applications are specifically incorporated by
reference herein.

 The present invention relates to libraries of
genetic packages that display and/or express a member
of a diverse family of peptides, polypeptides or
20 proteins and collectively display and/or express at
least a portion of the diversity of the family. In an
alternative embodiment, the invention relates to
libraries that include a member of a diverse family of
peptides, polypeptides or proteins and collectively
25 comprise at least a portion of the diversity of the
family. In a preferred embodiment, the displayed
and/or expressed polypeptides are human Fabs.

- 2 -

More specifically, the invention is directed to the methods of cleaving single-stranded nucleic acids at chosen locations, the cleaved nucleic acids encoding, at least in part, the peptides, polypeptides
5 or proteins displayed on the genetic packages of, and/or expressed in, the libraries of the invention. In a preferred embodiment, the genetic packages are filamentous phage or phagemids or yeast.

The present invention further relates to
10 vectors for displaying and/or expressing a diverse family of peptides, polypeptides or proteins.

The present invention further relates to methods of screening the libraries of the invention and to the peptides, polypeptides and proteins identified
15 by such screening.

BACKGROUND OF THE INVENTION

It is now common practice in the art to prepare libraries of genetic packages that display, express or comprise a member of a diverse family of
20 peptides, polypeptides or proteins and collectively display, express or comprise at least a portion of the diversity of the family. In many common libraries, the peptides, polypeptides or proteins are related to antibodies. Often, they are Fabs or single chain
25 antibodies.

In general, the DNAs that encode members of the families to be displayed and/or expressed must be amplified before they are cloned and used to display and/or express the desired member. Such amplification
30 typically makes use of forward and backward primers.

- 3 -

Such primers can be complementary to sequences native to the DNA to be amplified or complementary to oligonucleotides attached at the 5' or 3' ends of that DNA. Primers that are complementary to sequences native to the DNA to be amplified are disadvantaged in that they bias the members of the families to be displayed. Only those members that contain a sequence in the native DNA that is substantially complementary to the primer will be amplified. Those that do not will be absent from the family. For those members that are amplified, any diversity within the primer region will be suppressed.

For example, in European patent 368,684 B1, the primer that is used is at the 5' end of the V_H region of an antibody gene. It anneals to a sequence region in the native DNA that is said to be "sufficiently well conserved" within a single species. Such primer will bias the members amplified to those having this "conserved" region. Any diversity within this region is extinguished.

It is generally accepted that human antibody genes arise through a process that involves a combinatorial selection of V and J or V, D, and J followed by somatic mutations. Although most diversity occurs in the Complementary Determining Regions (CDRs), diversity also occurs in the more conserved Framework Regions (FRs) and at least some of this diversity confers or enhances specific binding to antigens (Ag). As a consequence, libraries should contain as much of the CDR and FR diversity as possible.

To clone the amplified DNAs of the peptides, polypeptides or proteins that they encode for display on a genetic package and/or for expression, the DNAs

- 4 -

must be cleaved to produce appropriate ends for ligation to a vector. Such cleavage is generally effected using restriction endonuclease recognition sites carried on the primers. When the primers are at the 5' end of DNA produced from reverse transcription of RNA, such restriction leaves deleterious 5' untranslated regions in the amplified DNA. These regions interfere with expression of the cloned genes and thus the display of the peptides, polypeptides and proteins coded for by them.

SUMMARY OF THE INVENTION

It is an object of this invention to provide novel methods for constructing libraries that display, express or comprise a member of a diverse family of peptides, polypeptides or proteins and collectively display, express or comprise at least a portion of the diversity of the family. These methods are not biased toward DNAs that contain native sequences that are complementary to the primers used for amplification. They also enable any sequences that may be deleterious to expression to be removed from the amplified DNA before cloning and displaying and/or expressing.

It is another object of this invention to provide a method for cleaving single-stranded nucleic acid sequences at a desired location, the method comprising the steps of:

(i) contacting the nucleic acid with a single-stranded oligonucleotide, the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired and including a sequence that with its complement

- 5 -

in the nucleic acid forms a restriction endonuclease recognition site that on restriction results in cleavage of the nucleic acid at the desired location; and

- 5 (ii) cleaving the nucleic acid solely at the recognition site formed by the complementation of the nucleic acid and the oligonucleotide;

the contacting and the cleaving steps being performed
10 at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur
15 at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

It is a further object of this invention to provide an alternative method for cleaving single-
20 stranded nucleic acid sequences at a desired location, the method comprising the steps of:

- (i) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the
25 oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired, and the double-stranded region of the oligonucleotide having a restriction endonuclease recognition
30 site; and

(ii) cleaving the nucleic acid solely at the cleavage site formed by the

- 6 -

complementation of the nucleic acid and the single-stranded region of the oligonucleotide;

the contacting and the cleaving steps being performed
5 at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur
10 at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

In an alternative embodiment of this object of the invention, the restriction endonuclease
15 recognition site is not initially located in the double-stranded part of the oligonucleotide. Instead, it is part of an amplification primer, which primer is complementary to the double-stranded region of the oligonucleotide. On amplification of the DNA-partially
20 double-stranded combination, the restriction endonuclease recognition site carried on the primer becomes part of the DNA. It can then be used to cleave the DNA.

Preferably, the restriction endonuclease
25 recognition site is that of a Type II-S restriction endonuclease whose cleavage site is located at a known distance from its recognition site.

It is another object of the present invention to provide a method of capturing DNA molecules that
30 comprise a member of a diverse family of DNAs and collectively comprise at least a portion of the diversity of the family. These DNA molecules in

- 7 -

single-stranded form have been cleaved by one of the methods of this invention. This method involves ligating the individual single-stranded DNA members of the family to a partially duplex DNA complex. The

5 method comprises the steps of:

(i) contacting a single-stranded nucleic acid sequence that has been cleaved with a restriction endonuclease with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acid in the region that remains after cleavage, the double-stranded region of the oligonucleotide including any sequences necessary to return the sequences that remain after cleavage into proper reading frame for expression and containing a restriction endonuclease recognition site 5' of those sequences; and

20 (ii) cleaving the partially double-stranded oligonucleotide sequence solely at the restriction endonuclease cleavage site contained within the double-stranded region of the partially double-stranded oligonucleotide.

As before, in this object of the invention, the restriction endonuclease recognition site need not be located in the double-stranded portion of the oligonucleotide. Instead, it can be introduced on amplification with an amplification primer that is used to amplify the DNA-partially double-stranded oligonucleotide combination.

- 8 -

It is another object of this invention to prepare libraries, that display, express or comprise a diverse family of peptides, polypeptides or proteins and collectively display, express or comprise at least
5 part of the diversity of the family, using the methods and DNAs described above.

It is an object of this invention to screen those libraries to identify useful peptides, polypeptides and proteins and to use those substances
10 in human therapy.

Additional objects of the invention are reflected in claims 1-116. Each of these claims is specifically incorporated by reference in this specification.

15 BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic of various methods that may be employed to amplify VH genes without using primers specific for VH sequences.

20 FIG. 2 is a schematic of various methods that may be employed to amplify VL genes without using primers specific for VL sequences.

FIG. 3 is a schematic of RACE amplification of antibody heavy and light chains.

25 FIG. 4 depicts gel analysis of amplification products obtained after the primary PCR reaction from 4 different patient samples.

FIG. 5 depicts gel analysis of cleaved kappa DNA from Example 2.

30 FIG. 6 depicts gel analysis of extender-cleaved kappa DNA from Example 2.

- 9 -

FIG. 7 depicts gel analysis of the PCR product from the extender-kappa amplification from Example 2.

FIG. 8 depicts gel analysis of purified PCR product from the extender-kappa amplification from Example 2.

FIG. 9 depicts gel analysis of cleaved and ligated kappa light chains from Example 2.

FIG. 10 is a schematic of the design for CDR1 and CDR2 synthetic diversity.

FIG. 11 is a schematic of the cloning schedule for construction of the heavy chain repertoire.

FIG. 12 is a schematic of the cleavage and ligation of the antibody light chain.

FIG. 13 depicts gel analysis of cleaved and ligated lambda light chains from Example 4.

FIG. 14 is a schematic of the cleavage and ligation of the antibody heavy chain.

FIG. 15 depicts gel analysis of cleaved and ligated lambda light chains from Example 5.

FIG. 16 is a schematic of a phage display vector.

FIG. 17 is a schematic of a Fab cassette.

FIG. 18 is a schematic of a process for incorporating fixed FR1 residues in an antibody lambda sequence.

FIG. 19 is a schematic of a process for incorporating fixed FR1 residues in an antibody kappa sequence.

FIG. 20 is a schematic of a process for incorporating fixed FR1 residues in an antibody heavy chain sequence.

- 10 -

TERMS

In this application, the following terms and abbreviations are used:

5	Sense strand	The upper strand of ds DNA as usually written. In the sense strand, 5'-ATG-3' codes for Met.
10	Antisense strand	The lower strand of ds DNA as usually written. In the antisense strand, 3'-TAC-5' would correspond to a Met codon in the sense strand.
15	Forward primer	A "forward" primer is complementary to a part of the sense strand and primes for synthesis of a new antisense-strand molecule. "Forward primer" and "lower-strand primer" are equivalent.
20	Backward primer	A "backward" primer is complementary to a part of the antisense strand and primes for synthesis of a new sense-strand molecule. "Backward primer" and "top-strand primer" are equivalent.
25		

- 11 -

	Bases	Bases are specified either by their position in a vector or gene as their position within a gene by codon and base. For example, "89.1" is the first base of codon 89, 89.2 is the second base of codon 89.
5		
	Sv	Streptavidin
	Ap	Ampicillin
10	ap ^R	A gene conferring ampicillin resistance.
	RERS	Restriction endonuclease recognition site
	RE	Restriction endonuclease -
15		cleaves preferentially at RERS
	URE	Universal restriction endonuclease
	Functionally complementary	Two sequences are sufficiently complementary so as to anneal under the chosen conditions.
20		
	AA	Amino acid
	PCR	Polymerization chain reaction

- 12 -

	GLGs	Germline genes
	Ab	Antibody: an immunoglobulin. The term also covers any protein having a binding domain which is homologous to an immunoglobulin binding domain. A few examples of antibodies within this definition are, <i>inter alia</i> , immunoglobulin isotypes and the Fab, F(ab ¹) ₂ , scfv, Fv, dAb and Fd fragments.
5		
10		
	Fab	Two chain molecule comprising an Ab light chain and part of a heavy-chain.
15		
	scFv	A single-chain Ab comprising either VH::linker::VL or VL::linker::VH
	w.t.	Wild type
20	HC	Heavy chain
	LC	Light chain
	VK	A variable domain of a Kappa light chain.
	VH	A variable domain of a heavy chain.
25		

- 13 -

VL A variable domain of a lambda
 light chain.

In this application when it is said that nucleic acids are cleaved solely at the cleavage site of a restriction endonuclease, it should be understood that minor cleavage may occur at random, e.g., at non-specific sites other than the specific cleavage site that is characteristic of the restriction endonuclease. The skilled worker will recognize that such non-specific, random cleavage is the usual occurrence. Accordingly, "solely at the cleavage site" of a restriction endonuclease means that cleavage occurs preferentially at the site characteristic of that endonuclease.

15 As used in this application and claims, the term "cleavage site formed by the complementation of the nucleic acid and the single-stranded region of the oligonucleotide" includes cleavage sites formed by the single-stranded portion of the partially double-
20 stranded oligonucleotide duplexing with the single-stranded DNA, cleavage sites in the double-stranded portion of the partially double-stranded oligonucleotide, and cleavage sites introduced by the amplification primer used to amplify the single-
25 stranded DNA-partially double-stranded oligonucleotide combination.

In the two methods of this invention for preparing single-stranded nucleic acid sequences, the first of those cleavage sites is preferred. In the methods of this invention for capturing diversity and cloning a family of diverse nucleic acid sequences, the latter two cleavage sites are preferred.

- 14 -

In this application, all references referred to are specifically incorporated by reference.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The nucleic acid sequences that are useful in
5 the methods of this invention, i.e., those that encode
at least in part the individual peptides, polypeptides
and proteins displayed, or expressed in or comprising
the libraries of this invention, may be native,
synthetic or a combination thereof. They may be mRNA,
10 DNA or cDNA. In the preferred embodiment, the nucleic
acids encode antibodies. Most preferably, they encode
Fabs.

The nucleic acids useful in this invention
may be naturally diverse, synthetic diversity may be
15 introduced into those naturally diverse members, or the
diversity may be entirely synthetic. For example,
synthetic diversity can be introduced into one or more
CDRs of antibody genes. Preferably, it is introduced
into CDR1 and CDR2 of immunoglobulins. Preferably,
20 natural diversity is captured in the CDR3 regions of
the immunoglobulin genes of this invention from B cells.
Most preferably, the nucleic acids of this invention
comprise a population of immunoglobulin genes that
comprise synthetic diversity in at least one, and more
25 preferably both of the CDR1 and CDR2 and diversity in
CDR3 captured from B cells.

Synthetic diversity may be created, for
example, through the use of TRIM technology (U.S.
5,869,644). TRIM technology allows control over
30 exactly which amino-acid types are allowed at
variegated positions and in what proportions. In TRIM
technology, codons to be diversified are synthesized

- 15 -

using mixtures of trinucleotides. This allows any set of amino acid types to be included in any proportion.

Another alternative that may be used to generate diversified DNA is mixed oligonucleotide synthesis. With TRIM technology, one could allow Ala and Trp. With mixed oligonucleotide synthesis, a mixture that included Ala and Trp would also necessarily include Ser and Gly. The amino-acid types allowed at the variegated positions are picked with reference to the structure of antibodies, or other peptides, polypeptides or proteins of the family, the observed diversity in germline genes, the observed somatic mutations frequently observed, and the desired areas and types of variegation.

In a preferred embodiment of this invention, the nucleic acid sequences for at least one CDR or other region of the peptides, polypeptides or proteins of the family are cDNAs produced by reverse transcription from mRNA. More preferably, the mRNAs are obtained from peripheral blood cells, bone marrow cells, spleen cells or lymph node cells (such as B-lymphocytes or plasma cells) that express members of naturally diverse sets of related genes. More preferable, the mRNAs encode a diverse family of antibodies. Most preferably, the mRNAs are obtained from patients suffering from at least one autoimmune disorder or cancer. Preferably, mRNAs containing a high diversity of autoimmune diseases, such as systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, antiphospholipid syndrome and vasculitis are used.

In a preferred embodiment of this invention, the cDNAs are produced from the mRNAs using reverse

- 16 -

transcription. In this preferred embodiment, the mRNAs are separated from the cell and degraded using standard methods, such that only the full length (i.e., capped) mRNAs remain. The cap is then removed and reverse
5 transcription used to produce the cDNAs.

The reverse transcription of the first (antisense) strand can be done in any manner with any suitable primer. See, e.g., HJ de Haard et al., Journal of Biological Chemistry, 274(26):18218-30
10 (1999). In the preferred embodiment of this invention where the mRNAs encode antibodies, primers that are complementary to the constant regions of antibody genes may be used. Those primers are useful because they do not generate bias toward subclasses of antibodies. In
15 another embodiment, poly-dT primers may be used (and may be preferred for the heavy-chain genes). Alternatively, sequences complementary to the primer may be attached to the termini of the antisense strand.

In one preferred embodiment of this
20 invention, the reverse transcriptase primer may be biotinylated, thus allowing the cDNA product to be immobilized on streptavidin (Sv) beads. Immobilization can also be effected using a primer labeled at the 5' end with one of a) free amine group, b) thiol, c)
25 carboxylic acid, or d) another group not found in DNA that can react to form a strong bond to a known partner on an insoluble medium. If, for example, a free amine (preferably primary amine) is provided at the 5' end of a DNA primer, this amine can be reacted with carboxylic
30 acid groups on a polymer bead using standard amide-forming chemistry. If such preferred immobilization is used during reverse transcription, the top strand RNA is degraded using well-known enzymes, such as a

- 17 -

combination of RNaseH and RNaseA, either before or after immobilization.

The nucleic acid sequences useful in the methods of this invention are generally amplified
5 before being used to display and/or express the peptides, polypeptides or proteins that they encode. Prior to amplification, the single-stranded DNAs may be cleaved using either of the methods described before. Alternatively, the single-stranded DNAs may be
10 amplified and then cleaved using one of those methods.

Any of the well known methods for amplifying nucleic acid sequences may be used for such amplification. Methods that maximize, and do not bias, diversity are preferred. In a preferred embodiment of
15 this invention where the nucleic acid sequences are derived from antibody genes, the present invention preferably utilizes primers in the constant regions of the heavy and light chain genes and primers to a synthetic sequence that are attached at the 5' end of
20 the sense strand. Priming at such synthetic sequence avoids the use of sequences within the variable regions of the antibody genes. Those variable region priming sites generate bias against V genes that are either of rare subclasses or that have been mutated at the
25 priming sites. This bias is partly due to suppression of diversity within the primer region and partly due to lack of priming when many mutations are present in the region complementary to the primer. The methods disclosed in this invention have the advantage of not
30 biasing the population of amplified antibody genes for particular V gene types.

The synthetic sequences may be attached to the 5' end of the DNA strand by various methods well

- 18 -

known for ligating DNA sequences together. RT CapExtension is one preferred method.

In RT CapExtension (derived from Smart PCR^(TM)), a short overlap (5'...GGG-3' in the upper-strand primer (USP-GGG) complements 3'-CCC....5' in the lower strand) and reverse transcriptases are used so that the reverse complement of the upper-strand primer is attached to the lower strand.

FIGs. 1 and 2 show schematics to amplify VH and VL genes using RT CapExtension. FIG. 1 shows a schematic of the amplification of VH genes. FIG. 1, Panel A shows a primer specific to the poly-dT region of the 3' UTR priming synthesis of the first, lower strand. Primers that bind in the constant region are also suitable. Panel B shows the lower strand extended at its 3' end by three Cs that are not complementary to the mRNA. Panel C shows the result of annealing a synthetic top-strand primer ending in three GGGs that hybridize to the 3' terminal CCCs and extending the reverse transcription extending the lower strand by the reverse complement of the synthetic primer sequence. Panel D shows the result of PCR amplification using a 5' biotinylated synthetic top-strand primer that replicates the 5' end of the synthetic primer of panel C and a bottom-strand primer complementary to part of the constant domain. Panel E shows immobilized double-stranded (ds) cDNA obtained by using a 5'-biotinylated top-strand primer.

FIG. 2 shows a similar schematic for amplification of VL genes. FIG. 2, Panel A shows a primer specific to the constant region at or near the 3' end priming synthesis of the first, lower strand. Primers that bind in the poly-dT region are also

- 19 -

suitable. Panel B shows the lower strand extended at its 3' end by three Cs that are not complementary to the mRNA. Panel C shows the result of annealing a synthetic top-strand primer ending in three GGGs that hybridize to the 3' terminal CCCs and extending the reverse transcription extending the lower strand by the reverse complement of the synthetic primer sequence. Panel D shows the result of PCR amplification using a 5' biotinylated synthetic top-strand primer that replicates the 5' end of the synthetic primer of panel C and a bottom-strand primer complementary to part of the constant domain. The bottom-strand primer also contains a useful restriction endonuclease site, such as AscI. Panel E shows immobilized ds cDNA obtained by using a 5'-biotinylated top-strand primer.

In FIGs. 1 and 2, each V gene consists of a 5' untranslated region (UTR) and a secretion signal, followed by the variable region, followed by a constant region, followed by a 3' untranslated region (which typically ends in poly-A). An initial primer for reverse transcription may be complementary to the constant region or to the poly A segment of the 3'-UTR. For human heavy-chain genes, a primer of 15 T is preferred. Reverse transcriptases attach several C residues to the 3' end of the newly synthesized DNA. RT CapExtension exploits this feature. The reverse transcription reaction is first run with only a lower-strand primer. After about 1 hour, a primer ending in GGG (USP-GGG) and more RTase are added. This causes the lower-strand cDNA to be extended by the reverse complement of the USP-GGG up to the final GGG. Using one primer identical to part of the attached synthetic sequence and a second primer complementary to a region

- 20 -

of known sequence at the 3' end of the sense strand, all the V genes are amplified irrespective of their V gene subclass.

In another preferred embodiment, synthetic
5 sequences may be added by Rapid Amplification of cDNA Ends (RACE) (see Frohman, M.A., Dush, M.K., & Martin, G.R. (1988) Proc. Natl. Acad. Sci. USA (85): 8998-9002).

FIG. 1 shows a schematic of RACE
10 amplification of antibody heavy and light chains. First, mRNA is selected by treating total or poly(A+) RNA with calf intestinal phosphatase (CIP) to remove the 5'-phosphate from all molecules that have them such as ribosomal RNA, fragmented mRNA, tRNA and genomic
15 DNA. Full length mRNA (containing a protective 7-methyl cap structure) is unaffected. The RNA is then treated with tobacco acid pyrophosphatase (TAP) to remove the cap structure from full length mRNAs leaving a 5'-monophosphate group. Next, a synthetic RNA
20 adaptor is ligated to the RNA population, only molecules which have a 5-phosphate (uncapped, full length mRNAs) will accept the adaptor. Reverse transcriptase reactions using an oligodT primer, and nested PCR (using one adaptor primer (located in the 5'
25 synthetic adaptor) and one primer for the gene) are then used to amplify the desired transcript.

In a preferred embodiment of this invention, the upper strand or lower strand primer may be also biotinylated or labeled at the 5' end with one of a)
30 free amino group, b) thiol, c) carboxylic acid and d) another group not found in DNA that can react to form a strong bond to a known partner as an insoluble medium. These can then be used to immobilize the labeled strand

- 21 -

after amplification. The immobilized DNA can be either single or double-stranded.

After amplification (using e.g., RT
CapExtension or RACE), the DNAs of this invention are
5 rendered single-stranded. For example, the strands can
be separated by using a biotinylated primer, capturing
the biotinylated product on streptavidin beads,
denaturing the DNA, and washing away the complementary
strand. Depending on which end of the captured DNA is
10 wanted, one will choose to immobilize either the upper
(sense) strand or the lower (antisense) strand.

To prepare the single-stranded amplified DNAs
for cloning into genetic packages so as to effect
display of, or for expression of, the peptides,
15 polypeptides or proteins encoded, at least in part, by
those DNAs, they must be manipulated to provide ends
suitable for cloning and display and/or expression. In
particular, any 5' untranslated regions and mammalian
signal sequences must be removed and replaced, in
20 frame, by a suitable signal sequence that functions in
the display or expression host. Additionally, parts of
the variable domains (in antibody genes) may be removed
and replaced by synthetic segments containing synthetic
diversity. The diversity of other gene families may
25 likewise be expanded with synthetic diversity.

According to the methods of this invention,
there are two ways to manipulate the single-stranded
DNAs for display and/or expression. The first method
comprises the steps of:

- 30 (i) contacting the nucleic acid with a
single-stranded oligonucleotide, the
oligonucleotide being functionally
complementary to the nucleic acid in the

- 22 -

region in which cleavage is desired and including a sequence that with its complement in the nucleic acid forms a restriction endonuclease recognition site that on
5 restriction results in cleavage of the nucleic acid at the desired location; and
(ii) cleaving the nucleic acid solely at the recognition site formed by the complementation of the nucleic acid and the
10 oligonucleotide;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the
15 nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

20 In this first method, short oligonucleotides are annealed to the single-stranded DNA so that restriction endonuclease recognition sites formed within the now locally double-stranded regions of the DNA can be cleaved. In particular, a recognition site
25 that occurs at the same position in a substantial fraction of the single-stranded DNAs is identical.

For antibody genes, this can be done using a catalog of germline sequences. See, e.g.,
"http://www.mrc-cpe.cam.ac.uk/imt-doc/restricted/ok.htm
30 1." Updates can be obtained from this site under the heading "Amino acid and nucleotide sequence alignments." For other families, similar comparisons

- 23 -

exist and may be used to select appropriate regions for cleavage and to maintain diversity.

For example, Table 1 depicts the DNA sequences of the FR3 regions of the 51 known human VH germline genes. In this region, the genes contain restriction endonuclease recognition sites shown in Table 2. Restriction endonucleases that cleave a large fraction of germline genes at the same site are preferred over endonucleases that cut at a variety of sites. Furthermore, it is preferred that there be only one site for the restriction endonucleases within the region to which the short oligonucleotide binds on the single-stranded DNA, e.g., about 10 bases on either side of the restriction endonuclease recognition site.

An enzyme that cleaves downstream in FR3 is also more preferable because it captures fewer mutations in the framework. This may be advantageous in some cases. However, it is well known that framework mutations exist and confer and enhance antibody binding. The present invention, by choice of appropriate restriction site, allows all or part of FR3 diversity to be captured. Hence, the method also allows extensive diversity to be captured.

Finally, in the methods of this invention restriction endonucleases that are active between about 37°C and about 75°C are used. Preferably, restriction endonucleases that are active between about 45°C and about 75°C may be used. More preferably, enzymes that are active above 50°C, and most preferably active about 55°C, are used. Such temperatures maintain the nucleic acid sequence to be cleaved in substantially single-stranded form.

- 24 -

Enzymes shown in Table 2 that cut many of the heavy chain FR3 germline genes at a single position include: *MaeIII*(24@4), *Tsp45I*(21@4), *HphI*(44@5), *BsaJI*(23@65), *AluI*(23@47), *BlpI*(21@48), *DdeI*(29@58),

5 *BglII*(10@61), *MslI*(44@72), *BsiEI*(23@74), *EaeI*(23@74), *EagI*(23@74), *HaeIII*(25@75), *Bst4CI*(51@86), *HpyCH4III*(51@86), *HinfI*(38@2), *MlyI*(18@2), *PleI*(18@2), *MnlI*(31@67), *HpyCH4V*(21@44), *BsmAI*(16@11), *BpmI*(19@12), *XmnI*(12@30), and *SacI*(11@51). (The notation used

10 means, for example, that *BsmAI* cuts 16 of the FR3 germline genes with a restriction endonuclease recognition site beginning at base 11 of FR3.)

For cleavage of human heavy chains in FR3, the preferred restriction endonucleases are: *Bst4CI* (or

15 *TaaI* or *HpyCH4III*), *BlpI*, *HpyCH4V*, and *MslI*. Because ACNGT (the restriction endonuclease recognition site for *Bst4CI*, *TaaI*, and *HpyCH4III*) is found at a consistent site in all the human FR3 germline genes, one of those enzymes is the most preferred for capture

20 of heavy chain CDR3 diversity. *BlpI* and *HpyCH4V* are complementary. *BlpI* cuts most members of the VH1 and VH4 families while *HpyCH4V* cuts most members of the VH3, VH5, VH6, and VH7 families. Neither enzyme cuts VH2s, but this is a very small family, containing only

25 three members. Thus, these enzymes may also be used in preferred embodiments of the methods of this invention.

The restriction endonucleases *HpyCH4III*, *Bst4CI*, and *TaaI* all recognize 5'-ACnGT-3' and cut upper strand DNA after n and lower strand DNA before

30 the base complementary to n. This is the most preferred restriction endonuclease recognition site for this method on human heavy chains because it is found in all germline genes. Furthermore, the restriction

- 25 -

endonuclease recognition region (ACnGT) matches the second and third bases of a tyrosine codon (tay) and the following cysteine codon (tgy) as shown in Table 3. These codons are highly conserved, especially the
5 cysteine in mature antibody genes.

Table 4 E shows the distinct oligonucleotides of length 22 (except the last one which is of length 20) bases. Table 5 C shows the analysis of 1617 actual heavy chain antibody genes. Of these, 1511 have the
10 site and match one of the candidate oligonucleotides to within 4 mismatches. Eight oligonucleotides account for most of the matches and are given in Table 4 F.1. The 8 oligonucleotides are very similar so that it is likely that satisfactory cleavage will be achieved with
15 only one oligonucleotide (such as H43.77.97.1-02#1) by adjusting temperature, pH, salinity, and the like. One or two oligonucleotides may likewise suffice whenever the germline gene sequences differ very little and especially if they differ very little close to the
20 restriction endonuclease recognition region to be cleaved. Table 5 D shows a repeat analysis of 1617 actual heavy chain antibody genes using only the 8 chosen oligonucleotides. This shows that 1463 of the sequences match at least one of the oligonucleotides to
25 within 4 mismatches and have the site as expected. Only 7 sequences have a second *Hpy*CH4III restriction endonuclease recognition region in this region.

Another illustration of choosing an appropriate restriction endonuclease recognition site
30 involves cleavage in FR1 of human heavy chains. Cleavage in FR1 allows capture of the entire CDR diversity of the heavy chain.

- 26 -

The germline genes for human heavy chain FR1 are shown in Table 6. Table 7 shows the restriction endonuclease recognition sites found in human germline genes FR1s. The preferred sites are *BsgI* (GTGCAG;39@4),

5 *BsoFI* (GCngc;43@6,11@9,2@3,1@12),
TseI (Gcwgc;43@6,11@9,2@3,1@12),
MspAI (CMGckg;46@7,2@1), *PvuII* (CAGctg;46@7,2@1),
AluI (AGct;48@82@2), *DdeI* (Ctnag;22@52,9@48),
HphI (tcacc;22@80), *BssKI* (Nccngg;35@39,2@40),

10 *BsaJI* (Ccnngg;32@40,2@41), *BstNI* (CCwgg;33@40),
ScrFI (CCngg;35@40,2@41), *EcoO109I* (RGgnccy;22@46,
11@43), *Sau96I* (Ggncc;23@47,11@44),
AvaII (Ggwcc;23@47,4@44), *PpuMI* (RGgwccy;22@46,4@43),
BsmFI (gtccc;20@48), *HinfI* (Gantc;34@16,21@56,21@77),

15 *TfiI* (21@77), *MlyI* (GAGTC;34@16), *MlyI* (gactc;21@56), and
AlwNI (CAGnnnctg;22@68). The more preferred sites are
MspAI and *PvuII*. *MspAI* and *PvuII* have 46 sites at 7-12
and 2 at 1-6. To avoid cleavage at both sites,
oligonucleotides are used that do not fully cover the

20 site at 1-6. Thus, the DNA will not be cleaved at that
site. We have shown that DNA that extends 3, 4, or 5
bases beyond a *PvuII*-site can be cleaved efficiently.

Another illustration of choosing an appropriate restriction endonuclease recognition site

25 involves cleavage in FR1 of human kappa light chains. Table 8 shows the human kappa FR1 germline genes and Table 9 shows restriction endonuclease recognition sites that are found in a substantial number of human kappa FR1 germline genes at consistent locations. Of

30 the restriction endonuclease recognition sites listed, *BsmAI* and *PflFI* are the most preferred enzymes. *BsmAI* sites are found at base 18 in 35 of 40 germline genes.

- 27 -

*Pfl*FI sites are found in 35 of 40 germline genes at base 12.

Another example of choosing an appropriate restriction endonuclease recognition site involves cleavage in *FR1* of the human lambda light chain. Table 10 shows the 31 known human lambda *FR1* germline gene sequences. Table 11 shows restriction endonuclease recognition sites found in human lambda *FR1* germline genes. *Hinf*I and *Dde*I are the most preferred restriction endonucleases for cutting human lambda chains in *FR1*.

After the appropriate site or sites for cleavage are chosen, one or more short oligonucleotides are prepared so as to functionally complement, alone or in combination, the chosen recognition site. The oligonucleotides also include sequences that flank the recognition site in the majority of the amplified genes. This flanking region allows the sequence to anneal to the single-stranded DNA sufficiently to allow cleavage by the restriction endonuclease specific for the site chosen.

The actual length and sequence of the oligonucleotide depends on the recognition site and the conditions to be used for contacting and cleavage. The length must be sufficient so that the oligonucleotide is functionally complementary to the single-stranded DNA over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location.

Typically, the oligonucleotides of this preferred method of the invention are about 17 to about 30 nucleotides in length. Below about 17 bases, annealing is too weak and above 30 bases there can be a

- 28 -

loss of specificity. A preferred length is 18 to 24 bases.

Oligonucleotides of this length need not be identical complements of the germline genes. Rather, a few mismatches taken may be tolerated. Preferably, however, no more than 1-3 mismatches are allowed. Such mismatches do not adversely affect annealing of the oligonucleotide to the single-stranded DNA. Hence, the two DNAs are said to be functionally complementary.

The second method to manipulate the single-stranded DNAs of this invention for display and/or expression comprises the steps of:

(i) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired, and the double-stranded region of the oligonucleotide having a restriction endonuclease recognition site; and

(ii) cleaving the nucleic acid solely at the cleavage site formed by the complementation of the nucleic acid and the single-stranded region of the oligonucleotide;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur

- 29 -

at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

As explained above, the cleavage site may be
5 formed by the single-stranded portion of the partially double-stranded oligonucleotide duplexing with the single-stranded DNA, the cleavage site may be carried in the double-stranded portion of the partially double-stranded oligonucleotide, or the cleavage site may be
10 introduced by the amplification primer used to amplify the single-stranded DNA-partially double-stranded oligonucleotide combination. In this embodiment, the first is preferred. And, the restriction endonuclease recognition site may be located in either the double-
15 stranded portion of the oligonucleotide or introduced by the amplification primer, which is complementary to that double-stranded region, as used to amplify the combination.

Preferably, the restriction endonuclease site
20 is that of a Type II-S restriction endonuclease, whose cleavage site is located at a known distance from its recognition site.

This second method, preferably, employs Universal Restriction Endonucleases ("URE"). UREs are
25 partially double-stranded oligonucleotides. The single-stranded portion or overlap of the URE consists of a DNA adapter that is functionally complementary to the sequence to be cleaved in the single-stranded DNA. The double-stranded portion consists of a restriction
30 endonuclease recognition site, preferably type II-S.

The URE method of this invention is specific and precise and can tolerate some (e.g., 1-3) mismatches in the complementary regions, i.e., it is

- 30 -

functionally complementary to that region. Further, conditions under which the URE is used can be adjusted so that most of the genes that are amplified can be cut, reducing bias in the library produced from those
5 genes.

The sequence of the single-stranded DNA adapter or overlap portion of the URE typically consists of about 14-22 bases. However, longer or shorter adapters may be used. The size depends on the
10 ability of the adapter to associate with its functional complement in the single-stranded DNA and the temperature used for contacting the URE and the single-stranded DNA at the temperature used for cleaving the DNA with the restriction enzyme. The adapter must be
15 functionally complementary to the single-stranded DNA over a large enough region to allow the two strands to associate such that the cleavage may occur at the chosen temperature and at the desired location. We prefer single-stranded or overlap portions of 14-17
20 bases in length, and more preferably 18-20 bases in length.

The site chosen for cleavage using the URE is preferably one that is substantially conserved in the family of amplified DNAs. As compared to the first
25 cleavage method of this invention, these sites do not need to be endonuclease recognition sites. However, like the first method, the sites chosen can be synthetic rather than existing in the native DNA. Such sites may be chosen by references to the sequences of
30 known antibodies or other families of genes. For example, the sequences of many germline genes are reported at <http://www.mrc-cpe.cam.ac.uk/imt-doc/restricted/ok.html>. For example, one preferred

- 31 -

site occurs near the end of FR3 -- codon 89 through the second base of codon 93. CDR3 begins at codon 95.

The sequences of 79 human heavy-chain genes are also available at

5 <http://www.ncbi.nlm.nih.gov/entre2/nucleotide.html>.

This site can be used to identify appropriate sequences for URE cleavage according to the methods of this invention. See, e.g., Table 12B.

Most preferably, one or more sequences are
10 identified using these sites or other available sequence information. These sequences together are present in a substantial fraction of the amplified DNAs. For example, multiple sequences could be used to allow for known diversity in germline genes or for
15 frequent somatic mutations. Synthetic degenerate sequences could also be used. Preferably, a sequence(s) that occurs in at least 65% of genes examined with no more than 2-3 mismatches is chosen

URE single-stranded adapters or overlaps are
20 then made to be complementary to the chosen regions. Conditions for using the UREs are determined empirically. These conditions should allow cleavage of DNA that contains the functionally complementary sequences with no more than 2 or 3 mismatches but that
25 do not allow cleavage of DNA lacking such sequences.

As described above, the double-stranded portion of the URE includes an endonuclease recognition site, preferably a Type II-S recognition site. Any enzyme that is active at a temperature necessary to
30 maintain the single-stranded DNA substantially in that form and to allow the single-stranded DNA adapter portion of the URE to anneal long enough to the single-

- 32 -

stranded DNA to permit cleavage at the desired site may be used.

The preferred Type II-S enzymes for use in the URE methods of this invention provide asymmetrical
5 cleavage of the single-stranded DNA. Among these are the enzymes listed in Table 13. The most preferred Type II-S enzyme is *FokI*.

When the preferred *FokI* containing URE is used, several conditions are preferably used to effect
10 cleavage:

- 1) Excess of the URE over target DNA should be present to activate the enzyme. URE present only in equimolar amounts to the target DNA would yield poor cleavage of ssDNA because
15 the amount of active enzyme available would be limiting.
- 2) An activator may be used to activate part of the *FokI* enzyme to dimerize without causing cleavage. Examples of appropriate activators
20 are shown in Table 14.
- 3) The cleavage reaction is performed at a temperature between 45°-75°C, preferably above 50°C and most preferably above 55°C.

The UREs used in the prior art contained a
25 14-base single-stranded segment, a 10-base stem (containing a *FokI* site), followed by the palindrome of the 10-base stem. While such UREs may be used in the methods of this invention, the preferred UREs of this invention also include a segment of three to eight
30 bases (a loop) between the *FokI* restriction endonuclease recognition site containing segments. In the preferred embodiment, the stem (containing the *FokI*

- 33 -

site) and its palindrome are also longer than 10 bases. Preferably, they are 10-14 bases in length. Examples of these "lollipop" URE adapters are shown in Table 15.

One example of using a URE to cleave an
5 single-stranded DNA involves the FR3 region of human heavy chain. Table 16 shows an analysis of 840 full-length mature human heavy chains with the URE recognition sequences shown. The vast majority (718/840=0.85) will be recognized with 2 or fewer
10 mismatches using five UREs (VHS881-1.1, VHS881-1.2, VHS881-2.1, VHS881-4.1, and VHS881-9.1). Each has a 20-base adaptor sequence to complement the germline gene, a ten-base stem segment containing a *FokI* site, a five base loop, and the reverse complement of the first
15 stem segment. Annealing those adapters, alone or in combination, to single-stranded antisense heavy chain DNA and treating with *FokI* in the presence of, e.g., the activator FOKIact, will lead to cleavage of the antisense strand at the position indicated.

20 Another example of using a URE(s) to cleave a single-stranded DNA involves the FR1 region of the human Kappa light chains. Table 17 shows an analysis of 182 full-length human kappa chains for matching by the four 19-base probe sequences shown. Ninety-six
25 percent of the sequences match one of the probes with 2 or fewer mismatches. The URE adapters shown in Table 17 are for cleavage of the sense strand of kappa chains. Thus, the adaptor sequences are the reverse complement of the germline gene sequences. The URE
30 consists of a ten-base stem, a five base loop, the reverse complement of the stem and the complementation sequence. The loop shown here is TTGTT, but other sequences could be used. Its function is to interrupt

- 34 -

the palindrome of the stems so that formation of a lollypop monomer is favored over dimerization. Table 17 also shows where the sense strand is cleaved.

Another example of using a URE to cleave a single-stranded DNA involves the human lambda light chain. Table 18 shows analysis of 128 human lambda light chains for matching the four 19-base probes shown. With three or fewer mismatches, 88 of 128 (69%) of the chains match one of the probes. Table 18 also shows URE adapters corresponding to these probes. Annealing these adapters to upper-strand ssDNA of lambda chains and treatment with *FokI* in the presence of FOKIact at a temperature at or above 45°C will lead to specific and precise cleavage of the chains.

The conditions under which the short oligonucleotide sequences of the first method and the UREs of the second method are contacted with the single-stranded DNAs may be empirically determined. The conditions must be such that the single-stranded DNA remains in substantially single-stranded form. More particularly, the conditions must be such that the single-stranded DNA does not form loops that may interfere with its association with the oligonucleotide sequence or the URE or that may themselves provide sites for cleavage by the chosen restriction endonuclease.

The effectiveness and specificity of short oligonucleotides (first method) and UREs (second method) can be adjusted by controlling the concentrations of the URE adapters/oligonucleotides and substrate DNA, the temperature, the pH, the concentration of metal ions, the ionic strength, the concentration of chaotropes (such as urea and

- 35 -

formamide), the concentration of the restriction endonuclease(e.g., *FokI*), and the time of the digestion. These conditions can be optimized with synthetic oligonucleotides having: 1) target germline
5 gene sequences, 2) mutated target gene sequences, or 3) somewhat related non-target sequences. The goal is to cleave most of the target sequences and minimal amounts of non-targets.

In accordance with this invention, the
10 single-stranded DNA is maintained in substantially that form using a temperature between about 37°C and about 75°C. Preferably, a temperature between about 45°C and about 75°C is used. More preferably, a temperature between 50°C and 60°C, most preferably between 55°C and
15 60°C, is used. These temperatures are employed both when contacting the DNA with the oligonucleotide or URE and when cleaving the DNA using the methods of this invention.

The two cleavage methods of this invention
20 have several advantages. The first method allows the individual members of the family of single-stranded DNAs to be cleaved preferentially at one substantially conserved endonuclease recognition site. The method also does not require an endonuclease recognition site
25 to be built into the reverse transcription or amplification primers. Any native or synthetic site in the family can be used.

The second method has both of these advantages. In addition, the preferred URE method
30 allows the single-stranded DNAs to be cleaved at positions where no endonuclease recognition site naturally occurs or has been synthetically constructed.

- 36 -

Most importantly, both cleavage methods permit the use of 5' and 3' primers so as to maximize diversity and then cleavage to remove unwanted or deleterious sequences before cloning, display and/or
5 expression.

After cleavage of the amplified DNAs using one of the methods of this invention, the DNA is prepared for cloning, display and/or expression. This is done by using a partially duplexed synthetic DNA
10 adapter, whose terminal sequence is based on the specific cleavage site at which the amplified DNA has been cleaved.

The synthetic DNA is designed such that when it is ligated to the cleaved single-stranded DNA in
15 proper reading frame so that the desired peptide, polypeptide or protein can be displayed on the surface of the genetic package and/or expressed. Preferably, the double-stranded portion of the adapter comprises the sequence of several codons that encode the amino
20 acid sequence characteristic of the family of peptides, polypeptides or proteins up to the cleavage site. For human heavy chains, the amino acids of the 3-23 framework are preferably used to provide the sequences required for expression of the cleaved DNA.

25 Preferably, the double-stranded portion of the adapter is about 12 to 100 bases in length. More preferably, about 20 to 100 bases are used. The double-stranded region of the adapter also preferably contains at least one endonuclease recognition site
30 useful for cloning the DNA into a suitable display and/or expression vector (or a recipient vector used to archive the diversity). This endonuclease restriction site may be native to the germline gene sequences used

- 37 -

to extend the DNA sequence. It may be also constructed using degenerate sequences to the native germline gene sequences. Or, it may be wholly synthetic.

The single-stranded portion of the adapter is
5 complementary to the region of the cleavage in the
single-stranded DNA. The overlap can be from about 2
bases up to about 15 bases. The longer the overlap,
the more efficient the ligation is likely to be. A
preferred length for the overlap is 7 to 10. This
10 allows some mismatches in the region so that diversity
in this region may be captured.

The single-stranded region or overlap of the
partially duplexed adapter is advantageous because it
allows DNA cleaved at the chosen site, but not other
15 fragments to be captured. Such fragments would
contaminate the library with genes encoding sequences
that will not fold into proper antibodies and are
likely to be non-specifically sticky.

One illustration of the use of a partially
20 duplexed adaptor in the methods of this invention
involves ligating such adaptor to a human FR3 region
that has been cleaved, as described above, at 5'-ACnGT-
3' using HpyCH4III, Bst4CI or TaaI.

Table 4 F.2 shows the bottom strand of the
25 double-stranded portion of the adaptor for ligation to
the cleaved bottom-strand DNA. Since the HpyCH4III-
Site is so far to the right (as shown in Table 3), a
sequence that includes the AflII-site as well as the
XbaI site can be added. This bottom strand portion of
30 the partially-duplexed adaptor, H43.XAExt,
incorporates both XbaI and AflII-sites. The top strand
of the double-stranded portion of the adaptor has
neither site (due to planned mismatches in the segments

- 38 -

opposite the *Xba*I and *Afl*III-Sites of H43.XAExt), but will anneal very tightly to H43.XAExt. H43AExt contains only the *Afl*III-site and is to be used with the top strands H43.ABr1 and H43.ABr2 (which have
5 intentional alterations to destroy the *Afl*III-site).

After ligation, the desired, captured DNA can be PCR amplified again, if desired, using in the preferred embodiment a primer to the downstream constant region of the antibody gene and a primer to
10 part of the double-standard region of the adapter. The primers may also carry restriction endonuclease sites for use in cloning the amplified DNA.

After ligation, and perhaps amplification, of the partially double-stranded adapter to the single-
15 stranded amplified DNA, the composite DNA is cleaved at chosen 5' and 3' endonuclease recognition sites.

The cleavage sites useful for cloning depend on the phage or phagemid or other vectors into which the cassette will be inserted and the available sites
20 in the antibody genes. Table 19 provides restriction endonuclease data for 75 human light chains. Table 20 shows corresponding data for 79 human heavy chains. In each Table, the endonucleases are ordered by increasing frequency of cutting. In these Tables, Nch is the
25 number of chains cut by the enzyme and Ns is the number of sites (some chains have more than one site).

From this analysis, *Sfi*I, *Not*I, *Afl*III, *Apa*LI, and *Asc*I are very suitable. *Sfi*I and *Not*I are preferably used in pCES1 to insert the heavy-chain
30 display segment. *Apa*LI and *Asc*I are preferably used in pCES1 to insert the light-chain display segment.

*Bst*EII-sites occur in 97% of germ-line JH genes. In rearranged V genes, only 54/79 (68%) of

- 39 -

heavy-chain genes contain a *BstEII*-Site and 7/61 of these contain two sites. Thus, 47/79 (59%) contain a single *BstEII*-Site. An alternative to using *BstEII* is to cleave via UREs at the end of JH and ligate to a synthetic oligonucleotide that encodes part of CH1.

One example of preparing a family of DNA sequences using the methods of this invention involves capturing human CDR 3 diversity. As described above, mRNAs from various autoimmune patients are reverse transcribed into lower strand cDNA. After the top strand RNA is degraded, the lower strand is immobilized and a short oligonucleotide used to cleave the cDNA upstream of CDR3. A partially duplexed synthetic DNA adapter is then annealed to the DNA and the DNA is amplified using a primer to the adapter and a primer to the constant region (after FR4). The DNA is then cleaved using *BstEII* (in FR4) and a restriction endonuclease appropriate to the partially double-stranded adapter (e.g., *XbaI* and *AflIII* (in FR3)). The DNA is then ligated into a synthetic VH skeleton such as 3-23.

One example of preparing a single-stranded DNA that was cleaved using the URE method involves the human Kappa chain. The cleavage site in the sense strand of this chain is depicted in Table 17. The oligonucleotide kapextURE is annealed to the oligonucleotides (kaBR01UR, kaBR02UR, kaBR03UR, and kaBR04UR) to form a partially duplex DNA. This DNA is then ligated to the cleaved soluble kappa chains. The ligation product is then amplified using primers kapextUREPCR and CKForeAsc (which inserts a *AscI* site after the end of C kappa). This product is then cleaved with *ApaLI* and *AscI* and ligated to similarly

- 40 -

cut recipient vector.

Another example involves the cleavage of
lambda light chains, illustrated in Table 18. After
cleavage, an extender (ON_LamEx133) and four bridge
5 oligonucleotides (ON_LamB1-133, ON_LamB2-133, ON_LamB3-133,
and ON_LamB4-133) are annealed to form a partially duplex
DNA. That DNA is ligated to the cleaved lambda-chain
sense strands. After ligation, the DNA is amplified
with ON_Lam133PCR and a forward primer specific to the
10 lambda constant domain, such as CL2ForeAsc or
CL7ForeAsc (Table 130).

In human heavy chains, one can cleave almost
all genes in FR4 (downstream, *i.e.*, toward the 3' end
of the sense strand, of CDR3) at a *BstEII*-Site that
15 occurs at a constant position in a very large fraction
of human heavy-chain V genes. One then needs a site in
FR3, if only CDR3 diversity is to be captured, in FR2,
if CDR2 and CDR3 diversity is wanted, or in FR1, if all
the CDR diversity is wanted. These sites are
20 preferably inserted as part of the partially double-
stranded adaptor.

The preferred process of this invention is to
provide recipient vectors (*e.g.*, for display and/or
expression) having sites that allow cloning of either
25 light or heavy chains. Such vectors are well known and
widely used in the art. A preferred phage display
vector in accordance with this invention is phage
MALIA3. This displays in gene III. The sequence of
the phage MALIA3 is shown in Table 21A (annotated) and
30 Table 21B (condensed).

The DNA encoding the selected regions of the
light or heavy chains can be transferred to the vectors
using endonucleases that cut either light or heavy

- 41 -

chains only very rarely. For example, light chains may be captured with *Apa*I and *Asc*I. Heavy-chain genes are preferably cloned into a recipient vector having *Sfi*I, *Nco*I, *Xba*I, *Afl*III, *Bst*EII, *Apa*I, and *Not*I sites. The
5 light chains are preferably moved into the library as *Apa*I-*Asc*I fragments. The heavy chains are preferably moved into the library as *Sfi*I-*Not*I fragments.

Most preferably, the display is had on the surface of a derivative of M13 phage. The most
10 preferred vector contains all the genes of M13, an antibiotic resistance gene, and the display cassette. The preferred vector is provided with restriction sites that allow introduction and excision of members of the diverse family of genes, as cassettes. The preferred
15 vector is stable against rearrangement under the growth conditions used to amplify phage.

In another embodiment of this invention, the diversity captured by the methods of the present invention may be displayed and/or expressed in a
20 phagemid vector (e.g., pCES1) that displays and/or expresses the peptide, polypeptide or protein. Such vectors may also be used to store the diversity for subsequent display and/or expression using other vectors or phage.

25 In another embodiment of this invention, the diversity captured by the methods of the present invention may be displayed and/or expressed in a yeast vector.

In another embodiment, the mode of display
30 may be through a short linker to anchor domains -- one possible anchor comprising the final portion of M13 III ("IIIstump") and a second possible anchor being the full length III mature protein.

- 42 -

The IIIstump fragment contains enough of M13
III to assemble into phage but not the domains involved
in mediating infectivity. Because the w.t. III
proteins are present the phage is unlikely to delete
5 the antibody genes and phage that do delete these
segments receive only a very small growth advantage.
For each of the anchor domains, the DNA encodes the
w.t. AA sequence, but differs from the w.t. DNA
sequence to a very high extent. This will greatly
10 reduce the potential for homologous recombination
between the anchor and the w.t. gene that is also
present (see Example 6).

Most preferably, the present invention uses a
complete phage carrying an antibiotic-resistance gene
15 (such as an ampicillin-resistance gene) and the display
cassette. Because the w.t. *iii* and possibly *viii* genes
are present, the w.t. proteins are also present. The
display cassette is transcribed from a regulatable
promoter (e.g., P_{LacZ}). Use of a regulatable promoter
20 allows control of the ratio of the fusion display gene
to the corresponding w.t. coat protein. This ratio
determines the average number of copies of the display
fusion per phage (or phagemid) particle.

Another aspect of the invention is a method
25 of displaying peptides, polypeptides or proteins (and
particularly Fabs) on filamentous phage. In the most
preferred embodiment this method displays FABs and
comprises:

- a) obtaining a cassette capturing a diversity of
30 segments of DNA encoding the elements:

$P_{reg}::RBS1::SS1::VL::CL::stop::RBS2::SS2::VH::CH1::$
linker::anchor::stop::,

- 43 -

where P_{reg} is a regulatable promoter, RBS1 is a first ribosome binding site, SS1 is a signal sequence operable in the host strain, VL is a member of a
5 diverse set of light-chain variable regions, CL is a light-chain constant region, stop is one or more stop codons, RBS2 is a second ribosome binding site, SS2 is a second signal sequence operable in the host strain, VH is a member of a diverse set of heavy-chain variable
10 regions, CH1 is an antibody heavy-chain first constant domain, linker is a sequence of amino acids of one to about 50 residues, anchor is a protein that will assemble into the filamentous phage particle and stop is a second example of one or more stop codons; and
15 b) positioning that cassette within the phage genome to maximize the viability of the phage and to minimize the potential for deletion of the cassette or parts thereof.

20 The DNA encoding the anchor protein in the above preferred cassette should be designed to encode the same (or a closely related) amino acid sequence as is found in one of the coat proteins of the phage, but with a distinct DNA sequence. This is to prevent
25 unwanted homologous recombination with the w.t. gene. In addition, the cassette should be placed in the intergenic region. The positioning and orientation of the display cassette can influence the behavior of the phage.

30 In one embodiment of the invention, a transcription terminator may be placed after the second stop of the display cassette above (e.g., Trp). This will reduce interaction between the display cassette

- 44 -

and other genes in the phage antibody display vector.

In another embodiment of the methods of this invention, the phage or phagemid can display and/or express proteins other than Fab, by replacing the Fab
5 portions indicated above, with other protein genes.

Various hosts can be used the display and/or expression aspect of this invention. Such hosts are well known in the art. In the preferred embodiment, where Fabs are being displayed and/or expressed, the
10 preferred host should grow at 30°C and be RecA⁻ (to reduce unwanted genetic recombination) and EndA⁻ (to make recovery of RF DNA easier). It is also preferred that the host strain be easily transformed by electroporation.

15 XL1-Blue MRF' satisfies most of these preferences, but does not grow well at 30°C. XL1-Blue MRF' does grow slowly at 38°C and thus is an acceptable host. TG-1 is also an acceptable host although it is RecA⁺ and EndA⁺. XL1-Blue MRF' is more preferred for
20 the intermediate host used to accumulate diversity prior to final construction of the library.

After display and/or expression, the libraries of this invention may be screened using well known and conventionally used techniques. The selected
25 peptides, polypeptides or proteins may then be used to treat disease. Generally, the peptides, polypeptides or proteins for use in therapy or in pharmaceutical compositions are produced by isolating the DNA encoding the desired peptide, polypeptide or protein from the
30 member of the library selected. That DNA is then used in conventional methods to produce the peptide, polypeptides or protein it encodes in appropriate host cells, preferably mammalian host cells, e.g., CHO

- 45 -

cells. After isolation, the peptide, polypeptide or protein is used alone or with pharmaceutically acceptable compositions in therapy to treat disease.

EXAMPLES

5 Example 1: RACE amplification of heavy and light chain antibody repertoires from autoimmune patients.

Total RNA was isolated from individual blood samples (50 ml) of 11 patients using a RNazol™ kit (CINNA/Biotechx), as described by the manufacturer. The
10 patients were diagnosed as follows:

1. SLE and phospholipid syndrome
2. limited systemic sclerosis
3. SLE and Sjogren syndrome
4. Limited Systemic sclerosis
- 15 5. Rheumatoid Arthritis with active vasculitis
6. Limited systemic sclerosis and Sjogren Syndrome
7. Rheumatoid Arthritis and (not active) vasculitis
8. SLE and Sjogren syndrome
9. SLE
- 20 10. SLE and (active) glomerulonephritis
11. Polyarthrititis/ Raynauds Phenomen

From these 11 samples of total RNA, Poly-A⁺ RNA was isolated using Promega PolyATtract® mRNA Isolation kit (Promega).

25 250 ng of each poly-A⁺ RNA sample was used to amplify antibody heavy and light chains with the GeneAacer™ kit (Invitrogen cat no. L1500-01). A schematic overview of the RACE procedure is shown in

- 46 -

FIG. 3.

Using the general protocol of the GeneRAacer™ kit, an RNA adaptor was ligated to the 5' end of all mRNAs. Next, a reverse transcriptase reaction was performed in the presence of oligo(dT15) specific primer under conditions described by the manufacturer in the GeneRAacer™ kit.

1/5 of the cDNA from the reverse transcriptase reaction was used in a 20 ul PCR reaction. For amplification of the heavy chain IgM repertoire, a forward primer based on the CH1 chain of IgM [HuCmFOR] and a backward primer based on the ligated synthetic adaptor sequence [5'A] were used. (See Table 22)

For amplification of the kappa and lambda light chains, a forward primer that contains the 3' coding-end of the cDNA [HuCkFor and HuCLFor2+HuCLfor7] and a backward primer based on the ligated synthetic adapter sequence [5'A] was used (See Table 22). Specific amplification products after 30 cycles of primary PCR were obtained.

FIG. 4 shows the amplification products obtained after the primary PCR reaction from 4 different patient samples. 8 ul primary PCR product from 4 different patients was analyzed on a agarose gel [labeled 1,2, 3 and 4]. For the heavy chain, a product of approximately 950 nt is obtained while for the kappa and lambda light chains the product is approximately 850 nt. M1-2 are molecular weight markers.

PCR products were also analyzed by DNA sequencing [10 clones from the lambda, kappa or heavy chain repertoires]. All sequenced antibody genes recovered contained the full coding sequence as well as

- 47 -

the 5' leader sequence and the V gene diversity was the expected diversity (compared to literature data).

50 ng of all samples from all 11 individual amplified samples were mixed for heavy, lambda light or
5 kappa light chains and used in secondary PCR reactions.

In all secondary PCRs approximately 1 ng template DNA from the primary PCR mixture was used in multiple 50 ul PCR reactions [25 cycles].

For the heavy chain, a nested biotinylated
10 forward primer [HuCm-Nested] was used, and a nested 5'end backward primer located in the synthetic adapter-sequence [5'NA] was used. The 5'end lower-strand of the heavy chain was biotinylated.

For the light chains, a 5'end biotinylated
15 nested primer in the synthetic adapter was used [5'NA] in combination with a 3'end primer in the constant region of Ckappa and Clambda, extended with a sequence coding for the AscI restriction site [kappa: HuCkForAscI, Lambda: HuCL2-FOR-ASC + HuCL7-FOR-ASC].
20 [5'end Top strand DNA was biotinylated]. After gel-analysis the secondary PCR products were pooled and purified with Promega Wizzard PCR cleanup. Approximately 25 ug biotinylated heavy chain, lambda and kappa light chain DNA was isolated from the 11
25 patients.

Example 2: Capturing kappa chains with BsmAI.

A repertoire of human-kappa chain mRNAs was prepared using the RACE method of Example 1 from a
30 collection of patients having various autoimmune diseases.

- 48 -

This Example followed the protocol of Example 1. Approximately 2 micrograms (ug) of human kappa-chain (Igkappa) gene RACE material with biotin attached to 5'-end of upper strand was immobilized as in Example 1 on 200 microliters (μL) of Seradyn magnetic beads. The lower strand was removed by washing the DNA with 2 aliquots 200 μL of 0.1 M NaOH (pH 13) for 3 minutes for the first aliquot followed by 30 seconds for the second aliquot. The beads were neutralized with 200 μL of 10 mM Tris (pH 7.5) 100 mM NaCl. The short oligonucleotides shown in Table 23 were added in 40 fold molar excess in 100 μL of NEB buffer 2 (50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl₂, 1 mM dithiothreitol pH 7.9) to the dry beads. The mixture was incubated at 95°C for 5 minutes then cooled down to 55°C over 30 minutes. Excess oligonucleotide was washed away with 2 washes of NEB buffer 3 (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl₂, 1 mM dithiothreitol pH 7.9). Ten units of BsmAI (NEB) were added in NEB buffer 3 and incubated for 1 h at 55°C. The cleaved downstream DNA was collected and purified over a Qiagen PCR purification column (FIGs. 5 and 6).

FIG. 5 shows an analysis of digested kappa single-stranded DNA. Approximately 151.5 pmol of adapter was annealed to 3.79 pmol of immobilized kappa single-stranded DNA followed by digestion with 15 U of BsmAI. The supernatant containing the desired DNA was removed and analyzed by 5% polyacrylamide gel along with the remaining beads which contained uncleaved full length kappa DNA. 189 pmol of cleaved single-stranded DNA was purified for further analysis. Five percent of the original full length ssDNA remained on the beads.

- 49 -

FIG. 6 shows an analysis of the extender -
cleaved kappa ligation. 180 pmol of pre-annealed
bridge/extender was ligated to 1.8 pmol of *BsmAI*
digested single-stranded DNA. The ligated DNA was
5 purified by Qiagen PCR purification column and analyzed
on a 5% polyacrylamide gel. Results indicated that the
ligation of extender to single-stranded DNA was 95%
efficient.

A partially double-stranded adaptor was
10 prepared using the oligonucleotide shown in Table 23.
The adaptor was added to the single-stranded DNA in 100
fold molar excess along with 1000 units of T4 DNA
ligase and incubated overnight at 16°C. The excess
oligonucleotide was removed with a Qiagen PCR
15 purification column. The ligated material was
amplified by PCR using the primers kapPCRT1 and kapfor
shown in Table 23 for 10 cycles with the program shown
in Table 24.

The soluble PCR product was run on a gel and
20 showed a band of approximately 700 n, as expected
(FIGs. 7 and 8). The DNA was cleaved with enzymes
ApaI and *AscI*, gel purified, and ligated to similarly
cleaved vector pCES1.

FIG. 7 shows an analysis of the PCR product
25 from the extender-kappa amplification. Ligated
extender-kappa single-stranded DNA was amplified with
primers specific to the extender and to the constant
region of the light chain. Two different template
concentrations, 10 ng versus 50 ng, were used as
30 template and 13 cycles were used to generate
approximately 1.5 ug of dsDNA as shown by 0.8% agarose
gel analysis.

- 50 -

FIG. 8 shows an analysis of the purified PCR product from the extender-kappa amplification.

Approximately 5 ug of PCR amplified extender-kappa double-stranded DNA was run out on a 0.8% agarose gel, cut out, and extracted with a GFX gel purification column. By gel analysis, 3.5 ug of double-stranded DNA was prepared.

The assay for capturing kappa chains with BsmA1 was repeated and produced similar results.

FIG 9A shows the DNA after it was cleaved and collected and purified over a Qiagen PCR purification column.

FIG. 9B shows the partially double-stranded adaptor ligated to the single-stranded DNA. This ligated material was then amplified (FIG. 9C). The gel showed a band of approximately 700 n.

Table 25 shows the DNA sequence of a kappa light chain captured by this procedure. Table 26 shows a second sequence captured by this procedure. The closest bridge sequence was complementary to the sequence 5'-agccacc-3', but the sequence captured reads 5'-Tgccacc-3', showing that some mismatch in the overlapped region is tolerated.

Example 3: Construction of Synthetic CDR1 and CDR2 Diversity in V-3-23 VH Framework.

Synthetic diversity in Complementary Determinant Region (CDR) 1 and 2 was created in the 3-23 VH framework in a two step process: first, a vector containing the 3-23 VH framework was constructed; and then, a synthetic CDR 1 and 2 was assembled and cloned into this vector.

- 51 -

For construction of the 3-23 VH framework, 8 oligonucleotides and two PCR primers (long oligonucleotides - TOPFR1A, BOTFR1B, BOTFR2, BOTFR3, F06, BOTFR4, ON-vgC1, and ON-vgC2 and primers - SFPRMET and BOTPCRPRIM, shown in Table 27) that overlap were designed based on the Genbank sequence of 3-23 VH framework region. The design incorporated at least one useful restriction site in each framework region, as shown in Table 27. In Table 27, the segments that were synthesized are shown as bold, the overlapping regions are underscored, and the PCR priming regions at each end are underscored.

A mixture of these 8 oligos was combined at a final concentration of 2.5uM in a 20ul PCR reaction. The PCR mixture contained 200uM dNTPs, 2.5mM MgCl₂, 0.02U *Pfu Turbo*TM DNA Polymerase, 1U Qiagen HotStart Taq DNA Polymerase, and 1X Qiagen PCR buffer. The PCR program consisted of 10 cycles of 94°C for 30s, 55°C for 30s, and 72°C for 30s.

The assembled 3-23 VH DNA sequence was then amplified, using 2.5ul of a 10-fold dilution from the initial PCR in 100ul PCR reaction. The PCR reaction contained 200uM dNTPs, 2.5mM MgCl₂, 0.02U *Pfu Turbo*TM DNA Polymerase, 1U Qiagen HotStart Taq DNA Polymerase, 1X Qiagen PCR Buffer and 2 outside primers (SFPRMET and BOTPCRPRIM) at a concentration of 1uM. The PCR program consisted of 23 cycles at 94°C for 30s, 55°C for 30s, and 72°C for 60s. The 3-23 VH DNA sequence was digested and cloned into pCES1 (phagemid vector) using the *Sfi*I and *Bst*EII restriction endonuclease sites. All restriction enzymes mentioned herein were supplied by New England BioLabs, Beverly, MA and used as per the manufacturer's instructions.

- 52 -

Stuffer sequences (shown in Table 28 and Table 29) were introduced into pCES1 to replace CDR1/CDR2 sequences (900 bases between *BspEI* and *XbaI* RE sites) and CDR3 sequences (358 bases between *AflIII* and *BstEII*) prior to cloning the CDR1/CDR2 diversity. This new vector was termed pCES5 and its sequence is given in Table 29.

Having stuffers in place of the CDRs avoids the risk that a parental sequence would be over-represented in the library. The stuffer sequences are fragments from the penicillase gene of *E. coli*. The CDR1-2 stuffer contains restriction sites for *BglII*, *Bsu36I*, *BclI*, *XcmI*, *MluI*, *PvuII*, *HpaI*, and *HincII*, the underscored sites being unique within the vector pCES5. The stuffer that replaces CDR3 contains the unique restriction endonuclease site *RsrII*.

A schematic representation of the design for CDR1 and CDR2 synthetic diversity is shown FIG. 10. The design was based on the presence of mutations in DP47/3-23 and related germline genes. Diversity was designed to be introduced at the positions within CDR1 and CDR2 indicated by the numbers in FIG. 10. The diversity at each position was chosen to be one of the three following schemes: 1 = ADEFGHIKLMNPQRSTVWY; 2 = YRWVGS; 3 = PS, in which letters encode equimolar mixes of the indicated amino acids.

For the construction of the CDR1 and CDR2 diversity, 4 overlapping oligonucleotides (ON-vgC1, ON_Br12, ON_CD2Xba, and ON-vgC2, shown in Table 27 and Table 30) encoding CDR1/2, plus flanking regions, were designed. A mixture of these 4 oligos was combined at a final concentration of 2.5uM in a 40ul PCR reaction. Two of the 4 oligos contained variegated sequences

- 53 -

positioned at the CDR1 and the CDR2. The PCR mixture contained 200uM dNTPs, 2.5U Pwo DNA Polymerase (Roche), and 1X Pwo PCR buffer with 2mM MgSO₄. The PCR program consisted of 10 cycles at 94°C for 30s, 60°C for 30s, and 72°C for 60s. This assembled CDR1/2 DNA sequence was amplified, using 2.5ul of the mixture in 100ul PCR reaction. The PCR reaction contained 200uM dNTPs, 2.5U Pwo DNA Polymerase, 1X Pwo PCR Buffer with 2mM MgSO₄ and 2 outside primers at a concentration of 1uM. The PCR program consisted of 10 cycles at 94°C for 30s, 60°C for 30s, and 72°C for 60s. These variegated sequences were digested and cloned into the 3-23 VH framework in place of the CDR1/2 stuffer.

We obtained approximately 7×10^7 independent transformants. CDR3 diversity either from donor populations or from synthetic DNA can be cloned into the vector containing synthetic CDR1 and CDR 2 diversity.

A schematic representation of this procedure is shown in FIG. 11. A sequence encoding the FR-regions of the human V3-23 gene segment and CDR regions with synthetic diversity was made by oligonucleotide assembly and cloning via *BspE*I and *Xba*I sites into a vector that complements the FR1 and FR3 regions. Into this library of synthetic VH segments, the complementary VH-CDR3 sequence (top right) was cloned via *Xba*I and *BstE*II sites. The resulting cloned CH genes contain a combination of designed synthetic diversity and natural diversity (see FIG. 11).

- 54 -

Example 4: Cleavage and ligation of the lambda light chains with HinfI.

A schematic of the cleavage and ligation of antibody light chains is shown in FIGs. 12A and 12B.

5 Approximately 2 ug of biotinylated human Lambda DNA prepared as described in Example 1 was immobilized on 200 ul Seradyn magnetic beads. The lower strand was removed by incubation of the DNA with 200 ul of 0.1 M NaOH (pH=13) for 3 minutes, the supernatant was removed
10 and an additional washing of 30 seconds with 200 ul of 0.1 M NaOH was performed. Supernatant was removed and the beads were neutralized with 200 ul of 10 mM Tris (pH=7.5), 100 mM NaCl. 2 additional washes with 200 ul NEB2 buffer 2, containing 10 mM Tris (pH=7.9), 50 mM
15 NaCl, 10 mM MgCl₂ and 1 mM dithiothreitol, were performed. After immobilization, the amount of ssDNA was estimated on a 5% PAGE-UREA gel.

About 0.8 ug ssDNA was recovered and incubated in 100 ul NEB2 buffer 2 containing 80 molar
20 fold excess of an equimolar mix of ON_Lam1aB7, ON_Lam2aB7, ON_Lam31B7 and ON_Lam3rB7 [each oligo in 20 fold molar excess] (see Table 31).

The mixture was incubated at 95° C for 5 minutes and then slowly cooled down to 50° C over a
25 period of 30 minutes. Excess of oligonucleotide was washed away with 2 washes of 200 ul of NEB buffer 2. 4 U/ug of *Hinf I* was added and incubated for 1 hour at 50° C. Beads were mixed every 10 minutes.

After incubation the sample was purified over
30 a Qiagen PCR purification column and was subsequently analysed on a 5% PAGE-urea gel (see FIG. 13A, cleavage was more than 70% efficient).

- 55 -

A schematic of the ligation of the cleaved light chains is shown in FIG. 12B. A mix of bridge/extender pairs was prepared from the Brg/Ext oligo's listed in Table 31 (total molar excess 100 fold) in 1000 U of T4 DNA Ligase (NEB) and incubated overnight at 16° C. After ligation of the DNA, the excess oligonucleotide was removed with a Qiagen PCR purification column and ligation was checked on a Urea-PAGE gel (see FIG. 13B; ligation was more than 95% efficient).

Multiple PCRs were performed containing 10 ng of the ligated material in an 50 ul PCR reaction using 25 pMol ON lamPlePCR and 25 pmol of an equimolar mix of Hu-CL2AscI/HuCL7AscI primer (see Example 1).

PCR was performed at 60° C for 15 cycles using Pfu polymerase. About 1 ug of dsDNA was recovered per PCR (see FIG. 13C) and cleaved with *ApaI* and *AscI* for cloning the lambda light chains in pCES2.

Example 5: Capture of human heavy-chain CDR3 population.

A schematic of the cleavage and ligation of antibody light chains is shown in FIGs. 14A and 14B.

Approximately 3 ug of human heavy-chain (IgM) gene RACE material with biotin attached to 5'-end of lower strand was immobilized on 300 uL of Seradyn magnetic beads. The upper strand was removed by washing the DNA with 2 aliquots 300 uL of 0.1 M NaOH (pH 13) for 3 minutes for the first aliquot followed by 30 seconds for the second aliquot. The beads were neutralized with 300 uL of 10 mM Tris (pH 7.5) 100 mM NaCl. The REaptors (oligonucleotides used to make

- 56 -

single-stranded DNA locally double-stranded) shown in Table 32 were added in 30 fold molar excess in 200 uL of NEB buffer 4 (50 mM Potassium Acetate, 20 mM Tris-Acetate, 10 mM Magnesium Acetate, 1 mM dithiothreitol pH 7.9) to the dry beads. The REadaptors were incubated with the single-stranded DNA at 80 °C for 5 minutes then cooled down to 55 °C over 30 minutes. Excess REadaptors were washed away with 2 washes of NEB buffer 4. Fifteen units of HpyCH4III (NEB) were added in NEB buffer 4 and incubated for 1 hour at 55 °C. The cleaved downstream DNA remaining on the beads was removed from the beads using a Qiagen Nucleotide removal column (see FIG. 15).

The Bridge/Extender pairs shown in Table 33 were added in 25 molar excess along with 1200 units of T4 DNA ligase and incubated overnight at 16 °C. Excess Bridge/Extender was removed with a Qiagen PCR purification column. The ligated material was amplified by PCR using primers H43.XAExtPCR2 and Hucumnest shown in Table 34 for 10 cycles with the program shown in Table 35.

The soluble PCR product was run on a gel and showed a band of approximately 500 n, as expected (see FIG. 15B). The DNA was cleaved with enzymes *SfiI* and *NotI*, gel purified, and ligated to similarly cleaved vector PCES1.

Example 6: Description of Phage Display Vector CJRA05, a member of the library built in vector DY3F7.

Table 36 contains an annotated DNA sequence of a member of the library, CJRA05, see FIG. 16. Table 36 is to be read as follows: on each line everything

- 57 -

that follows an exclamation mark "!" is a comment. All occurrences of A, C, G, and T before "!" are the DNA sequence. Case is used only to show that certain bases constitute special features, such as restriction sites, ribosome binding sites, and the like, which are labeled below the DNA. CJRA05 is a derivative of phage DY3F7, obtained by cloning an *Apa*LI to *Not*I fragment into these sites in DY3F31. DY3F31 is like DY3F7 except that the light chain and heavy chain genes have been replaced by "stuffer" DNA that does not code for any antibody. DY3F7 contains an antibody that binds streptavidin, but did not come from the present library.

The phage genes start with gene ii and continue with genes x, v, vii, ix, viii, iii, vi, i, and iv. Gene iii has been slightly modified in that eight codons have been inserted between the signal sequence and the mature protein and the final amino acids of the signal sequence have been altered. This allows restriction enzyme recognition sites *Eag*I and *Xba*I to be present. Following gene iv is the phage origin of replication (*ori*). After *ori* is *bla* which confers resistance to ampicillin (*ApR*). The phage genes and *bla* are transcribed in the same sense.

After *bla*, is the Fab cassette (illustrated in FIG. 17) comprising:

- a) *PlacZ* promoter,
- b) A first Ribosome Binding Site (*RBS1*),
- c) The signal sequence form M13 iii,
- d) An *Apa*LI RERS,
- e) A light chain (a kappa L20::JK1 shortened by one codon at the V-J boundary in this case),
- f) An *Asc*I RERS,

- 58 -

- g) A second Ribosome Binding Site (RBS2),
- h) A signal sequence, preferably PelB, which contains,
- i) An *SfiI* RERS,
- 5 j) A synthetic 3-23 V region with diversity in CDR1 and CDR2,
- k) A captured CDR3,
- l) A partially synthetic J region (FR4 after *BstEII*),
- m) CH1,
- 10 n) A *NotI* RERS,
- o) A His6 tag,
- p) A cMyc tag,
- q) An amber codon,
- r) An anchor DNA that encodes the same amino-acid
- 15 sequence as codons 273 to 424 of M13 iii (as shown in Table 37).
- s) Two stop codons,
- t) An *AvrII* RERS, and
- u) A trp terminator.

20 The anchor (item r) encodes the same amino-acid sequence as do codons 273 to 424 of M13 iii but the DNA is approximately as different as possible from the wild-type DNA sequence. In Table 36, the III' stump runs from base 8997 to base 9455. Below the

25 DNA, as comments, are the differences with wild-type iii for the comparable codons with "!W.T" at the ends of these lines. Note that Met and Trp have only a single codon and must be left as is. These AA types are rare. Ser codons can be changed at all three base,

30 while Leu and Arg codons can be changed at two.

In most cases, one base change can be introduced per codon. This has three advantages: 1) recombination with the wild-type gene carried elsewhere

- 59 -

on the phage is less likely, 2) new restriction sites can be introduced, facilitating construction; and 3) sequencing primers that bind in only one of the two regions can be designed.

5 The fragment of M13 III shown in CJRA05 is the preferred length for the anchor segment. Alternative longer or shorter anchor segments defined by reference to whole mature III protein may also be utilized.

10 The sequence of M13 III consists of the following elements: Signal Sequence::Domain 1 (D1)::Linker 1 (L1)::Domain 2 (D2)::Linker 2 (L2)::Domain 3 (D3)::Transmembrane Segment (TM)::Intracellular anchor (IC) (see Table 38).

15 The pIII anchor (also known as trpIII) preferably consists of D2::L2::D3::TM::IC. Another embodiment for the pIII anchor consists of D2'::L2::D3::TM::IC (where D2' comprises the last 21 residues of D2 with the first 109 residues deleted). A
20 further embodiment of the pIII anchor consists of D2'(C>S)::L2::D3::TM::IC (where D2'(C>S) is D2' with the single C converted to S), and d) D3::TM::IC.

Table 38 shows a gene fragment comprising the
25 recombinant enterokinase cleavage site, and the whole of mature M13 III protein. The DNA used to encode this sequence is intentionally very different from the DNA of wild-type gene iii as shown by the lines denoted "W.T." containing the w.t. bases where these differ
30 from this gene. III is divided into domains denoted "domain 1", "linker 1", "domain 2", "linker 2", "domain 3", "transmembrane segment", and "intracellular anchor".

- 60 -

Alternative preferred anchor segments
(defined by reference to the sequence of Table 38)
include:

- codons 1-29 joined to codons 104-435, deleting
5 domain 1 and retaining linker 1 to the end;
- codons 1-38 joined to codons 104-435, deleting
domain 1 and retaining the rEK cleavage site plus linker
1 to the end from III;
- codons 1-29 joined to codons 236-435, deleting
10 domain 1, linker 1, and most of domain 2 and retaining
linker 2 to the end;
- codons 1-38 joined to codons 236-435, deleting
domain 1, linker 1, and most of domain 2 and retaining
linker 2 to the end and the rEK cleavage site;
- 15 codons 1-29 joined to codons 236-435 and changing
codon 240 to Ser(e.g., agc), deleting domain 1, linker
1, and most of domain 2 and retaining linker 2 to the
end; and
- codons 1-38 joined to codons 236-435 and changing
20 codon 240 to Ser(e.g., agc), deleting domain 1, linker
1, and most of domain 2 and retaining linker 2 to the
end and the rEK cleavage site.

The constructs would most readily be made by
methods similar to those of Wang and Wilkinson
25 (Biotechniques 2001: 31(4)722-724) in which PCR is used
to copy the vector except the part to be deleted and
matching restriction sites are introduced or retained
at either end of the part to be kept. Table 39 shows
the oligonucleotides to be used in deleting parts of
30 the III anchor segment. The DNA shown in Table 38 has
an *NheI* site before the DINDRMA recombinant
enterokinase cleavage site (rEKCS). If *NheI* is used in
the deletion process with this DNA, the rEKCS site

- 61 -

would be lost. This site could be quite useful in cleaving Fabs from the phage and might facilitate capture of very high-affinity antibodies. One could mutagenize this sequence so that the *NheI* site would
5 follow the rEKCS site, an Ala Ser amino-acid sequence is already present. Alternatively, one could use *SphI* for the deletions. This would involve a slight change in amino acid sequence but would be of no consequence.

**Example 7 : Selection of antigen binders from an
10 enriched library of human antibodies using phage vector
DY3F31.**

In this example the human antibody library used is described in de Haard et al., (Journal of Biological Chemistry, 274 (26): 18218-30 (1999)). This
15 library, consisting of a large non-immune human Fab phagemid library, was first enriched on antigen, either on streptavidin or on phenyl-oxazolone (phOx). The methods for this are well known in the art. Two preselected Fab libraries, the first one selected once
20 on immobilized phOx-BSA (R1-ox) and the second one selected twice on streptavidin (R2-strep), were chosen for recloning.

These enriched repertoires of phage antibodies, in which only a very low percentage have
25 binding activity to the antigen used in selection, were confirmed by screening clones in an ELISA for antigen binding. The selected Fab genes were transferred from the phagemid vector of this library to the DY3F31 vector via *ApaI*-*NotI* restriction sites.

30 DNA from the DY3F31 phage vector was pretreated with ATP dependent DNase to remove

- 62 -

chromosomal DNA and then digested with *ApaI* and *NotI*.
An extra digestion with *AscI* was performed in between
to prevent self-ligation of the vector. The *ApaI/NotI*
Fab fragment from the preselected libraries was
5 subsequently ligated to the vector DNA and transformed
into competent XL1-blue MRF' cells.

Libraries were made using vector:insert
ratios of 1:2 for phOx-library and 1:3 for STREP
library, and using 100 ng ligated DNA per 50 μ l of
10 electroporation-competent cells (electroporation
conditions : one shock of 1700 V, 1 hour recovery of
cells in rich SOC medium, plating on ampicillin-
containing agar plates).

This transformation resulted in a library
15 size of 1.6×10^6 for R1-ox in DY3F31 and 2.1×10^6 for
R2-strep in DY3F31. Sixteen colonies from each library
were screened for insert, and all showed the correct
size insert (± 1400 bp) (for both libraries).

Phage was prepared from these Fab libraries
20 as follows. A representative sample of the library was
inoculated in medium with ampicillin and glucose, and
at OD 0.5, the medium exchanged for ampicillin and 1 mM
IPTG. After overnight growth at 37 °C, phage was
harvested from the supernatant by PEG-NaCl
25 precipitation. Phage was used for selection on antigen.
R1-ox was selected on phOx-BSA coated by passive
adsorption onto immunotubes and R2-strep on
streptavidin coated paramagnetic beads (Dynal, Norway),
in procedures described in de Haard et. al. and Marks
30 et. al., Journal of Molecular Biology, 222(3): 581-97
(1991). Phage titers and enrichments are given in
Table 40.

- 63 -

Clones from these selected libraries, dubbed R2-ox and R3-strep respectively, were screened for binding to their antigens in ELISA. 44 clones from each selection were picked randomly and screened as phage or soluble Fab for binding in ELISA. For the libraries in DY3F31, clones were first grown in 2TY-2% glucose-50 µg/ml AMP to an OD600 of approximately 0.5, and then grown overnight in 2TY-50 µg/ml AMP +/- 1mM IPTG. Induction with IPTG may result in the production of both phage-Fab and soluble Fab. Therefore the (same) clones were also grown without IPTG. Table 41 shows the results of an ELISA screening of the resulting supernatant, either for the detection of phage particles with antigen binding (Anti-M13 HRP = anti-phage antibody), or for the detection of human Fabs, be it on phage or as soluble fragments, either with using the anti-myc antibody 9E10 which detects the myc-tag that every Fab carries at the C-terminal end of the heavy chain followed by a HRP-labeled rabbit-anti-Mouse serum (column 9E10/RAM-HRP), or with anti-light chain reagent followed by a HRP-labeled goat-anti-rabbit antiserum(anti-CK/CL Gar-HRP).

The results shows that in both cases antigen-binders are identified in the library, with as Fabs on phage or with the anti-Fab reagents (Table 41). IPTG induction yields an increase in the number of positives. Also it can be seen that for the phOx-clones, the phage ELISA yields more positives than the soluble Fab ELISA, most likely due to the avid binding of phage. Twenty four of the ELISA-positive clones were screened using PCR of the Fab-insert from the vector, followed by digestion with *BstNI*. This yielded 17 different patterns for the phOx-binding

- 64 -

Fab's in 23 samples that were correctly analyzed, and 6 out of 24 for the streptavidin binding clones. Thus, the data from the selection and screening from this pre-enriched non-immune Fab library show that the
5 DY3F31 vector is suitable for display and selection of Fab fragments, and provides both soluble Fab and Fab on phage for screening experiments after selection.

Example 8: Selection of Phage-antibody libraries on streptavidin magnetic beads.

10 The following example describes a selection in which one first depletes a sample of the library of binders to streptavidin and optionally of binders to a non-target (i.e., a molecule other than the target that one does not want the selected Fab to bind). It is
15 hypothesized that one has a molecule, termed a "competitive ligand", which binds the target and that an antibody which binds at the same site would be especially useful.

For this procedure Streptavidin Magnetic
20 Beads (Dynal) were blocked once with blocking solution (2% Marvel Milk, PBS (pH 7.4), 0.01% Tween-20 ("2%MPBST")) for 60 minutes at room temperature and then washed five times with 2%MPBST. 450 μ L of beads were blocked for each depletion and subsequent
25 selection set.

Per selection, 6.25 μ L of biotinylated depletion target (1 mg/mL stock in PBST) was added to 0.250 mL of washed, blocked beads (from step 1). The target was allowed to bind overnight, with tumbling, at
30 4°C. The next day, the beads are washed 5 times with PBST.

- 65 -

Per selection, 0.010 mL of biotinylated target antigen (1 mg/mL stock in PBST) was added to 0.100 mL of blocked and washed beads (from step 1). The antigen was allowed to bind overnight, with
5 tumbling, at 4°C. The next day, the beads were washed 5 times with PBST.

In round 1, 2×10^{12} up to 10^{13} plaque forming units (pfu) per selection were blocked against non-specific binding by adding to 0.500 mL of 2%MPBS
10 (=2%MPBST without Tween) for 1 hr at RT (tumble). In later rounds, 1011 pfu per selection were blocked as done in round 1.

Each phage pool was incubated with 50 µL of depletion target beads (final wash supernatant removed
15 just before use) on a Labquake rotator for 10 min at room temperature. After incubation, the phage supernatant was removed and incubated with another 50 µL of depletion target beads. This was repeated 3 more times using depletion target beads and twice using
20 blocked streptavidin beads for a total of 7 rounds of depletion, so each phage pool required 350 µL of depletion beads.

A small sample of each depleted library pool was taken for titering. Each library pool was added to
25 0.100 mL of target beads (final wash supernatant was removed just before use) and allowed to incubate for 2 hours at room temperature (tumble).

Beads were then washed as rapidly as possible (e.g., 3 minutes total) with 5 X 0.500 mL PBST and then
30 2X with PBS. Phage still bound to beads after the washing were eluted once with 0.250 mL of competitive ligand (~1 µM) in PBST for 1 hour at room temperature on a Labquake rotator. The eluate was removed, mixed

- 66 -

with 0.500 mL Minimal A salts solution and saved. For a second selection, 0.500 mL 100 mM TEA was used for elution for 10 min at RT, then neutralized in a mix of 0.250 mL of 1 M Tris, pH 7.4 + 0.500 mL Min A salts.

5 After the first selection elution, the beads can be eluted again with 0.300 mL of non-biotinylated target (1 mg/mL) for 1 hr at RT on a Labquake rotator. Eluted phage are added to 0.450 mL Minimal A salts.

 Three eluates (competitor from 1st selection, target from 1st selection and neutralized TEA elution from 2nd selection) were kept separate and a small aliquot taken from each for titering. 0.500 mL Minimal A salts were added to the remaining bead aliquots after competitor and target elution and after TEA elution.

15 Take a small aliquot from each was taken for titering.

 Each elution and each set of eluted beads was mixed with 2X YT and an aliquot (e.g., 1 mL with 1. E 10/mL) of XL1-Blue MRF' E. coli cells (or other F' cell line) which had been chilled on ice after having been grown to mid-logarithmic phase, starved and concentrated (see procedure below - "Mid-Log prep of XL-1 blue MRF' cells for infection").

 After approximately 30 minutes at room temperature, the phage/cell mixtures were spread onto Bio-Assay Dishes (243 X 243 X 18 mm, Nalge Nunc) containing 2XYT, 1mM IPTG agar. The plates were incubated overnight at 30°C. The next day, each amplified phage culture was harvested from its respective plate. The plate was flooded with 35 mL TBS or LB, and cells were scraped from the plate. The resuspended cells were transferred to a centrifuge bottle. An additional 20 mL TBS or LB was used to remove any cells from the plate and pooled with the

- 67 -

cells in the centrifuge bottle. The cells were centrifuged out, and phage in the supernatant was recovered by PEG precipitation. Over the next day, the amplified phage preps were titered.

5 In the first round, two selections yielded five amplified eluates. These amplified eluates were panned for 2-3 more additional rounds of selection using ~1. E 12 input phage/round. For each additional round, the depletion and target beads were prepared the
10 night before the round was initiated.

For the elution steps in subsequent rounds, all elutions up to the elution step from which the amplified elution came from were done, and the previous elutions were treated as washes. For the
15 bead infection amplified phage, for example, the competitive ligand and target elutions were done and then tossed as washes (see below). Then the beads were used to infect E. coli. Two pools, therefore, yielded a total of 5 final elutions at the end of the
20 selection.

1st selection set

- A. Ligand amplified elution: elute w/ ligand for 1 hr, keep as elution
- 25 B. Target amplified elution: elute w/ ligand for 1 hr, toss as wash elute w/ target for 1 hr, keep as elution
- C. Bead infect. amp. elution: elute w/ ligand for 1 hr, toss as wash elute w/ target
30 for 1 hr, toss as wash elute w/ cell infection, keep as elution

- 68 -

2nd selection set

- A. TEA amplified elution; elute w/ TEA
10min, keep as elution
- B. Bead infect. amp. elution; elute w/
TEA 10min, toss as wash elute w/ cell
infection, keep as elution

Mid-log prep of XL1 blue MRF' cells for infection

(based on Barbas et al. Phage Display manual procedure)

- Culture XL1 blue MRF' in NZCYM (12.5 mg/mL
tet) at 37°C and 250 rpm overnight. Started a 500 mL
culture in 2 liter flask by diluting cells 1/50 in
NZCYM/tet (10 mL overnight culture added) and incubated
at 37°C at 250 rpm until OD600 of 0.45 (1.5-2 hrs) was
reached. Shaking was reduced to 100 rpm for 10 min.
- When OD600 reached between 0.55-0.65, cells were
transferred to 2 x 250 mL centrifuge bottles,
centrifuged at 600 g for 15 min at 4°C. Supernatant
was poured off. Residual liquid was removed with a
pipette.
- The pellets were gently resuspended (not
pipetting up and down) in the original volume of 1 X
Minimal A salts at room temp. The resuspended cells
were transferred back into 2-liter flask, shaken at 100
rpm for 45 min at 37°C. This process was performed in
order to starve the cells and restore pili. The cells
were transferred to 2 x 250 mL centrifuge bottles, and
centrifuged as earlier.

The cells were gently resuspended in ice cold
Minimal A salts (5 mL per 500 mL original culture).

- 69 -

The cells were put on ice for use in infections as soon as possible.

The phage eluates were brought up to 7.5 mL with 2XYT medium and 2.5 mL of cells were added. Beads
5 were brought up to 3 mL with 2XYT and 1 mL of cells were added. Incubated at 37°C for 30 min. The cells were plated on 2XYT, 1 mM IPTG agar large NUNC plates and incubated for 18 hr at 30°C.

**Example 9: Incorporation of synthetic region in FR1/3
10 region.**

Described below are examples for incorporating of fixed residues in antibody sequences for light chain kappa and lambda genes, and for heavy chains. The experimental conditions and
15 oligonucleotides used for the examples below have been described in previous examples (e.g., Examples 3 & 4).

The process for incorporating fixed FR1 residues in an antibody lambda sequence consists of 3 steps (see FIG. 18): (1) annealing of single-stranded
20 DNA material encoding VL genes to a partially complementary oligonucleotide mix (indicated with Ext and Bridge), to anneal in this example to the region encoding residues 5-7 of the FR1 of the lambda genes (indicated with X..X; within the lambda genes the
25 overlap may sometimes not be perfect); (2) ligation of this complex; (3) PCR of the ligated material with the indicated primer ('PCRpr') and for example one primer based within the VL gene. In this process the first few residues of all lambda genes will be encoded by the
30 sequences present in the oligonucleotides (Ext., Bridge

- 70 -

or PCRpr). After the PCR, the lambda genes can be cloned using the indicated restriction site for ApaLI.

The process for incorporating fixed FR1 residues in an antibody kappa sequence (FIG. 19) consists of 3 steps : (1) annealing of single-stranded DNA material encoding VK genes to a partially complementary oligonucleotide mix (indicated with Ext and Bri), to anneal in this example to the region encoding residues 8-10 of the FR1 of the kappa genes (indicated with X..X; within the kappa genes the overlap may sometimes not be perfect) ; (2) ligation of this complex; (3) PCR of the ligated material with the indicated primer ('PCRpr') and for example one primer based within the VK gene. In this process the first few (8) residues of all kappa genes will be encoded by the sequences present in the oligonucleotides (Ext., Bridge or PCRpr.). After the PCR, the kappa genes can be cloned using the indicated restriction site for ApaLI.

The process of incorporating fixed FR3 residues in an antibody heavy chain sequence (FIG. 20) consists of 3 steps : (1) annealing of single-stranded DNA material encoding part of the VH genes (for example encoding FR3, CDR3 and FR4 regions) to a partially complementary oligonucleotide mix (indicated with Ext and Bridge), to anneal in this example to the region encoding residues 92-94 (within the FR3 region) of VH genes (indicated with X..X; within the VH genes the overlap may sometimes not be perfect); (2) ligation of this complex; (3) PCR of the ligated material with the indicated primer ('PCRpr') and for example one primer based within the VH gene (such as in the FR4 region). In this process certain residues of all VH genes will be encoded by the sequences present in the

- 71 -

oligonucleotides used here, in particular from PCRpr
(for residues 70-73), or from Ext/Bridge
oligonucleotides (residues 74-91). After the PCR, the
partial VH genes can be cloned using the indicated
5 restriction site for *XbaI*.

It will be understood that the foregoing is
only illustrative of the principles of this invention
and that various modifications can be made by those
skilled in the art without departing from the scope of
10 and spirit of the invention.

```

! VHI
! 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
agg gtc acc atg acc agg gac acg tcc atc agc aca gcc tac atg
5 ! 81 82 82a 82b 82c 83 84 85 86 87 88 89 90 91 92
gag ctg agc agg ctg aga tct gac gac acg gcc gtg tat tac tgt
! 93 94 95
gcg aga ga ! 1-02# 1
aga gtc acc att acc agg gac aca tcc gcg agc aca gcc tac atg
10 gag ctg agc agc ctg aga tct gaa gac acg gct gtg tat tac tgt
gcg aga ga ! 1-03# 2
aga gtc acc atg acc agg aac acc tcc ata agc aca gcc tac atg
gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
gcg aga gg ! 1-08# 3
15 aga gtc acc atg acc aca gac aca tcc acg agc aca gcc tac atg
gag ctg agg agc ctg aga tct gac gac acg gcc gtg tat tac tgt
gcg aga ga ! 1-18# 4
aga gtc acc atg acc gag gac aca tct aca gac aca gcc tac atg
gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
20 gca aca ga ! 1-24# 5
aga gtc acc att acc agg gac agg tct atg agc aca gcc tac atg
gag ctg agc agc ctg aga tct gag gac aca gcc atg tat tac tgt
gca aga ta ! 1-45# 6
aga gtc acc atg acc agg gac acg tcc acg agc aca gtc tac atg
25 gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
gcg aga ga ! 1-46# 7
aga gtc acc att acc agg gac atg tcc aca agc aca gcc tac atg
gag ctg agc agc ctg aga tcc gag gac acg gcc gtg tat tac tgt
gcg gca ga ! 1-58# 8
30 aga gtc acg att acc gcg gac gaa tcc acg agc aca gcc tac atg
gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
gcg aga ga ! 1-69# 9
aga gtc acg att acc gcg gac aaa tcc acg agc aca gcc tac atg
gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
35 gcg aga ga ! 1-e# 10
aga gtc acc ata acc gcg gac acg tct aca gac aca gcc tac atg
gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
gca aca ga ! 1-f# 11

```

- 73 -

! VH2

agg ctc acc atc acc aag gac acc tcc aaa aac cag gtg gtc ctt
aca atg acc aac atg gac cct gtg gac aca gcc aca tat tac tgt
gca cac aga c! 2-05# 12

5 agg ctc acc atc tcc aag gac acc tcc aaa agc cag gtg gtc ctt
acc atg acc aac atg gac cct gtg gac aca gcc aca tat tac tgt
gca cgg ata c! 2-26# 13

agg ctc acc atc tcc aag gac acc tcc aaa aac cag gtg gtc ctt
aca atg acc aac atg gac cct gtg gac aca gcc acg tat tac tgt
10 gca cgg ata c! 2-70# 14

! VH3

cga ttc acc atc tcc aga gac aac gcc aag aac tca ctg tat ctg
caa atg aac agc ctg aga gcc gag gac acg gct gtg tat tac tgt
gcg aga ga ! 3-07# 15

15 cga ttc acc atc tcc aga gac aac gcc aag aac tcc ctg tat ctg
caa atg aac agt ctg aga gct gag gac acg gcc ttg tat tac tgt
gca aaa gat a! 3-09#16

cga ttc acc atc tcc agg gac aac gcc aag aac tca ctg tat ctg
caa atg aac agc ctg aga gcc gag gac acg gcc gtg tat tac tgt
20 gcg aga ga ! 3-11# 17

cga ttc acc atc tcc aga gaa aat gcc aag aac tcc ttg tat ctt
caa atg aac agc ctg aga gcc ggg gac acg gct gtg tat tac tgt
gca aga ga ! 3-13# 18

25 aga ttc acc atc tca aga gat gat tca aaa aac acg ctg tat ctg
caa atg aac agc ctg aaa acc gag gac aca gcc gtg tat tac tgt
acc aca ga ! 3-15# 19

cga ttc acc atc tcc aga gac aac gcc aag aac tcc ctg tat ctg
caa atg aac agt ctg aga gcc gag gac acg gcc ttg tat cac tgt
gcg aga ga ! 3-20# 20

30 cga ttc acc atc tcc aga gac aac gcc aag aac tca ctg tat ctg
caa atg aac agc ctg aga gcc gag gac acg gct gtg tat tac tgt
gcg aga ga ! 3-21# 21

cgg ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
caa atg aac agc ctg aga gcc gag gac acg gcc gta tat tac tgt
gcg aaa ga ! 3-23# 22

35 cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
gcg aaa ga ! 3-30# 23

40 cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
gcg aga ga ! 3303# 24

- 74 -

cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
gcg aaa ga ! 3305# 25
5 cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
caa atg aac agc ctg aga gcc gag gac acg gct gtg tat tac tgt
gcg aga ga ! 3-33# 26
cga ttc acc atc tcc aga gac aac agc aaa aac tcc ctg tat ctg
caa atg aac agt ctg aga act gag gac acc gcc ttg tat tac tgt
gca aaa gat a! 3-43#27
10 cga ttc acc atc tcc aga gac aat gcc aag aac tca ctg tat ctg
caa atg aac agc ctg aga gac gag gac acg gct gtg tat tac tgt
gcg aga ga ! 3-48# 28
aga ttc acc atc tca aga gat ggt tcc aaa agc atc gcc tat ctg
caa atg aac agc ctg aaa acc gag gac aca gcc gtg tat tac tgt
15 act aga ga ! 3-49# 29
cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctt
caa atg aac agc ctg aga gcc gag gac acg gcc gtg tat tac tgt
gcg aga ga ! 3-53# 30
aga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctt
20 caa atg ggc agc ctg aga gct gag gac atg gct gtg tat tac tgt
gcg aga ga ! 3-64# 31
aga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctt
caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
gcg aga ga ! 3-66# 32
25 aga ttc acc atc tca aga gat gat tca aag aac tca ctg tat ctg
caa atg aac agc ctg aaa acc gag gac acg gcc gtg tat tac tgt
gct aga ga ! 3-72# 33
agg ttc acc atc tcc aga gat gat tca aag aac acg gcg tat ctg
caa atg aac agc ctg aaa acc gag gac acg gcc gtg tat tac tgt
30 act aga ca ! 3-73# 34
cga ttc acc atc tcc aga gac aac gcc aag aac acg ctg tat ctg
caa atg aac agt ctg aga gcc gag gac acg gct gtg tat tac tgt
gca aga ga ! 3-74# 35
aga ttc acc atc tcc aga gac aat tcc aag aac acg ctg cat ctt
35 caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
aag aaa ga ! 3-d# 36
! VH4
cga gtc acc ata tca gta gac aag tcc aag aac cag ttc tcc ctg
aag ctg agc tct gtg acc gcc gcg gac acg gcc gtg tat tac tgt
40 gcg aga ga ! 4-04# 37
cga gtc acc atg tca gta gac acg tcc aag aac cag ttc tcc ctg

- 75 -

aag ctg agc tct gtg acc gcc gtg gac acg gcc gtg tat tac tgt
gcg aga aa ! 4-28# 38
cga gtt acc ata tca gta gac acg tct aag aac cag ttc tcc ctg
aag ctg agc tct gtg act gcc gcg gac acg gcc gtg tat tac tgt
5 gcg aga ga ! 4301# 39
cga gtc acc ata tca gta gac agg tcc aag aac cag ttc tcc ctg
aag ctg agc tct gtg acc gcc gcg gac acg gcc gtg tat tac tgt
gcc aga ga ! 4302# 40
cga gtt acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
10 aag ctg agc tct gtg act gcc gca gac acg gcc gtg tat tac tgt
gcc aga ga ! 4304# 41
cga gtt acc ata tca gta gac acg tct aag aac cag ttc tcc ctg
aag ctg agc tct gtg act gcc gcg gac acg gcc gtg tat tac tgt
gcg aga ga ! 4-31# 42
15 cga gtc acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
aag ctg agc tct gtg acc gcc gcg gac acg gct gtg tat tac tgt
gcg aga ga ! 4-34# 43
cga gtc acc ata tcc gta gac acg tcc aag aac cag ttc tcc ctg
aag ctg agc tct gtg acc gcc gca gac acg gct gtg tat tac tgt
20 gcg aga ca ! 4-39# 44
cga gtc acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
aag ctg agc tct gtg acc gct gcg gac acg gcc gtg tat tac tgt
gcg aga ga ! 4-59# 45
cga gtc acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
25 aag ctg agc tct gtg acc gct gcg gac acg gcc gtg tat tac tgt
gcg aga ga ! 4-61# 46
cga gtc acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
aag ctg agc tct gtg acc gcc gca gac acg gcc gtg tat tac tgt
gcg aga ga ! 4-b# 47
30 ! VH5
cag gtc acc atc tca gcc gac aag tcc atc agc acc gcc tac ctg
cag tgg agc agc ctg aag gcc tcg gac acc gcc atg tat tac tgt
gcg aga ca ! 5-51# 48
cac gtc acc atc tca gct gac aag tcc atc agc act gcc tac ctg
35 cag tgg agc agc ctg aag gcc tcg gac acc gcc atg tat tac tgt
gcg aga ! 5-a# 49
! VH6
cga ata acc atc aac cca gac aca tcc aag aac cag ttc tcc ctg
cag ctg aac tct gtg act ccc gag gac acg gct gtg tat tac tgt
40 gca aga ga ! 6-1# 50
! VH7

- 76 -

cgg ttt gtc ttc tcc ttg gac acc tct gtc agc acg gca tat ctg
cag atc tgc agc cta aag gct gag gac act gcc gtg tat tac tgt
gcg aga ga ! 74.1# 51

- 77 -

Table 2: Enzymes that either cut 15 or more human GLGs or have 5+-base recognition in FR3

Typical entry:

Rename Recognition #sites
 GLGid#:base# GLGid#:base# GLGid#:base#.....

5

BstEII Ggtacc 2
 1: 3 48: 3
 There are 2 hits at base# 3

10

MaeIII gtnac 36
 1: 4 2: 4 3: 4 4: 4 5: 4 6: 4
 7: 4 8: 4 9: 4 10: 4 11: 4 37: 4
 37: 58 38: 4 38: 58 39: 4 39: 58 40: 4
 40: 58 41: 4 41: 58 42: 4 42: 58 43: 4
 43: 58 44: 4 44: 58 45: 4 45: 58 46: 4
 46: 58 47: 4 47: 58 48: 4 49: 4 50: 58
 There are 24 hits at base# 4

25

Tsp45I gtsac 33
 1: 4 2: 4 3: 4 4: 4 5: 4 6: 4
 7: 4 8: 4 9: 4 10: 4 11: 4 37: 4
 37: 58 38: 4 38: 58 39: 58 40: 4 40: 58
 41: 58 42: 58 43: 4 43: 58 44: 4 44: 58
 45: 4 45: 58 46: 4 46: 58 47: 4 47: 58
 48: 4 49: 4 50: 58
 There are 21 hits at base# 4

30

HphI tcacc 45
 1: 5 2: 5 3: 5 4: 5 5: 5 6: 5
 7: 5 8: 5 11: 5 12: 5 12: 11 13: 5
 14: 5 15: 5 16: 5 17: 5 18: 5 19: 5
 20: 5 21: 5 22: 5 23: 5 24: 5 25: 5
 26: 5 27: 5 28: 5 29: 5 30: 5 31: 5
 32: 5 33: 5 34: 5 35: 5 36: 5 37: 5
 38: 5 40: 5 43: 5 44: 5 45: 5 46: 5
 47: 5 48: 5 49: 5
 There are 44 hits at base# 5

- 78 -

NlaIII CATG

26

1: 9 1: 42 2: 42 3: 9 3: 42 4: 9
 4: 42 5: 9 5: 42 6: 42 6: 78 7: 9
 7: 42 8: 21 8: 42 9: 42 10: 42 11: 42
 5 12: 57 13: 48 13: 57 14: 57 31: 72 38: 9
 48: 78 49: 78

There are 11 hits at base# 42

There are 1 hits at base# 48 Could cause raggedness.

10 BsaJI Ccnngg

37

1: 14 2: 14 5: 14 6: 14 7: 14 8: 14
 8: 65 9: 14 10: 14 11: 14 12: 14 13: 14
 14: 14 15: 65 17: 14 17: 65 18: 65 19: 65
 20: 65 21: 65 22: 65 26: 65 29: 65 30: 65
 15 33: 65 34: 65 35: 65 37: 65 38: 65 39: 65
 40: 65 42: 65 43: 65 48: 65 49: 65 50: 65
 51: 14

There are 23 hits at base# 65

There are 14 hits at base# 14

20

AluI AGct

42

1: 47 2: 47 3: 47 4: 47 5: 47 6: 47
 7: 47 8: 47 9: 47 10: 47 11: 47 16: 63
 23: 63 24: 63 25: 63 31: 63 32: 63 36: 63
 25 37: 47 37: 52 38: 47 38: 52 39: 47 39: 52
40: 47 40: 52 41: 47 41: 52 42: 47 42: 52
43: 47 43: 52 44: 47 44: 52 45: 47 45: 52
46: 47 46: 52 47: 47 47: 52 49: 15 50: 47

There are 23 hits at base# 47

30 There are 11 hits at base# 52 Only 5 bases from 47

BlpI GCtnagc

21

1: 48 2: 48 3: 48 5: 48 6: 48 7: 48
 8: 48 9: 48 10: 48 11: 48 37: 48 38: 48
 35 39: 48 40: 48 41: 48 42: 48 43: 48 44: 48
 45: 48 46: 48 47: 48

There are 21 hits at base# 48

- 79 -

MwoI GCNNNNNnngc 19
 1: 48 2: 28 19: 36 22: 36 23: 36 24: 36
 25: 36 26: 36 35: 36 37: 67 39: 67 40: 67
 41: 67 42: 67 43: 67 44: 67 45: 67 46: 67
 5 47: 67

There are 10 hits at base# 67

There are 7 hits at base# 36

DdeI Ctnag 71
 10 1: 49 1: 58 2: 49 2: 58 3: 49 3: 58
 3: 65 4: 49 4: 58 5: 49 5: 58 5: 65
 6: 49 6: 58 6: 65 7: 49 7: 58 7: 65
 8: 49 8: 58 9: 49 9: 58 9: 65 10: 49
10: 58 10: 65 11: 49 11: 58 11: 65 15: 58
 15 16: 58 16: 65 17: 58 18: 58 20: 58 21: 58
 22: 58 23: 58 23: 65 24: 58 24: 65 25: 58
25: 65 26: 58 27: 58 27: 65 28: 58 30: 58
31: 58 31: 65 32: 58 32: 65 35: 58 36: 58
36: 65 37: 49 38: 49 39: 26 39: 49 40: 49
 20 41: 49 42: 26 42: 49 43: 49 44: 49 45: 49
 46: 49 47: 49 48: 12 49: 12 51: 65

There are 29 hits at base# 58

There are 22 hits at base# 49 Only nine base from 58

There are 16 hits at base# 65 Only seven bases from 58

25

BglIII Agatct 11
 1: 61 2: 61 3: 61 4: 61 5: 61 6: 61
 7: 61 9: 61 10: 61 11: 61 51: 47
 There are 10 hits at base# 61

30

BstYI Rgatcy 12
 1: 61 2: 61 3: 61 4: 61 5: 61 6: 61
 7: 61 8: 61 9: 61 10: 61 11: 61 51: 47
 There are 11 hits at base# 61

35

- 80 -

Hpy188I TCNGa

17

1: 64 2: 64 3: 64 4: 64 5: 64 6: 64
 7: 64 8: 64 9: 64 10: 64 11: 64 16: 57
 20: 57 27: 57 35: 57 48: 67 49: 67

- 5 There are 11 hits at base# 64
 There are 4 hits at base# 57
 There are 2 hits at base# 67 Could be ragged.

MslI CAYNNnnRTG

44

10 1: 72 2: 72 3: 72 4: 72 5: 72 6: 72
 7: 72 8: 72 9: 72 10: 72 11: 72 15: 72
 17: 72 18: 72 19: 72 21: 72 23: 72 24: 72
 25: 72 26: 72 28: 72 29: 72 30: 72 31: 72
 32: 72 33: 72 34: 72 35: 72 36: 72 37: 72
 15 38: 72 39: 72 40: 72 41: 72 42: 72 43: 72
 44: 72 45: 72 46: 72 47: 72 48: 72 49: 72
 50: 72 51: 72

There are 44 hits at base# 72

20 BsiEI CGRYcg

23

1: 74 3: 74 4: 74 5: 74 7: 74 8: 74
 9: 74 10: 74 11: 74 17: 74 22: 74 30: 74
 33: 74 34: 74 37: 74 38: 74 39: 74 40: 74
 41: 74 42: 74 45: 74 46: 74 47: 74

- 25 There are 23 hits at base# 74

EaeI Yggccr

23

30 1: 74 3: 74 4: 74 5: 74 7: 74 8: 74
 9: 74 10: 74 11: 74 17: 74 22: 74 30: 74
 33: 74 34: 74 37: 74 38: 74 39: 74 40: 74
 41: 74 42: 74 45: 74 46: 74 47: 74

There are 23 hits at base# 74

EagI Cggccg

23

35 1: 74 3: 74 4: 74 5: 74 7: 74 8: 74
 9: 74 10: 74 11: 74 17: 74 22: 74 30: 74
 33: 74 34: 74 37: 74 38: 74 39: 74 40: 74
 41: 74 42: 74 45: 74 46: 74 47: 74

There are 23 hits at base# 74

- 81 -

HaeIII GGcc

27

1: 75 3: 75 4: 75 5: 75 7: 75 8: 75
 9: 75 10: 75 11: 75 16: 75 17: 75 20: 75
 5 22: 75 30: 75 33: 75 34: 75 37: 75 38: 75
 39: 75 40: 75 41: 75 42: 75 45: 75 46: 75
 47: 75 48: 63 49: 63

There are 25 hits at base# 75

10 Bst4CI ACNgt 65°C 63 Sites There is a third isoschismer

1: 86 2: 86 3: 86 4: 86 5: 86 6: 86
 7: 34 7: 86 8: 86 9: 86 10: 86 11: 86
 12: 86 13: 86 14: 86 15: 36 15: 86 16: 53
 16: 86 17: 36 17: 86 18: 86 19: 86 20: 53
 15 20: 86 21: 36 21: 86 22: 0 22: 86 23: 86
 24: 86 25: 86 26: 86 27: 53 27: 86 28: 36
 28: 86 29: 86 30: 86 31: 86 32: 86 33: 36
 33: 86 34: 86 35: 53 35: 86 36: 86 37: 86
 38: 86 39: 86 40: 86 41: 86 42: 86 43: 86
 20 44: 86 45: 86 46: 86 47: 86 48: 86 49: 86
 50: 86 51: 0 51: 86

There are 51 hits at base# 86 All the other sites are well away

HpyCH4III ACNgt

63

25 1: 86 2: 86 3: 86 4: 86 5: 86 6: 86
 7: 34 7: 86 8: 86 9: 86 10: 86 11: 86
 12: 86 13: 86 14: 86 15: 36 15: 86 16: 53
 16: 86 17: 36 17: 86 18: 86 19: 86 20: 53
 20: 86 21: 36 21: 86 22: 0 22: 86 23: 86
 30 24: 86 25: 86 26: 86 27: 53 27: 86 28: 36
 28: 86 29: 86 30: 86 31: 86 32: 86 33: 36
 33: 86 34: 86 35: 53 35: 86 36: 86 37: 86
 38: 86 39: 86 40: 86 41: 86 42: 86 43: 86
 44: 86 45: 86 46: 86 47: 86 48: 86 49: 86
 35 50: 86 51: 0 51: 86

There are 51 hits at base# 86

- 82 -

HinfI Gantc 43

2: 2 3: 2 4: 2 5: 2 6: 2 7: 2
8: 2 9: 2 9: 22 10: 2 11: 2 15: 2
16: 2 17: 2 18: 2 19: 2 19: 22 20: 2
5 21: 2 23: 2 24: 2 25: 2 26: 2 27: 2
28: 2 29: 2 30: 2 31: 2 32: 2 33: 2
33: 22 34: 22 35: 2 36: 2 37: 2 38: 2
40: 2 43: 2 44: 2 45: 2 46: 2 47: 2
50: 60

10 There are 38 hits at base# 2

MlyI GAGTCNNNNNn 18

2: 2 3: 2 4: 2 5: 2 6: 2 7: 2
8: 2 9: 2 10: 2 11: 2 37: 2 38: 2
15 40: 2 43: 2 44: 2 45: 2 46: 2 47: 2

There are 18 hits at base# 2

PleI gagtc 18

2: 2 3: 2 4: 2 5: 2 6: 2 7: 2
20 8: 2 9: 2 10: 2 11: 2 37: 2 38: 2
40: 2 43: 2 44: 2 45: 2 46: 2 47: 2

There are 18 hits at base# 2

AciI Ccgc 24

2: 26 9: 14 10: 14 11: 14 27: 74 37: 62
25 37: 65 38: 62 39: 65 40: 62 40: 65 41: 65
42: 65 43: 62 43: 65 44: 62 44: 65 45: 62
46: 62 47: 62 47: 65 48: 35 48: 74 49: 74

There are 8 hits at base# 62
There are 8 hits at base# 65

30 There are 3 hits at base# 14
There are 3 hits at base# 74
There are 1 hits at base# 26
There are 1 hits at base# 35

-"- Gcgg 11

35 8: 91 9: 16 10: 16 11: 16 37: 67 39: 67
40: 67 42: 67 43: 67 45: 67 46: 67

There are 7 hits at base# 67
There are 3 hits at base# 16
There are 1 hits at base# 91

- 83 -

BsiHKAI GWGCWc 20
 2: 30 4: 30 6: 30 7: 30 9: 30 10: 30
 12: 89 13: 89 14: 89 37: 51 38: 51 39: 51
 5 40: 51 41: 51 42: 51 43: 51 44: 51 45: 51
 46: 51 47: 51
 There are 11 hits at base# 51

Bsp1286I GDGCHc 20
 10 2: 30 4: 30 6: 30 7: 30 9: 30 10: 30
 12: 89 13: 89 14: 89 37: 51 38: 51 39: 51
 40: 51 41: 51 42: 51 43: 51 44: 51 45: 51
 46: 51 47: 51
 There are 11 hits at base# 51

15 HgiAI GWGCWc 20
 2: 30 4: 30 6: 30 7: 30 9: 30 10: 30
 12: 89 13: 89 14: 89 37: 51 38: 51 39: 51
 40: 51 41: 51 42: 51 43: 51 44: 51 45: 51
 20 46: 51 47: 51
 There are 11 hits at base# 51

BsoFI GCngc 26
 2: 53 3: 53 5: 53 6: 53 7: 53 8: 53
 25 8: 91 9: 53 10: 53 11: 53 31: 53 36: 36
 37: 64 39: 64 40: 64 41: 64 42: 64 43: 64
 44: 64 45: 64 46: 64 47: 64 48: 53 49: 53
 50: 45 51: 53
 There are 13 hits at base# 53
 30 There are 10 hits at base# 64

TseI Gcwgc 17
 2: 53 3: 53 5: 53 6: 53 7: 53 8: 53
 9: 53 10: 53 11: 53 31: 53 36: 36 45: 64
 46: 64 48: 53 49: 53 50: 45 51: 53
 35 There are 13 hits at base# 53

- 84 -

MnlI gagg

34

3: 67 3: 95 4: 51 5: 16 5: 67 6: 67
 7: 67 8: 67 9: 67 10: 67 11: 67 15: 67
 16: 67 17: 67 19: 67 20: 67 21: 67 22: 67
 5 23: 67 24: 67 25: 67 26: 67 27: 67 28: 67
 29: 67 30: 67 31: 67 32: 67 33: 67 34: 67
 35: 67 36: 67 50: 67 51: 67

There are 31 hits at base# 67

10 HpyCH4V TGca

34

5: 90 6: 90 11: 90 12: 90 13: 90 14: 90
 15: 44 16: 44 16: 90 17: 44 18: 90 19: 44
 20: 44 21: 44 22: 44 23: 44 24: 44 25: 44
 26: 44 27: 44 27: 90 28: 44 29: 44 33: 44
 15 34: 44 35: 44 35: 90 36: 38 48: 44 49: 44
 50: 44 50: 90 51: 44 51: 52

There are 21 hits at base# 44

There are 1 hits at base# 52

20 AccI GTmkac

13 5-base recognition

7: 37 11: 24 37: 16 38: 16 39: 16 40: 16
 41: 16 42: 16 43: 16 44: 16 45: 16 46: 16
 47: 16

There are 11 hits at base# 16

25

SacII CCGCgg

8 6-base recognition

9: 14 10: 14 11: 14 37: 65 39: 65 40: 65
 42: 65 43: 65

There are 5 hits at base# 65

30 There are 3 hits at base# 14

TfiI Gawtc

24

9: 22 15: 2 16: 2 17: 2 18: 2 19: 2
 19: 22 20: 2 21: 2 23: 2 24: 2 25: 2
 35 26: 2 27: 2 28: 2 29: 2 30: 2 31: 2
 32: 2 33: 2 33: 22 34: 22 35: 2 36: 2

There are 20 hits at base# 2

- 85 -

BsmAI Nnnnnngagac 19
15: 11 16: 11 20: 11 21: 11 22: 11 23: 11
24: 11 25: 11 26: 11 27: 11 28: 11 28: 56
30: 11 31: 11 32: 11 35: 11 36: 11 44: 87
5 48: 87

There are 16 hits at base# 11

BpmI ctccag 19
15: 12 16: 12 17: 12 18: 12 20: 12 21: 12
10 22: 12 23: 12 24: 12 25: 12 26: 12 27: 12
28: 12 30: 12 31: 12 32: 12 34: 12 35: 12
36: 12

There are 19 hits at base# 12

15 XmnI GAANNnnttc 12
37: 30 38: 30 39: 30 40: 30 41: 30 42: 30
43: 30 44: 30 45: 30 46: 30 47: 30 50: 30
There are 12 hits at base# 30

20 BsrI NCcagt 12
37: 32 38: 32 39: 32 40: 32 41: 32 42: 32
43: 32 44: 32 45: 32 46: 32 47: 32 50: 32
There are 12 hits at base# 32

25 BanII GRGCYc 11
37: 51 38: 51 39: 51 40: 51 41: 51 42: 51
43: 51 44: 51 45: 51 46: 51 47: 51
There are 11 hits at base# 51

30 Ecl136I GAGctc 11
37: 51 38: 51 39: 51 40: 51 41: 51 42: 51
43: 51 44: 51 45: 51 46: 51 47: 51
There are 11 hits at base# 51

35 SacI GAGCTc 11
37: 51 38: 51 39: 51 40: 51 41: 51 42: 51
43: 51 44: 51 45: 51 46: 51 47: 51
There are 11 hits at base# 51

- 86 -

Table 3: Synthetic 3-23 FR3 of human heavy chains showing positions of possible cleavage sites

```

! Sites engineered into the synthetic gene are shown in upper case
DNA
! with the RE name between vertical bars (as in | XbaI |).
5 ! RERSs frequently found in GLGs are shown below the synthetic
sequence
! with the name to the right (as in gtn ac=MaeIII(24), indicating
that
! 24 of the 51 GLGs contain the site).
10 !
!
! |---FR3---
! 89 90 (codon #
in
! R F
15 synthetic 3-23)

! Allowed DNA |cgc|ttc| 6
! |cgn|tty|
! |agr|
! ga ntc =
20 HinfI(38)
! ga gtc =
PleI(18)
! ga wtc =
TfiI(20)
25 ! gtn ac =
MaeIII(24)
! gts ac =
Tsp45I(21)
! tc acc =
30 HphI(44)
!
! -----FR3-----
! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
! T I S R D N S K N T L Y L Q M
35 |act|atc|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg| 51
!allowed|acn|ath|tcn|cgn|gay|aay|tcn|aar|aay|acn|ttr|tay|ttr|car|atg|
! |agy|agr| |agy| |ctn| |ctn|
! | ga|gac = BsmAI(16) ag ct =
AluI(23)
40 ! c|tcc ag = BpmI(19) g ctn agc =
BlpI(21)

```

- 87 -

```

!           |           |           g aan nnn ttc = XmnI(12)
!           | XbaI  |           tg ca = HpyCH4V(21)
!
!   ---FR3----->|
5  !   106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
!       N   S   L   R   A   E   D   T   A   V   Y   Y   C   A   K
!       |aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgc|gct|aaa| 96
!allowed|aay|tcn|ttr|cgn|gcn|gar|gay|acn|gcn|gtn|tay|tay|tgy|gcn|aar|
!       |agy|ctn|agr|           |           |
10 !           |           | cc nng g = BsaJI(23)           ac ngt = Bst4CI(51)
!           |           | aga tct = BglII(10)           |           ac ngt = HpyCH4III(51)
!           |           | Rga tcY = BstYI(11)           |           ac ngt = TaaI(51)
!           |           |           c ayn nnn rtc = MslI(44)
!           |           |           cg ryc g = BsiEI(23)
15 !           |           |           yg gcc r = EaeI(23)
!           |           |           cg gcc g = EagI(23)
!           |           |           |g gcc = HaeIII(25)
!           |           |           gag g = MnlI(31)|
!           |AflII |           | PstI |

```

- 88 -

Table 4: REaptors, Extenders, and Bridges used for Cleavage and Capture of Human Heavy Chains in FR3.

A: HpyCH4V Probes of actual human HC genes

!HpyCH4V in FR3 of human HC, bases 35-56; only those with TGca site

5	TGca;10,		
	RE recognition:tgca	of length 4 is expected at	
10	10		
	1	6-1	agttctccctgcagctgaactc
	2	3-11,3-07,3-21,3-72,3-48	cactgtatctgcaaatgaacag
10	3	3-09,3-43,3-20	ccctgtatctgcaaatgaacag
	4	5-51	ccgcctacctgcagtggagcag
	5	3-15,3-30,3-30.5,3-30.3,3-74,3-23,3-33	cgctgtatctgcaaatgaacag
	6	7-4.1	cgcatatctgcagatctgcag
	7	3-73	cgcggtatctgcaaatgaacag
15	8	5-a	ctgcctacctgcagtggagcag
	9	3-49	tcgcctatctgcaaatgaacag

B: HpyCH4V REaptors, Extenders, and Bridges

B.1 REaptors

! Cutting HC lower strand:

20 ! TmKeller for 100 mM NaCl, zero formamide

! Edapters for cleavage

		T_m^W	T_m^K
(ON_HCFR36-1)	5'-agttctcccTGCAgctgaactc-3'	68.0	64.5
(ON_HCFR36-1A)	5'-ttctcccTGCAgctgaactc-3'	62.0	62.5
(ON_HCFR36-1B)	5'-ttctcccTGCAgctgaac-3'	56.0	59.9
25 (ON_HCFR33-15)	5'-cgctgtatcTGCAaatgaacag-3'	64.0	60.8
(ON_HCFR33-15A)	5'-ctgtatcTGCAaatgaacag-3'	56.0	56.3
(ON_HCFR33-15B)	5'-ctgtatcTGCAaatgaac-3'	50.0	53.1
(ON_HCFR33-11)	5'-cactgtatcTGCAaatgaacag-3'	62.0	58.9
(ON_HCFR35-51)	5'-ccgcctaccTGCAgtggagcag-3'	74.0	70.1
30 !			

B.2 Segment of synthetic 3-23 gene into which captured CDR3 is to be cloned

! XbaI...

!D323* cgCttcacTaag tcT aga gac aaC tcT aag aaT acT ctC taC

35 ! scab..... designed gene 3-23 gene.....
!

- 89 -

```

! HpyCH4V
! .. .. AflIII...
! Ttg caG atg aac agc TtA agG . . .
! .....
5 !
    B.3 Extender and Bridges
! Extender (bottom strand):
!
(ON_HCHpyEx01) 5'-cAAgTAgAgAgTATtCtTAgAgTTgTcTcTAgAcTTAgTgAAgcg-3'
10 ! ON_HCHpyEx01 is the reverse complement of
! 5'-cgCttcacTaag tcT aga gac aaC tcT aag aaT acT ctC taC Ttg -3'
!
! Bridges (top strand, 9-base overlap):
!
15 (ON_HCHpyBr016-1) 5'-cgCttcacTaag tcT aga gac aaC tcT aag-
aaT acT ctC taC Ttg CAgctgaac-3' {3'-term C is
blocked}
!
! 3-15 et al. + 3-11
20 (ON_HCHpyBr023-15) 5'-cgCttcacTaag tcT aga gac aaC tcT aag-
aaT acT ctC taC Ttg CAaatgaac-3' {3'-term C is
blocked}
!
! 5-51
25 (ON_HCHpyBr045-51) 5'-cgCttcacTaag tcT aga gac aaC tcT aag-
aaT acT ctC taC Ttg CAgtgaggac-3' {3'-term C is
blocked}
!
! PCR primer (top strand)
30 !
(ON_HCHpyPCR) 5'-cgCttcacTaag tcT aga gac-3'
!


---


C: B1pI Probes from human HC GLGs
1 1-58,1-03,1-08,1-69,1-24,1-45,1-46,1-f,1-e
35 acatggaGCTGAGCagcctgag
2 1-02
acatqqaGCTGAGCaqgctgag

```

- 90 -

3 1-18
 acatggagctgaggagcctgag
 4 5-51, 5-a
 acctgcagtggagcagcctgaa
 5 5 3-15, 3-73, 3-49, 3-72
 atctgcaaataaacagcctgaa
 6 3303, 3-33, 3-07, 3-11, 3-30, 3-21, 3-23, 3305, 3-48
 atctgcaaataaacagcctgag
 7 3-20, 3-74, 3-09, 3-43
 10 atctgcaaataaacagcctgag
 8 74.1
 atctgcagatctgcagcctaaa
 9 3-66, 3-13, 3-53, 3-d
 atcttcaaataaacagcctgag
 15 10 3-64
 atcttcaaataagggcagcctgag
 11 4301, 4-28, 4302, 4-04, 4304, 4-31, 4-34, 4-39, 4-59, 4-61, 4-b
 ccctgaaGCTGAGCtctgtgac
 12 6-1
 20 ccctgcagctgaactctgtgac
 13 2-70, 2-05
 tccttacaatgaccaacatgga
 14 2-26
 tccttaccatgaccaacatgga

25 **D: B1pI REaptors, Extenders, and Bridges**

D.1 REaptors

		T_m^W	T_m^K
(B1pF3HC1-58)	5'-ac atg gaG CTG AGC agc ctg ag-3'	70	66.
			4
30 (B1pF3HC6-1)	5'-cc ctg aag ctg agc tct gtg ac-3'	70	66.
			4

! B1pF3HC6-1 matches 4-30.1, not 6-1.

D.2 Segment of synthetic 3-23 gene into which captured CDR3 is to be cloned

35 !
 B1pI
 ! XbaI...

- 91 -

!D323* cgCttcacTaag TCT AGA gac aaC tcT aag aaT acT ctC taC Ttg
caG atg aac

!

!

AflII...

5 !

agC TTA AGG

D.3 Extender and Bridges

! Bridges

(BlpF3Br1) 5'-cgCttcacTcag tcT aga gaT aaC AGT aaA aaT acT TtG-
taC Ttg caG Ctg a|GC agc ctg-3'

10 (BlpF3Br2) 5'-cgCttcacTcag tcT aga gaT aaC AGT aaA aaT acT TtG-
taC Ttg caG Ctg a|gc tct gtg-3'

!

| lower strand is cut here

! Extender

(BlpF3Ext) 5'-TcAgcTgcAAgTAcAAgTATTTTAcTgTTATcTcTAaAcTgAgTgAAgcg-

15 3'

! BlpF3Ext is the reverse complement of:

! 5'-cgCttcacTcag tcT aga gaT aaC AGT aaA aaT acT TtG taC Ttg caG
Ctg a-3'

!

20 (BlpF3PCR) 5'-cgCttcacTcag tcT aga gaT aaC-3'

E: **HpyCH4III** Distinct GLG sequences surrounding site, bases 77-98

	1	102#1,118#4,146#7,169#9,1e#10,311#17,353#30,404#37,4301
		ccgtgtattactgtgcgagaga
	2	103#2,307#15,321#21,3303#24,333#26,348#28,364#31,366#32
25		ctgtgtattactgtgcgagaga
	3	108#3
		ccgtgtattactgtgcgagagg
	4	124#5,1f#11
		ccgtgtattactgtgcaacaga
30	5	145#6
		ccatgtattactgtgcaagata
	6	158#8
		ccgtgtattactgtgcggcaga
	7	205#12
35		ccacatattactgtgcacacag
	8	226#13
		ccacatattactgtgcacggat

- 92 -

	9	270#14
	ccacgtattactgtgcacggat	
	10	309#16, 343#27
	ccttgtattactgtgcaaaaga	
5	11	313#18, 374#35, 61#50
	ctgtgtattactgtgcaagaga	
	12	315#19
	ccgtgtattactgtaccacaga	
	13	320#20
10	ccttgtatcactgtgcgagaga	
	14	323#22
	ccgtatattactgtgcaaaga	
	15	330#23, 3305#25
	ctgtgtattactgtgcaaaga	
15	16	349#29
	ccgtgtattactgtactagaga	
	17	372#33
	ccgtgtattactgtgctagaga	
	18	373#34
20	ccgtgtattactgtactagaca	
	19	3d#36
	ctgtgtattactgtaagaaaga	
	20	428#38
	ccgtgtattactgtgcgagaaa	
25	21	4302#40, 4304#41
	ccgtgtattactgtgccagaga	
	22	439#44
	ctgtgtattactgtgcgagaca	
	23	551#48
30	ccatgtattactgtgcgagaca	
	24	5a#49
	ccatgtattactgtgcgaga	

F: HpyCH4III REaptors, Extenders, and Bridges
F.1 REaptors

35	! ONs for cleavage of HC(lower) in FR3(bases 77-97)		
	! For cleavage with HpyCH4III, Bst4CI, or TaaI		
	! cleavage is in lower chain before base 88.		
	!	77 788 888 888 889 999 999 9	
	!	78 901 234 567 890 123 456 7	T _m "
40	T _m ^K		
	(H43.77.97.1-02#1)	5'-cc gtg tat tAC TGT gcg aga g-3'	6462.6
	(H43.77.97.1-03#2)	5'-c cc gtg tat tAC TGT gcg aga g-3'	6260.6
	(H43.77.97.108#3)	5'-cc gtg tat tAC TGT gcg aga g-3'	6462.6
	(H43.77.97.323#22)	5'-cc g t at tat tac tgt gcg a aa a g-3'	6058.7
45	(H43.77.97.330#23)	5'-c cc gtg tat tac tgt gcg a aa a g-3'	6058.7

- 93 -

(H43.77.97.439#44) 5'-c~~g~~gtg tat tac tgt gcg aga ~~g~~-3' 6260.6
 (H43.77.97.551#48) 5'-cc~~g~~gtg tat tac tgt gcg aga ~~g~~-3' 6260.6
 (H43.77.97.5a#49) 5'-cc~~g~~gtg tat tAC TGT gcg aga ~~g~~-3' 5858.3

F.2 Extender and Bridges

- 5 ! XbaI and AflIII sites in bridges are bunged
 (H43.XABr1) 5'-gggtgtagtga-
 |TCT|AGt|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-
 |aac|agC|TTt|AGg|qct|qag|qac|aCT|GCA|Gtc|tac|tat tgt gcg aga-3'
 (H43.XABr2) 5'-gggtgtagtga-
 10 ! |TCT|AGt|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-
 |aac|agC|TTt|AGg|qct|qag|qac|aCT|GCA|Gtc|tac|tat tgt gcg aaa-3'
 (H43.XAExt) 5'-ATAgTAGAcT gcAgTgTccT cAgcccTTAA gCTgTTcATc
 TgcAAGTAGA-
 gAgTATTcTT AgAgTTgTcT cTAgATcAcT AcAcc-3'
 15 !H43.XAExt is the reverse complement of
 ! 5'-gggtgtagtga-
 ! |TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-
 ! |aac|agC|TTA|AGg|qct|qag|qac|aCT|GCA|Gtc|tac|tat -3'

 (H43.XAPCR) 5'-gggtgtagtga |TCT|AGA|gac|aac-3'
 20 ! XbaI and AflIII sites in bridges are bunged
 (H43.ABr1) 5'-gggtgtagtga-
 |aac|agC|TTt|AGg|qct|qag|qac|aCT|GCA|Gtc|tac|tat tgt gcg aga-3'
 (H43.ABr2) 5'-gggtgtagtga-
 |aac|agC|TTt|AGg|qct|qag|qac|aCT|GCA|Gtc|tac|tat tgt gcg aaa-3'
 25 (H43.AExt) 5'-ATAgTAGAcTgcAgTgTccTcAgcccTTAAgcTgTTTcAcTAcAcc-3'
 !(H43.AExt) is the reverse complement of 5'-gggtgtagtga-
 ! |aac|agC|TTA|AGg|qct|qag|qac|aCT|GCA|Gtc|tac|tat -3'
 (H43.APCR) 5'-gggtgtagtga |aac|agC|TTA|AGg|qct|q-3'

Table 5: Analysis of frequency of matching REaptors in actual V genes

A: HpyCH4V in HC at bases 35-56

94

Number of mismatches..... Number																
Id	Ntot	0	1	2	3	4	5	6	7	8	9	10	Cut	Id	Probe	
5	1	510	5	11	274	92	61	25	22	11	1	3	5	443	6-1	agttctcccTGCAGctgaactc
	2	192	54	42	32	24	15	2	3	10	3	1	6	167	3-11	cactgtatcTGCaaatgaacag
	3	58	19	7	17	6	5	1	0	1	0	2	0	54	3-09	ccctgtatcTGCaaatgaacag
	4	267	42	33	9	8	8	82	43	22	8	11	1	100	5-51	cgcctaccTGCAGtggagcag
	5	250	111	59	41	24	7	5	1	0	0	2	0	242	3-15	cgtgtatcTGCaaatgaacag
10	6	7	0	2	0	1	0	0	0	0	0	4	0	3	7-4.1	cggcatatcTGCAGatctgcag
	7	7	0	2	2	0	0	2	1	0	0	0	0	4	3-73	cggcgtatcTGCaaatgaacag
	8	26	10	4	1	3	1	2	1	3	1	0	0	19	5-a	ctgcctaccTGCAGtggagcag
	9	21	8	2	3	1	6	1	0	0	0	0	0	20	3-49	tcgcctatcTGCaaatgaacag
	1338	249	162	379	149	103	120	71	47	13	23	12	1052			
15	249	411	790	939	1162	1280	1316									
	1042	1233	1293	1338												

<u>Id</u>	<u>Probe</u>	<u>dotted probe</u>
6-1	agttctcccTGCAGctgaactc	agttctcccTGCAGctgaactc
3-11	cactgtatcTGCaaatgaacag	cac.g.at.....aa.....ag
3-09	ccctgtatcTGCaaatgaacag	ccc.g.at.....aa.....ag

5-51 cgcctaccTGCAgtggagcag ccgc..a.....tg..g.ag
3-15 cgctgtatTGCaatgaacag c.c.g.at.....aa.....ag
7-4.1 cggcatatcTGCAgatctgcag c.gca.at.....a.ctg.ag
3-73 cggcgtatcTGCAaatgaacag c.gcg.at.....aa.....ag
5 ctgcctaccTGCAgtggagcag ctgc..a.....tg..g.ag
3-49 tcgcctatcTGCAaatgaacag tcgc..at.....aa.....ag

Seqs with the expected RE site only.....1004
(Counts only cases with 4 or fewer mismatches)
Seqs with only an unexpected site..... 0
10 Seqs with both expected and unexpected..... 48
(Counts only cases with 4 or fewer mismatches)
Seqs with no sites..... 0

B: Bipl in HC

Id		Ntot	0	1	2	3	4	5	6	7	8	Ncut	Name
15	1	133	73	16	11	13	6	9	1	4	0	119	1-58 acatggaGCTGAGCagcctgag
	2	14	11	1	0	0	0	0	1	0	1	12	1-02 acatggagctgagcaggctgag
	3	34	17	8	2	6	1	0	0	0	0	0	1-18 acatggagctgaggagcctgag
	4	120	50	32	16	10	9	1	1	1	0	2	5-51 acctgcagtggagcagcctgaa
	5	55	13	11	10	17	3	1	0	0	0	0	3-15 atctgcaaatgaacagcctgaa

6	340	186	88	41	15	6	3	0	1	0	0	3303	atctgcaaatgaacagcctgag
7	82	25	16	25	12	1	3	0	0	0	0	3-20	atctgcaaatgaacagtctgag
8	3	0	2	0	1	0	0	0	0	0	0	74.1	atctgcagatctgcagcctaaa
9	23	18	2	2	1	0	0	0	0	0	0	3-66	atcttcaaatgaacagcctgag
10	2	1	0	1	0	0	0	0	0	0	0	3-64	atcttcaaatgggcagcctgag
11	486	249	78	81	38	21	10	4	4	1	467	4301	ccctgaagctgagctctgtgac
12	16	6	3	1	0	1	1	3	1	0	1	6-1	ccctgcagctgaactctgtgac
13	28	15	8	2	2	1	0	0	0	0	0	2-70	tccttacaatgaccaacatgga
14	2	0	2	0	0	0	0	0	0	0	0	2-26	tccttaccatgaccaacatgga
5													
10													

Name	Full sequence	Dot mode
1-58	acatggaGCTGAGCagcctgag	acatggaGCTGAGCagcctgag
1-02	acatggagctgagcaggctgagg.....
1-18	acatggagctgaggagcctgagg.....
5-51	acctgcagtgagcagcctgaa	..C..C..tg.....a
3-15	atctgcaaatgaacagcctgaa	.tc..C..aa...a.....a
3-30.3	atctgcaaatgaacagcctgag	.tc..C..aa...a.....
3-20	atctgcaaatgaacagctctgag	.tc..C..aa...a...t.....
7-4.1	atctgcagatctgcagcctaaa	.tc..C..a.ct.....a.a
3-66	atcttcaaatgaacagcctgag	.tc.tc..aa...a.....
3-64	atcttcaaatgggcagcctgag	.tc.tc..aa..g.....
4-30.1	ccctgaagctgagctctgtgac	c.C..a.....tctg...c
6-1	ccctgcagctgaactctgtgac	c.C..C.....a.tctg...c
2-70	tccttacaatgaccaacacatgga	t.C.tacaa...C..a.a..ga
15 2-26	tccttaccatgaccaacacatgga	t.C.tacca...C..a.a..ga

Seqs with the expected RE site only..... 597 (counting sequences with 4 or fewer mismatches)

Seqs with only an unexpected site..... 2

Seqs with both expected and unexpected.... 2

Seqs with no sites..... 686

C: HpyCH4III, Bst4CI, or TaaI in HC

In scoring whether the RE site of interest is present, only ONs that have 4 or fewer mismatches are counted.

Number of sequences..... 1617

Id	Ntot	0	1	2	3	4	5	6	7	8	Ncut	acngt	acngt
1	244	78	92	43	18	10	1	2	0	0	241	102#1,1	ccgtgtattactgtgcgagaga
2	457	69	150	115	66	34	11	8	3	1	434	103#2,3	ctgtgtattactgtgcgagaga
3	173	52	45	36	22	14	3	0	0	1	169	108#3	ccgtgtattactgtgcgagagg
4	16	0	3	2	2	1	6	0	1	1	8	124#5,1	ccgtgtattactgtgcacacaga
5	4	0	0	1	0	1	1	0	1	0	2	145#6	ccatgtattactgtgcaagata
6	15	1	0	1	0	6	4	1	1	1	8	158#8	ccgtgtattactgtgcggcaga
7	23	4	8	5	2	2	1	1	0	0	21	205#12	ccacatattactgtgcacacag
8	9	1	1	1	0	3	2	1	0	0	6	226#13	ccacatattactgtgcacggat
9	7	1	3	1	1	0	0	1	0	0	6	270#14	ccacgtattactgtgcacggat
10	23	7	3	5	5	2	1	0	0	0	22	309#16,	ccttgtattactgtgcacaaaga
11	35	5	10	7	6	3	3	0	1	0	31	313#18,	ctgtgtattactgtgcaagaga
12	18	2	3	2	2	6	1	0	2	0	15	315#19	ccgtgtattactgtaccacaga
13	3	1	2	0	0	0	0	0	0	0	3	320#20	ccttgtattactgtgcgagaga
14	117	29	23	28	22	8	4	2	1	0	110	323#22	ccgtgtattactgtgcgaaga
15	75	21	25	13	9	1	4	2	0	0	69	330#23,	ctgtgtattactgtgcgaaga
16	14	2	2	2	3	0	3	1	1	0	9	349#29	ccgtgtattactgtactagaga
17	2	0	0	1	0	0	1	0	0	0	1	372#33	ccgtgtattactgtgctagaga
18	1	0	0	1	0	0	0	0	0	0	1	373#34	ccgtgtattactgtactagaca
19	2	0	0	0	0	0	0	0	0	2	0	3d#36	ctgtgtattactgtgaagaaga
20	34	4	9	9	4	5	3	0	0	0	31	428#38	ccgtgtattactgtgcgagaaa
21	17	5	4	2	2	3	1	0	0	0	16	430#40	ccgtgtattactgtgccaagaga
22	75	15	17	24	7	10	1	1	0	0	73	439#44	ctgtgtattactgtgcgagaca
23	40	14	15	4	5	1	0	1	0	0	39	551#48	ccatgtattactgtgcgagaca
24	213	26	56	60	42	20	7	2	0	0	204	5a#49	ccatgtattactgtgcgaagaAA

100

Group	337	471	363	218	130	58	23	11	6
Cumulative	337	808	1171	1389	1519	1577	1600	1611	1617
Seqs with the expected RE site only.....	1511								
Seqs with only an unexpected site.....	0								
Seqs with both expected and unexpected....	8								
Seqs with no sites.....	0								

5

[illegible]

```

    Seqs with the expected RE site only.....1463 / 1617
    Seqs with only an unexpected site.....      0
30  Seqs with both expected and unexpected....      7
    Seqs with no sites.....                      0

```

- 102 -

Table 6: Human HC GLG FR1 Sequences

VH Exon - Nucleotide sequence alignment

VH1		
5	1-02	CAG GTG CAG CTG GTG CAG TCT GGG GCT GAG GTG AAG AAG CCT GGG GCC TCA GTG AAG GTC TCC TGC AAG GCT TCT GGA TAC ACC TTC ACC
	1-03	cag gtC cag ctT gtg cag tct ggg gct gag gtg aag aag cct ggg gcc tca gtg aag gtT tcc tgc aag gct tct gga tac acc ttc acT
	1-08	cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg gcc tca gtg aag gtc tcc tgc aag gct tct gga tac acc ttc acc
10	1-18	cag gtT cag ctg gtg cag tct ggA gct gag gtg aag aag cct ggg gcc tca gtg aag gtc tcc tgc aag gct tct ggT tac acc ttT acc
	1-24	cag gtC cag ctg gtA cag tct ggg gct gag gtg aag aag cct ggg gcc tca gtg aag gtc tcc tgc aag gTt tcC gga. tac acc Ctc acT
	1-45	cag Atg cag ctg gtg cag tct ggg gct gag gtg aag aag Act ggg Tcc tca gtg aag gtT tcc tgc aag gct tcC gga tac acc ttc acc
15	1-46	cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg gcc tca gtg aag gtT tcc tgc aag gcA tct gga tac acc ttc acc
	1-58	caA Atg cag ctg gtg cag tct ggg Cct gag gtg aag aag cct ggg Acc tca gtg aag gtc tcc tgc aag gct tct gga tTc acc ttT acT
	1-69	cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg Tcc tcG gtg aag gtc tcc tgc aag gct tct gga GGc acc ttc aGc
20	1-e	cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg Tcc tcG gtg aag gtc tcc tgc aag gct tct gga GGc acc ttc aGc
	1-f	Gag gtC cag ctg gtA cag tct ggg gct gag gtg aag aag cct ggg gcT Aca gtg aaA Atc tcc tgc aag gTt tct gga tac acc ttc acc
	25	
VH2		
30	2-05	CAG ATC ACC TTG AAG GAG TCT GGT CCT ACG CTG GTG AAA CCC ACA CAG ACC CTC ACG CTG ACC TGC ACC TTC TCT GGG TTC TCA CTC AGC
	2-26	cag Gtc acc ttg aag gag tct ggt cct GTg ctg gtg aaa ccc aca Gag acc ctc acg ctg acc tgc acc Gtc tct ggg ttc tca ctc agc
	2-70	cag Gtc acc ttg aag gag tct ggt cct Gcg ctg gtg aaa ccc aca cag acc ctc acA ctg acc tgc acc ttc tct ggg ttc tca ctc agc
VH3		
35	3-07	GAG GTG CAG CTG GTG GAG TCT GGG GGA GGC TTG GTC CAG CCT GGG GGG TCC CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTT AGT
	3-09	gaA gtg cag ctg gtg gag tct ggg gga ggc ttg gtA cag cct ggC Agg tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ttt GAt
	3-11	Cag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc Aag cct ggA ggg tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ttC agt
40	3-13	gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtA cag cct ggg ggg tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ttC agt
	3-15	gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtA Aag cct ggg ggg tcc ctT aga ctc tcc tgt gca gcc tct gga ttc acT ttC agt

- 103 -

3-20 gag gtg cag ctg gtg gag tct ggg gga ggT Gtg gtA cGg cct ggg ggg tcc ctg aga ctc
 tcc tgt gca gcc tct gga ttc acc ttt GAt
 3-21 gag gtg cag ctg gtg gag tct ggg gga ggc Ctg gtc Aag cct ggg ggg tcc ctg aga ctc
 tcc tgt gca gcc tct gga ttc acc ttC agt
 5 3-23 gag gtg cag ctg Ttg gag tct ggg gga ggc ttg gtA cag cct ggg ggg tcc ctg aga ctc
 tcc tgt gca gcc tct gga ttc acc ttt agC
 3-30 Cag gtg cag ctg gtg gag tct ggg gga ggc Gtg gtc cag cct ggg Agg tcc ctg aga ctc
 tcc tgt gca gcc tct gga ttc acc ttC agt
 10 3-30.3 Cag gtg cag ctg gtg gag tct ggg gga ggc Gtg gtc cag cct ggg Agg tcc ctg aga ctc
 tcc tgt gca gcc tct gga ttc acc ttC agt
 3-30.5 Cag gtg cag ctg gtg gag tct ggg gga ggc Gtg gtc cag cct ggg Agg tcc ctg aga ctc
 tcc tgt gca gcc tct gga ttc acc ttC agt
 3-33 Cag gtg cag ctg gtg gag tct ggg gga ggc Gtg gtc cag cct ggg Agg tcc ctg aga ctc
 tcc tgt gca gcG tct gga ttc acc ttC agt
 15 3-43 gaA gtg cag ctg gtg gag tct ggg gga gTc Gtg gtA cag cct ggg ggg tcc ctg aga ctc
 tcc tgt gca gcc tct gga ttc acc ttt GAt
 3-48 gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtA cag cct ggg ggg tcc ctg aga ctc
 tcc tgt gca gcc tct gga ttc acc ttC agt
 3-49 gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtA cag ccA ggg Cgg tcc ctg aga ctc
 20 tcc tgt Aca gcT tct gga ttc acc ttt Ggt
 3-53 gag gtg cag ctg gtg gag Act ggA gga ggc ttg Atc cag cct ggg ggg tcc ctg aga ctc
 tcc tgt gca gcc tct ggG ttc acc GtC agt
 3-64 gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc cag cct ggg ggg tcc ctg aga ctc
 tcc tgt gca gcc tct gga ttc acc ttC agt
 25 3-66 gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc cag cct ggg ggg tcc ctg aga ctc
 tcc tgt gca gcc tct gga ttc acc GtC agt
 3-72 gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc cag cct ggA ggg tcc ctg aga ctc
 tcc tgt gca gcc tct gga ttc acc ttC agt
 3-73 gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc cag cct ggg ggg tcc ctg aAa ctc
 30 tcc tgt gca gcc tct ggG ttc acc ttC agt
 3-74 gag gtg cag ctg gtg gag tcC ggg gga ggc ttA gtT cag cct ggg ggg tcc ctg aga ctc
 tcc tgt gca gcc tct gga ttc acc ttC agt
 3-d gag gtg cag ctg gtg gag tct Cgg gga gTc ttg gtA cag cct ggg ggg tcc ctg aga ctc
 tcc tgt gca gcc tct gga ttc acc GtC agt
 35 VH4
 4-04 CAG GTG CAG CTG CAG GAG TCG GGC CCA GGA CTG GTG AAG CCT TCG GGG ACC CTG TCC CTC
 ACC TGC GCT GTC TCT GGT GGC TCC ATC AGC
 4-28 cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcg gAC acc ctg tcc ctc
 acc tgc gct gtc tct ggt TAC tcc atc agc
 40 4-30.1 cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcA CAg acc ctg tcc ctc
 acc tgc Act gtc tct ggt ggc tcc atc agc
 4-30.2 cag Ctg cag ctg cag gag tcC ggc Tca gga ctg gtg aag cct tcA CAg acc ctg tcc ctc
 acc tgc gct gtc tct ggt ggc tcc atc agc

- 104 -

4-30.4 cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcA CAg acc ctg tcc ctc
 acc tgc Act gtc tct ggt ggc tcc atc agc
 4-31 cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcA CAg acc ctg tcc ctc
 acc tgc Act gtc tct ggt ggc tcc atc agc
 5 4-34 cag gtg cag ctA cag Cag tGg ggc Gca gga ctg Ttg aag cct tcg gAg acc ctg tcc ctc
 acc tgc gct gtc tAt ggt ggG tcc Ttc agT
 4-39 cag CtG cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcg gAg acc ctg tcc ctc
 acc tgc Act gtc tct ggt ggc tcc atc agc
 4-59 cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcg gAg acc ctg tcc ctc
 10 acc tgc Act gtc tct ggt ggc tcc atc agT
 4-61 cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcg gAg acc ctg tcc ctc
 acc tgc Act gtc tct ggt ggc tcc Gtc agc
 4-b cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcg gAg acc ctg tcc ctc
 acc tgc gct gtc tct ggt TAc tcc atc agc
 15 VH5
 5-51 GAG GTG CAG CTG GTG CAG TCT GGA GCA GAG GTG AAA AAG CCC GGG GAG TCT CTG AAG ATC
 TCC TGT AAG GGT TCT GGA TAC AGC TTT ACC
 5-a gaA gtg cag ctg gtg cag tct gga gca gag gtg aaa aag ccc ggg gag tct ctg aGg atc
 tcc tgt aag ggt tct gga tac agc ttt acc
 20 VH6
 6-1 CAG GTA CAG CTG CAG CAG TCA GGT CCA GGA CTG GTG AAG CCC TCG CAG ACC CTC TCA CTC
 ACC TGT GCC ATC TCC GGG GAC AGT GTC TCT
 VH7
 7-4.1 CAG GTG CAG CTG GTG CAA TCT GGG TCT GAG TTG AAG AAG CCT GGG GCC TCA GTG AAG GTT
 25 TCC TGC AAG GCT TCT GGA TAC ACC TTC ACT

- 105 -

Table 7: RERS sites in Human HC GLG FR1s where there are at least 20 GLGs cut

BsgI GTGCAG		71 (cuts 16/14 bases to right)					
5	1: 4	1: 13	2: 13	3: 4	3: 13	4: 13	
	6: 13	7: 4	7: 13	8: 13	9: 4	9: 13	
	10: 4	10: 13	15: 4	15: 65	16: 4	16: 65	
	17: 4	17: 65	18: 4	18: 65	19: 4	19: 65	
	20: 4	20: 65	21: 4	21: 65	22: 4	22: 65	
10	23: 4	23: 65	24: 4	24: 65	25: 4	25: 65	
	26: 4	26: 65	27: 4	27: 65	28: 4	28: 65	
	29: 4	30: 4	30: 65	31: 4	31: 65	32: 4	
	32: 65	33: 4	33: 65	34: 4	34: 65	35: 4	
	35: 65	36: 4	36: 65	37: 4	38: 4	39: 4	
15	41: 4	42: 4	43: 4	45: 4	46: 4	47: 4	
	48: 4	48: 13	49: 4	49: 13	51: 4		
	There are 39 hits at base# 4						
	There are 21 hits at base# 65						
BbvI GCAGC		65					
20	1: 6	3: 6	6: 6	7: 6	8: 6	9: 6	
	10: 6	15: 6	15: 67	16: 6	16: 67	17: 6	
	17: 67	18: 6	18: 67	19: 6	19: 67	20: 6	
	20: 67	21: 6	21: 67	22: 6	22: 67	23: 6	
	23: 67	24: 6	24: 67	25: 6	25: 67	26: 6	
25	26: 67	27: 6	27: 67	28: 6	28: 67	29: 6	
	30: 6	30: 67	31: 6	31: 67	32: 6	32: 67	
	33: 6	33: 67	34: 6	34: 67	35: 6	35: 67	
	36: 6	36: 67	37: 6	38: 6	39: 6	40: 6	
	41: 6	42: 6	43: 6	44: 6	45: 6	46: 6	
30	47: 6	48: 6	49: 6	50: 12	51: 6		
	There are 43 hits at base# 6						
	Bolded sites very near sites						
	listed below						
BbvI gctgc		13					
35	37: 9	38: 9	39: 9	40: 3	40: 9	41: 9	
	42: 9	44: 3	44: 9	45: 9	46: 9	47: 9	

- 106 -

50: 9

There are 11 hits at base# 9

	BsoFI GCngc						78
5	1: 6	3: 6	6: 6	7: 6	8: 6	9: 6	
	10: 6	15: 6	15: 67	16: 6	16: 67	17: 6	
	17: 67	18: 6	18: 67	19: 6	19: 67	20: 6	
	20: 67	21: 6	21: 67	22: 6	22: 67	23: 6	
	23: 67	24: 6	24: 67	25: 6	25: 67	26: 6	
10	26: 67	27: 6	27: 67	28: 6	28: 67	29: 6	
	30: 6	30: 67	31: 6	31: 67	32: 6	32: 67	
	33: 6	33: 67	34: 6	34: 67	35: 6	35: 67	
	36: 6	36: 67	<u>37: 6</u>	<u>37: 9</u>	<u>38: 6</u>	<u>38: 9</u>	
	39: 6	39: 9	<u>40: 3</u>	<u>40: 6</u>	<u>40: 9</u>	41: 6	
15	41: 9	42: 6	42: 9	43: 6	<u>44: 3</u>	<u>44: 6</u>	
	<u>44: 9</u>	<u>45: 6</u>	<u>45: 9</u>	<u>46: 6</u>	<u>46: 9</u>	<u>47: 6</u>	
	<u>47: 9</u>	48: 6	49: 6	50: 9	50: 12	51: 6	

There are 43 hits at base# 6 These often occur together.

There are 11 hits at base# 9

20 There are 2 hits at base# 3

There are 21 hits at base# 67

	TseI Gcwgc						78
	1: 6	3: 6	6: 6	7: 6	8: 6	9: 6	
25	10: 6	15: 6	15: 67	16: 6	16: 67	17: 6	
	17: 67	18: 6	18: 67	19: 6	19: 67	20: 6	
	20: 67	21: 6	21: 67	22: 6	22: 67	23: 6	
	23: 67	24: 6	24: 67	25: 6	25: 67	26: 6	
	26: 67	27: 6	27: 67	28: 6	28: 67	29: 6	
30	30: 6	30: 67	31: 6	31: 67	32: 6	32: 67	
	33: 6	33: 67	34: 6	34: 67	35: 6	35: 67	
	36: 6	36: 67	<u>37: 6</u>	<u>37: 9</u>	<u>38: 6</u>	<u>38: 9</u>	
	<u>39: 6</u>	<u>39: 9</u>	<u>40: 3</u>	<u>40: 6</u>	<u>40: 9</u>	<u>41: 6</u>	
	<u>41: 9</u>	<u>42: 6</u>	<u>42: 9</u>	43: 6	<u>44: 3</u>	<u>44: 6</u>	
35	<u>44: 9</u>	<u>45: 6</u>	<u>45: 9</u>	<u>46: 6</u>	<u>46: 9</u>	<u>47: 6</u>	
	<u>47: 9</u>	48: 6	49: 6	<u>50: 9</u>	<u>50: 12</u>	51: 6	

There are 43 hits at base# 6 Often together.

There are 11 hits at base# 9

- 107 -

There are 2 hits at base# 3

There are 1 hits at base# 12

There are 21 hits at base# 67

5 MspAII CMGckg 48

1:	7	3:	7	4:	7	5:	7	6:	7	7:	7
8:	7	9:	7	10:	7	11:	7	15:	7	16:	7
17:	7	18:	7	19:	7	20:	7	21:	7	22:	7
23:	7	24:	7	25:	7	26:	7	27:	7	28:	7
29:	7	30:	7	31:	7	32:	7	33:	7	34:	7
35:	7	36:	7	37:	7	38:	7	39:	7	<u>40:</u>	<u>1</u>
<u>40:</u>	<u>7</u>	41:	7	42:	7	<u>44:</u>	<u>1</u>	<u>44:</u>	<u>7</u>	45:	7
46:	7	47:	7	48:	7	49:	7	50:	7	51:	7

There are 46 hits at base# 7

15 PvuII CAGctg 48

1:	7	3:	7	4:	7	5:	7	6:	7	7:	7
8:	7	9:	7	10:	7	11:	7	15:	7	16:	7
17:	7	18:	7	19:	7	20:	7	21:	7	22:	7
23:	7	24:	7	25:	7	26:	7	27:	7	28:	7
29:	7	30:	7	31:	7	32:	7	33:	7	34:	7
35:	7	36:	7	37:	7	38:	7	39:	7	<u>40:</u>	<u>1</u>
<u>40:</u>	<u>7</u>	41:	7	42:	7	<u>44:</u>	<u>1</u>	<u>44:</u>	<u>7</u>	45:	7
46:	7	47:	7	48:	7	49:	7	50:	7	51:	7

20 There are 46 hits at base# 7

25 There are 2 hits at base# 1

AluI AGct 54

1:	8	2:	8	3:	8	4:	8	4:	24	5:	8
6:	8	7:	8	8:	8	9:	8	10:	8	11:	8
15:	8	16:	8	17:	8	18:	8	19:	8	20:	8
21:	8	22:	8	23:	8	24:	8	25:	8	26:	8
27:	8	28:	8	29:	8	29:	69	30:	8	31:	8
32:	8	33:	8	34:	8	35:	8	36:	8	37:	8
38:	8	39:	8	<u>40:</u>	<u>2</u>	<u>40:</u>	<u>8</u>	41:	8	42:	8
43:	8	<u>44:</u>	<u>2</u>	<u>44:</u>	<u>8</u>	45:	8	46:	8	47:	8
48:	8	48:	82	49:	8	49:	82	50:	8	51:	8

30

35

- 108 -

There are 48 hits at base# 8

There are 2 hits at base# 2

DdeI Ctnag

48

5 1: 26 1: 48 2: 26 2: 48 3: 26 3: 48
 4: 26 4: 48 5: 26 5: 48 6: 26 6: 48
 7: 26 7: 48 8: 26 8: 48 9: 26 10: 26
 11: 26 12: 85 13: 85 14: 85 15: 52 16: 52
 17: 52 18: 52 19: 52 20: 52 21: 52 22: 52
 10 23: 52 24: 52 25: 52 26: 52 27: 52 28: 52
 29: 52 30: 52 31: 52 32: 52 33: 52 35: 30
 35: 52 36: 52 40: 24 49: 52 51: 26 51: 48

There are 22 hits at base# 52 52 and 48 never together.

There are 9 hits at base# 48

15 There are 12 hits at base# 26 26 and 24 never together.

HphI tcacc

42

1: 86 3: 86 6: 86 7: 86 8: 80 11: 86
 12: 5 13: 5 14: 5 15: 80 16: 80 17: 80
 20 18: 80 20: 80 21: 80 22: 80 23: 80 24: 80
 25: 80 26: 80 27: 80 28: 80 29: 80 30: 80
 31: 80 32: 80 33: 80 34: 80 35: 80 36: 80
 37: 59 38: 59 39: 59 40: 59 41: 59 42: 59
 43: 59 44: 59 45: 59 46: 59 47: 59 50: 59

25 There are 22 hits at base# 80 80 and 86 never together

There are 5 hits at base# 86

There are 12 hits at base# 59

BssKI Nccngg

50

30 1: 39 2: 39 3: 39 4: 39 5: 39 7: 39
 8: 39 9: 39 10: 39 11: 39 15: 39 16: 39
 17: 39 18: 39 19: 39 20: 39 21: 29 21: 39
 22: 39 23: 39 24: 39 25: 39 26: 39 27: 39
 28: 39 29: 39 30: 39 31: 39 32: 39 33: 39
 35 34: 39 35: 19 35: 39 36: 39 37: 24 38: 24
 39: 24 41: 24 42: 24 44: 24 45: 24 46: 24
 47: 24 48: 39 48: 40 49: 39 49: 40 50: 24
 50: 73 51: 39

There are 35 hits at base# 39 39 and 40 together twice.

- 109 -

There are 2 hits at base# 40

BsaJI Ccngg 47

	1: 40	2: 40	3: 40	4: 40	5: 40	7: 40
5	8: 40	9: 40	9: 47	10: 40	10: 47	11: 40
	15: 40	18: 40	19: 40	20: 40	21: 40	22: 40
	23: 40	24: 40	25: 40	26: 40	27: 40	28: 40
	29: 40	30: 40	31: 40	32: 40	34: 40	35: 20
	35: 40	36: 40	37: 24	38: 24	39: 24	41: 24
10	42: 24	44: 24	45: 24	46: 24	47: 24	<u>48: 40</u>
	<u>48: 41</u>	<u>49: 40</u>	<u>49: 41</u>	50: 74	51: 40	

There are 32 hits at base# 40 40 and 41 together twice

There are 2 hits at base# 41

There are 9 hits at base# 24

15 There are 2 hits at base# 47

BstNI CCwgg 44

PspGI ccwgg

ScrFI(\$M.HpaII) CCwgg

20	1: 40	2: 40	3: 40	4: 40	5: 40	7: 40
	8: 40	9: 40	10: 40	11: 40	15: 40	16: 40
	17: 40	18: 40	19: 40	20: 40	21: 30	21: 40
	22: 40	23: 40	24: 40	25: 40	26: 40	27: 40
	28: 40	29: 40	30: 40	31: 40	32: 40	33: 40
25	34: 40	35: 40	36: 40	37: 25	38: 25	39: 25
	41: 25	42: 25	44: 25	45: 25	46: 25	47: 25
	50: 25	51: 40				

There are 33 hits at base# 40

30 ScrFI CCngg 50

	1: 40	2: 40	3: 40	4: 40	5: 40	7: 40
	8: 40	9: 40	10: 40	11: 40	15: 40	16: 40
	17: 40	18: 40	19: 40	20: 40	21: 30	21: 40
	22: 40	23: 40	24: 40	25: 40	26: 40	27: 40
35	28: 40	29: 40	30: 40	31: 40	32: 40	33: 40
	34: 40	35: 20	35: 40	36: 40	37: 25	38: 25
	39: 25	41: 25	42: 25	44: 25	45: 25	46: 25

- 110 -

47: 25 48: 40 48: 41 49: 40 49: 41 50: 25
 50: 74 51: 40

There are 35 hits at base# 40

There are 2 hits at base# 41

5

EcoO109I RGgnccy 34

1: 43 2: 43 3: 43 4: 43 5: 43 6: 43
 7: 43 8: 43 9: 43 10: 43 15: 46 16: 46
 17: 46 18: 46 19: 46 20: 46 21: 46 22: 46
 10 23: 46 24: 46 25: 46 26: 46 27: 46 28: 46
 30: 46 31: 46 32: 46 33: 46 34: 46 35: 46
 36: 46 37: 46 43: 79 51: 43

There are 22 hits at base# 46 46 and 43 never together

There are 11 hits at base# 43

15 NlaIV GGNncc 71

1: 43 2: 43 3: 43 4: 43 5: 43 6: 43
 7: 43 8: 43 9: 43 9: 79 10: 43 10: 79
15: 46 15: 47 16: 47 17: 46 17: 47 18: 46
18: 47 19: 46 19: 47 20: 46 20: 47 21: 46
 20 21: 47 22: 46 22: 47 23: 47 24: 47 25: 47
26: 47 27: 46 27: 47 28: 46 28: 47 29: 47
30: 46 30: 47 31: 46 31: 47 32: 46 32: 47
33: 46 33: 47 34: 46 34: 47 35: 46 35: 47
36: 46 36: 47 37: 21 37: 46 37: 47 37: 79
 25 38: 21 39: 21 39: 79 40: 79 41: 21 41: 79
 42: 21 42: 79 43: 79 44: 21 44: 79 45: 21
 45: 79 46: 21 46: 79 47: 21 51: 43

There are 23 hits at base# 47 46 & 47 often together

There are 17 hits at base# 46 There are 11 hits at base# 43

30 Sau96I Ggncc 70

1: 44 2: 3 2: 44 3: 44 4: 44 5: 3 5: 44 6: 44
 7: 44 8: 22 8: 44 9: 44 10: 44 11: 3 12: 22 13: 22
 14: 22 15: 33 15: 47 16: 47 17: 47 18: 47 19: 47 20: 47
 21: 47 22: 47 23: 33 23: 47 24: 33 24: 47 25: 33 25: 47
 35 26: 33 26: 47 27: 47 28: 47 29: 47 30: 47 31: 33 31: 47
 32: 33 32: 47 33: 33 33: 47 34: 33 34: 47 35: 47 36: 47
37: 21 37: 22 37: 47 38: 21 38: 22 39: 21 39: 22 41: 21
 41: 22 42: 21 42: 22 43: 80 44: 21 44: 22 45: 21 45: 22
 46: 21 46: 22 47: 21 47: 22 50: 22 51: 44

- 111 -

There are 23 hits at base# 47 These do not occur together.

There are 11 hits at base# 44

There are 14 hits at base# 22 These do occur together.

There are 9 hits at base# 21

5

BsmAI GTCTCnnnnn 22
 1: 58 3: 58 4: 58 5: 58 8: 58 9: 58
 10: 58 13: 70 36: 18 37: 70 38: 70 39: 70
 40: 70 41: 70 42: 70 44: 70 45: 70 46: 70
 10 47: 70 48: 48 49: 48 50: 85
 There are 11 hits at base# 70

-"- Nnnnnngagac 27
 13: 40 15: 48 16: 48 17: 48 18: 48 20: 48
 15 21: 48 22: 48 23: 48 24: 48 25: 48 26: 48
 27: 48 28: 48 29: 48 30: 10 30: 48 31: 48
 32: 48 33: 48 35: 48 36: 48 43: 40 44: 40
 45: 40 46: 40 47: 40
 There are 20 hits at base# 48

20

AvaII Ggwcc 44
 Sau96I(\$M.HaeIII) Ggwcc 44
 2: 3 5: 3 6: 44 8: 44 9: 44 10: 44
 11: 3 12: 22 13: 22 14: 22 15: 33 15: 47
 25 16: 47 17: 47 18: 47 19: 47 20: 47 21: 47
 22: 47 23: 33 23: 47 24: 33 24: 47 25: 33
 25: 47 26: 33 26: 47 27: 47 28: 47 29: 47
 30: 47 31: 33 31: 47 32: 33 32: 47 33: 33
 33: 47 34: 33 34: 47 35: 47 36: 47 37: 47
 30 43: 80 50: 22
 There are 23 hits at base# 47 44 & 47 never together
 There are 4 hits at base# 44

PpuMI RGgwccy 27
 35 6: 43 8: 43 9: 43 10: 43 15: 46 16: 46
 17: 46 18: 46 19: 46 20: 46 21: 46 22: 46
 23: 46 24: 46 25: 46 26: 46 27: 46 28: 46

- 112 -

30: 46 31: 46 32: 46 33: 46 34: 46 35: 46
 36: 46 37: 46 43: 79

There are 22 hits at base# 46 43 and 46 never occur together.

There are 4 hits at base# 43

5

BsmFI GGGAC 3

8: 43 37: 46 50: 77

-"- gtccc 33

15: 48 16: 48 17: 48 1: 0 1: 0 20: 48
 10 21: 48 22: 48 23: 48 24: 48 25: 48 26: 48
 27: 48 28: 48 29: 48 30: 48 31: 48 32: 48
 33: 48 34: 48 35: 48 36: 48 37: 54 38: 54
 39: 54 40: 54 41: 54 42: 54 43: 54 44: 54
 45: 54 46: 54 47: 54

15 There are 20 hits at base# 48

There are 11 hits at base# 54

HinfI Gantc 80

8: 77 12: 16 13: 16 14: 16 15: 16 15: 56
 20 15: 77 16: 16 16: 56 16: 77 17: 16 17: 56
 17: 77 18: 16 18: 56 18: 77 19: 16 19: 56
 19: 77 20: 16 20: 56 20: 77 21: 16 21: 56
 21: 77 22: 16 22: 56 22: 77 23: 16 23: 56
 23: 77 24: 16 24: 56 24: 77 25: 16 25: 56
 25 25: 77 26: 16 26: 56 26: 77 27: 16 27: 26
 27: 56 27: 77 28: 16 28: 56 28: 77 29: 16
 29: 56 29: 77 30: 56 31: 16 31: 56 31: 77
 32: 16 32: 56 32: 77 33: 16 33: 56 33: 77
 34: 16 35: 16 35: 56 35: 77 36: 16 36: 26
 30 36: 56 36: 77 37: 16 38: 16 39: 16 40: 16
 41: 16 42: 16 44: 16 45: 16 46: 16 47: 16
 48: 46 49: 46

There are 34 hits at base# 16

35 TfiI Gawtc 21

8: 77 15: 77 16: 77 17: 77 18: 77 19: 77
 20: 77 21: 77 22: 77 23: 77 24: 77 25: 77
 26: 77 27: 77 28: 77 29: 77 31: 77 32: 77

- 113 -

33: 77 35: 77 36: 77

There are 21 hits at base# 77

MlyI GAGTC

38

5 12: 16 13: 16 14: 16 15: 16 16: 16 17: 16
 18: 16 19: 16 20: 16 21: 16 22: 16 23: 16
 24: 16 25: 16 26: 16 27: 16 27: 26 28: 16
 29: 16 31: 16 32: 16 33: 16 34: 16 35: 16
 36: 16 36: 26 37: 16 38: 16 39: 16 40: 16
 10 41: 16 42: 16 44: 16 45: 16 46: 16 47: 16
 48: 46 49: 46

There are 34 hits at base# 16

-"- GACTC

21

15 15: 56 16: 56 17: 56 18: 56 19: 56 20: 56
 21: 56 22: 56 23: 56 24: 56 25: 56 26: 56
 27: 56 28: 56 29: 56 30: 56 31: 56 32: 56
 33: 56 35: 56 36: 56

There are 21 hits at base# 56

20

PleI gagtc

38

12: 16 13: 16 14: 16 15: 16 16: 16 17: 16
 18: 16 19: 16 20: 16 21: 16 22: 16 23: 16
 24: 16 25: 16 26: 16 27: 16 27: 26 28: 16
 25 29: 16 31: 16 32: 16 33: 16 34: 16 35: 16
 36: 16 36: 26 37: 16 38: 16 39: 16 40: 16
 41: 16 42: 16 44: 16 45: 16 46: 16 47: 16
 48: 46 49: 46

There are 34 hits at base# 16

30 -"- gactc

21

15: 56 16: 56 17: 56 18: 56 19: 56 20: 56
 21: 56 22: 56 23: 56 24: 56 25: 56 26: 56
 27: 56 28: 56 29: 56 30: 56 31: 56 32: 56
 33: 56 35: 56 36: 56

35 There are 21 hits at base# 56

AlwNI CAGNNNctg

26

15: 68 16: 68 17: 68 18: 68 19: 68 20: 68

- 114 -

21: 68	22: 68	23: 68	24: 68	25: 68	26: 68
27: 68	28: 68	29: 68	30: 68	31: 68	32: 68
33: 68	34: 68	35: 68	36: 68	39: 46	40: 46
41: 46	42: 46				

5 There are 22 hits at base# 68

- 115 -

Table 8: Kappa FR1 GLGs

	!	1	2	3	4	5	6	7	8	9	10	11	12	
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
	!	13	14	15	16	17	18	19	20	21	22	23		
5		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	012
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	02
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	018
10		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	08
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	A20
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
15		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	A30
		AAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCT	GCC	ATG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L14
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCA	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L1
20		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCC	TCA	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L15
		GCC	ATC	CAG	TTG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	L4
		GCC	ATC	CAG	TTG	ACC	CAG	TCT	CCA	TCC	TCC	CTG	TCT	
25		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	L18
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCT	TCC	GTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L5
		GAC	ATC	CAG	ATG	ACC	CAG	TCT	CCA	TCT	TCT	GTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L19
30		GAC	ATC	CAG	TTG	ACC	CAG	TCT	CCA	TCC	TTC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	L8
		GCC	ATC	CGG	ATG	ACC	CAG	TCT	CCA	TTC	TCC	CTG	TCT	
		GCA	TCT	GTA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGC	!	L23
		GCC	ATC	CGG	ATG	ACC	CAG	TCT	CCA	TCC	TCA	TTC	TCT	
35		GCA	TCT	ACA	GGA	GAC	AGA	GTC	ACC	ATC	ACT	TGT	!	L9

- 116 -

	GTC ATC TGG ATG ACC CAG TCT CCA TCC TTA CTC TCT	
	GCA TCT ACA GGA GAC AGA GTC ACC ATC AGT TGT !	L24
	GCC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG TCT	
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !	L11
5	GAC ATC CAG ATG ACC CAG TCT CCT TCC ACC CTG TCT	
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !	L12
	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCC CTG CCC	
	GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC !	O11
	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCC CTG CCC	
10	GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC !	O1
	GAT GTT GTG ATG ACT CAG TCT CCA CTC TCC CTG CCC	
	GTC ACC CTT GGA CAG CCG GCC TCC ATC TCC TGC !	A17
	GAT GTT GTG ATG ACT CAG TCT CCA CTC TCC CTG CCC	
	GTC ACC CTT GGA CAG CCG GCC TCC ATC TCC TGC !	A1
15	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCT CTG TCC	
	GTC ACC CCT GGA CAG CCG GCC TCC ATC TCC TGC !	A18
	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCT CTG TCC	
	GTC ACC CCT GGA CAG CCG GCC TCC ATC TCC TGC !	A2
	GAT ATT GTG ATG ACT CAG TCT CCA CTC TCC CTG CCC	
20	GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC !	A19
	GAT ATT GTG ATG ACT CAG TCT CCA CTC TCC CTG CCC	
	GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC !	A3
	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCC TCA CCT	
	GTC ACC CTT GGA CAG CCG GCC TCC ATC TCC TGC !	A23
25	GAA ATT GTG TTG ACG CAG TCT CCA GGC ACC CTG TCT	
	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	A27
	GAA ATT GTG TTG ACG CAG TCT CCA GCC ACC CTG TCT	
	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	A11
	GAA ATA GTG ATG ACG CAG TCT CCA GCC ACC CTG TCT	
30	GTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	L2
	GAA ATA GTG ATG ACG CAG TCT CCA GCC ACC CTG TCT	
	GTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	L16
	GAA ATT GTG TTG ACA CAG TCT CCA GCC ACC CTG TCT	
	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	L6
35	GAA ATT GTG TTG ACA CAG TCT CCA GCC ACC CTG TCT	

- 117 -

	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	L20
	GAA ATT GTA ATG ACA CAG TCT CCA GCC ACC CTG TCT	
	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !	L25
	GAC ATC GTG ATG ACC CAG TCT CCA GAC TCC CTG GCT	
5	GTG TCT CTG GGC GAG AGG GCC ACC ATC AAC TGC !	B3
	GAA ACG ACA CTC ACG CAG TCT CCA GCA TTC ATG TCA	
	GCG ACT CCA GGA GAC AAA GTC AAC ATC TCC TGC !	B2
	GAA ATT GTG CTG ACT CAG TCT CCA GAC TTT CAG TCT	
	GTG ACT CCA AAG GAG AAA GTC ACC ATC ACC TGC !	A26
10	GAA ATT GTG CTG ACT CAG TCT CCA GAC TTT CAG TCT	
	GTG ACT CCA AAG GAG AAA GTC ACC ATC ACC TGC !	A10
	GAT GTT GTG ATG ACA CAG TCT CCA GCT TTC CTC TCT	
	GTG ACT CCA GGG GAG AAA GTC ACC ATC ACC TGC !	A14

Table 9 RERS sites found in Human Kappa FR1 GLGs

	MslI	FokI --> <-- -->	PfFI	BsrI	BsmAI	MnlI	HpyCH 4V
VKI							
O12 1-69	3	3 23	12 49	15	18 47	26	36
O2 101-169	103	103 123	112 149	115	118 147	126	136
O18 201-269	203	203 223	212 249	215	218 247	226	236
O8 301-369	303	303 323	312 349	315	318 347	326	336
A20 401-469	403	403 423	412 449	415	418 447	426	436
A30 501-569	503	503 523	512 549	515	518 547	526	536
L14 601-669	603	603	612 649	615	618 647	-	636
L1 701-769	703	703 723	712 749	715	718 747	726	736
L15 801-869	803	803 823	812 849	815	818 847	826	836
L4 901-969	-	903 923	912 949	906 915	918 947	926	936
L18 1001-1069	-	1003	1012 1049	1006 1015	1018 1047	1026	1036
L5 1101-1169	1103	-	1112 1149	1115	1118 1147	-	1136
L19 1201-1269	1203	1203	1212 1249	1215	1218 1247	-	1236
L8 1301-1369	-	1303 1323	1312 1349	1306 1315	1318 1347	-	1336
L23 1401-1469	1403	1403 1408	1412 1449	1415	1418 1447	-	1436
L9 1501-1569	1503	1503 1508 1523	1512 1549	1515	1518 1547	1526	1536

5

10

15

	MslI	FokI -> <- ->	PflFI	BsrI	BsmAI	MnlI	HpyCH 4V
L24 1601-1669	1603	1608 1623	1612 1649	1615	1618 1647	-	1636
L11 1701-1769	1703	1703 1723	1712 1749	1715	1718 1747	1726	1736
L12 1801-1869	1803	1803	1812 1849	1815	1818 1847	-	1836
VKII							
O11 1901-1969	-	-	-	-	-	1956	-
O1 2001-2069	-	-	-	-	-	2056	-
A17 2101-2169	-	-	2112	-	2118	2156	-
A1 2201-2269	-	-	2212	-	2218	2256	-
A18 2301-2369	-	-	-	-	-	2356	-
A2 2401-2469	-	-	-	-	-	2456	-
A19 2501-2569	-	-	2512	-	2518	2556	-
A3 2601-2669	-	-	2612	-	2618	2656	-
A23 2701-2769	-	-	-	-	-	2729 2756	-
VKIII							
A27 2801-2869	-	-	2812	-	2818 2839	2860	-
A11 2901-2969	-	-	2912	-	2918 2939	2960	-
L2 3001-3069	-	-	3012	-	3018 3039	3060	-
L16 3101-3169	-	-	3112	-	3118 3139	3160	-

	MslI	FokI --> <-- --> .	PstFI	BsrI	BsmAI	MnlI	HpyCH 4V
L6 3201-3269	-	-	3212	-	3218 3239	3260	-
L20 3301-3369	-	-	3312	-	3318 3339	3360	-
L25 3401-3469	-	-	3412	-	3418 3439	3460	-
VKIV							
B3 3501-3569	3503	-	3512	3515	3518 3539	3551<	-
VKV							
B2 3601-3669	-	-	3649	-	3618 3647		-
VKVI							
A26 3701-3769	-	-	3712	-	3718		-
A10 3801-3869	-	-	3812	-	3818		-
A14 3901-3969	-	-	3912	-	3918	3930>	-

Table 9 RERS sites found in Human Kappa FR1 GLGs, continued

	SfaNI	SfiI	HinfI	MlyI --> --> <--	MaeIII Tsp45I same sites	HphI xx38 xx56 xx62	HpaII MspI xx06 xx52
VKI							
O12 1-69	37	41	53	53	55	56	-
O2 101-169	137	141	153	153	155	156	-
O18 201-269	237	241	253	253	255	256	-
O8 301-369	337	341	353	353	355	356	-
A20 401-469	437	441	453	453	455	456	-
A30 501-569	537	541	553	553	555	556	-
L14 601-669	637	641	653	653	655	656	-
L1 701-769	737	741	753	753	755	756	-
L15 801-869	837	841	853	853	855	856	-
L4 901-969	937	941	953	953	955	956	-
L18 1001-1069	1037	1041	1053	1053	1055	1056	-
L5 1101-1169	1137	1141	1153	1153	1155	1156	-
L19 1201-1269	1237	1241	1253	1253	1255	1256	-
L8 1301-1369	1337	1341	1353	1353	1355	1356	-
L23 1401-1469	1437	1441	1453	1453	1455	1456	1406
L9 1501-1569	1537	1541	1553	1553	1555	1556	1506

	SfaNI	Scl	HinfI	MlyI --> --> <--	MaeIII Tsp45I same sites	HphI xx38 xx56 xx62	HpaII MspI xx06 xx52
L24 1601-1669	1637	1641	1653	1653	1655	1656	
L11 1701-1769	1737	1741	1753	1753	1755	1756	
L12 1801-1869	1837	1841	1853	1853	1855	1856	
VKII							
O11 1901-1969	-	-	1918	1918	1937	1938	1952
O1 2001-2069	-	-	2018	2018	2037	2038	2052
A17 2101-2169	-	-	2112	2112	2137	2138	2152
A1 2201-2269	-	-	2212	2212	2237	2238	2252
A18 2301-2369	-	-	2318	2318	2337	2338	2352
A2 2401-2469	-	-	2418	2418	2437	2438	2452
A19 2501-2569	-	-	2512	2512	2537	2538	2552
A3 2601-2669	-	-	2612	2612	2637	2638	2652
A23 2701-2769	-	-	2718	2718	2737	2731* 2738*	-
VKIII							
A27 2801-2869	-	-	-	-			-
A11 2901-2969	-	-	-	-			-
L2 3001-3069	-	-	-	-			-

5

10

15

	SfaNI	SfiI	HinfI	MlyI -> --> <-- -> --> <--	MaeIII Tsp45I same sites	HphI xx38 xx56 xx62	HpaII MspI xx06 xx52
L16 3101-3169	-	-	-	-			-
L6 3201-3269	-	-	-	-			-
L20 3301-3369	-	-	-	-			-
L25 3401-3469	-	-	-	-			-
VKIV							
B3 3501-3569	-	-	3525	3525			-
VKV							
B2 3601-3669	-	-	3639	3639			-
VKVI							
A26 3701-3769	-	-	3712 3739	3712 3739	3737 3755	3756 3762	-
A10 3801-3869	-	-	3812 3839	3812 3839	3837 3855	3856 3862	-
A14 3901-3969	-	-	3939	3939	3937 3955	3956 3962	-

Table 9 RERS sites found in Human Kappa FR1, continued

	BsaI xx29 xx42 xx43	BssKI (NstNI) xx22 xx30 xx43	BpmI xx20 xx41 xx44 --> --> <--	BsrFI Cac8I NaeI NgoMIV	HaeIII	Tsp509I
VKI						
O12 1-69	-	-	-	-	-	-
O2 101-169	-	-	-	-	-	-
O18 201-269	-	-	-	-	-	-
O8 301-369	-	-	-	-	-	-
A20 401-469	-	-	-	-	-	-
A30 501-569	-	-	-	-	-	-
L14 601-669	-	-	-	-	-	-
L1 701-769	-	-	-	-	-	-
L15 801-869	-	-	-	-	-	-
L4 901-969	-	-	-	-	-	-
L18 1001-1069	-	-	-	-	-	-
L5 1101-1169	-	-	-	-	-	-
L19 1201-1269	-	-	-	-	-	-
L8 1301-1369	-	-	-	-	-	-
L23 1401-1469	-	-	-	-	-	-

5

10

15

	BsaI xx29 xx42 xx43	BssKI (NstNI) xx22 xx30 xx43	BpmI xx20 xx41 xx44 --> --> <--	BsrFI Cac8I NaeI NgoMIV	HaeIII	Tsp509I
L9 1501-1569	-	-	-	-	-	-
L24 1601-1669	-	-	-	-	-	-
L11 1701-1769	-	-	-	-	-	-
L12 1801-1869	-	-	-	-	-	-
VKII						
O11 1901-1969	1942	1943	1944	1951	1954	-
O1 2001-2069	2042	2043	2044	2051	2054	-
A17 2101-2169	2142	-	-	2151	2154	-
A1 2201-2269	2242	-	-	2251	2254	-
A18 2301-2369	2342	2343	-	2351	2354	-
A2 2401-2469	2442	2443	-	2451	2454	-
A19 2501-2569	2542	2543	2544	2551	2554	-
A3 2601-2669	2642	2643	2644	2651	2654	-
A23 2701-2769	2742	-	-	2751	2754	-
VKIII						
A27 2801-2869	2843	2822 2843	2820 2841	-	-	2803
A11 2901-2969	2943	2943	2920 2941	-	-	2903

5

10

15

	BsaJI xx29 xx42 xx43	BssKI (NstNI) xx22 xx30 xx43	BpmI xx20 xx41 xx44 --> --> <--	BsrFI Cac8I NaeI NgoMIV	HaeIII	Tsp509I
L2 3001-3069	3043	3043	3041	-	-	-
L16 3101-3169	3143	3143	3120 3141	-	-	-
L6 3201-3269	3243	3243	3220 3241	-	-	3203
L20 3301-3369	3343	3343	3320 3341	-	-	3303
L25 3401-3469	3443	3443	3420 3441	-	-	3403
VKIV						
B3 3501-3569	3529	3530	3520	-	3554	
VKV						
B2 3601-3669		3643	3620 3641	-	-	
VKVI						
A26 3701-3769		-	3720	-	-	3703
A10 3801-3869		-	3820	-	-	3803
A14 3901-3969	3943	3943	3920 3941	-	-	-

- 127 -

Table 10 Lambda FR1 GLG sequences

! VL1

CAG TCT GTG CTG ACT CAG CCA CCC TCG GTG TCT GAA
 GCC CCC AGG CAG AGG GTC ACC ATC TCC TGT ! 1a
 5 cag tct gtg ctg acG cag ccG ccc tcA gtg tct gGG
 gcc ccA Ggg cag agg gtc acc atc tcc tgC ! 1e
 cag tct gtg ctg act cag cca ccc tcA gCg tct gGG
 Acc ccc Ggg cag agg gtc acc atc tcT tgt ! 1c
 cag tct gtg ctg act cag cca ccc tcA gCg tct gGG
 10 Acc ccc Ggg cag agg gtc acc atc tcT tgt ! 1g
 cag tct gtg Ttg acG cag ccG ccc tcA gtg tct gCG
 gcc ccA GgA cag aAg gtc acc atc tcc tgC ! 1b

! VL2

CAG TCT GCC CTG ACT CAG CCT CCC TCC GCG TCC GGG
 15 TCT CCT GGA CAG TCA GTC ACC ATC TCC TGC ! 2c
 cag tct gcc ctg act cag cct cGc tcA gTg tcc ggg
 tct cct gga cag tca gtc acc atc tcc tgc ! 2e
 cag tct gcc ctg act cag cct Gcc tcc gTg tcT ggg
 tct cct gga cag tcG Atc acc atc tcc tgc ! 2a2
 20 cag tct gcc ctg act cag cct ccc tcc gTg tcc ggg
 tct cct gga cag tca gtc acc atc tcc tgc ! 2d
 cag tct gcc ctg act cag cct Gcc tcc gTg tcT ggg
 tct cct gga cag tcG Atc acc atc tcc tgc ! 2b2

! VL3

25 TCC TAT GAG CTG ACT CAG CCA CCC TCA GTG TCC GTG
 TCC CCA GGA CAG ACA GCC AGC ATC ACC TGC ! 3r
 tcc tat gag ctg act cag cca cTc tca gtg tcA gtg
 Gcc cTG gga cag acG gcc agG atT acc tgT ! 3j
 tcc tat gag ctg acA cag cca ccc tcG gtg tcA gtg
 30 tcc cca gga caA acG gcc agG atc acc tgc ! 3p
 tcc tat gag ctg acA cag cca ccc tcG gtg tcA gtg
 tcc cTa gga cag aTG gcc agG atc acc tgc ! 3a
 tcT tCt gag ctg act cag GAC ccT GcT gtg tcT gtg
 Gcc TTG gga cag aca gTc agG atc acA tgc ! 3l

- 128 -

tcc tat gTg ctg act cag cca ccc tca gtg tcA gtg
 Gcc cca gga Aag acG gcc agG atT acc tgT ! 3h
 tcc tat gag ctg acA cag cTa ccc tcG gtg tcA gtg
 tcc cca gga cag aca gcc agG atc acc tgc ! 3e
 5 tcc tat gag ctg aTG cag cca ccc tcG gtg tcA gtg
 tcc cca gga cag acG gcc agG atc acc tgc ! 3m
 tcc tat gag ctg acA cag cca Tcc tca gtg tcA gtg
 tcT ccG gga cag aca gcc agG atc acc tgc ! V2-19
 VL4
 10 CTG CCT GTG CTG ACT CAG CCC CCG TCT GCA TCT GCC
 TTG CTG GGA GCC TCG ATC AAG CTC ACC TGC ! 4c
 cAg cct gtg ctg act caA TcA TcC tct gcC tct gcT
 tCC ctg gga Tcc tcg Gtc aag ctc acc tgc ! 4a
 cAg cTt gtg ctg act caA TcG ccC tct gcC tct gcc
 15 tCC ctg gga gcc tcg Gtc aag ctc acc tgc ! 4b
 ! VL5
 CAG CCT GTG CTG ACT CAG CCA CCT TCC TCC TCC GCA
 TCT CCT GGA GAA TCC GCC AGA CTC ACC TGC ! 5e
 cag Gct gtg ctg act cag ccG Gct tcc CTc tcT gca
 20 tct cct gga gCa tcA gcc agT ctc acc tgc ! 5c
 cag cct gtg ctg act cag cca Tct tcc CAT tcT gca
 tct Tct gga gCa tcA gTc aga ctc acc tgc ! 5b
 ! VL6
 AAT TTT ATG CTG ACT CAG CCC CAC TCT GTG TCG GAG
 25 TCT CCG GGG AAG ACG GTA ACC ATC TCC TGC ! 6a
 ! VL7
 CAG ACT GTG GTG ACT CAG GAG CCC TCA CTG ACT GTG
 TCC CCA GGA GGG ACA GTC ACT CTC ACC TGT ! 7a
 cag Gct gtg gtg act cag gag ccc tca ctg act gtg
 30 tcc cca gga ggg aca gtc act ctc acc tgt ! 7b
 ! VL8
 CAG ACT GTG GTG ACC CAG GAG CCA TCG TTC TCA GTG
 TCC CCT GGA GGG ACA GTC ACA CTC ACT TGT ! 8a

- 129 -

! VL9

CAG CCT GTG CTG ACT CAG CCA CCT TCT GCA TCA GCC
TCC CTG GGA GCC TCG GTC ACA CTC ACC TGC ! 9a

! VL10

5

CAG GCA GGG CTG ACT CAG CCA CCC TCG GTG TCC AAG
GGC TTG AGA CAG ACC GCC ACA CTC ACC TGC ! 10a

- 130 -

Table 11 RERSs found in human lambda FR1 GLGs

! There are 31 lambda GLGs

MlyI NnnnnnGACTC 25

	1: 6	3: 6	4: 6	6: 6	7: 6	8: 6
5	9: 6	10: 6	11: 6	12: 6	15: 6	16: 6
	20: 6	21: 6	22: 6	23: 6	23: 50	24: 6
	25: 6	25: 50	26: 6	27: 6	28: 6	30: 6
	31: 6					

There are 23 hits at base# 6

10

-"- GAGTCNNNNNn 1

26: 34

MwoI GCNNNNNnngc 20

15	1: 9	2: 9	3: 9	4: 9	11: 9	11: 56
	12: 9	13: 9	14: 9	16: 9	17: 9	18: 9
	19: 9	20: 9	23: 9	24: 9	25: 9	26: 9
	30: 9	31: 9				

There are 19 hits at base# 9

20 HinfI Gantc 27

	1: 12	3: 12	4: 12	6: 12	7: 12	8: 12
	9: 12	10: 12	11: 12	12: 12	15: 12	16: 12
	20: 12	21: 12	22: 12	23: 12	23: 46	23: 56
	24: 12	25: 12	25: 56	26: 12	26: 34	27: 12
25	28: 12	30: 12	31: 12			

There are 23 hits at base# 12

PleI gactc 25

	1: 12	3: 12	4: 12	6: 12	7: 12	8: 12
	9: 12	10: 12	11: 12	12: 12	15: 12	16: 12
30	20: 12	21: 12	22: 12	23: 12	23: 56	24: 12
	25: 12	25: 56	26: 12	27: 12	28: 12	30: 12
	31: 12					

There are 23 hits at base# 12

35 -"- gagtc 1

- 131 -

26: 34

DdeI Ctnag

32

1: 14 2: 24 3: 14 3: 24 4: 14 4: 24
 5 5: 24 6: 14 7: 14 7: 24 8: 14 9: 14
 10: 14 11: 14 11: 24 12: 14 12: 24 15: 5
 15: 14 16: 14 16: 24 19: 24 20: 14 23: 14
 24: 14 25: 14 26: 14 27: 14 28: 14 29: 30
 30: 14 31: 14

10 There are 21 hits at base# 14

BsaJI Ccnngg

38

1: 23 1: 40 2: 39 2: 40 3: 39 3: 40
 4: 39 4: 40 5: 39 11: 39 12: 38 12: 39
 15 13: 23 13: 39 14: 23 14: 39 15: 38 16: 39
 17: 23 17: 39 18: 23 18: 39 21: 38 21: 39
 21: 47 22: 38 22: 39 22: 47 26: 40 27: 39
 28: 39 29: 14 29: 39 30: 38 30: 39 30: 47
 31: 23 31: 32

20 There are 17 hits at base# 39

There are 5 hits at base# 38**There are 5 hits at base# 40 Makes cleavage ragged.**

MnlI cctc

35

1: 23 2: 23 3: 23 4: 23 5: 23 6: 19
 25 6: 23 7: 19 8: 23 9: 19 9: 23 10: 23
 11: 23 13: 23 14: 23 16: 23 17: 23 18: 23
 19: 23 20: 47 21: 23 21: 29 21: 47 22: 23
 22: 29 22: 35 22: 47 23: 26 23: 29 24: 27
 27: 23 28: 23 30: 35 30: 47 31: 23

30 There are 21 hits at base# 23

There are 3 hits at base# 19**There are 3 hits at base# 29****There are 1 hits at base# 26****There are 1 hits at base# 27 These could make cleavage ragged.**

35 -- gagg

7

1: 48 2: 48 3: 48 4: 48 27: 44 28: 44
29: 44

5	1: 40	2: 39	3: 39	3: 40	4: 39	4: 40
	5: 39	6: 31	6: 39	7: 31	7: 39	8: 39
	9: 31	9: 39	10: 39	11: 39	12: 38	12: 52
	13: 39	13: 52	14: 52	16: 39	16: 52	17: 39
	17: 52	18: 39	18: 52	19: 39	19: 52	21: 38
10	22: 38	23: 39	24: 39	26: 39	27: 39	28: 39
	29: 14	29: 39	30: 38			

15 There are 3 hits at base# 40 Ragged

	1: 41	2: 40	5: 40	6: 40	7: 40	8: 40
	9: 40	10: 40	11: 40	12: 39	12: 53	13: 40
20	13: 53	14: 53	16: 40	16: 53	17: 40	17: 53
	18: 40	18: 53	19: 53	21: 39	22: 39	23: 40
	24: 40	27: 40	28: 40	29: 15	29: 40	30: 39

There are 1 hits at base# 41 Ragged

30	1: 41	2: 40	5: 40	6: 40	7: 40	8: 40
	9: 40	10: 40	11: 40	12: 39	12: 53	13: 40
	13: 53	14: 53	16: 40	16: 53	17: 40	17: 53
	18: 40	18: 53	19: 53	21: 39	22: 39	23: 40
	24: 40	27: 40	28: 40	29: 15	29: 40	30: 39

35 There are 7 hits at base# 53

- 133 -

There are 4 hits at base# 39

There are 1 hits at base# 41

ScrFI CCngg 39

5	1: 41	2: 40	3: 40	3: 41	4: 40	4: 41
	5: 40	6: 32	6: 40	7: 32	7: 40	8: 40
	9: 32	9: 40	10: 40	11: 40	12: 39	12: 53
	13: 40	13: 53	14: 53	16: 40	16: 53	17: 40
	17: 53	18: 40	18: 53	19: 40	19: 53	21: 39
10	22: 39	23: 40	24: 40	26: 40	27: 40	28: 40
	29: 15	29: 40	30: 39			

There are 21 hits at base# 40

There are 4 hits at base# 39

There are 3 hits at base# 41

15

MaeIII gtnac 16

	1: 52	2: 52	3: 52	4: 52	5: 52	6: 52
	7: 52	9: 52	26: 52	27: 10	27: 52	28: 10
	28: 52	29: 10	29: 52	30: 52		

20 There are 13 hits at base# 52

Tsp45I gtsac 15

	1: 52	2: 52	3: 52	4: 52	5: 52	6: 52
	7: 52	9: 52	27: 10	27: 52	28: 10	28: 52

25 29: 10 29: 52 30: 52

There are 12 hits at base# 52

HphI tcacc 26

	1: 53	2: 53	3: 53	4: 53	5: 53	6: 53
30	7: 53	8: 53	9: 53	10: 53	11: 59	13: 59
	14: 59	17: 59	18: 59	19: 59	20: 59	21: 59
	22: 59	23: 59	24: 59	25: 59	27: 59	28: 59
	30: 59	31: 59				

There are 16 hits at base# 59

- 134 -

There are 10 hits at base# 53

BspMI ACCTGCNNNNn

14

11: 61 13: 61 14: 61 17: 61 18: 61 19: 61
5 20: 61 21: 61 22: 61 23: 61 24: 61 25: 61
30: 61 31: 61

There are 14 hits at base# 61 Goes into CDR1

- 135 -

Table 12: Matches to URE FR3 adapters in 79 human HC.

A. List of Heavy-chains genes sampled

	AF008566	AF103367	HSA235674	HSU94417	S83240
	AF035043	AF103368	HSA235673	HSU94418	SABVH369
5	AF103026	AF103369	HSA240559	HSU96389	SADEIGVH
	af103033	AF103370	HSCB201	HSU96391	SAH2IGVH
	AF103061	af103371	HSIGGVHC	HSU96392	SDA3IGVH
	AF103072	AF103372	HSU44791	HSU96395	SIGVHTTD
	af103078	AF158381	HSU44793	HSZ93849	SUK4IGVH
10	AF103099	E05213	HSU82771	HSZ93850	
	AF103102	E05886	HSU82949	HSZ93851	
	AF103103	E05887	HSU82950	HSZ93853	
	AF103174	HSA235661	HSU82952	HSZ93855	
	AF103186	HSA235664	HSU82961	HSZ93857	
15	af103187	HSA235660	HSU86522	HSZ93860	
	AF103195	HSA235659	HSU86523	HSZ93863	
	af103277	HSA235678	HSU92452	MCOMFRAA	
	af103286	HSA235677	HSU94412	MCOMFRVA	
	AF103309	HSA235676	HSU94415	S82745	
20	af103343	HSA235675	HSU94416	S82764	

Table 12B. Testing all distinct GLGs from bases 89.1 to 93.2 of the heavy variable domain

	Id	Nb	0	1	2	3	4		SEQ ID
	NO:								
25	1	38	15	11	10	0	2	Seq1 gtgtattactgtgc	25
	2	19	7	6	4	2	0	Seq2 gtAtattactgtgc	26
	3	1	0	0	1	0	0	Seq3 gtgtattactgtAA	27
	4	7	1	5	1	0	0	Seq4 gtgtattactgtAc	28
	5	0	0	0	0	0	0	Seq5 Ttgtattactgtgc	29
30	6	0	0	0	0	0	0	Seq6 TtgtatCactgtgc	30
	7	3	1	0	1	1	0	Seq7 ACAtattactgtgc	31
	8	2	0	2	0	0	0	Seq8 ACgtattactgtgc	32
	9	9	2	2	4	1	0	Seq9 ATgtattactgtgc	33
	Group		26	26	21	4	2		
35	Cumulative		26	52	73	77	79		

Table 12C Most important URE recognition seqs in FR3 Heavy

	1	VHSzy1	GTGtattactgtgc	(ON_SHC103)	(SEQ ID NO:25)
	2	VHSzy2	GTAAtattactgtgc	(ON_SHC323)	(SEQ ID NO:26)
	3	VHSzy4	GTGtattactgtac	(ON_SHC349)	(SEQ ID NO:28)
40	4	VHSzy9	ATGtattactgtgc	(ON_SHC5a)	(SEQ ID NO:33)

Table 12D, testing 79 human HC V genes with four probes

Number of sequences..... 79
 Number of bases..... 29143

- 136 -

		Number of mismatches								
	Id	Best	0	1	2	3	4	5		
5	1	39	15	11	10	1	2	0	Seq1	gtgtattactgtgc (SEQ ID NO:25)
	2	22	7	6	5	3	0	1	Seq2	gtAtattactgtgc (SEQ ID NO:26)
	3	7	1	5	1	0	0	0	Seq4	gtgtattactgtAc (SEQ ID NO:28)
	4	11	2	4	4	1	0	0	Seq9	ATgtattactgtgc (SEQ ID NO:33)
	Group		25	26	20	5	2			
10	Cumulative		25	51	71	76	78			

One sequence has five mismatches with sequences 2, 4, and 9; it is scored as best for 2.

Id is the number of the adapter.

Best is the number of sequence for which the identified

15 adapter was the best available.

The rest of the table shows how well the sequences match the adapters. For example, there are 10 sequences that match VHSzyl(Id=1) with 2 mismatches and are worse for all other adapters. In this sample, 90% come within 2 bases of one of

20 the four adapters.

- 137 -

Table 13

The following list of enzymes was taken from
<http://rebase.neb.com/cgi-bin/asymmlist>.

- 5 I have removed the enzymes that a) cut within the recognition, b) cut on both sides of the recognition, or c) have fewer than 2 bases between recognition and closest cut site.

REBASE Enzymes
 04/13/2001

10	Type II restriction enzymes with asymmetric recognition sequences:			
	Enzymes	Recognition Sequence	Isoschizomers	Suppliers
	AarI	CACCTGCNNNN^NNNN	-	y
	AceIII	CAGCTCNNNNNNN^NNNN	-	-
	Bbr7I	GAAGACNNNNNNN^NNNN	-	-
15	BbvI	GCAGCNNNNNNNN^NNNN	-	y
	BbvII	GAAGACNN^NNNN	-	-
	Bce83I	CTTGAGNNNNNNNNNNNNNN NN^	-	-
	BceAI	ACGGCNNNNNNNNNNNN^NN	-	y
	BceFI	ACGGCNNNNNNNNNNNN^N	-	-
20	BciVI	GTATCCNNNNN N^	BfuI	y
	BfiI	ACTGGGNNNN N^	BmrI	y
	BinI	GGATCNNNN^N	-	-
	BscAI	GCATCNNNN^NN	-	-
	BseRI	GAGGAGNNNNNNNN NN^	-	y
25	BsmFI	GGGACNNNNNNNNNN^NNNN	BspLU11III	y
	BspMI	ACCTGCNNNN^NNNN	Acc36I	y
	EciI	GGCGGANNNNNNNNNN NN^	-	y
	Eco57I	CTGAAGNNNNNNNNNNNN NN^	BspKT5I	y
	FauI	CCCGCNNNN^NN	BstFZ438I	y
30	FokI	GGATGNNNNNNNNNN^NNNN	BstPZ418I	y
	GsuI	CTGGAGNNNNNNNNNNNN NN^	-	y
	HgaI	GACGCNNNNN^NNNNN	-	y
	HphI	GGTGANNNNNN N^	AsuHPI	y
	MboII	GAAGANNNNNN N^	-	y
35	MlyI	GAGTCNNNNN^	SchI	y
	MmeI	TCCRACNNNNNNNNNNNNNNNN NN^	-	-
	MnlI	CCTCNNNNNN N^	-	y
	PleI	GAGTCNNNN^N	PpsI	y
	RleAI	CCCACANNNNNNNNN NNN^	-	-
40	SfaNI	GCATCNNNNN^NNNN	BspST5I	y
	SspD5I	GGTGANNNNNNN^	-	-
	Sth132I	CCCGNNNN^NNNN	-	-
	StsI	GGATGNNNNNNNNNN^NNNN	-	-
	TaqII	GACCGANNNNNNNN NN^, CACCCANNNNNNNN NN^	-	-
45	Tth111II	CAARCANNNNNNNNN NN^	-	-
	UbaPI	CGAACG	-	-

The notation is ^ means cut the upper strand and _ means cut the lower strand. If the upper and lower strand are cut at the same place, then only ^ appears.

Table 14

(FOK)act) 5'-cAcaTccgTg TTgTT cAcgATgTg-3'

(VHEX881) 5'-AATAGTAGAc TgcAgTgTcc TcAgccCTTA AgcTgTtCAT cTgcAAgTAG-
AgAgTATTCT TAGAgTTgTc TcTAGAcTTA gTgAAgcg-3'

5 ! note that VHEX881 is the reverse complement of the ON below

! [RC] 5'-cgCttcacTaag-

! Scab.....

! Synthetic 3-23 as in Table 206

! |TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-

10 ! XbaI...

! |aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|t-3'

! AflII...

(VHBA881) 5'-cgCttcacTaag-

|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-

15 |aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgt gcg ag-3'

(VHBB881) 5'-cgCttcacTaag-

|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-

|aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgt Acg ag-3'

(VH881PCR) 5'-cgCttcacTaag|TCT|AGA|gac|aac -3'

- 139 -

Table 15: Use of *FokI* as "Universal Restriction Enzyme"*FokI* - for dsDNA, | represents sites of cleavage

5' - cacGGATGtg--nnnnnnn|nnnnnnn-3' (SEQ ID NO:15)
 5 3' - gtgCCTACac--nnnnnnnnnn|nnn-5' (SEQ ID NO:16)
 RECOG
 NITION of *FokI*

Case I

10 5' - ...gtg|tatt-actgtgc..Substrate....-3' (SEQ ID NO:17)
 3' - cac-ataa|tgacacg-
 gtGTAGGcac\
 5' - caCATCCgtg/ (SEQ ID NO:18)

Case II

15 5' - ...gtgtatt|agac-tgc..Substrate....-3' (SEQ ID NO:19)
 |cacataa-tctg|acg-5'
 /gtgCCTACac
 \cacGGATGtg-3' (SEQ ID NO:20)

Case III (Case I rotated 180 degrees)

20 /gtgCCTACac-5'
 \cacGGATGtg-
 |gtgtatt|acag-tcc-3' Adapter (SEQ ID NO:21)
 3' - ...cacagaa-tgtc|agg..substrate....-5' (SEQ ID NO:22)

Case IV (Case II rotated 180 degrees)

25 3' - gtGTAGGcac\ (SEQ ID NO:23)
 |cacATCCgtg/
 5' - gag|tctc-actgagc
 Substrate 3' - ...ctc-agag|tgactcg...-5' (SEQ ID NO:24)

Improved *FokI* adapters*FokI* - for dsDNA, | represents sites of cleavage


30 Case I
 Stem 11, loop 5, stem 11, recognition 17

35 5' - ...catgtg|tatt-actgtgc..Substrate....-3'
 3' - gtacac-ataa|tgacacg-
 gtGTAGGcacG T
 5' - caCATCCgtgc C
 |TT|

- 140 -


Case II

Stem 10, loop 5, stem 10, recognition 18




Case III (Case I rotated 180 degrees)

Stem 11, loop 5, stem 11, recognition 20




Case IV (Case II rotated 180 degrees)

Stem 11, loop 4, stem 11, recognition 17



BseRI



Stem 11, loop 5, stem 11, recognition 19




Table 16 Human heavy chains bases 88.1 to 94.2

Number of sequences..... 840

Id	Ntot	Number of Mismatches.....							Name	Sequence.....	Dot form.....
		0	1	2	3	4	5	6			
1	364	152	97	76	26	7	4	2	0	VHS881-1.1	gctgtgtattactgtgcgag
2	265	150	60	33	13	5	4	0	0	VHS881-1.2	gccgtgtattactgtgcgag
3	96	14	34	16	10	5	7	9	1	VHS881-2.1	gccgtgtattactgtgcgag
4	20	0	3	4	9	2	2	0	0	VHS881-4.1	gccgtgtattactgtgcgag
5	95	25	36	18	11	2	2	0	1	VHS881-9.1	gccatgtattactgtgcgag
840	341	230	147	69	21	19	11	2			
341	571	718	787	808	827	838	840				

88 89 90 91 92 93 94 95 Codon number as in Table 195

Recognition..... Stem..... Loop. Stem.....

(VHS881-1.1) 5'-gctgtgtat|tact-gtgcgag cAcATccgTg TTgTT cAcgATgTg-3'

(VHS881-1.2) 5'-gccgtgtat|tact-gtgcgag cAcATccgTg TTgTT cAcgATgTg-3'

(VHS881-2.1) 5'-gccgtgtat|tact-gtgcgag cAcATccgTg TTgTT cAcgATgTg-3'

(VHS881-4.1) 5'-gccgtgtat|tact-gtgcgag cAcATccgTg TTgTT cAcgATgTg-3'

(VHS881-9.1) 5'-gccatgtat|tact-gtgcgag cAcATccgTg TTgTT cAcgATgTg-3'

| site of substrate cleavage

(FOK)act) 5'-cAcATccgTg TTgTT cAcgATgTg-3'

(VHEx881) 5'-AATAgTAgAc TgcAgTgTcc TcAgcccTTA AgcTgTTcAT cTgcAAGTAG-
AgAgTATTCt TAGAgTTgTc TcTAGAcTTA gTgAAgag-3'

! note that VHEx881 is the reverse complement of the ON below

25 ! [RC] 5'-cgCttacTaag-

! Scab.....

! Synthetic 3-23 as in Table 206

! |TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-

! XbaI...

30 ! |aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|t-3'

```

1      ARII...
(VHBA881) 5'-cgCttcacTaag-
          |TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-
          |aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgt|gcg|ag-3'
5 (VHBB881) 5'-cgCttcacTaag-
          |TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-
          |aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgt|Acg|ag-3'
(VH881PCR) 5'-cgCttcacTaag|TCT|AGA|gac|aac-3'

```


I FokI. FokI.

What happens in the upper strand:

(SzkB1230-O12*) 5'-gac cca gtc | tcc a-tc ctc c-3'
| Site of cleavage in substrate

5

(SzkB1230-A17*) 5'-gac tca gtc | tcc a-ct ctc c-3'

(SzkB1230-A27*) 5'-gac gca gtc | tcc a-gg cac c-3'

10 (SzkB1230-A11*) 5'-gac gca gtc | tcc a-gc cac c-3'

(kapextURE) 5'-ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg-3' !sense strand
Scab.....ApaLI.

(kapextUREPCR) 5'-ccTctactctTgTcAcAgTg-3'
Scab.....

15 (kaBR01UR) 5'-ggAggATggA cIggATgTcT TgTgcAcTgT gAcAaAgATa gAgg-3'
! [RC] 5'-ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg tcc a-tc ctc c-3' ON above is R.C. of this one
(kaBR02UR) 5'-ggAggATggA cIggATgTcT TgTgcAcTgT gAcAaAgATa gAgg-3'
! [RC] 5'-ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg tcc a-tc ctc c-3' ON above is R.C. of this one
(kaBR03UR) 5'-ggTggcTggA cIggATgTcT TgTgcAcTgT gAcAaAgATa gAgg-3'
! [RC] 5'-ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg tcc a-gg cac c-3' ON above is R.C. of this one
(kaBR04UR) 5'-ggTggcTggA cIggATgTcT TgTgcAcTgT gAcAaAgATa gAgg-3'
! [RC] 5'-ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg tcc a-gc cac c-3' ON above is R.C. of this one
Scab.....ApaLI.

20

Table 18 Lambda URE adapters bases 13.3 to 19.3

Number of sequences..... 128											
Number of mismatches.....											
		Name								Sequence.....	Dot form.....
	Id	Nrot	0	1	2	3	4	5	6	7	8
5	1	58	45	7	1	0	0	2	2	1	VL133-2a2
		gtrctctggacagtcgac gtrctctggacagtcgac									
	2	16	10	1	0	1	0	1	0	2	VL133-3l
		ggctctgggacagacgac g.cttg.....a.ag..									
	3	17	6	0	0	4	1	1	5	0	VL133-2c
		gtrctctgggacagtcgacag..									
10	4	37	3	0	10	4	4	3	7	4	2
		VL133-1c									
		ggcccccaggcgagggtc g.c.a..g...ag.g..									
	128	64	8	11	5	8	5	11	11	5	
	64	72	83	88	96	101	112	123	128		
15	Stem..... loop. Stem..... Recognition.....										
	(VL133-2a2)	5'-cAcATccgTg TTgTT cAcggATgTg gATcgAcTgTccAggAgAc-3'									
	[RC]	5'-gtctctggacagtcgac cAcATccgTg AAcAA cAcggATgTg-3'									
	Recognition..... Stem..... Loop. Stem.....										
20	Stem..... loop. Stem..... Recognition.....										
	(VL133-3l)	5'-cAcATccgTg TTgTT cAcggATgTg gAcTgTcTgTccAAggccc-3'									
	[RC]	5'-ggctctgggacagacgac cAcATccgTg AAcAA cAcggATgTg-3'									
	Recognition..... Stem..... Loop. Stem.....										
25	Stem..... loop. Stem..... Recognition.....										
	(VL133-2c)	5'-cAcATccgTg TTgTT cAcggATgTg gAcTgAcTgTccAggAgAc-3'									
	[RC]	5'-gtrctctggacagtcgac cAcATccgTg AAcAA cAcggATgTg-3'									
	Recognition..... Stem..... Loop. Stem.....										
30	Stem..... loop. Stem..... Recognition.....										
	(VL133-1c)	5'-cAcATccgTg TTgTT cAcggATgTg gAcctcTgcccTggggccc-3'									
	[RC]	5'-ggcccccaggcgagggtc cAcATccgTg AAcAA cAcggATgTg-3'									

- 146 -

What happens in the top strand:

```

!           | site of cleavage in the upper strand
(VL133-2a2*) 5'-g tct cct g|ga cag tcg atc
!
5 (VL133-3l*) 5'-g gcc ttg g|ga cag aca gtc
!
(VL133-2c*) 5'-g tct cct g|ga cag tca gtc
!
(VL133-1c*) 5'-g gcc cca g|gg cag agg gtc
10 !
! The following Extenders and Bridges all encode the AA sequence of 2a2 for codons 1-15
!           1
(ON_LamEx133) 5'-ccTcTgAcTgAgT gcA cAg -
!
15 !           2 3 4 5 6 7 8 9 10 11 12
AGt gcT TtA acC caA ccG gcT AGT gtT AGC ggT-
!
!           13 14 15
tcC ccG g! 2a2
20 !           1
(ON_LamB1-133) [RC] 5'-ccTcTgAcTgAgT gcA cAg -
!
!           2 3 4 5 6 7 8 9 10 11 12
AGt gcT TtA acC caA ccG gcT AGT gtT AGC ggT-
25 !
!           13 14 15
tcC ccG g ga cag tcg at-3'! 2a2 N.B. the actual seq is the
! reverse complement of the
! one shown.
30 !
(ON_LamB2-133) [RC] 5'-ccTcTgAcTgAgT gcA cAg -
!
!           2 3 4 5 6 7 8 9 10 11 12
AGt gcT TtA acC caA ccG gcT AGT gtT AGC ggT-
35 !
!           13 14 15
tcC ccG g ga cag aca gt-3'! 3l N.B. the actual seq is the
! reverse complement of the
! one shown.
40 !
(ON_LamB3-133) [RC] 5'-ccTcTgAcTgAgT gcA cAg -
!
!           2 3 4 5 6 7 8 9 10 11 12
45 AGt gcT TtA acC caA ccG gcT AGT gtT AGC ggT-
!
!           13 14 15
tcC ccG g ga cag tca gt -3'! 2c N.B. the actual seq is the
! reverse complement of the
! one shown.
50 !
! (ON_LamB4-133) [RC] 5'-ccTcTgAcTgAgT gcA cAg -

```


- 147 -

```

!
!       2   3   4   5   6   7   8   9   10  11  12
!       AGt gcT TtA acC caA ccG gcT AGT gtT AGC ggT-s
!
5  !       13  14  15
!       tcC ccG g  gg cag agg gt-3' ! 1c  N.B. the actual seq is the
!                                     reverse complement of the
!                                     one shown.
!
10 (ON_Lam133PCR)  5'-ccTcTgAcTgAgT gcA cAg AGt gc-3'

```

- 148 -

Table 19: Cleavage of 75 human light chains.

	Enzyme	Recognition*	Nch	Ns	Planned location of site
	AfeI	AGCgct	0	0	
5	AflII	Cttaag	0	0	HC FR3
	AgeI	Accggt	0	0	
	AscI	GGGcgcc	0	0	After LC
	BglII	Agatct	0	0	
	BsiWI	Cgtacg	0	0	
	BspDI	ATcgat	0	0	
10	BssHII	Gcgcg	0	0	
	BstBI	TTcgaa	0	0	
	DraIII	CACNNNgtg	0	0	
	EagI	Cggccg	0	0	
	FseI	GGCCGGcc	0	0	
15	FspI	TGCgca	0	0	
	HpaI	GTTaac	0	0	
	MfeI	Caattg	0	0	HC FR1
	MluI	Acgcgt	0	0	
	NcoI	Ccatgg	0	0	Heavy chain signal
20	NheI	Gctagc	0	0	HC/anchor linker
	NotI	GCggccgc	0	0	In linker after HC
	NruI	TCGcga	0	0	
	PacI	TTAATtaa	0	0	
	PmeI	GTTTaaac	0	0	
25	PmlI	CACgtg	0	0	
	PvuI	CGATcg	0	0	
	SacII	CCGCgg	0	0	
	SalI	Gtcgac	0	0	
	SfiI	GGCCNNNNggcc	0	0	Heavy Chain signal
30	SgfI	GCGATcg	0	0	
	SnaBI	TACgta	0	0	
	StuI	AGGcct	0	0	
	XbaI	Tctaga	0	0	HC FR3
35	AatII	GACGTc	1	1	
	AclI	AAcggt	1	1	
	AseI	ATtaat	1	1	
	BsmI	GAATGCN	1	1	
	BspEI	Tccgga	1	1	HC FR1
	BstXI	CCANNNNNntgg	1	1	HC FR2
40	DrdI	GACNNNNngtc	1	1	
	HindIII	Aagctt	1	1	
	PciI	Acatgt	1	1	
	SapI	gaagagc	1	1	
	ScaI	AGTact	1	1	
45	SexAI	Accwgt	1	1	
	SpeI	Actagt	1	1	
	TliI	Ctcgag	1	1	
	XhoI	Ctcgag	1	1	
	BcgI	cgannnnntgc	2	2	
50	BlpI	GCtnagc	2	2	
	BssSI	Ctcgtg	2	2	
	BstAPI	GCANNNNntgc	2	2	
	EspI	GCtnagc	2	2	
	KasI	Ggcgcc	2	2	
55	PflMI	CCANNNNntgg	2	2	
	XmnI	GAANNnttc	2	2	
	ApaLI	Gtgcac	3	3	LC signal seq

- 149 -

	NaeI	GCCggc	3	3	
	NgoMI	Gccggc	3	3	
	PvuII	CAGctg	3	3	
	RsrII	CGgwcg	3	3	
5	BsrBI	GAGcgg	4	4	
	BsrDI	GCAATGNNn	4	4	
	BstZ17I	GTAtac	4	4	
	EcoRI	Gaattc	4	4	
	SphI	GCATGc	4	4	
10	SspI	AATatt	4	4	
	AccI	GTmkac	5	5	
	BclI	Tgatca	5	5	
	BsmBI	Nnnnnngagacg	5	5	
	BsrGI	Tgtaca	5	5	
15	DraI	TTTaaa	6	6	
	NdeI	CAtatg	6	6	HC FR4
	SwaI	ATTTaaat	6	6	
	BamHI	Ggatcc	7	7	
	SacI	GAGCTc	7	7	
20	BciVI	GTATCCNNNNNN	8	8	
	BsaBI	GATNNnnatc	8	8	
	NsiI	ATGCAt	8	8	
	Bsp120I	Gggccc	9	9	CH1
	ApaI	GGGCCc	9	9	CH1
25	PspOoMI	Gggccc	9	9	
	BspHI	Tcatga	9	11	
	EcoRV	GATatc	9	9	
	AhdI	GACNNNngtc	11	11	
	BbsI	GAAGAC	11	14	
30	PsiI	TTATAa	12	12	
	BsaI	GGTCTCnnnn	13	15	
	XmaI	Cccggg	13	14	
	AvaI	Cycgrg	14	16	
	BglI	GCCNNNNnggc	14	17	
35	AlwNI	CAGNNNctg	16	16	
	BspMI	ACCTGC	17	19	
	XcmI	CCANNNNNnnnttg	17	26	
	BstEII	Ggtnacc	19	22	HC FR4
	Sse8387I	CCTGCAGg	20	20	
40	AvrII	Cctagg	22	22	
	HincII	GTYrac	22	22	
	BsgI	GTGCAG	27	29	
	MscI	TGGcca	30	34	
	BseRI	NNnnnnnnnnctcctc	32	35	
45	Bsu36I	CCtnagg	35	37	
	PstI	CTGCAG	35	40	
	EciI	nnnnnnnnntccgcc	38	40	
	PpuMI	RGgwccy	41	50	
	StyI	Ccwwgg	44	73	
50	EcoO109I	RGgnccy	46	70	
	Acc65I	Ggtacc	50	51	
	KpnI	GGTACc	50	51	
	BpmI	ctccag	53	82	
	AvaII	Ggwcc	71	124	

55 * cleavage occurs in the top strand after the last upper-case base. For REs that cut palindromic sequences, the lower strand is cut at the symmetrical site.

- 150 -

Table 20: Cleavage of 79 human heavy chains

	Enzyme	Recognition	Nch	Ns	Planned location of site
	AfeI	AGCgct	0	0	
5	AflIII	Cttaag	0	0	HC FR3
	AscI	GGGcgccc	0	0	After LC
	BsiWI	Cgtacg	0	0	
	BspDI	ATcgat	0	0	
	BssHII	Gcgcg	0	0	
10	FseI	GGCCGGcc	0	0	
	HpaI	GTTaac	0	0	
	NheI	Gctagc	0	0	HC Linker
	NotI	GCGgccc	0	0	In linker, HC/anchor
	NruI	TCGcga	0	0	
	NsiI	ATGCAt	0	0	
15	PacI	TTAATtaa	0	0	
	PciI	Acatgt	0	0	
	PmeI	GTTTaaac	0	0	
	PvuI	CGATcg	0	0	
20	RsrII	CGgwccg	0	0	
	SapI	gaagagc	0	0	
	SfiI	GGCCNNNNnggcc	0	0	HC signal seq
	SgfI	GCGATcgc	0	0	
	SwaI	ATTTaaat	0	0	
25	AclI	AACgtt	1	1	
	AgeI	Accggt	1	1	
	AseI	ATtaat	1	1	
	AvrII	Cctagg	1	1	
	BsmI	GAATGCN	1	1	
30	BsrBI	GAGcgg	1	1	
	BsrDI	GCAATGNNn	1	1	
	DraI	TTTaaa	1	1	
	FspI	TGCgca	1	1	
	HindIII	Aagctt	1	1	
35	MfeI	Caattg	1	1	HC FR1
	NaeI	GCCggc	1	1	
	NgoMI	Gccggc	1	1	
	SpeI	Actagt	1	1	
	Acc65I	Ggtacc	2	2	
40	BstBI	TTcgaa	2	2	
	KpnI	GGTACc	2	2	
	MluI	Acgcgt	2	2	
	NcoI	Ccatgg	2	2	In HC signal seq
	NdeI	CAtatg	2	2	HC FR4
	PmlI	CACgtg	2	2	
45	XcmI	CCANNNNNnnntgg	2	2	
	BcgI	cgannnnntgc	3	3	
	BclI	Tgatca	3	3	
	BglI	GCCNNNNnggc	3	3	
50	BsaBI	GATNNnnatc	3	3	
	BsrGI	Tgtaca	3	3	
	SnaBI	TACgta	3	3	
	Sse8387I	CCTGCAGg	3	3	
	ApaLI	Gtgcac	4	4	LC Signal/FR1
55	BspHI	Tcatga	4	4	
	BssSI	Ctcgtg	4	4	
	PsiI	TTAtaa	4	5	

- 151 -

	SphI	GCATGc	4	4	
	AhdI	GACNNNnngtc	5	5	
	BspEI	Tccgga	5	5	HC FR1
	MscI	TGGcca	5	5	
5	SacI	GAGCTc	5	5	
	ScaI	AGTact	5	5	
	SexAI	Accwgt	5	6	
	SspI	AATatt	5	5	
	TliI	Ctcgag	5	5	
10	XhoI	Ctcgag	5	5	
	BbsI	GAAGAC	7	8	
	BstAPI	GCANNNNntgc	7	8	
	BstZ17I	GTatac	7	7	
	EcoRV	GATatc	7	7	
15	EcoRI	Gaattc	8	8	
	BlpI	GCtnagc	9	9	
	Bsu36I	CCtnagg	9	9	
	DraIII	CACNNNgtg	9	9	
	EspI	GCtnagc	9	9	
20	StuI	AGGcct	9	13	
	XbaI	Tctaga	9	9	HC FR3
	Bsp120I	Gggccc	10	11	CH1
	ApaI	GGGCCc	10	11	CH1
	PspOoMI	Gggccc	10	11	
25	BciVI	GTATCCNNNNNN	11	11	
	SalI	Gtcgac	11	12	
	DrdI	GACNNNnngtc	12	12	
	KasI	Ggcgcc	12	12	
	XmaI	Cccggg	12	14	
30	BglII	Agatct	14	14	
	HincII	GTYrac	16	18	
	BamHI	Ggatcc	17	17	
	PflMI	CCANNNNntgg	17	18	
	BsmBI	Nnnnnngagacg	18	21	
35	BstXI	CCANNNNntgg	18	19	HC FR2
	XmnI	GAANNnnttc	18	18	
	SacII	CCGCgg	19	19	
	PstI	CTGCAG	20	24	
	PvuII	CAGctg	20	22	
40	AvaI	Cycgrg	21	24	
	EagI	Cggccg	21	22	
	AatII	GACGTc	22	22	
	BspMI	ACCTGC	27	33	
	AccI	GTmkac	30	43	
45	StyI	Ccwwgg	36	49	
	AlwNI	CAGNNNctg	38	44	
	BsaI	GGTCTCNnnnn	38	44	
	PpuMI	RGgwccy	43	46	
	BsgI	GTGCAG	44	54	
50	BseRI	NNnnnnnnnnctcctc	48	60	
	EciI	nnnnnnnnntccgcc	52	57	
	BstEII	Ggtnacc	54	61	HC Fr4, 47/79 have one
	EcoO109I	RGgnccy	54	86	
	BpmI	ctccag	60	121	
55	AvaII	Ggwcc	71	140	

- 152 -

Table 21: MALIA3, annotated
! MALIA3 9532 bases

```

-----
5  ! 1 aat gct act act att agt aga att gat gcc acc ttt tca gct cgc gcc
    ! gene ii continued
    49 cca aat gaa aat ata gct aaa cag gtt att gac cat ttg cga aat gta
    97 tct aat ggt caa act aaa tct act cgt tcg cag aat tgg gaa tca act
145 gtt aca tgg aat gaa act tcc aga cac cgt act tta gtt gca tat tta
193 aaa cat gtt gag cta cag cac cag att cag caa tta agc tct aag cca
10 241 tcc gca aaa atg acc tct tat caa aag gag caa tta aag gta ctc tct
    289 aat cct gac ctg ttg gag ttt gct tcc ggt ctg gtt cgc ttt gaa gct
    337 cga att aaa acg cga tat ttg aag tct ttc ggg ctt cct ctt aat ctt
    385 ttt gat gca atc cgc ttt gct tct gac tat aat agt cag ggt aaa gac
    433 ctg att ttt gat tta tgg tca ttc tcg ttt tct gaa ctg ttt aaa gca
15 481 ttt gag ggg gat tca ATG aat att tat gac gat tcc gca gta ttg gac
    ! RBS?..... Start gene x, ii continues
    529 gct atc cag tct aaa cat ttt act att acc ccc tct ggc aaa act tct
    577 ttt gca aaa gcc tct cgc tat ttt ggt ttt tat cgt cgt ctg gta aac
    625 gag ggt tat gat agt gtt gct ctt act atg cct cgt aat tcc ttt tgg
20 673 cgt tat gta tct gca tta gtt gaa tgt ggt att cct aaa tct caa ctg
    721 atg aat ctt tct acc tgt aat aat gtt gtt ccg tta gtt cgt ttt att
    769 aac gta gat ttt tct tcc caa cgt cct gac tgg tat aat gag cca gtt
    817 ctt aaa atc gca TAA
    ! End X & II
25 832 ggtaattca ca
    !
    ! M1 E5 Q10 T15
    843 ATG att aaa gtt gaa att aaa cca tct caa gcc caa ttt act act cgt
    ! Start gene V
30 891 tct ggt gtt tct cgt cag ggc aag cct tat tca ctg aat gag cag ctt
    !
    ! S17 S20 P25 E30
    939 tgt tac gtt gat ttg ggt aat gaa tat ccg gtt ctt gtc aag att act
35 987 ctt gat gaa ggt cag cca gcc tat gcg cct ggt cTG TAC Acc gtt cat
    ! D50 A55 L60
    ! BsrGI...
40 1035 ctg tcc tct ttc aaa gtt ggt cag ttc ggt tcc ctt atg att gac cgt
    !
    ! P85 K87 end of V
    1083 ctg cgc ctc gtt ccg gct aag TAA C
45 1108 ATG gag cag gtc gcg gat ttc gac aca att tat cag gcg atg
    ! Start gene VII
    !
50 1150 ata caa atc tcc gtt gta ctt tgt ttc gcg ctt ggt ata atc
    !
    ! VII and IX overlap.
    ! ..... S2 V3 L4 V5 S10
    1192 gct ggg ggt caa agA TGA gt gtt tta gtg tat tct ttc gcc tct ttc gtt
    ! End VII
55 1242 tta ggt tgg tgc ctt cgt agt ggc att acg tat ttt acc cgt tta atg gaa
    ! start IX
    ! L13 W15 G20 T25 E29

```

- 153 -

```

!
! 1293 act tcc tc
!
! .... stop of IX, IX and VIII overlap by four bases
5 1301 ATG aaa aag tct tta gtc ctc aaa gcc tct gta gcc gtt gct acc ctc
! Start signal sequence of viii.
!
! 1349 gtt ccg atg ctg tct ttc gct gct gag ggt gac gat ccc gca aaa gcg
! mature VIII --->
10 1397 gcc ttt aac tcc ctg caa gcc tca gcg acc gaa tat atc ggt tat gcg
1445 tgg gcg atg gtt gtt gtc att
1466 gtc ggc gca act atc ggt atc aag ctg ttt aag
1499 aaa ttc acc tcg aaa gca ! 1515
! ..... -35 ..
15 1517 agc tga taaaccgat acaattaaag gctccttttg
! ..... -10 ...
!
! 1552 gagccttttt ttttGGAGAt ttt ! S.D. underlined
20 1575 caac GTG aaa aaa tta tta ttc gca att cct tta gtt ! 1611
!
! <----- III signal sequence ----->
! M K K L L F A I P L V
! 1612 gtt cct ttc tat tct cac aGT gcA Cag tCT
! ApaLI...
!
! 1642 GTC GTG ACG CAG CCG CCC TCA GTG TCT GGG GCC CCA GGG CAG
30 AGG GTC ACC ATC TCC TGC ACT GGG AGC AGC TCC AAC ATC GGG GCA
! BstEII...
! 1729 GGT TAT GAT GTA CAC TGG TAC CAG CAG CTT CCA GGA ACA GCC CCC AAA
! 1777 CTC CTC ATC TAT GGT AAC AGC AAT CGG CCC TCA GGG GTC CCT GAC CGA
! 1825 TTC TCT GGC TCC AAG TCT GGC ACC TCA GCC TCC CTG GCC ATC ACT
35 1870 GGG CTC CAG GCT GAG GAT GAG GCT GAT TAT
1900 TAC TGC CAG TCC TAT GAC AGC AGC CTG AGT
1930 GGC CTT TAT GTC TTC GGA ACT GGG ACC AAG GTC ACC GTC
! BstEII...
! 1969 CTA GGT CAG CCC AAG GCC AAC CCC ACT GTC ACT
40 2002 CTG TTC CCG CCC TCC TCT GAG GAG CTC CAA GCC AAC AAG GCC ACA CTA
2050 GTG TGT CTG ATC AGT GAC TTC TAC CCG GGA GCT GTG ACA GTG GCC TGG
2098 AAG GCA GAT AGC AGC CCC GTC AAG GCG GGA GTG GAG ACC ACC ACA CCC
2146 TCC AAA CAA AGC AAC AAC AAG TAC GCG GCC AGC AGC TAT CTG AGC CTG
2194 ACG CCT GAG CAG TGG AAG TCC CAC AGA AGC TAC AGC TGC CAG GTC ACG
45 2242 CAT GAA GGG AGC ACC GTG GAG AAG ACA GTG GCC CCT ACA GAA TGT TCA
2290 TAA TAA ACCG CCTCCACCGG GCGCGCCAAT TCTATTTCAGGAGACAGTC ATA
! AscI.....
!
! PelB signal----->
! M K Y L L P T A A A G L L L L
50 2343 ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC
!
! 16 17 18 19 20 21 22
! A A Q P A M A
55 2388 gcG GCC cag ccG GCC atg gcc
! SfiI.....
! NgoMI... (1/2)
! NcoI.....

```

```

5      2409      FR1(DP47/V3-23)-----
                23 24 25 26 27 28 29 30
                E  V  Q  L  L  E  S  G
                gaa|gtt|CAA|TTG|tta|gag|tct|ggt|
                | MfeI |
10     2433      -----FR1-----
                31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
                G  G  L  V  Q  P  G  G  S  L  R  L  S  C  A
                |ggc|ggt|ctt|ggt|cag|cct|ggt|ggt|tct|tta|cgt|ctt|tct|tgc|gct|
15     2478      ----FR1----->|...CDR1.....|---FR2-----
                46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
                A  S  G  F  T  F  S  S  Y  A  M  S  W  V  R
                |gct|TCC|GGA|ttc|act|ttc|tct|tCG|TAC|Gct|atg|tct|tgg|ggt|cgC|
                | BspEI |                | BsiWI|                |BstXI.
20     2523      -----FR2----->|...CDR2.....
                61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
                Q  A  P  G  K  G  L  E  W  V  S  A  I  S  G
                |CAa|gct|ccT|GGT|aaa|ggt|ttg|gag|tgg|ggt|tct|gct|atc|tct|ggt|
                ...BstXI                |
25     2568      .....CDR2.....|---FR3---
                76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
                S  G  G  S  T  Y  Y  A  D  S  V  K  G  R  F
                |tct|ggt|ggc|agt|act|tac|tat|gct|gac|tcc|ggt|aaa|ggt|cgc|ttc|
30     2613      -----FR3-----
                91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
                T  I  S  R  D  N  S  K  N  T  L  Y  L  Q  M
                |act|atc|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|
                | XbaI |
35     2658      ---FR3----->|
                106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
                N  S  L  R  A  E  D  T  A  V  Y  Y  C  A  K
                |aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgc|gct|aaa|
                |AflIII |                | PstI |
40     2703      .....CDR3.....|---FR4-----
                121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
                D  Y  E  G  T  G  Y  A  F  D  I  W  G  Q  G
                |gac|tat|gaa|ggt|act|ggt|tat|gct|ttc|gaC|ATA|TGg|ggt|caa|ggt|
                | NdeI | (1/4)
45     2748      -----FR4----->|
                136 137 138 139 140 141 142
                T  M  V  T  V  S  S
                |act|atG|GTC|ACC|gtc|tct|agt
                | BstEII |
50     From BstEII onwards, pV323 is same as pCES1, except as noted.
55     BstEII sites may occur in light chains; not likely to be unique in final
        vector.

```



```

143 144 145 146 147 148 149 150 151 152
A S T K G P S V F P
2769 gcc tcc acc aaG GGC CCA tcg GTC TTC ccc
Bsp120I. BbsI... (2/2)
ApaI....

153 154 155 156 157 158 159 160 161 162 163 164 165 166 167
L A P S S K S T S G G T A A L
2799 ctg gca ccC TCC TCc aag agc acc tct ggg ggc aca gcg gcc ctg
BseRI... (2/2)

168 169 170 171 172 173 174 175 176 177 178 179 180 181 182
G C L V K D Y F P E P V T V S
2844 ggc tgc ctg GTC AAG GAC TAC TTC CCc gaA CCG GTg acg gtg tcg
AgeI....

183 184 185 186 187 188 189 190 191 192 193 194 195 196 197
W N S G A L T S G V H T F P A
2889 tgg aac tca GGC GCC ctg acc agc ggc gtc cac acc ttc ccg gct
KasI... (1/4)

198 199 200 201 202 203 204 205 206 207 208 209 210 211 212
V L Q S S G L Y S L S S V V T
2934 gtc cta cag tCt agc GGa ctc tac tcc ctc agc agc gta gtg acc
(Bsu36I...) (knocked out)

213 214 215 216 217 218 219 220 221 222 223 224 225 226 227
V P S S S L G T Q T Y I C N V
2979 gtg ccC tCt tct agc tTG Ggc acc cag acc tac atc tgc aac gtg
(BstXI.....) N.B. destruction of BstXI & BpmI sites.

228 229 230 231 232 233 234 235 236 237 238 239 240 241 242
N H K P S N T K V D K K V E P
3024 aat cac aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc

243 244 245
K S C A A A H H H H H S A
3069 aaa tct tgt GCG GCC GcT cat cac cac cat cat cac tct gct
NotI.....

E Q K L I S E E D L N G A A
3111 gaa caa aaa ctc atc tca gaa gag gat ctg aat ggt gcc gca

D I N D D R M A S G A
3153 GAT ATC aac gat gat cgt atg gct AGC ggc gcc
rEK cleavage site..... NheI... KasI...
EcoRV..

Domain 1 -----
A E T V E S C L A
3183 gct gaa act gtt gaa agt tgt tta gca

K P H T E I S F
3210 aaa ccc cat aca gaa aat tca ttt

T N V W K D D K T
3234 aCT AAC GTC TGG AAA GAC GAC AAA Act

```

- 156 -

```

!
!       L   D   R   Y   A   N   Y   E   G   C   L   W   N   A   T   G   V
3261 tta gat cgt tac gct aac tat gag ggt tgt ctg tgG AAT GCt aca ggc gtt
!
!                                     BsmI
5
!       V   V   C   T   G   D   E   T   Q   C   Y   G   T   W   V   P   I
3312 gta gtt tgt act ggt GAC GAA ACT CAG TGT TAC GGT ACA TGG GTT cct att
!
!       G   L   A   I   P   E   N
10 3363 ggg ctt gct atc cct gaa aat
!
! L1 linker -----
!       E   G   G   G   S   E   G   G   G   S
3384 gag ggt ggt ggc tct gag ggt ggc ggt tct
15
!       E   G   G   G   S   E   G   G   G   T
3414 gag ggt ggc ggt tct gag ggt ggc ggt act
!
! Domain 2 -----
20 3444 aaa cct cct gag tac ggt gat aca cct att ccg ggc tat act tat atc aac
3495 cct ctc gac ggc act tat ccg cct ggt act gag caa aac ccc gct aat cct
3546 aat cct tct ctt GAG GAG tct cag cct ctt aat act ttc atg ttt cag aat
!
!                                     BseRI
3597 aat agg ttc cga aat agg cag ggg gca tta act gtt tat acg ggc act
25 3645 gtt act caa ggc act gac ccc gtt aaa act tat tac cag tac act cct
3693 gta tca tca aaa gcc atg tat gac gct tac tgg aac ggt aaa ttC AGA
!
!                                     AlwNI
3741 GAC TGc gct ttc cat tct ggc ttt aat gaa gat cca ttc gtt tgt gaa
!
!                                     AlwNI
30 3789 tat caa ggc caa tcg tct gac ctg cct caa cct cct gtc aat gct
!
3834 ggc ggc ggc tct
! start L2 -----
35 3846 ggt ggt ggt tct
3858 ggt ggc ggc tct
3870 gag ggt ggt ggc tct gag ggt ggc ggt tct
3900 gag ggt ggc ggc tct gag gga ggc ggt tcc
3930 ggt ggt ggc tct ggt ! end L2
!
! Domain 3 -----
40
!       S   G   D   F   D   Y   E   K   M   A   N   A   N   K   G   A
3945 tcc ggt gat ttt gat tat gaa aag atg gca aac gct aat aag ggg gct
!
!       M   T   E   N   A   D   E   N   A   L   Q   S   D   A   K   G
45 3993 atg acc gaa aat gcc gat gaa aac gcg cta cag tct gac gct aaa ggc
!
!       K   L   D   S   V   A   T   D   Y   G   A   A   I   D   G   F
4041 aaa ctt gat tct gtc gct act gat tac ggt gct gct atc gat ggt ttc
!
50
!       I   G   D   V   S   G   L   A   N   G   N   G   A   T   G   D
4089 att ggt gac gtt tcc ggc ctt gct aat ggt aat ggt gct act ggt gat
!
!       F   A   G   S   N   S   Q   M   A   Q   V   G   D   G   D   N
55 4137 ttt gct ggc tct aat tcc caa atg gct caa gtc ggt gac ggt gat aat
!
!       S   P   L   M   N   N   F   R   Q   Y   L   P   S   L   P   Q
4185 tca cct tta atg aat aat ttc cgt caa tat tta cct tcc ctc cct caa

```

- 157 -

```

!
!       S   V   E   C   R   P   F   V   F   S   A   G   K   P   Y   E
4233 tcg gtt gaa tgt cgc cct ttt gtc ttt agc gct ggt aaa cca tat gaa
!
5 !       F   S   I   D   C   D   K   I   N   L   F   R
4281 ttt tct att gat tgt gac aaa ata aac tta ttc cgt
!                                     End Domain 3
!
!       G   V   F   A   F   L   L   Y   V   A   T   F   M   Y   V   F140
10 ! 4317 ggt gtc ttt gcg ttt ctt tta tat gtt gcc acc ttt atg tat gta ttt
!      start transmembrane segment
!
!       S   T   F   A   N   I   L
15 ! 4365 tct acg ttt gct aac ata ctg
!
!       R   N   K   E   S
! 4386 cgt aat aag gag tct TAA ! stop of iii
!      Intracellular anchor.
!
20 !       M1 P2 V   L   L5   G   I   P   L   L10 L   R   F   L   G15
4404 tc ATG cca gtt ctt ttg ggt att ccg tta tta ttg cgt ttc ctc ggt
!      Start VI
!
! 4451 ttc ctt ctg gta act ttg ttc ggc tat ctg ctt act ttt ctt aaa aag
25 ! 4499 ggc ttc ggt aag ata gct att gct att tca ttg ttt ctt gct ctt att
! 4547 att ggg ctt aac tca att ctt gtg ggt tat ctc tct gat att agc gct
! 4595 caa tta ccc tct gac ttt gtt cag ggt gtt cag tta att ctc ccg tct
! 4643 aat gcg ctt ccc tgt ttt tat gtt att ctc tct gta aag gct gct att
! 4691 ttc att ttt gac gtt aaa caa aaa atc gtt tct tat ttg gat tgg gat
30 !
!       M1 A2 V3       F5       L10       G13
! 4739 aaa TAA t ATG gct gtt tat ttt gta act ggc aaa tta ggc tct gga
!      end VI      Start gene I
!
35 !       14  15  16  17  18  19  20  21  22  23  24  25  26  27  28
!       K   T   L   V   S   V   G   K   I   Q   D   K   I   V   A
! 4785 aag acg ctc gtt agc gtt ggt aag att cag gat aaa att gta gct
!
!       29  30  31  32  33  34  35  36  37  38  39  40  41  42  43
!       G   C   K   I   A   T   N   L   D   L   R   L   Q   N   L
40 ! 4830 ggg tgc aaa ata gca act aat ctt gat tta agg ctt caa aac ctc
!
!       44  45  46  47  48  49  50  51  52  53  54  55  56  57  58
!       P   Q   V   G   R   F   A   K   T   P   R   V   L   R   I
45 ! 4875 ccg caa gtc ggg agg ttc gct aaa acg cct cgc gtt ctt aga ata
!
!       59  60  61  62  63  64  65  66  67  68  69  70  71  72  73
!       P   D   K   P   S   I   S   D   L   L   A   I   G   R   G
! 4920 ccg gat aag cct tct ata tct gat ttg ctt gct att ggg cgc ggt
50 !
!       74  75  76  77  78  79  80  81  82  83  84  85  86  87  88
!       N   D   S   Y   D   E   N   K   N   G   L   L   V   L   D
! 4965 aat gat tcc tac gat gaa aat aaa aac ggc ttg ctt gtt ctc gat
!
55 !       89  90  91  92  93  94  95  96  97  98  99 100 101 102 103
!       E   C   G   T   W   F   N   T   R   S   W   N   D   K   E
! 5010 gag tgc ggt act tgg ttt aat acc cgt tct tgg aat gat aag gaa
!

```

- 158 -

```

!      104 105 106 107 108 109 110 111 112 113 114 115 116 117 118
!      R  Q  P  I  I  D  W  F  L  H  A  R  K  L  -G
5055 aga cag ccg att att gat tgg ttt cta cat gct cgt aaa tta gga
5      !
!      119 120 121 122 123 124 125 126 127 128 129 130 131 132 133
!      W  D  I  I  F  L  V  Q  D  L  S  I  V  D  K
5100 tgg gat att att ttt ctt gtt cag gac tta tct att gtt gat aaa
10     !
!      134 135 136 137 138 139 140 141 142 143 144 145 146 147 148
!      Q  A  R  S  A  L  A  E  H  V  V  Y  C  R  R
5145 cag gcg cgt tct gca tta gct gaa cat gtt gtt tat tgt cgt cgt
15     !
!      149 150 151 152 153 154 155 156 157 158 159 160 161 162 163
!      L  D  R  I  T  L  P  F  V  G  T  L  Y  S  L
5190 ctg gac aga att act tta cct ttt gtc ggt act tta tat tct ctt
20     !
!      164 165 166 167 168 169 170 171 172 173 174 175 176 177 178
!      I  T  G  S  K  M  P  L  P  K  L  H  V  G  V
5235 att act ggc tcg aaa atg cct ctg cct aaa tta cat gtt ggc gtt
25     !
!      179 180 181 182 183 184 185 186 187 188 189 190 191 192 193
!      V  K  Y  G  D  S  Q  L  S  P  T  V  E  R  W
5280 gtt aaa tat ggc gat tct caa tta agc cct act gtt gag cgt tgg
30     !
!      194 195 196 197 198 199 200 201 202 203 204 205 206 207 208
!      L  Y  T  G  K  N  L  Y  N  A  Y  D  T  K  Q
5325 ctt tat act ggt aag aat ttg tat aac gca tat gat act aaa cag
35     !
!      209 210 211 212 213 214 215 216 217 218 219 220 221 222 223
!      A  F  S  S  N  Y  D  S  G  V  Y  S  Y  L  T
5370 gct ttt tct agt aat tat gat tcc ggt gtt tat tct tat tta acg
40     !
!      224 225 226 227 228 229 230 231 232 233 234 235 236 237 238
!      P  Y  L  S  H  G  R  Y  F  K  P  L  N  L  G
5415 cct tat tta tca cac ggt cgg tat ttc aaa cca tta aat tta ggt
45     !
!      239 240 241 242 243 244 245 246 247 248 249 250 251 252 253
!      Q  K  M  K  L  T  K  I  Y  L  K  K  F  S  R
5460 cag aag atg aaa tta act aaa ata tat ttg aaa aag ttt tct cgc
50     !
!      254 255 256 257 258 259 260 261 262 263 264 265 266 267 268
!      V  L  C  L  A  I  G  F  A  S  A  F  T  Y  S
5505 gtt ctt tgt ctt gcg att gga ttt gca tca gca ttt aca tat agt
55     !
!      269 270 271 272 273 274 275 276 277 278 279 280 281 282 283
!      Y  I  T  Q  P  K  P  E  V  K  K  V  V  S  Q
5550 tat ata acc caa cct aag ccg gag gtt aaa aag gta gtc tct cag
55     !
!      284 285 286 287 288 289 290 291 292 293 294 295 296 297 298
!      T  Y  D  F  D  K  F  T  I  D  S  S  Q  R  L
5595 acc tat gat ttt gat aaa ttc act att gac tct tct cag cgt ctt
!
!      299 300 301 302 303 304 305 306 307 308 309 310 311 312 313
!      N  L  S  Y  R  Y  V  F  K  D  S  K  G  K  L
5640 aat cta agc tat cgc tat gtt ttc aag gat tct aag gga aaa TTA
!                                     PacI

```

- 159 -

```

!       314 315 316 317 318 319 320 321 322 323 324 325 326 327 328
!       I   N   S   D   D   L   Q   K   Q   G   Y   S   L   T   Y
!
5685 ATT AAt agc gac gat tta cag aag caa ggt tat tca ctc aca tat
!       PacI
5
!       329 330 331 332 333 334 335 336 337 338 339 340 341 342 343
!       i   I   D   L   C   T   V   S   I   K   K   G   N   S   N   E
!       iv                                     M1 K
5730 att gat tta tgt act gtt tcc att aaa aaa ggt aat tca aAT Gaa
!                                     Start IV
10
!       344 345 346 347 348 349
!       i   I   V   K   C   N   .End of I
!       iv   L3 L   N5 V   I7 N   F V10
15 5775 att gtt aaa tgt aat TAA T TTT GTT
!       IV continued.....
5800 ttc ttg atg ttt gtt tca tca tct tct ttt gct cag gta att gaa atg
5848 aat aat tcg cct ctg cgc gat ttt gta act tgg tat tca aag caa tca
20 5896 ggc gaa tcc gtt att gtt tct ccc gat gta aaa ggt act gtt act gta
5944 tat tca tct gac gtt aaa cct gaa aat cta cgc aat ttc ttt att tct
5992 gtt tta cgt gct aat aat ttt gat atg gtt ggt tca att cct tcc ata
6040 att cag aag tat aat cca aac aat cag gat tat att gat gaa ttg cca
6088 tca tct gat aat cag gaa tat gat gat aat tcc gct cct tct ggt ggt
25 6136 ttc ttt gtt ccg caa aat gat aat gtt act caa act ttt aaa att aat
6184 aac gtt cgg gca aag gat tta ata cga gtt gtc gaa ttg ttt gta aag
6232 tct aat act tct aaa tcc tca aat gta tta tct att gac ggc tct aat
6280 cta tta gtt gtt TCT gca cct aaa gat att tta gat aac ctt cct caa
!       ApaLI removed
6328 ttc ctt tct act gtt gat ttg cca act gac cag ata ttg att gag ggt
30 6376 ttg ata ttt gag gtt cag caa ggt gat gct tta gat ttt tca ttt gct
6424 gct ggc tct cag cgt ggc act gtt gca ggc ggt gtt aat act gac cgc
6472 ctc acc tct gtt tta tct tct gct ggt ggt tcg ttc ggt att ttt aat
6520 ggc gat gtt tta ggg cta tca gtt cgc gca tta aag act aat agc cat
6568 tca aaa ata ttg tct gtg cca cgt att ctt acg ctt tca ggt cag aag
35 6616 ggt tct atc tct gtt GGC CAG aat gtc cct ttt att act ggt cgt gtg
!       MscI
6664 act ggt gaa tct gcc aat gta aat aat cca ttt cag acg att gag cgt
6712 caa aat gta ggt att tcc atg agc gtt ttt cct gtt gca atg gct ggc
6760 ggt aat att gtt ctg gat att acc agc aag gcc gat agt ttg agt tct
40 6808 tct act cag gca agt gat gtt att act aat caa aga agt att gct aca
6856 acg gtt aat ttg cgt gat gga cag act ctt tta ctc ggt ggc ctc act
6904 gat tat aaa aac act tct caa gat tct ggc gta ccg ttc ctg tct aaa
6952 atc cct tta atc ggc ctc ctg ttt agc tcc cgc tct gat tcc aac gag
7000 gaa agc acg tta tac gtg ctc gtc aaa gca acc ata gta cgc gcc ctg
45 7048 TAG cggcgcatt
!       End IV
7060 aagcgcggcg ggtgtggtgg ttacgcgcag cgtgaccgct acacttgcca gcgcctagc
7120 gcccgctcct ttcgctttct tcccttcctt tctcgccacg ttcGCCGGCt ttccccgtca
!       NgoMI
50 7180 agctctaaat cgggggctcc ctttaggggt ccgatttagt gctttacggc acctcgaccc
7240 caaaaaactt gatttgggtg atggttCACG TAGTGggcca tcgccctgat agacggtttt
!       DraIII
7300 tcgccctttG ACGTTGGAGT Ccagcttctt taatagtgga ctcttggtcc aaactggaac
!       DrdI
55 7360 aacactcaac cctatctcgg gctattcttt tgatttataa gggattttgc cgatttcgga
7420 accaccatca aacaggattt tcgcctgctg gggcaaacca gcgtggaccg cttgctgcaa
7480 ctctctcagg gccaggcggg gaagggcaat CAGCTGttgc cCGTCTCact ggtgaaaaga
!       PvuII. BsmBI.
60 7540 aaaaccaccc tGGATCC AAGCTT
!       BamHI HindIII (1/2)

```

- 160 -

```

!               Insert carrying bla gene
7563      gcagggtg gcacttttcg gggaaatgtg cgcggaaccc
7600 ctatttgttt atttttctaa atacattcaa atatGTATCC gctcatgaga caataaccct
!               BciVI
5 7660 gataaatgct tcaataatat tgaaaaAGGA AGAgT
!               RBS.?...
!               Start bla gene
7695 ATG agt att caa cat ttc cgt gtc gcc ctt att ccc ttt ttt gcg gca ttt
7746 tgc ctt cct gtt ttt gct cac cca gaa acg ctg gtg aaa gta aaa gat gct
10 7797 gaa gat cag ttg ggC gCA CGA Gtg ggt tac atc gaa ctg gat ctc aac agc
!               BssSI...
!               ApaLI removed
7848 ggt aag atc ctt gag agt ttt cgc ccc gaa gaa cgt ttt cca atg atg agc
7899 act ttt aaa gtt ctg cta tgt cat aca cta tta tcc cgt att gac gcc ggg
15 7950 caa gaG CAA CTC GGT CGC cgg gcg cgg tat tct cag aat gac ttg gtt gAG
!               BcgI
8001 TAC Tca cca gtc aca gaa aag cat ctt acg gat ggc atg aca gta aga gaa
!               ScaI
8052 tta tgc agt gct gcc ata acc atg agt gat aac act gcg gcc aac tta ctt
20 8103 ctg aca aCG ATC Gga gga ccg aag gag cta acc gct ttt ttg cac aac atg
!               PvuI
8154 ggg gat cat gta act cgc ctt gat cgt tgg gaa ccg gag ctg aat gaa gcc
8205 ata cca aac gac gag cgt gac acc acg atg cct gta gca atg cca aca acg
8256 tTG CGC Aaa cta tta act ggc gaa cta ctt act cta gct tcc cgg caa caa
25 !               FspI....
!
8307 tta ata gac tgg atg gag gcg gat aaa gtt gca gga cca ctt ctg cgc tcg
8358 GCC ctt ccG GcT ggc tgg ttt att gct gat aaa tct gga gcc ggt gag cgt
!               BglI
30 8409 gGG TCT Cgc ggt atc att gca gca ctg ggg cca gat ggt aag ccc tcc cgt
!               BsaI
8460 atc gta gtt atc tac acG ACg ggg aGT Cag gca act atg gat gaa cga aat
!               AhdI
35 8511 aga cag atc gct gag ata ggt gcc tca ctg att aag cat tgg TAA ctgt
!               stop
8560 cagaccaagt ttactcatat atactttaga ttgatttaaa acttcatttt taatttaaaa
8620 ggatctaggt gaagatcctt tttgataatc tcatgaccaa aatcccttaa cgtgagtttt
8680 cgttccactg tacgtaagac cccc
8704 AAGCTT GTCGAC tgaa tggcgaatgg cgctttgcct
40 !               HindIII SalI..
!               (2/2) HincII
8740 ggtttccggc accagaagcg gtgccgaaa gctggctgga gtgcgatcct
!
45 8790 CCTGAGG
!               Bsu36I
8797      ccgat actgtcgtcg tcccctcaaa ctggcagatg
8832 cacggttacg atgcgcccac ctacaccaac gtaacctatc ccattacggt caatccgcgcg
8892 tttgttccca cggagaatcc gacgggttgt tactcgtca catttaatgt tgatgaaagc
8952 tggctacagg aaggccagac gcgaattatt tttgatggcg ttctattgg ttaaaaaatg
50 9012 agctgattta acaaaaattt aacgcgaatt ttaacaaaat attaacgttt acaATTTTAA
!               SwaI...
9072 Tatttgctta tacaatcttc ctgttttttg ggctttttctg attatcaacc GGGGTACat
!               RBS?
55 9131 ATG att gac atg cta gtt tta cga tta ccg ttc atc gat tct ctt gtt tgc
!               Start gene II
9182 tcc aga ctc tca ggc aat gac ctg ata gcc ttt gtA GAT CTc tca aaa ata
!               BglIII...
9233 gct acc ctc tcc ggc atg aat tta tca gct aga acg gtt gaa tat cat att

```

- 161 -

9284 gat ggt gat ttg act gtc tcc ggc ctt tct cac cct ttt gaa tct tta cct
9335 aca cat tac tca ggc att gca ttt aaa ata tat gag ggt tct aaa aat ttt
9386 tat cct tgc gtt gaa ata aag gct tct ccc gca aaa gta tta cag ggt cat
9437 aat gtt ttt ggt aca acc gat tta gct tta tgc tct gag gct tta ttg ctt
5 9488 aat ttt gct aat tct ttg cct tgc ctg tat gat tta ttg gat gtt ! 9532
! gene II continues

- 162 -

Table 21B: Sequence of MALIA3, condensed

LOCUS	MALIA3	9532	CIRCULAR
ORIGIN			
1	AATGCTACTA	CTATTAGTAG	AATTGATGCC
5 61	ATAGCTAAAC	AGGTATTGA	CCATTTGCGA
121	CGTTCGCAGA	ATTGGGAATC	AACGTGTACA
181	GTTGCATATT	TAAAACATGT	TGAGCTACAG
241	TCCGCAAAAA	TGACCTCTTA	TCAAAGGAG
361	TCTTTCGGGC	TTCCTCTTAA	TCTTTTTGAT
10 421	CAGGGTAAAG	ACCTGATTTT	TGATTTATGG
481	TTTGAGGGGG	ATTCAATGAA	TATTTATGAC
541	AAACATTTTA	CTATTACCCC	CTCTGGCAAA
601	GGTTTTTATC	GTCGTCTGGT	AAACGAGGGT
661	AATTCCTTTT	GGCGTTATGT	ATCTGCATTA
15 721	ATGAATCTTT	CTACCTGTAA	TAATGTTGTT
781	TCTTCCCAAC	GTCCTGACTG	GTATAATGAG
841	CAATGATTAA	AGTTGAAATT	AAACCATCTC
901	CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG
961	AATATCCGGT	TCTTGTCAAG	ATTACTCTTG
20 1021	TGTACACCGT	TCATCTGTCC	TCTTTCAAAG
1081	GTCTGCGCCT	CGTTCCGGCT	AAGTAACATG
1141	CAGGCGATGA	TACAAATCTC	CGTTGTACTT
1201	CAAAGATGAG	TGTTTTAGTG	TATTCTTTTCG
1261	GTGGCATTAC	GTATTTTACC	CGTTTAATGG
25 1321	CAAAGCCTCT	GTAGCCGTTG	CTAACCTCGT
1381	CGATCCCGCA	AAAGCGGCCT	TTAACCTCCT
1441	TGCGTGGGCG	ATGGTTGTTG	TCATTGTCTGG
1501	ATTACCTCG	AAAGCAAGCT	GATAAACCGA
1561	TTTTTGGAGA	TTTTCAACGT	GAAAAAATTA
30 1621	TATTCTCACA	GTGCACAGTC	TGTCGTGACG
1681	CAGAGGGTCA	CCATCTCCTG	CACCTGGGAGC
1741	CACTGGTACC	AGCAGCTTCC	AGGAACAGCC
1801	CGGCCCTCAG	GGGTCCCTGA	CCGATTCTCT
1861	GCCATCACTG	GGCTCCAGGC	TGAGGATGAG
35 1921	AGCCTGAGTG	GCCTTTATGT	CTTCGGAAC
1981	AAGGCCAACC	CCACTGTGAC	TCTGTTCCCG
2041	GCCACACTAG	TGTGTCTGAT	CAGTGACTTC
2101	GCAGATAGCA	GCCCCGTCAA	GGCGGGAGTG
2161	AACAAGTACG	CGGCCAGCAG	CTATCTGAGC
40 2221	AGCTACAGCT	GCCAGGTCAC	GCATGAAGGG
2281	GAATGTTTAT	AATAAACCGC	CTCCACCGGG
2341	TAATGAAATA	CCTATTGCCT	ACGGCAGCCG
2401	CCATGGCCGA	AGTTCAATTG	TTAGAGTCTG
2461	TACGTCTTTC	TTGCGCTGCT	TCCGGATTCA
45 2521	GCCAAGCTCC	TGGTAAAGGT	TTGGAGTGGG
2581	CTTACTATGC	TGACTCCGTT	AAAGGTCGCT
2641	CTCTCTACTT	GCAGATGAAC	AGCTTAAGGG
2701	AAGACTATGA	AGGTACTGGT	TATGCTTTTCG
2761	TCTCTAGTGC	CTCCACCAAG	GGCCCATCGG
50 2821	CCTCTGGGGG	CACAGCGGGC	CTGGGCTGCC
2881	CGGTGTCGTG	GAAGTCAGGC	GCCCTGACCA
2941	AGTCTAGCGG	ACTCTACTCC	CTCAGCAGCG
3001	CCCAGACCTA	CATCTGCAAC	GTGAATCACA
3061	TTGAGCCCAA	ATCTTGTGCG	GCCGCTCATC
55 3121	TCATCTCAGA	AGAGGATCTG	AATGGTGCCG
3181	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA
3241	TCTGAAAGA	CGACAAAAC	TTAGATCGTT
			ACGCTAACTA
			TGAGGGTTGT
			CTGTGGAATG

	3301	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	TGGGTTCCTA
	3361	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	TCTGAGGGTG
	3421	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	ATTCCGGGCT
	3481	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCTTGG	TACTGAGCAA	AACCCCGCTA
5	3541	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	CAGAATAATA
	3601	GGTTCGGA	TAGGCAGGGG	GCATTAAGTG	TTTATACGGG	CACGTGTACT	CAAGGCACTG
	3661	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	TATGACGCTT
	3721	ACTGGAACGG	TAAATTCAGA	GACTGCGCTT	TCCATCTTGG	CTTTAATGAA	GATCCATTCTG
	3781	TTTGTGAATA	TCAAGGCCAA	TCGCTGAC	TGCCCTCAACC	TCCTGTCAAT	GCTGGCGGCG
10	3841	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	GGCGGTTCTG
	3901	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCGGGT	GATTTTGATT
	3961	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	GAAAACGCGC
	4021	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT	GCTGCTATCG
	4081	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	GGTGATTTTG
15	4141	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	TTAATGAATA
	4201	ATTTCOGTCA	ATATTTACCT	TCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	TTTGTCTTTA
	4261	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	TCCGTGGGTG
	4321	TCTTTCGTT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG	TTTGCTAACA
	4381	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCCGT	TATTATTGCG
20	4441	TTTCCTCGGT	TTCTTCTGG	TACTTTGTT	CGGCTATCTG	CTTACTTTTC	TTAAAAAGGG
	4501	CTTCGGTAAG	ATAGCTATTG	CTATTTTCATT	GTTTCTTGCT	CTTATTATTG	GGCTTAAGTC
	4561	AATTCTTGTTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT	TTGTTCAGGG
	4621	TGTTCAAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTTATC	TCTCTGTA
	4681	GGCTGCTATT	TTCATTTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTTTG	ATTGGGATAA
25	4741	ATAATATGGC	TGTTTATTTT	GTAAGTGGCA	AATTAGGCTC	TGGAAAGACG	CTCGTTAGCG
	4801	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	CTTGATTTAA
	4861	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAC	GCCTCGCGTT	CTTAGAATAC
	4921	CGGATAAGCC	TTCTATATCT	GATTTCCTTG	CTATTGGGCG	CGGTAATGAT	TCCACGATG
	4981	AAAATAAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCGGTAC	TTGGTTTAA	ACCCGTTCTT
30	5041	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT	AAATTAGGAT
	5101	GGGATATTAT	TTTCTTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	CGTCTGCA
	5161	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	TTTGTCGGTA
	5221	CTTTATATT	TCTTATTACT	GGCTCGAAAA	TGCTCTGCC	TAAATTACAT	GTTGGCGTTG
	5281	TTAAATATGG	CGATTCTCAA	TAAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	ACTGGTAAGA
35	5341	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTCTAG	TAATTATGAT	TCCGGTGTTT
	5401	ATTCTTATTT	AACGCCTTAT	TTATCACACG	GTCGGTATTT	CAAACCATT	AATTTAGGTC
	5461	AGAAGATGAA	ATTAAGTAAA	ATATATTGTA	AAAAGTTTTC	TCGCGTTCTT	TGCTTTGCGA
	5521	TGGGATTTGC	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	GAGGTTAAAA
	5581	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCATAT	TGACTCTTCT	CAGCGTCTTA
40	5641	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	AGCGACGATT
	5701	TACAGAAGCA	AGGTATTTC	CTCACATATA	TTGATTTATG	TACTGTTTCC	ATTAATAAAG
	5761	GTAATTCAAA	TGAAATGTTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	TGTTTCATCA
	5821	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCTC	TGCGCGATTT	TGTAACCTGG
	5881	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAAAAGG	TACTGTTACT
45	5941	GTATATT	CTGACGTTAA	ACCTGAAAT	CTACGCAATT	TCTTTATTTT	TGTTTACGTT
	6001	GCTAATAATT	TTGATATGTT	TGGTTCAATT	CCTTCCATAA	TTCAAGAGTA	TAATCCAAAC
	6061	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	TGATAATTCC
	6121	GCTCCTTCTG	GTGGTTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	TTTTAAATTT
	6181	AATAACGTTT	GGGCAAAGGA	TTTAATACGA	GTTGTCGAAT	TGTTTGTA	GCTTAATACT
50	6241	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	TTCTGCACCT
	6301	AAAGATATTT	TAGATAACCT	TCCTCAATTC	CTTTCTACTG	TTGATTTGCC	AACTGACCAG
	6361	ATATTGATTG	AGGGTTTGAT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	TTTTTCATTT
	6421	GCTGCTGGCT	CTCAGCGTGG	CAGTGTGCA	GGCGGTGTTA	ATACTGACCG	CCTCACCTCT
	6481	GTTTTATCTT	CTGCTGGTGG	TTCGTTCCGT	ATTTTAAATG	GCGATGTTTT	AGGGCTATCA
55	6541	GTTGCGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	TATTCTTACG
	6601	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTTAT	TACTGGTTCGT
	6661	GTGACTGGTG	AATCTGCCAA	TGTAAATAAT	CCATTTTCTA	CGATTGAGCG	TCAAAATGTA
	6721	GGTATTTCCA	TGAGCGTTTT	TCTGTTGCA	ATGGCTGGCG	GTAATATTGT	TCTGGATATT

6781	ACCAGCAAGG	CCGATAGTTT	GAGTTCCTCT	ACTCAGGCAA	GTGATGTTAT	TACTAATCAA
6841	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTTACT	CGGTGGCCTC
6901	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	AATCCCTTTA
6961	ATCGGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	ATACGTGCTC
5 7021	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATT	AGCGCGGCGG	GTGTGGTGGT
7081	TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTAGCG	CCCCTCCTT	TCGCTTTCTT
7141	CCCTTCCTTT	CTCGCCACGT	TCGCCGGCTT	TCCCCGTCAA	GCTCTAAATC	GGGGGCTCCC
7201	TTTAGGGTTC	CGATTTAGTG	CTTTACGGCA	CCTCGACCCC	AAAAAACTTG	ATTTGGGTGA
7261	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	CGTTGGAGTC
10 7321	CACGTTCTTT	AATAGTGGAC	TCTTGTTCCA	AACTGGAACA	ACACTCAACC	CTATCTCGGG
7381	CTATTCTTTT	GATTTATAAG	GGATTTTGCC	GATTTTCGGAA	CCACCATCAA	ACAGGATTTT
7441	CGCCTGCTGG	GGCAAACCG	CGTGGACCGT	TTGCTGCAAC	TCTCTCAGGG	CCAGGCGGTG
7501	AAGGGCAATC	AGCTGTTGCC	CGTCTCACTG	GTGAAAAGAA	AAACCACTT	GGATCCAAGC
7561	TTGCAGGTGG	CACTTTTCGG	GGAAATGTGC	GCGGAACCCC	TATTTGTTTA	TTTTTCTAAA
15 7621	TACATTCAAA	TATGTATCCG	CTCATGAGAC	AATAACCTG	ATAAATGCTT	CAATAATATT
7681	GAAAAAGGAA	GAGTATGAGT	ATTCAACATT	TCCGTGTCCG	CCTTATTCCC	TTTTTTGCGG
7741	CATTTTGCC	TCCTGTTT	GCTCACCAG	AAACGCTGGT	GAAAGTAAAA	GATGCTGAAG
7801	ATCAGTTGGG	CGCACGAGTG	GGTTACATCG	AACTGGATCT	CAACAGCGGT	AAGATCCTTG
7861	AGAGTTTTCG	CCCCGAAGAA	CGTTTTCCAA	TGATGAGCAC	TTTTAAAGTT	CTGCTATGTC
20 7921	ATACACTATT	ATCCCGTATT	GACGCCGGGC	AAGAGCAACT	CGGTGCGCGG	GCGCGGTATT
7981	CTCAGAATGA	CTTGGTTGAG	TACTCACCAG	TCACAGAAAA	GCATCTTACG	GATGGCATGA
8041	CAGTAAGAGA	ATTATGCAGT	GCTGCCATAA	CCATGAGTGA	TAACACTGCG	GCCAACTTAC
8101	TTCTGACAA	GATCGGAGGA	CCGAAGGAGC	TAACCGCTTT	TTTGACAAAC	ATGGGGGATC
8161	ATGTAACTCG	CCTTGATCGT	TGGGAACCGG	AGCTGAATGA	AGCCATACCA	AACGACGAGC
25 8221	GTGACACCAC	GATGCCTGTA	GCAATGCCAA	CAACGTTGCG	CAAACCTATTA	ACTGGCGAAC
8281	TACTTACTCT	AGCTTCCCGG	CAACAATTAA	TAGACTGGAT	GGAGGCGGAT	AAAGTTGCAG
8341	GACCACTTCT	GCGCTCGGCC	CTTCCGGCTG	GCTGGTTTAT	TGCTGATAAA	TCTGGAGCCG
8401	GTGAGCGTGG	GTCTCGCGGT	ATCATTGCAG	CACTGGGGCC	AGATGGTAAG	CCCTCCCGTA
8461	TCGTAGTTAT	CTACACGACG	GGGAGTCAGG	CAACTATGGA	TGAACGAAAT	AGACAGATCG
30 8521	CTGAGATAGG	TGCCTCACTG	ATTAAGCATT	GGTAACGTG	AGACCAAGTT	TACTCATATA
8581	TACTTTAGAT	TGATTTAAAA	CTTCATTTT	AATTTAAAAG	GATCTAGGTG	AAGATCCTTT
8641	TTGATAATCT	CATGACCAAA	ATCCCTTAAC	GTGAGTTTTC	GTTCCACTGT	ACGTAAGACC
8701	CCCAAGCTTG	TCGACTGAAT	GGCGAATGGC	GCTTTGCCTG	GTTTCCGCA	CCAGAAGCGG
8761	TGCCGGAAG	CTGGCTGGAG	TGCGATCTTC	CTGAGGCCGA	TACTGTCGTC	GTCCCCCTCAA
35 8821	ACTGGCAGAT	GCACGGTTAC	GATGCGCCCA	TCTACACCAA	CGTAACCTAT	CCCATTACGG
8881	TCAATCCGCC	GTTTGTTCCT	ACGGAGAATC	CGACGGGTG	TTACTCGCTC	ACATTTAATG
8941	TTGATGAAAG	CTGGCTACAG	GAAGGCCAGA	CGCGAATTAT	TTTTGATGGC	GTTCCATTATG
9001	GTTAAAAAAT	GAGCTGATTT	AACAAAAATT	TAACGCGAAT	TTTAACAAAA	TATTAACGTT
9061	TACAATTTAA	ATATTTGCTT	ATACAATCTT	CCTGTTTTTG	GGGCTTTTCT	GATTATCAAC
40 9121	CGGGGTACAT	ATGATTGACA	TGCTAGTTTT	ACGATTACCG	TTCATCGATT	CTCTGTTTGT
9181	CTCCAGACTC	TCAGGCAATG	ACCTGATAGC	CTTTGTAGAT	CTCTCAAAAA	TAGCTACCCT
9241	CTCCGGCATG	AATTTATCAG	CTAGAACGGT	TGAATATCAT	ATTGATGGTG	ATTTGACTGT
9301	CTCCGGCCTT	TCTCACCTT	TTGAATCTTT	ACCTACACAT	TACTCAGGCA	TTGCATTTAA
9361	AATATATGAG	GGTTCTAAAA	ATTTTATCC	TTGCGTTGAA	ATAAAGGCTT	CTCCCGCAAA
45 9421	AGTATTACAG	GGTCATAATG	TTTTTGGTAC	AACCGATTTA	GCTTTATGCT	CTGAGGCTTT
9481	ATTGCTTAAT	TTTGCTAATT	CTTTCCTTG	CCTGTATGAT	TTATTGGATG	TT

Table 22: Primers used in RACE amplification:

Heavy chain	
HuCh-For (1st PCR)	5'-TGG AAG AGG CAC GTT CTT TTC TTT-3'
HuCh-Nested (2nd PCR)	5' CTT TTC TTT GTT GCC GTT GGG GTG-3'
Kappa light chain	
HuKFor (1st PCR)	5'-ACA CTC TCC CCT GTT GAA GCT CTT-3'
HuKForAsci(2nd PCR)	5'-ACC GCC TCC ACC GGG CGC GGC TTA TTA ACA CTC TCC CCT GTT GAA GCT CTT-3'
Lambda light chain	
HuClambdaFor (1st PCR)	
HuCL2-FOR	5'-TGA ACA TTC TGT AGG GGC CAC TG-3'
HuCL7-FOR	5'-AGA GCA TTC TGC AGG GGC CAC TG-3'
HuClambdaForAsci (2nd PCR)	
HuCL2-FOR-ASC	5'-ACC GCC TCC ACC GGG CGC GGC TTA TTA TGA ACA TTC TGT AGG GGC CAC TG-3'
HuCL7-FOR-ASC	5'-ACC GCC TCC ACC GGG CGC GGC TTA TTA AGA GCA TTC TGC AGG GGC CAC TG-3'
GeneRacer 5' Primers provided with the kit (Invitrogen)	
5'A 1st PCR	5'CGACTGGAGCACGAGGACACTGA 3'
20 5'NA 2nd PCR	5'GGACACTGACATGGACTGAAGGAGTA-3'

Table 23: ONs used in Capture of kappa light chains using CJ method and *BsmAI*

All ONs are written 5' to 3'.

REdapters (6)	
ON_20SK15012	gggAagATggAgAcTgggTc
ON_20SK15L12	gggAagATggAgAcTgggTc
ON_20SK15A17	gggAagATggAgAcTgAgTc
ON_20SK15A27	gggTgccTggAgAcTgcgTc
ON_20SK15A11	gggTggcTggAgAcTgcgTc
ON_20SK15B3	gggAgTcTggAgAcTgggTc
Bridges (6)	
kapbril1012	gggAagATggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
kapbril1112	gggAagATggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
kapbril1A17	gggAagATggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
kapbril1A27	gggTgccTggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
kapbril1A11	gggTggcTggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
kapbril1B3	gggAgTcTggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg
Extender (5' biotinylated)	
kapextl1bio	ccTcTgTcAcAgTgcAcAagAcATccAgATgAcccAgTcTcc
Primers	
kapPCRtl	ccTcTgTcAcAgTgcAcAagAc
kapfor	5'-aca ctc tcc cct gtt gaa gct ctt-3'

Table 24: PCR program for amplification of kappa DNA

5	95°C	5 minutes	50 ng
	95°C	15 seconds	
	65°C	30 seconds	
	72°C	1 minute	
	72°C	7 minutes	
	4°C	hold	1x
Reagents (100 ul reaction):			
10	Template		4U
	10x turbo PCR buffer		200 µM each
	turbo Pfu		300 nM
	dNTPs		300 nM
	kaPCRT1		300 nM
	kapfor		

- 168 -

Table 25: h3401-h2 captured Via CJ with BsmAI

! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
 ! S A Q D I Q M T Q S P A T L S
 aGT GCA Caa gac atc cag atg acc cag tct cca gcc acc ctg tct
 5 ! ApaLI... a gcc acc ! L25,L6,L20,L2,L16,A11
 ! Extender.....Bridge...

 ! 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
 ! V S P G E R A T L S C R A S Q
 10 ! gtg tct cca ggg gaa agg gcc acc ctc tcc tgc agg gcc agt cag

 ! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
 ! S V S N N L A W Y Q Q K P G Q
 ! agt gtt agt aac aac tta gcc tgg tac cag cag aaa cct ggc cag
 15
 ! 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
 ! V P R L L I Y G A S T R A T D
 ! gtt ccc agg ctc ctc atc tat ggt gca tcc acc agg gcc act gat

 20 ! 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
 ! I P A R F S G S G S G T D F T
 ! atc cca gcc agg ttc agt ggc agt ggg tct ggg aca gac ttc act

 ! 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
 25 ! L T I S R L E P E D F A V Y Y
 ! ctc acc atc agc aga ctg gag cct gaa gat ttt gca gtg tat tac

 ! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
 ! C Q R Y G S S P G W T F G Q G
 30 ! tgt cag cgg tat ggt agc tca ccg ggg tgg acg ttc ggc caa ggg

 ! 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
 ! T K V E I K R T V A A P S V F
 ! acc aag gtg gaa atc aaa cga act gtg gct gca cca tct gtc ttc
 35
 ! 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
 ! I F P P S D E Q L K S G T A S
 ! atc ttc ccg cca tct gat gag cag ttg aaa tct gga act gcc tct

 40 ! 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
 ! V V C L L N N F Y P R E A K V
 ! gtt gtg tgc ctg ctg aat aac ttc tat ccc aga gag gcc aaa gta

 ! 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
 45 ! Q W K V D N A L Q S G N S Q E
 ! cag tgg aag gtg gat aac gcc ctc caa tgc ggt aac tcc cag gag

 ! 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
 ! S V T E Q D S K D S T Y S L S
 50 ! agt gtc aca gag cag gac agc aag gac agc acc tac agc ctc agc

- 169 -

! 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195
! S T L T L S K A D Y E K H K V
agc acc ctg acg ctg agc aaa gca gac tac gag aaa cac aaa gtc

5 ! 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
! Y A C E V T H Q G L S S P V T
tac gcc tgc gaa gtc acc cat cag ggc ctg agc tcg cct gtc aca

10 ! 211 212 213 214 215 216 217 218 219 220 221 222 223
! K S F N K G E C K G E F A
aag agc ttc aac aaa gga gag tgt aag ggc gaa ttc gc.....

- 170 -

Table 26: h3401-d8 KAPPA captured with CJ and *Bsm*AI

! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
 ! S A Q D I Q M T Q S P A T L S
 5 aGT GCA Caa gac atc cag atg acc cag tct cct gcc acc ctg tct
 ! ApaLI...Extender.....g gcc acc ! L25,L6,L20,L2,L16,A11
 ! A GCC ACC CTG TCT ! L2

! 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
 10 ! V S P G E R A T L S C R A S Q
 gtg tct cca ggt gaa aga gcc acc ctc tcc tgc agg gcc agt cag
 ! GTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC ! L2

! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
 15 ! N L L S N L A W Y Q Q K P G Q
 aat ctt ctc agc aac tta gcc tgg tac cag cag aaa cct ggc cag

! 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
 20 ! A P R L L I Y G A S T G A I G
 gct ccc agg ctc ctc atc tat ggt gct tcc acc ggg gcc att ggt

! 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
 ! I P A R F S G S G S G T E F T
 25 atc cca gcc agg ttc agt ggc agt ggg tct ggg aca gag ttc act

! 76 77 78 79 80 81 82 83 84 85 86 87 88 89.90
 ! L T I S S L Q S E D F A V Y F
 ctc acc atc agc agc ctg cag tct gaa gat ttt gca gtg tat ttc

! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
 30 ! C Q Q Y G T S P P T F G G G T
 tgt cag cag tat ggt acc tca ccg ccc act ttc ggc gga ggg acc

! 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
 35 ! K V E I K R T V A A P S V F I
 aag gtg gag atc aaa cga act gtg gct gca cca tct gtc ttc atc

! 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
 40 ! F P P S D E Q L K S G T A S V
 ttc ccg cca tct gat gag cag ttg aaa tct gga act gcc tct gtt

! 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
 ! V C P L N N F Y P R E A K V Q
 45 gtg tgc ccg ctg aat aac ttc tat ccc aga gag gcc aaa gta cag

! 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
 ! W K V D N A L Q S G N S Q E S
 tgg aag gtg gat aac gcc ctc caa tgc ggt aac tcc cag gag agt

! 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
 50 ! V T E Q D N K D S T Y S L S S
 gtc aca gag cag gac aac aag gac agc acc tac agc ctc agc agc

- 171 -

! 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195

! T L T L S K V D Y E K H E V Y

acc ctg acg ctg agc aaa gta gac tac gag aaa cac gaa gtc tac

5 ! 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210

! A C E V T H Q G L S S P V T K

gcc tgc gaa gtc acc cat cag ggc ctt agc tcg ccc gtc acg aag

! 211 212 213 214 215 216 217 218 219 220 221 222 223

10 ! S F N R G E C K K E F V

agc ttc aac agg gga gag tgt aag aaa gaa ttc gtt t

- 172 -

Table 27: V3-23 VH framework with variegated codons shown

```

!
!           17 18 19 20 21 22
!           A Q P A M A
5 5'-cig tct gaa cG GCC cag ccG GCC aig gcc 29
   3'-gac aga ctt gc cgg gtc ggc cgg tac cgg
   Scab.....SfiI.....
   NgoMI...
   NcoI....
10
!           FR1(DP47/V3-23)-----
!           23 24 25 26 27 28 29 30
!           E V Q L L E S G
!           gaa|ggt|CAA|TTG|tta|gag|tct|ggt| 53
15 ctt|caalgtt|aac|aat|ctc|aga|cca|
   | MfeI |
!
! -----FR1-----
! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
20 G G L V Q P G G S L R L S C A
   |ggc|ggt|ctt|gtt|cag|cct|ggt|ggt|tct|tta|cgt|ctt|tgc|gct| 98
   |cgg|cca|gaat|aat|gtc|gga|cca|cca|aga|aat|gca|gaa|aga|acg|cga|
!
! Sites to be varied--> *** *** ***
25 ---FR1----->|...CDR1.....|---FR2-----
   46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
   A S G F T F S S Y A M S W V R
   |gct|TCC|CGA|ttc|act|tct|tct|TCG|TAC|Gct|atg|tct|tgg|gtt|cgc| 143
   |cga|agg|cct|aag|tga|aag|aga|agc|atg|cga|tac|aga|cc|caa|gcg|
30 | BspEI | | BsiWI | | BstXI.
!
! Sites to be varies--> *** *** ***
! ---FR2----->|...CDR2.....
35 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
   Q A P G K G L E W V S A I S G
   |CAa|gct|ccT|GGt|aaa|ggt|ttg|gag|tgg|gtt|tct|gct|atc|tct|ggt| 188
   |gtt|cga|gga|cca|ttt|cca|aac|ctc|acc|caa|aga|cga|tag|aga|cca|
! ...BstXI |
!
40 *** ***
! ---CDR2-----|---FR3---
! 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
! S G G S T Y Y A D S V K G R F
! |tct|ggt|ggc|agt|act|tac|tat|gct|gac|tcc|gtt|aaa|ggt|cgc|ttc| 233
45 |aga|cca|ccg|tca|tga|atg|ata|cga|ctg|agg|caa|ttt|cca|gcg|aag|
!
! ---FR3-----
! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
! T I S R D N S K N T L Y L Q M
50 |act|atc|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg| 278
! |tga|tag|aga|tct|ctg|ttg|aga|ttc|tta|tga|gag|atg|aac|gtc|tac|
! | XbaI |
!
! ---FR3----->|
55 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
! N S L R A E D T A V Y Y C A K
! |aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgc|gct|aaa| 323
! |ttg|tcg|aat|tcc|cga|ctc|ctg|tga|cgt|cag|atg|ata|acg|cga|ttt|

```

- 173 -

```

!      |AflII|      |PstI|
!
!      .....CDR3.....|---FR4-----
!      121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
5      !      D Y E G T G Y A F D I W G Q G
!      |gac|tat|gaa|ggg|act|ggg|tat|gct|ttc|gaC|ATA|TGg|ggg|caa|ggg| 368
!      |ctg|ata|ctt|cca|tga|cca|ata|tga|aag|ctg|tat|acc|cca|ggt|cca|
!      |NdeI|
!
10      !      -----FR4----->|
!      136 137 138 139 140 141 142
!      T M V T V S S
!      |act|atG|GTC|ACC|gtc|tct|agt- 389
!      |tga|tac|cag|tgg|cag|aga|tca-
15      !      |BstEII|
!
!      143 144 145 146 147 148 149 150 151 152
!      A S T K G P S V F P
!      gcc tcc acc aaG GGC CCa tgc GTC TTC ccc-3' 419
20      !      cgg agg tgg ttc ccg ggt agc cag aag ggg-5'
!      BspI20I. BbsI...(2/2)
!      ApaI....

(SFPRMET) 5'-ctg tct gaa cG GCC cag ccG-3'
(TOPFR1A) 5'-ctg tct gaa cG GCC cag ccG GCC atg gcc-
25      !      gaa|gtt|CAA|TTG|tta|gag|tct|ggg|-
!      |ggc|ggg|ctt|gtt|cag|cct|ggg|ggg|tct|tta-3'
(BOTFR1B) 3'-caa|gtc|gga|cca|cca|aga|aat|gca|gaa|aga|acg|cga|-
!      |cga|agg|cct|aag|tga|aag-5' ! bottom strand
(BOTFR2) 3'-acc|caa|gcg|-
30      !      |gtt|cga|gga|cca|ttt|cca|aac|ctc|acc|caa|aga|-5' ! bottom strand
(BOTFR3) 3'- a|cga|ctg|agg|caa|ttt|cca|gcg|aag|-
!      |tga|tag|aga|tct|ctg|ttg|aga|ttc|tta|tga|gag|atg|aac|gtc|tac|-
!      |ttg|tcg|aat|tcc|cga|ctc|ctg|tga-5'
(F06) 5'-gC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgc|gct|aaa|-
35      !      |gac|tat|gaa|ggg|act|ggg|tat|gct|ttc|gaC|ATA|TGg|ggg|c-3'
(BOTFR4) 3'-cga|aag|ctg|tat|acc|cca|ggt|cca|-
!      |tga|tac|cag|tgg|cag|aga|tca-
!      cgg agg tgg ttc ccg ggt agc cag aag ggg-5' ! bottom strand
(BOTPRCPRIM) 3'-gg ttc ccg ggt agc cag aag ggg-5'
40      !
!      CDR1 diversity
!
!      (ON-vgC1) 5'-lgctTCC|GGA|ttc|act|tct|<1>|TAC|<1>|atg|<1>
!      CDR1.....6859
45      !      tgg|gtt|cgc|CAa|gct|ccT|GG-3'
!
!      <1> stands for an equimolar mix of {ADEF GHIKLMNPQRSTVWY}; no C
!      (this is not a sequence)
!
50      !      CDR2 diversity
!
!      (ON-vgC2) 5'-ggg|tgg|gag|tgg|gtt|tct|<2>|atc|<2>|<3>|-
!      CDR2.....
!      |tct|ggg|ggc|<1>|act|<1>|tat|gct|gac|tcc|gtt|aaa|gg-3'
55      !      CDR2.....
!      <1> is an equimolar mixture of {ADEF GHIKLMNPQRSTVWY}; no C
!      <2> is an equimolar mixture of {YRWVGS}; no ACDEFHIKLMNPQT

```

- 174 -

! <3> is an equimolar mixture of {PS}; no ACDEFGHIKLMNQRTVWY

Table 28: Stuffer used in VH

1 TCCGGAGCTT CAGATCTGTT TGCCTTTTTG TGGGTGGTG CAGATCGCGT TACGGAGATC
61 GACCGACTGC TTGAGCAAAA GCCACGCTTA ACTGCTGATC AGGCATGGGA TGTTATTCGC
121 CAAACCAAGTC GTCAGGATCT TAACCTGAGG CTTTTTTTAC CTACTCTGCA AGCAGCGACA
181 TCTGGTTTGA CACAGAGCGA TCCGCGTCGT CAGTTGGTAG AAACATTAAAC ACGTTGGGAT
241 GGCATCAATT TGCTTAATGA TGATGGTAA ACCTGGCAGC AGCCAGGCTC TGCCATCCTG
301 AACGTTTGGC TGACCAAGTAT GTTGAAGCGT ACCGTAGTGG CTGCCGTACC TATGCCATTT
361 GATAAGTGGT ACAGCGCCAG TGGCTACGAA ACAACCCAGG ACGGCCCAAC TGGTTGCGTG
421 AATATAAGTG TTGGAGCAAA AATTTGTAT GAGCGGTGC AGGAGACAA ATCACCATC
481 CCACAGGCGG TTGATCTGTT TGTGGGAAA CCACAGCAGG AGGTTGTGTT GGCTGCGCTG
541 GAAGATACCT GGGAGACTCT TTCCAAACGC TATGGCAATA ATGTGAGTAA CTGGAAAACA
601 CCTGCAATGG CCTTAACGTT CCGGGCAAT AATTTCTTTG GTGTACCGCA GGCCGACGG
661 GAAGAAACGC GTCATCAGGC GGAGTATCAA AACCGTGGA CAGAAAACGA TATGATTGTT
721 TTCTCACCAA CGACAAGCGA TCGTCTGTG CTTGCCTGGG ATGTGGTCGC ACCCGTCAAG
781 AGTGGGTTTA TTGCTCCCGA TGGAAACAGT GATAAGCACT ATGAAGATCA GCTGAAAAATG
841 TACGAAAAAT TTGGCCGTAA GTCGCTCTGG TTAACGAAGC AGGATGTGGA GGCGCATAAAG
901 GAGTCGTCTA GA

Table 29: DNA sequence of pCESS

```

! pCESS 6680 bases = pCes4 with stuffers in CDR1-2 and CDR3 2000.12.13
!
! Ngene = 6680
! Useful REs (cut MAAnoLI fewer than 3 times) 2000.06.05
!
! Non-cutters
! Acc65I Ggtacc Afel AGCgct AvrII Cctagg
! BsaBI GATNnnatc BsiWI Cgtacg BsmFI Nnnnnnnnnnnnnngtccc
! BsrGI Tgtaca BstAPI GCANNNNntgc BstBI TTcgaa
! BstZ17I GTAtac BtrI CACgtg Ecl136I GAGctc
! EcoRV GATatc FseI GGCCGGcc KpnI GGTACc
! MscI TGGcca NruI TCGcca NsiI ATGCAI
! PacI TTAATtaa PmlI GTTTaaac PmlI CACgtg
! PpuMI RgGwccy PshAI GACNNnmgc SacI GAGCTc
! SacII CCGCgg SbfI CCTGCagg SexAI Accwgtt
! SgfI GCGATcgc SnaBI TACgta SpeI Actagt
! SphI GCATGc Sse8387I CCTGCagg StuI AGGcct
! SwaI ATTTaat XmaI Ccgggg
20 !
! cutters
! Enzymes that cut more than 3 times.
! AlwNI CAGNNNcig 5
! BsgI ctgcac 4
25 ! BsrFI Rccggy 5
! EarI CTCTTCNnnn 4
! Faul nNNNNNGCGGG 10
!
! Enzymes that cut from 1 to 3 times.
30 !
! EcoO109I RGnccy 3 7 2636 4208
! BssSI Cctgig 1 12
! "- Caccag 1 1703
! BspHI Tcatga 3 43 148 1156
35 ! AatII GACGTc 1 65

```

```

!BciVI GTATCCNNNNNN 2 140 1667
!Eco57I CTGAAG 1 301
!"- ctcag 2 1349
!Aval CyeGr 3 319 2347 6137
!BsiHKA! GWGCWc 3 401 2321 4245
!HgiAI GWGCWc 3 401 2321 4245
!BglI gcannnnntcg 1 461
!ScaI AGTact 1 505
!PvuI CGATcg 3 616 3598 5926
!FspI TGCgca 2 763 5946
!BglI GCCNNNNHnggc 3 864 2771 5952
!BpmI CTGGAG 1 898
!"- ctcag 1 4413
!BsaI GGTCNnnnn 1 916
!AhdI GACNNNngtc 1 983
!EarI 1051 GACNNNngtc 1 983
!DrdI GACNNNNngtc 3 1768 6197 6579
!SapI gaagac 1 1998
!PvuI CAGctg 3 2054 3689 5896
!PflMI CCANNNNntgg 3 2233 3943 3991
!HindIII Aagctt 1 2235
!ApaLI Gtgcac 1 2321
!BspMI Nnnnnnnngcaggt 1 2328
!"- ACCTGCNNNNn 2 3460
!PstI CTGCAg 1 2335
!AccI GTmkac 2 2341 2611
!HincII GTYrac 2 2341 3730
!SalI Gtgcac 1 2341
!TliI Ctcgag 1 2347
!XhoI Ctcgag 1 2347
!BbsI gtctc 2 2383 4219
!BipI GCnagc 1 2580
!EspI GCnagc 1 2580
!SgrAI CRccggyg 1 2648
!AgiI Accggt 2 2649 4302
!AscI GGcgccc 1 2689
!BssHII Gcgcg 1 2690

```

5
 10
 15
 20
 25
 30
 35

!SfiI GGCCNNNNnggcc 1 2770
 !NaeI GCGcgc 2 2776 6349
 !NgoMIV Gcgggc 2 2776 6349
 !BtgI Ccrrgg 3 2781 3553 5712
 !DsaI Ccrrgg 3 2781 3553 5712
 !NcoI Ccatgg 1 2781
 !StyI Ccwwgg 3 2781 4205 4472
 !MfeI Caatgg 1 2795
 !BspEI Tcggga 1 2861
 !BglII Agatct 1 2872
 !BclI Tgatca 1 2956
 !Bsu36I CCtnagg 3 3004 4143 4373
 !XcmI CCANNNNNnnntgg 1 3215
 !MluI Acgctt 1 3527
 !HpaI GTTaac 1 3730
 !XbaI Tctaga 1 3767
 !
 !AflII Cttaag 1 3811
 !BsmI NGcattc 1 3821
 !"- GAATGCN 1 4695
 !RsrII CGgwcgc 1 3827
 !NheI Gctagc 1 4166
 !BstEII Ggtnacc 1 4182
 !BsmBI CGTCTCnynn 2 4188 6625
 !"- Nnnnnngagagc 1 6673
 !ApaI GGGCCc 1 4209
 !BanII GRGCYc 3 4209 4492 6319
 !BspI20I Gggccc 1 4209
 !PspOMI Gggccc 1 4209
 !BseRI NNnnnnnnnctctc 1 4226
 !"- GAGGAGNNNNNNNNN 1 4957
 !EcoNI CCTNNnnnagg 1 4278
 !PflI GACNnglc 1 4308
 !TthI1111 GACNnglc 1 4308
 !KasI Gggccc 2 4327 5967
 !BstXI CCANNNNNntgg 1 4415
 !NotI GCggccc 1 4507


```

5      1EagI Cgccc      1 4508
      1BamHI Ggacc      1 5169
      1BspDIA Tcgat      1 5476
      1NdeI CAtag      1 5672
      1EcoRI Gaattc      1 5806
      1PstI JTAaa      1 6118
      1DraIII CACNNNGtg      1 6243
      1BsaAI YACgr      1 6246
      1-----
10      1 gacgaagg cCTCGTGata cgctatttt talaggtaa tgcatagata alaatggtt
      1 BssSI.(1/2)
      61 ctaGACGTC agtggcact ttgggggaa atggcgagg aacctctatt tgtttattt
      1 AatII.
      121 tctaatata ttaataaG TATCCgctca tgagacaata acccigataa atgcttcaat
      1 BciVI.(1 of 2)
      181 aatattgaaa aaggaaagat
      1 Base # 201 to 1061 = ApR gene from pUC119 with some RE sites removed
15      1
      1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
      1 M S I Q H F R V A L I P F F A
      201 atg agt att caa cat ttc cgt gtc gcc ctt att ccc ttt ttt ggg
      1
      16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
      1 A F C L P V F A H P E T L V K
      25 246 gca ttt tgc ctt cct gtt ttt gct cac cca gaa acg cgt gttg aaa
      1
      31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
      1 V K D A E D Q L G A R V G Y I
      291 gta aaa gat gct gaa gat cag ttg ggt gcc cga gttg ggt tac atc
      30      1
      46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
      1 E L D L N S G K I L E S F R P
      336 gaa ctg gat ctc aac agc ggt aag atc ctt gag agt ttt cgc ccc
      1
      61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
      1 E E R F P M M S T F K V L L C
      381 gaa gaa cgt ttt cca atg atg agc act ttt aaa gtt cttg cta tgt

```

```

5      76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
      G A V L S R I D A G Q E Q L G
      426 ggc ggc gta tta tcc cgt att gac gcc ggg caa gaG CAa ctc ggT
          Bgl.....
      91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
      R R I H Y S Q N D L V E Y S P
      471 CGc cgc ala cac tat tct cag aat gac ttg gtt gAG TAC Tca cca
          Scal....
10      106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
      V T E K H L T D G M T V R E L
      516 gtc aca gaa aag cat ctt acg gat ggc atg aca gta aga gaa tta
      121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
      C S A A I T M S D N T A A N L
      561 tgc agt gct gcc ala acc atg agt gat aac act gcc gcc aac tta
      136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
      L L T T I G G P K E L T A F L
      606 ctt ctg aca aCG ATC Gga gga ccg aag gag cta acc gct ttt ttg
          PvuI.... (1/2)
25      151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
      H N M G D H V T R L D R W E P
      651 cac aac atg ggg gat cat gta act cgc ctt gat cgt tgg gaa ccg
      166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
      E L N E A I P N D E R D T T M
      696 gag ctg aat gaa gcc ata cca aac gac gag cgt gac acc acg atg
      181 182 183 184 185 186 187 188 189 190 191 192 193 194 195
      P V A M A T T L R K L L T G E
      741 cct gta GCA ATG gca aca acg tTG CGC Aaa cta tta act ggc gaa
          BsrDI..(1/2)      FspI... (1/2)
35

```

```

! 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
! L L T L A S R Q Q L I D W M E
786 cta ctt act cta gct tcc cgg caa tta ata gac tgg alg gag
!
5 ! 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225
! A D K V A G P L L R S A L P A
831 ggc gat aaa gtt gca gga cca ctt ctg cgc tgc gcc ctt cgc gct
!
! 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240
! G W F I A D K S G A G E R G S
10 ! 876 ggc tgg ttt att gct gat aaa tCT GGA Gcc ggt gag cgt gGG TCT
! BpmI....(1/2) BsaI....
!
! 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255
! R G I I A A L G P D G K P S R
15 ! 921 Cgc ggt atC ATT GCA gca ctg ggg cca gat ggt aag ccc tcc cgt
! BsaI..... BsrDI...(2/2)
!
! 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270
! I V V I Y T T G S Q A T M D E
20 ! 966 atc gta gtt atc tac acG ACg ggg aGT Cag gca act atg gat gaa
! AhdI.....
!
! 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285
! R N R Q I A E I G A S L I K H
25 ! 1011 cga aat aga cag atc gct gag ata ggt gcc tca ctg att aag cat
!
! 286 287
! W .
!
30 ! 1056 tgg taa
! 1062
! 1081 catataact ttgatgtat ttaaaactc attttaatt taaaaggatc taggtgaaga
! 1141 tcttttga taatcctg accaaatcc cttaacgtga gttttgtc cactgagcgt
! 1201 cagaccctgt agaaagatc aaaggatctt ctgagatcc tttttctg cgcgtactt
! 1261 gcctttgca aacaaaaa ccaccgtctac cagcgggtgt tigtgtccg gatcaagagc
! 1321 taccactct ttaccgaag gtaactgct tcaagcagagc gcagatacca aatactgccc
! 1381 ttctagtga gccgtagtta ggccaccact tcaagaactc tgtagcaccg cctacatacc

```

```

1441  tgcctcgt aatcctgta ccagtgcgtg ctgcagtag cgataagtcg tgcctaacg
1501  ggtagact aagacgtag ttaccgata aggcgcagcg gtcgggctga acggggggtt
1561  cgtgcataa gccagcttg gagcgaaga cctacacga actagagatc ctacagcgtg
1621  agcattaga aagcgccacg ctcccgag ggagaaaggc ggacagGTAT CCggaagcg
5      BclVI.. (2 of 2)
1681  gcagggtcgg aacaggagag cgCACGAGGg agcttcagg gggaacgcc tggatctt
      BssSI.(2/2)
1741  atagtcctg cgggttcgc cactctgac ttgagctcg atttttga tgcctgcag
1801  ggggcgag cctatggaa aacgcagca acgggctt ttacggtc ctggccttt
1861  gctggcctt tgcACATG Ttctctcg cgtatccc tgattcttg gataacgta
10      PciI...
1921  ttaccgctt tgagtgcgt galaccgtc gccgcagccg aacgacgag cgcagcgagt
1981  cagtgcgga ggaagcgGAA GAGCgcca taccgaacc gccctcccc gcgcgtggc
      SapI...
15 2041  cgattcatta atGCAGCTGg cagcagagt ttccgactg gaaagcgggc agtgagcgca
      PvuII.(1/3)
2101  acgcaatTAA TGTgagtag ctcactcatt aggcaccca ggcTTTACAc ttatgcttc
      --35.. Plac      --10..
2161  cggctcgtat gtgtgtgga atttgagcg gataacaatt tcacaCAGGA AACAGCTATG
20 2221  ACcagatta cgCCAAGCTT TGGagcctt tttaggaga tticcaac
      PstI.....
      Hind3.
      signal::linker::CLight
25      1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
      fM K K L L F A I P L V P F Y
2269  gtg aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat
30      Linker..... End of FR4
      16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
      S H S A Q V Q L Q V D L E I K
2314  tct cac aGT GCA Cag gtc eaa CTG CAG GTC GAC CTC GAG atc aaa
      ApaLI..... PstI... XhoI...
35      BspMI...
      Sall...
      AccI...(1/2)

```



```

136 137 138 139 140
G E C . .
2674 gga gag tgt taa taa GG CCGCCCaatt
Ascl.....
BssHII.
2701 ctattcaag gagacagtca ta
PeIB::3-23(stuffed)::CH1::III fusion gene
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
M K Y L L P T A A A G L L L
2723 atg aaa tac cta tfg cct aeg gca gcc get gga tfg tta ctc
-----
16 17 18 19 20 21 22
A A Q P A M A
2768 gcG GCC cag ccG GCC atg gcc
SfiI.....
NcoMIV..(1/2)
NcoI....
2789 FRI(DP47/V3-23)-----
23 24 25 26 27 28 29 30
E V Q L L E S G
gaa|gtt(CAA)|TTG|tta|gag|ct|ggd|
|MfeI |
2813 |ggc|ggg|ctt|gtt|cag|ctt|ggg|ggg|ctt|ta|cgt|ctt|ctt|gct|gct|
FR1-----
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
G G L V Q P G G S L R L S C A

```

```

!  ----FR1----
!  46 47 48
!  A S G
2858 |gt|TCC|GGA|
5  |BspEI|

!  Stuffer for CDR1, FR2, and CDR2----->
!  There are no stop codons in this stuffer.
!  2867          gcttcAGATC Tgtttgctt
!  BglII..
2887 ttgtgagggt gggtgagatc ggcgttacgga gatcgaccga cgtcttgagc aaaagccacg
2947 cttaacgtT GATCAggeat gggagtgat tgcctcaaac agtgcgagg atctaacct
!  BclI..
3007 gagcctttt ttacctact tgcagcagc gacatc'gggt tggacacaga gcgatcccg
3067 tgcgcagttg gtagaaacat taacacgttg ggaigcatic aattgctta atgaigatgg
3127 taaaac'gg cagcagccag gctctgccaat cctgaacgtt tggc'gacca g'atg'gaa
3187 gcgtaccgta gtgctgcg taccatgCC Attgataag TGGtaccagc cag'tggc'a
!  XcmI.....
3247 cgaacaacc caggacggcc caactggttc gctgaalata ag'tgtggag caaaaattt
3307 g'atgaggcg g'g'caggagg acaaatcacc aatccacag gcggttgatc t'gtt'ctgg
3367 gaaaccacag caggagggtg t'gttggctgc c'gtggaaat acc'gggaga ct'ttccaa
3427 acgctatggc aa'aa'g'g'a g'uaac'ggaa aacacc'gca atggccttaa cgttccgggc
3487 aa'aa'atttc ttgg'gttac cgcaggccgc agcgggaagaa ACOCGTc'atc agcggagta
!  MluI..
3547 tcaaac'cgt ggaacagaaa acgata'gat t'gtttctca ccaacgacaa g'cgatc'cc
3607 t'gtgctg'cc tggagat'gg tgcacc'cgg t'cagag'tggg t'tat'gctc ccg'atggaac
3667 ag'ttgataag cactatgag atcagct'gaa aat'g'acgaa aatttggcc g'taagtcgct
!  PvuII.
3727 ctgGTTAACg aagcaggatg tggaggcgca taaggatcg
30  |HpaI..
!  |HincII(2/2)

!  ----FR3-----
!  4 5 6 7 8 9 10 11 12 13 14 15 16
!  93 94 95 96 97 98 99 100 101 102 103 104 105
!  S R D N S K N T L Y L Q M
3767 |TCT|AGA|gac|aac|ctc|aag|aat|act|ctc|tac|tg|cag|atg|

```



```

181 182 183 184 185 186 187 188 189 190 191 192 193 194 195
! L T S G V H T F P A V L Q S S
!
4333 ctg acc agc ggc gtc cac acc ttc ccg gct cta cag tcc tca
!
5
196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
! G L Y S L S V V T V P S S
!
4378 gga ctc tac tcc ctc agc agc gta gfg acc gfg ccc tcc agc agc
!
211 212 213 214 215 216 217 218 219 220 221 222 223 224 225
! L G T Q T Y I C N V N H K P S
!
4423 ttg ggc acc cag acc tac atc tgc aac gfg aat cac aag ccc agc
!
226 227 228 229 230 231 232 233 234 235 236 237 238
! N T K V D K K V E P K S C
!
4468 aac acc aag gfg gac aag AAA GTT GAG CCC AAA TCT TGT
! ON-TQHCforw.....
!
Poly His linker
139 140 141 142 143 144 145 146 147 148 149 150
! A A A H H H H H G A A
!
4507 GCG GCC GCa cat cat cat cac cat cac ggg gcc gca
! Notl.....
! Eagl....
!
151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
! E Q K L I S E D L N G A A
!
4543 gaa caa aaa ctc atc tca gaa gag gat ctg aat ggg gcc gca tag
!
Mature III----->...
166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
! T V E S C L A K P H T E N S F
!
4588 act gtt gaa agt tgt tta gca aaa cct cat aca gaa aat tca ttt
!
181 182 183 184 185 186 187 188 189 190 191 192 193 194 195
! T N V W K D K T L D R Y A N
!
4633 act aac gtc tgg aaa gac gac aaa act tta gat cgt tac gct aac
!

```

196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
Y E G C L W N A T G V V C T
4678 tat gag ggc tgt ctg tG AAT GCt aca ggc gtt gtg gtt tgt act
BsmI....
211 212 213 214 215 216 217 218 219 220 221 222 223 224 225
G D E T Q C Y G T W V P I G L
4723 ggt gac gaa act cag tgt tac ggt aca tgg gtt cct att ggg ctt
226 227 228 229 230 231 232 233 234 235 236 237 238 239 240
A I P E N E G G S E G G S
4768 gct atc cct gaa aat gag ggt ggt tct gag ggt ggc ggt tct
241 242 243 244 245 246 247 248 249 250 251 252 253 254 255
E G G S E G G T K P P E Y
4813 gag ggt ggc ggt tct gag ggt ggc ggt act aaa cct cct gag tac
256 257 258 259 260 261 262 263 264 265 266 267 268 269 270
G D T P I P G Y T Y I N P L D
4858 ggt gat aca cct att ccg ggc tat act tat atc aac cct ctc gac
271 272 273 274 275 276 277 278 279 280 281 282 283 284 285
G T Y P P G T E Q N P A N P N
4903 ggc act tat ccg cct ggt act gag caa aac ccc gct aat cct aat
286 287 288 289 290 291 292 293 294 295 296 297 298 299 300
P S L E S Q P L N T F M F Q
4948 cct tct ctt GAG GAG tct cag cct ctt aat act ttc atg ttt cag
BseRI..(2/2)
301 302 303 304 305 306 307 308 309 310 311 312 313 314 315
N N R F R N R Q G A L T V Y T
4993 aat aat agg ttc cga aat agg cag ggt gca tta act gtt tat acg
316 317 318 319 320 321 322 323 324 325 326 327 328 329 330
G T V T Q G T D P V K T Y Y Q
5038 ggc act gtt act caa ggc act gac ccc gtt aaa act tat tac cag

331 332 333 334 335 336 337 338 339 340 341 342 343 344 345
Y T P V S S K A M Y D A Y W N
5083 tac act cct gta tca aaa gcc atg tat gac gct tac tgg aac
346 347 348 349 350 351 352 353 354 355 356 357 358 359 360
G K F R D C A F H S G F N E D
5128 ggt aaa tic aga gac tgc ttc cat tct ggc ttt aat gaG GAT
BamHI..
361 362 363 364 365 366 367 368 369 370 371 372 373 374 375
P F V C E Y Q G Q S S D L P Q
5173 CCa ttc gtt tgt gaa tat caa ggc caa tgc tct gAC CTG Cct caa
BamHI..
BspMI...(2/2)
376 377 378 379 380 381 382 383 384 385 386 387 388 389 390
P P V N A G G G S G G S G G
5218 cct cct gtc aat gct ggc ggc tct ggt ggt tct ggt ggc
391 392 393 394 395 396 397 398 399 400 401 402 403 404 405
G S E G G S E G G S E G G
5263 ggc tct gag ggt ggc tct gag ggt ggc tct gag ggt ggc
406 407 408 409 410 411 412 413 414 415 416 417 418 419 420
G S E G G S G G S G S G D
5308 ggc tct gag ggt ggc tcc ggt ggc ggc tcc ggt tcc ggt gat
421 422 423 424 425 426 427 428 429 430 431 432 433 434 435
F D Y E K M A N A N K G A M T
5353 ttt gat tat gaa aaa atg gca aac gct aat aag ggg gct atg acc
436 437 438 439 440 441 442 443 444 445 446 447 448 449 450
E N A D E N A L Q S D A K G K
5398 gaa aat gcc gat gaa aac gcg cta cag tct gac gct aaa ggc aaa

5 ! 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465
! L D S V A T D Y G A A I D G F
5443 ctt gat tct gtc gct act gat tac ggt gct gct ATC GAT ggt ttc
! BspDI..
! 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480
! I G D V S G L A N G N G A T G
5488 att ggt gac gtt tcc ggc ctt gct aat ggt aat ggt gct acf ggt
! 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495
! D F A G S N S Q M A Q V G D G
5533 gat ttt gct ggc tct aat tcc caa atg gct caa gtc ggt gac ggt
! 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510
! D N S P L M N N F R Q Y L P S
5578 gat aat tca cct tta atg aat aat ttc cgt caa tat tta cct tct
! 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525
! L P Q S V E C R P Y V F G A G
5623 tgg cct cag tgg gtt gaa tgt cgc cct tat gtc ttt ggc gct ggt
! 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540
! K P Y E F S I D C D K I N L F
5668 aaa cCA TAT Gaa ttt tct att gat tgt gac aaa ata aac tta ttc
! NdeI....
! 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555
! R G V F A F L L Y V A T F M Y
5713 cgt ggt gtc ttt gcg ttt ctt tta tat gtt gcc acc ttt atg tat
! 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570
! V F S T F A N I L R N K E S
5758 gta ttt tgg acg ttt gct aac ata ctg cgt aat aag gag tct taa
!

```

! 571
!
! 5803 taa GAATTC
! EcoRI.
5 5812 actggccgt cgttttaca cgtcgtgact ggggaaaccc tggcgttacc caacttaac
5871 gcttgcgc acatcccc ttcgccgt ggcgtatag cgaagagcc cgcacCGATC
! PvuII..
5931 Gcccttcca acagtTGGGC Agccigaatg gcgaatGGCG CCtgatcgg tatcttcc
! ...PvuII... (3/3) FspI... (2/2) KspI... (2/2)
5991 ttacgcact gtcggtatt tcacacgca tataatgt aaacgttaatt atttgttaa
6051 aattcgtt aaatttgt taatcagct caatttaa ccaataggcc gaaatcgca
6111 aaatcccTTA TAAatcaaaa gaatagccg agatagggtt gatttgtt ccagtttga
! PstI...
6171 acaagagtc actatnaag aacgtgact ccaacgtcaa agggcgaaaa accgtctatc
6231 agggcgatg ccCACuacGT Gaaccalcac ccaatcaag ttttgggg tggagtgcc
! DraIII....
6291 gtaagcact aaatcggaac cctaaggga gcccccgatt tagagctga cggggaaaGC
! NgoMIV..
6351 CGGCgaact ggcgagaag gaagggaaga aagcgaagg agcgggcgt agggcgttgg
! ...NgoMIV (2/2)
6411 caagtgtgac ggtcacgctg cgcgtacaa ccacacccg cgcgtttaa ggcgcgtac
6471 agggcggtg ctaagtgtg ttgacgggtt gcagtcicag tacaatcgc tctgatccg
6531 calagtaag ccagcccca caccgcca caccgctga cgcgcctga cgggcttgc
6591 tgcctcggc atcgcctac agacaagctg tgaccgttc cgggagctgc algtgtcaga
6651 ggtttcacg gtcacacg aaacgcgca

```

Table 30: Oligonucleotides used to clone CDR1/2 diversity

All sequences are 5' to 3'.

1) ON_CD1Bsp, 30 bases

5 A c c T c A c T g g c T T c c g g A
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

10 T T c A c T T T c T c T
 19 20 21 22 23 24 25 26 27 28 29 30

2) ON_Br12, 42 bases

15 A g A A A c c c A c T c c A A A c c
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

T T T A c c A g g A g c T T g g c g
 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36

20 A A c c c A
 37 38 39 40 41 42

3) ON_CD2Xba, 51 bases

25 g g A A g g c A g T g A T c T A g A
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

g A T A g T g A A g c g A c c T T T
 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36

30 A A c g g A g T c A g c A T A
 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51

4) ON_BotXba, 23 bases

35 g g A A g g c A g T g A T c T A g A
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

40 g A T A g
 19 20 21 22 23

Table 31: Bridge/Extender Oligonucleotides

	ON_Lam1aB7(rc)GTGCTGACTCAGCCACCCTC.	20
	ON_Lam2aB7(rc)GCCCTGACTCAGCCTGCCTC.	20
	ON_Lam31B7(rc)GAGCTGACTCAGG.ACCCTGC	20
5	ON_Lam3rB7(rc)GAGCTGACTCAGCCACCCTC.	20
	ON_LamHf1cBrg(rc)	CCTCGACAGCGAAGTGCACAGAGCGTCTTGACTCAGCC.....	38
	ON_LamHf1cExt	CCTCGACAGCGAAGTGCACAGAGCGTCTTG.....	30
	ON_LamHf2b2Brg(rc)	CCTCGACAGCGAAGTGCACAGAGCGCTTTGACTCAGCC.....	38
	ON_LamHf2b2Ext	CCTCGACAGCGAAGTGCACAGAGCGCTTTG.....	30
10	ON_LamHf2dBrg(rc)	CCTCGACAGCTAAGTGCACAGAGCGCTTTGACTCAGCC.....	38
	ON_LamHf2dExt	CCTCGACAGCGAAGTGCACAGAGCGCTTTG.....	30
	ON_LamHf31Brg(rc)	CCTCGACAGCGAAGTGCACAGAGCGAATTGACTCAGCC.....	38
	ON_LamHf31Ext	CCTCGACAGCGAAGTGCACAGAGCGAATTG.....	30
	ON_LamHf3rBrg(rc)	CCTCGACAGCGAAGTGCACAGTACGAATTGACTCAGCC.....	38
15	ON_LamHf3rExt	CCTCGACAGCGAAGTGCACAGTACGAATTG.....	30
	ON_lamPlePCR	CCTCGACAGCGAAGTGCACAG.....	21
	Consensus		

- 194 -

Table 32: Oligonucleotides used to make SSDNA locally
double-stranded

Adapters (8)

	H43HF3.1?02#1	5'-cc	gtg	tat	tac	tgt	gcg	aga	g-3'
5	H43.77.97.1-03#2	5'-ct	gtg	tat	tac	tgt	gcg	aga	g-3'
	H43.77.97.323#22	5'-cc	gta	tat	tac	tgt	gcg	aga	g-3'
	H43.77.97.330#23	5'-cc	gtg	tat	tac	tgt	gcg	aga	g-3'
	H43.77.97.439#44	5'-cc	gtg	tat	tac	tgt	gcg	aga	c-3'
	H43.77.97.551#48	5'-cc	atg	tat	tac	tgt	gcg	aga	c-3'

Table 33: Bridge/extender pairs

Bridges (2)

H43.XABr1

5 5'ggtgtagtgaTCTAGtgacaactctaagaatactctctacttgcagatgaacagCTTtAGgg
ctgaggacaCTGCAGtctactattgtgcgaga-3'

H43.XABr2

10 5'ggtgtagtgaTCTAGtgacaactctaagaatactctctacttgcagatgaacagCTTtAGgg
ctgaggacaCTGCAGtctactattgtgcgaaa-3'

Extender

H43.XAExt

15 5'ATAgTAgAcTgcAgTgTccTcAgcccTTAAgcTgTTcATcTgcAAgTAgAgAgTATTcTTAg
AgTTgTcTcTAgATcAcTAcAcc-3'

- 196 -

Table 34: PCR primers

	<u>Primers</u>
	H43.XAPCR2 gactgggTgTAgTgATcTAg
5	Hucmnest cttttctttgttgccgttggggtg

- 197 -

Table 35: PCR program for amplification of heavy chain CDR3 DNA

	95 degrees C	5 minutes	
	95 degrees C	20 seconds	
5	60 degrees C	30 seconds	repeat 20x
	72 degrees C	1 minute	
	72 degrees C	7 minutes	
	4 degrees C	hold	
<u>Reagents</u> (100 ul reaction):			
10	Template	5ul ligation mix	
	10x PCR buffer	1x	
	Taq	5U	
	dNTPs	200 uM each	
	MgCl2	2mM	
15	H43.XAPCR2-biotin	400 nM	
	Hucmnest	200 nM	

- 198 -

! Table 36: Annotated sequence of CJR DY3F7 (CJR-A05) 10251 bases

! Non-cutters

5	!BclI Tgatca	BsiWI Cgtacg	BssSI Caccag
	!BstZ17I GTAtac	BtrI CACgtg	EcoRV GATatc
	!FseI GGCCGGcc	HpaI GTTaaac	MluI Acgcgt
	!PmeI GTTTaaac	PmlI CACgtg	PpuMI RGgwccy
	!RsrII CGgwccg	SapI GCTCTTC	SexAI Accwgggt
10	!SgfI GCGATcgc	SgrAI CRccggyg	SphI GCATGc
	!StuI AGGcct	XmaI Cccggg	

! cutters

15 ! Enzymes that cut from 1 to 4 times and other features

	!End of genes II and X		829		
	!Start gene V		843		
	!BsrGI Tgtaca	1	1021		
20	!BspMI Nnnnnnnnnngcaggt	3	1104	5997	9183
	!-"- ACCTGCNNNNn	1	2281		
	!End of gene V		1106		
	!Start gene VII		1108		
	!BsaBI GATNNnnatc	2	1149	3967	
25	!Start gene IX		1208		
	!End gene VII		1211		
	!SnaBI TACgta	2	1268	7133	
	!BspHI Tcatga	3	1299	6085	7093
	!Start gene VIII		1301		
30	!End gene IX		1304		
	!End gene VIII		1522		
	!Start gene III		1578		
	!EagI Cggccg	2	1630	8905	
	!XbaI Tctaga	2	1643	8436	
35	!KasI Ggcgcc	4	1650	8724	9039 9120
	!BsmI GAATGCN	2	1769	9065	
	!BseRI GAGGAGNNNNNNNNNN	2	2031	8516	
	!-"- NNNnnnnnnnctcctc	2	7603	8623	
	!AlwNI CAGNNNctg	3	2210	8072	8182
40	!BspDI ATcgat	2	2520	9883	
	!NdeI CATatg	3	2716	3796	9847
	!End gene III		2846		
	!Start gene VI		2848		
	!AfeI AGCgct	1	3032		
45	!End gene VI		3187		
	!Start gene I		3189		
	!EarI CTCTTCNnnn	2	4067	9274	
	!-"- Nnnnngaagag	2	6126	8953	
	!PacI TTAATtaa	1	4125		
50	!Start gene IV		4213		
	!End gene I		4235		
	!BsmFI Nnnnnnnnnnnnnngtccc	2	5068	9515	
	!MscI TGGcca	3	5073	7597	9160
	!PsiI TTAtaa	2	5349	5837	
55	!End gene IV		5493		
	!Start ori		5494		
	!NgoMIV Gccggc	3	5606	8213	9315
	!BanII GRGCYc	4	5636	8080	8606 8889
	!DraIII CACNNNgtg	1	5709		
60	!DrdI GACNNNNngtc	1	5752		
	!AvaI Cycgrg	2	5818	7240	

- 199 -

	!PvuII CAGctg	1	5953		
	!BsmBI CGTCTCnNNnn	3	5964	8585	9271
	!End ori region		5993		
	!BamHI Ggatcc	1	5994		
5	!HindIII Aagctt	3	6000	7147	7384
	!BciVI GTATCCNNNNNN	1	6077		
	!Start bla		6138		
	!Eco57I CTGAAG	2	6238	7716	
	!SpeI Actagt	1	6257		
10	!BcgI gcannnnnnntcg	1	6398		
	!ScaI AGTact	1	6442		
	!PvuI CGATcg	1	6553		
	!FspI TGCgca	1	6700		
	!BglI GCCNNNNnggc	3	6801	8208	8976
15	!BsaI GGTCTCnNNnn	1	6853		
	!AhdI GACNNNngtc	1	6920		
	!Eam1105I GACNNNngtc	1	6920		
	!End bla		6998		
	!AccI GTmkac	2	7153	8048	
20	!HincII GTYrac	1	7153		
	!SalI Gtcgac	1	7153		
	!XhoI Ctcgag	1	7240		
	!Start PlacZ region		7246		
	!End PlacZ region		7381		
25	!PflMI CCANNNNntgg	1	7382		
	!RBS1		7405		
	!start M13-iii signal seq for LC		7418		
	!ApaLI Gtgcac	1	7470		
	!end M13-iii signal seq		7471		
30	!Start light chain kappa L20:JK1		7472		
	!PflFI GACNngtc	3	7489	8705	9099
	!SbfI CCTGCagg	1	7542		
	!PstI CTGCag	1	7543		
	!KpnI GGTACc	1	7581		
35	!XcmI CCANNNNNnnntgg	2	7585	9215	
	!NsiI ATGCAc	2	7626	9503	
	!BsgI ctgcac	1	7809		
	!BbsI gtcttc	2	7820	8616	
	!BlpI GCtnagc	1	8017		
40	!EspI GCtnagc	1	8017		
	!EcoO109I RGgnccy	2	8073	8605	
	!Ecl136I GAGctc	1	8080		
	!SacI GAGCTc	1	8080		
	!End light chain		8122		
45	!AscI GGcgcgcc	1	8126		
	!BssHII Gcgcgcc	1	8127		
	!RBS2		8147		
	!SfiI GGCCNNNNnggcc	1	8207		
	!NcoI Ccatgg	1	8218		
50	!Start 3-23, FR1		8226		
	!MfeI Caattg	1	8232		
	!BspEI Tccgga	1	8298		
	!Start CDR1		8316		
	!Statt FR2		8331		
55	!BstXI CCANNNNNntgg	2	8339	8812	
	!EcoNI CCTNNnnnagg	2	8346	8675	
	!Start FR3		8373		
	!XbaI Tctaga	2	8436	1643	
	!AflIII Cttaag	1	8480		
60	!Start CDR3		8520		
	!AatII GACGTc	1	8556		

- 200 -

```

!Start FR4                                8562
!PshAI GACNNnngtc                        2 8573 9231
!BstEII Ggtnacc                          1 8579
!Start CH1                                8595
5 !ApaI GGGCCc                            1 8606
!Bsp120I Gggccc                          1 8606
!PspOMI Gggccc                          1 8606
!AgeI Accggt                             1 8699
!Bsu36I CCTnagg                          2 8770 9509
10 !End of CH1                            8903
!NotI GCggccgc                          1 8904
!Start His6 tag                          8913
!Start cMyc tag                          8931
!Amber codon                             8982
15 !NheI Gctagc                          1 8985
!Start M13 III Domain 3                  8997
!NruI TCGcga                            1 9106
!BstBI TTCgaa                           1 9197
!EcoRI Gaattc                           1 9200
20 !XcmI CCANNNNNnnnntgg                1 9215
!BstAPI GCANNNNntgc                     1 9337
!SacII CCGCgg                          1 9365
!End IIIstump anchor                    9455
!AvrII Cctagg                          1 9462
25 !trp terminator                       9470
!SwaI ATTTaaat                          1 9784
!Start gene II                          9850
!BglII Agatct                          1 9936
-----
30 1 aat gct act act att agt aga att gat gcc acc ttt tca gct cgc gcc
! gene ii continued
49 cca aat gaa aat ata gct aaa cag gtt att gac cat ttg cga aat gta
97 tct aat ggt caa act aaa tct act cgt tcg cag aat tgg gaa tca act
35 145 gtt aTa tgg aat gaa act tcc aga cac cgt act tta gtt gca tat tta
193 aaa cat gtt gag cta cag caT TaT att cag caa tta agc tct aag cca
241 tcc gca aaa atg acc tct tat caa aag gag caa tta aag gta ctc tct
289 aat cct gac ctg ttg gag ttt gct tcc ggt ctg gtt cgc ttt gaa gct
337 cga att aaa acg cga tat ttg aag tct ttc ggg ctt cct ctt aat ctt
40 385 ttt gat gca atc cgc ttt gct tct gac tat aat agt cag ggt aaa gac
433 ctg att ttt gat tta tgg tca ttc tcg ttt tct gaa ctg ttt aaa gca
481 ttt gag ggg gat tca ATG aat att tat gac gat tcc gca gta ttg gac
! Start gene x, ii continues
529 gct atc cag tct aaa cat ttt act att acc ccc tct ggc aaa act tct
577 ttt gca aaa gcc tct cgc tat ttt ggt ttt tat cgt cgt ctg gta aac
45 625 gag ggt tat gat agt gtt gct ctt act atg cct cgt aat tcc ttt tgg
673 cgt tat gta tct gca tta gtt gaa tgt ggt att cct aaa tct caa ctg
721 atg aat ctt tct acc tgt aat aat gtt gtt ccg tta gtt cgt ttt att
769 aac gta gat ttt tct tcc caa cgt cct gac tgg tat aat gag cca gtt
817 ctt aaa atc gca TAA
50 ! End X & II
832 ggtaattca ca
!
! M1 E5 Q10 T15
55 843 ATG att aaa gtt gaa att aaa cca tct caa gcc caa ttt act act cgt
! Start gene V
!
! S17 S20 P25 E30
891 tct ggt gtt tct cgt cag ggc aag cct tat tca ctg aat gag cag ctt
!
60 ! V35 E40 V45
939 tgt tac gtt gat ttg ggt aat gaa tat ccg gtt ctt gtc aag att act

```

- 201 -

```

!
!           D50                     A55                     L60
!   987 ctt gat gaa ggt cag cca gcc tat gcg cct ggt cTG TAC Acc gtt cat
!                                     BsrGI...
5 !           L65                     V70                     S75                     R80
!   1035 ctg tcc tct ttc aaa gtt ggt cag ttc ggt tcc ctt atg att gac cgt
!
!           P85           K87 end of V
!   1083 ctg cgc ctc gtt ccg gct aag TAA C
10 !
!   1108 ATG gag cag gtc gcg gat ttc gac aca att tat cag gcg atg
!       Start gene VII
!
!   1150 ata caa atc tcc gtt gta ctt tgt ttc gcg ctt ggt ata atc
15 !
!           VII and IX overlap.
!           ..... S2 V3 L4 V5                     S10
!   1192 gct ggg ggt caa agA TGA gt gtt tta gtg tat tct ttT gcc tct ttc gtt
!           End VII
20 !           |start IX
!           L13           W15                     G20                     T25                     E29
!   1242 tta ggt tgg tgc ctt cgt agt ggc att acg tat ttt acc cgt tta atg gaa
!
!   1293 act tcc tc
25 !
!       .... stop of IX, IX and VIII overlap by four bases
!   1301 ATG aaa aag tct tta gtc ctc aaa gcc tct gta gcc gtt gct acc ctc
!       Start signal sequence of viii.
!
!   1349 gtt ccg atg ctg tct ttc gct gct gag ggt gac gat ccc gca aaa gcg
!           mature VIII --->
!   1397 gcc ttt aac tcc ctg caa gcc tca gcg acc gaa tat atc ggt tat gcg
!   1445 tgg gcg atg gtt gtt gtc att
!   1466 gtc ggc gca act atc ggt atc aag ctg ttt aag
35 !
!   bases 1499-1539 are probable promoter for iii
!   1499 aaa ttc acc tcg aaa gca ! 1515
!       ..... -35 ..
!
!   1517       agc tga taaaccgat acaattaaag gctccttttg
!           ..... -10 ...
!
!   1552 gagccttttt ttt GGAGAt ttt ! S.D. uppercase, there may be 9 Ts
45 !
!       <----- III signal sequence ----->
!           M K K L L F A I P L V V P F
!   1574 caac GTG aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc ! 1620
!
!           Y S G A A E S H L D G A
50 !   1620 tat tct ggc gCG GCC Gaa tca caT CTA GAc ggc gcc
!           EagI.... XbaI....
!
!   Domain 1 -----
!           A E T V E S C L A
55 !   1656       gct gaa act gtt gaa agt tgt tta gca
!
!           K S H T E I S F T N V W K D D K T
!   1683 aaA Tcc cat aca gaa aat tca ttt aCT AAC GTC TGG AAA GAC GAC AAA ACT
!
!           L D R Y A N Y E G S L W N A T G V
60 !   1734 tta gat cgt tac gct aac tat gag ggC tgt ctg tgG AAT GcT aca ggc gtt

```

- 202 -

```

!                                     BsmI....
!
!       V   V   C   T   G   D   E   T   Q   C   Y   G   T   W   V   P   I
5 1785 gta gtt tgt act ggt GAC GAA ACT CAG TGT TAC GGT ACA TGG GTT cct att
!
!       G   L   A   I   P   E   N
1836 ggg ctt gct atc cct gaa aat
!
! L1 linker -----
10 !       E   G   G   G   S   E   G   G   G   S
1857 gag ggt ggt ggc tct gag ggt ggc ggt tct
!
!       E   G   G   G   S   E   G   G   G   T
15 1887 gag ggt ggc ggt tct gag ggt ggc ggt act
!
! Domain 2 -----
1917 aaa cct cct gag tac ggt gat aca cct att ccg ggc tat act tat atc aac
1968 cct ctc gac ggc act tat ccg cct ggt act gag caa aac ccc gct aat cct
20 2019 aat cct tct ctt GAG GAG tct cag cct ctt aat act ttc atg ttt cag aat
!
!       BseRI..
2070 aat agg ttc cga aat agg cag ggg gca tta act gtt tat acg ggc act
2118 gtt act caa ggc act gac ccc gtt aaa act tat tac cag tac act cct
2166 gta tca tca aaa gcc atg tat gac gct tac tgg aac ggt aaa ttC AGA
!
!                                     AlwNI
25 2214 GAC TGc gct ttc cat tct ggc ttt aat gaG gat TTa ttT gtt tgt gaa
!
!       AlwNI
2262 tat caa ggc caa tcg tct gac ctg cct caa cct cct gtc aat gct
!
!
2307 ggc ggc ggc tct
30 ! start L2 -----
2319 ggt ggt ggt tct
2331 ggt ggc ggc tct
2343 gag ggt ggt ggc tct gag gga ggc ggt tcc
2373 ggt ggt ggc tct ggt ! end L2
35 !
! Many published sequences of M13-derived phage have a longer linker
! than shown here by repeats of the EGGGS motif two more times.
!
! Domain 3 -----
40 !       S   G   D   F   D   Y   E   K   M   A   N   A   N   K   G   A
2388 tcc ggt gat ttt gat tat gaa aag atg gca aac gct aat aag ggg gct
!
!       M   T   E   N   A   D   E   N   A   L   Q   S   D   A   K   G
45 2436 atg acc gaa aat gcc gat gaa aac gcg cta cag tct gac gct aaa ggc
!
!       K   L   D   S   V   A   T   D   Y   G   A   A   M   D   G   F
2484 aaa ctt gat tct gtc gct act gat tac ggt gct gct atc gat ggt ttc
!
!       I   G   D   V   S   G   L   A   N   G   N   G   A   T   G   D
50 2532 att ggt gac gtt tcc ggc ctt gct aat ggt aat ggt gct act ggt gat
!
!       F   A   G   S   N   S   Q   M   A   Q   V   G   D   G   D   N
2580 ttt gct ggc tct aat tcc caa atg gct caa gtc ggt gac ggt gat aat
!
!       S   P   L   M   N   N   F   R   Q   Y   L   P   S   L   P   Q
55 2628 tca cct tta atg aat aat ttc cgt caa tat tta cct tcc ctc cct caa
!
!       S   V   E   C   R   P   F   V   F   G   A   G   K   P   Y   E
60 2676 tcg gtt gaa tgt cgc cct ttt gtc ttt Ggc gct ggt aaa cca tat gaa
!
!       F   S   I   D   C   D   K   I   N   L   F   R

```


- 203 -

```

2724 ttt tct att gat tgt gac aaa ata aac tta ttc cgt
                                     End Domain 3
!
!
!   G   V   F   A   F   L   L   Y   V   A   T   F   M   Y   V   F140
5 2760 ggt gtc ttt gcg ttt ctt tta tat gtt gcc acc ttt atg tat gta ttt
!   start transmembrane segment
!
!   S   T   F   A   N   I   L
10 2808 tct acg ttt gct aac ata ctg
!
!   R   N   K   E   S
!   2829 cgt aat aag gag tct TAA ! stop of iii
!   Intracellular anchor.
!
!   M1 P2 V L L5 G I P L L10 L R F L G15
15 2847 tc ATG cca gtt ctt ttg ggt att ccg tta tta ttg cgt ttc ctc ggt
!   Start VI
!
!   2894 ttc ctt ctg gta act ttg ttc ggc tat ctg ctt act ttt ctt aaa aag
20 2942 ggc ttc ggt aag ata gct att gct att tca ttg ttt ctt gct ctt att
2990 att ggg ctt aac tca att ctt gtg ggt tat ctc tct gat att agc gct
3038 caa tta ccc tct gac ttt gtt cag ggt gtt cag tta att ctc ccg tct
3086 aat gcg ctt ccc tgt ttt tat gtt att ctc tct gta aag gct gct att
25 3134 ttc att ttt gac gtt aaa caa aaa atc gtt tct tat ttg gat tgg gat
!
!   M1 A2 V3 F5 L10 G13
3182 aaa TAA t ATG gct gtt tat ttt gta act ggc aaa tta ggc tct gga
!   end VI Start gene I
!
!   K   T   L   V   S   V   G   K   I   Q   D   K   I   V   A
30 3228 aag acg ctc gtt agc gtt ggt aag att cag gat aaa att gta gct
!
!   G   C   K   I   A   T   N   L   D   L   R   L   Q   N   L
35 3273 ggg tgc aaa ata gca act aat ctt gat tta agg ctt caa aac ctc
!
!   P   Q   V   G   R   F   A   K   T   P   R   V   L   R   I
3318 ccg caa gtc ggg agg ttc gct aaa acg cct cgc gtt ctt aga ata
!
!   P   D   K   P   S   I   S   D   L   L   A   I   G   R   G
40 3363 ccg gat aag cct tct ata tct gat ttg ctt gct att ggg cgc ggt
!
!   N   D   S   Y   D   E   N   K   N   G   L   L   V   L   D
3408 aat gat tcc tac gat gaa aat aaa aac ggc ttg ctt gtt ctc gat
!
!   E   C   G   T   W   F   N   T   R   S   W   N   D   K   E
45 3453 gag tgc ggt act tgg ttt aat acc cgt tct tgg aat gat aag gaa
!
!   R   Q   P   I   I   D   W   F   L   H   A   R   K   L   G
3498 aga cag ccg att att gat tgg ttt cta cat gct cgt aaa tta gga
50
!   W   D   I   I   F   L   V   Q   D   L   S   I   V   D   K
3543 tgg gat att att ttt ctt gtt cag gac tta tct att gtt gat aaa
!
!   Q   A   R   S   A   L   A   E   H   V   V   Y   C   R   R
55 3588 cag gcg cgt tct gca tta gct gaa cat gtt gtt tat tgt cgt cgt
!
!   L   D   R   I   T   L   P   F   V   G   T   L   Y   S   L
3633 ctg gac aga att act tta cct ttt gtc ggt act tta tat tct ctt
!
!   I   T   G   S   K   M   P   L   P   K   L   H   V   G   V
60 3678 att act ggc tcg aaa atg cct ctg cct aaa tta cat gtt ggc gtt

```

- 204 -

```

!
!       V   K   Y   G   D   S   Q   L   S   P   T   V   E   R   W
3723 gtt aaa tat ggc gat tct caa tta agc cct act gtt gag cgt tgg
!
5 !       L   Y   T   G   K   N   L   Y   N   A   Y   D   T   K   Q
3768 ctt tat act ggt aag aat ttg tat aac gca tat gat act aaa cag
!
!       A   F   S   S   N   Y   D   S   G   V   Y   S   Y   L   T
3813 gct ttt tct agt aat tat gat tcc ggt gtt tat tct tat tta acg
10 !
!       P   Y   L   S   H   G   R   Y   F   K   P   L   N   L   G
3858 cct tat tta tca cac ggt cgg tat ttc aaa cca tta aat tta ggt
!
!       Q   K   M   K   L   T   K   I   Y   L   K   K   F   S   R
15 3903 cag aag atg aaa tta act aaa ata tat ttg aaa aag ttt tct cgc
!
!       V   L   C   L   A   I   G   F   A   S   A   F   T   Y   S
3948 gtt ctt tgt ctt gcg att gga ttt gca tca gca ttt aca tat agt
!
20 !       Y   I   T   Q   P   K   P   E   V   K   K   V   V   S   Q
3993 tat ata acc caa cct aag ccg gag gtt aaa aag gta gtc tct cag
!
!       T   Y   D   F   D   K   F   T   I   D   S   S   Q   R   L
4038 acc tat gat ttt gat aaa ttc act att gac tct tct cag cgt ctt
25 !
!       N   L   S   Y   R   Y   V   F   K   D   S   K   G   K   L
4083 aat cta agc tat cgc tat gtt ttc aag gat tct aag gga aaa TTA
!                                     PacI
!
30 !       I   N   S   D   D   L   Q   K   Q   G   Y   S   L   T   Y
4128 ATT AAt agc gac gat tta cag aag caa ggt tat tca ctc aca tat
!       PacI
!
!       i   I   D   L   C   T   V   S   I   K   K   G   N   S   N   E
35 !       iv                                     M1 K
4173 att gat tta tgt act gtt tcc att aaa aaa ggt aat tca aAT Gaa
!                                     Start IV
!
!       i   I   V   K   C   N   .End of I
40 !       iv   L3 L   N5 V   I7 N   F V10
4218 att gtt aaa tgt aat TAA T TTT GTT
!       IV continued.....
4243 ttc ttg atg ttt gtt tca tca tct tct ttt gct cag gta att gaa atg
4291 aat aat tcg cct ctg cgc gat ttt gta act tgg tat tca aag caa tca
45 4339 ggc gaa tcc gtt att gtt tct ccc gat gta aaa ggt act gtt act gta
4387 tat tca tct gac gtt aaa cct gaa aat cta cgc aat ttc ttt att tct
4435 gtt tta cgt gcA aat aat ttt gat atg gtA ggt tcT aAC cct tcc atT
4483 att cag aag tat aat cca aac aat cag gat tat att gat gaa ttg cca
4531 tca tct gat aat cag gaa tat gat gat aat tcc gct cct tct ggt ggt
50 4579 ttc ttt gtt ccg caa aat gat aat gtt act caa act ttt aaa att aat
4627 aac gtt cgg gca aag gat tta ata cga gtt gtc gaa ttg ttt gta aag
4675 tct aat act tct aaa tcc tca aat gta tta tct att gac ggc tct aat
4723 cta tta gtt gtt agt gcT cct aaa gat att tta gat aac ctt cct caa
4771 ttc ctt tcA act gtt gat ttg cca act gac cag ata ttg att gag ggt
55 4819 ttg ata ttt gag gtt cag caa ggt gat gct tta gat ttt tca ttt gct
4867 gct ggc tct cag cgt ggc act gtt gca ggc ggt gtt aat act gac cgc
4915 ctc acc tct gtt tta tct tct gct ggt ggt tcg ttc ggt att ttt aat
4963 ggc gat gtt tta ggg cta tca gtt cgc gca tta aag act aat agc cat
5011 tca aaa ata ttg tct gtg cca cgt att ctt acg ctt tca ggt cag aag
60 5059 ggt tct atc tct gtT GGC CAg aat gtc cct ttt att act ggt cgt gtg
!                                     MscI....

```

- 205 -

```

5107 act ggt gaa tct gcc aat gta aat aat cca ttt cag acg att gag cgt
5155 caa aat gta ggt att tcc atg agc gtt ttt cct gtt gca atg gct ggc
5203 ggt aat att gtt ctg gat att acc agc aag gcc gat agt ttg agt tct
5251 tct act cag gca agt gat gtt att act aat caa aga agt att gct aca
5299 acg gtt aat ttg cgt gat gga cag act ctt tta ctc ggt ggc ctc act
5347 gat tat aaa aac act tct caG gat tct ggc gta ccg ttc ctg tct aaa
5395 atc cct tta atc ggc ctc ctg ttt agc tcc cgc tct gat tct aac gag
5443 gaa agc acg tta tac gtg ctc gtc aaa gca acc ata gta cgc gcc ctg
5491 TAG cggcgcatt
10 ! End IV
5503 aagcgcggcg ggtgtggtgg ttacgcgcag cgtgaccgct acacttgcca ggcgcctagc
5563 gcccgctcct ttgcgtttct tcccttcctt tctcgccacg ttcGCCGGCt ttccccgtca
! NgoMI.
5623 agctctaaat cgggggctcc ctttaggggtt ccgatttagt gctttacggc acctcgaccc
15 5683 caaaaaactt gatttgggtg atggttCACG TAGTGggcca tcgccctgat agacggtttt
! DraIII....
5743 tcgccctttG ACGTTGGAGT Ccactgttctt taatagtgga ctcttgttcc aaactggaac
! DrdI.....
5803 aacactcaac cctatctcgg gctattcttt tgatttataa gggattttgc cgatttcgga
20 5863 accaccatca aacaggattt tcgcctgctg gggcaaacca gcgtggaccg cttgctgcaa
5923 ctctctcagg gccaggcggg gaagggcaat CAGCTGttgc cCGTCTCact ggtgaaaaga
! PvuII. BsmBI.
5983 aaaaccacccc tGGATCC AAGCTT
! BamHI HindIII (1/2)
25 ! Insert carrying bla gene
6006 gcagggtg gcacttttcg gggaaatgtg cgcggaaaccc
6043 ctatttgttt atttttctaa atacattcaa atatGTATCC gctcatgaga caataaccct
! BciVI
6103 gataaatgct tcaataatat tgaaaaAGGA AGAgT
30 ! RBS.?...
! Start bla gene
6138 ATG agt att caa cat ttc cgt gtc gcc ctt att ccc ttt ttt gcg gca ttt
6189 tgc ctt cct gtt ttt gct cac cca gaa acg ctg gtg aaa gta aaa gat gct
6240 gaa gat cag ttg ggC gCA CTA GTg ggt tac atc gaa ctg gat ctc aac agc
35 ! SpeI....
! ApaLI & BssSI Removed
6291 ggt aag atc ctt gag agt ttt cgc ccc gaa gaa cgt ttt cca atg atg agc
6342 act ttt aaa gtt ctg cta tgt GGC GcG Gta tta tcc cgt att gac gcc ggg
6393 caa gaG CAA CTC GGT CGc cgC ATA cAC tat tct cag aat gac ttg gtt gAG
40 ! BcgI..... ScaI
6444 TAC Tca cca gtc aca gaa aag cat ctt acg gat ggc atg aca gta aga gaa
! ScaI.
6495 tta tgc agt gct gcc ata acc atg agt gat aac act gcg gcc aac tta ctt
6546 ctg aca aCG ATC Gga gga ccg aag gag cta acc gct ttt ttg cac aac atg
45 ! PvuI....
6597 ggg gat cat gta act cgc ctt gat cgt tgg gaa ccg gag ctg aat gaa gcc
6648 ata cca aac gac gag cgt gac acc acg atg cct gta gca atg Gca aca acg
6699 tTG CGC Aaa cta tta act ggc gaa cta ctt act cta gct tcc cgg caa caa
! FspI....
50 !
6750 tta ata gac tgg atg gag gcg gat aaa gtt gca gga cca ctt ctg cgc tcg
6801 GCC ctt ccG Gct ggc tgg ttt att gct gat aaa tct gga gcc ggt gag cgt
! BglI.....
6852 gGG TCT Cgc ggt atc att gca gca ctg ggg cca gat ggt aag ccc tcc cgt
55 ! BsaI....
6903 atc gta gtt atc tac acG ACg ggg aGT Cag gca act atg gat gaa cga aat
! AhdI.....
6954 aga cag atc gct gag ata ggt gcc tca ctg att aag cat tgg TAA ctgt
! stop
60 7003 cagaccaagt ttactcatat atactttaga ttgatttaaa acttcatttt taatttaaaa
7063 ggatctaggt gaagatcctt tttgataatc tcatgaccaa aatcccttaa cgtgagtttt

```

- 206 -

```

7123 cgttccactg tacgtaagac cccc
7147 AAGCTT  GTCGAC tgaa tggcgaatgg cgctttgcct
!      HindIII  SalI..
!      (2/2)    HincII
5  7183 ggtttccggc accagaagcg gtgccggaaa gctggctgga gtgcgatctt
!
! Start of Fab-display cassette, the Fab DSR-A05, selected for
! binding to a protein antigen.
!
10 7233 CCTGAcG CTCGAG
!      xBsu36I XhoI..
!
! PlacZ promoter is in the following block
!
15 7246          cgcaacgc aattaatgtg agttagctca
7274 ctcattaggc accccaggct ttacacttta tgcttccggc tcgtatgttg
7324 tgttgaattg tgagcggata acaatttcac acaggaaaca gctatgacca
7374 tgattacgCC AagcttTGA gccttttttt tgagatattt caac
!      PflMI.....
20 !      Hind3. (there are 3)
! Gene iii signal sequence:
!      1  2  3  4  5  6  7  8  9 10 11 12 13 14 15
!      M  K  K  L  L  F  A  I  P  L  V  V  P  F  Y
25 7418 gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat
!
!      16 17 18          Start light chain (L20:JK1)
!      S  H  S  A  Q  D  I  Q  M  T  Q  S  P  A
7463 tct cac aGT GCA Caa gac atc cag atg acc cag tct cca gcc
!      ApaLI...
30 !      Sequence supplied by extender.....
!
!      T  L  S  L
7505 acc ctg tct ttg
!
35 !      S  P  G  E  R  A  T  L  S  C  R  A  S  Q  G
7517 tct cca ggg gaa aga gcc acc ctc tcc tgc agg gcc agt cag Ggt
!
!      V  S  S  Y  L  A  W  Y  Q  Q  K  P  G  Q  A
7562 gtt agc agc tac tta gcc tgg tac cag cag aaa cct ggc cag gct
40 !
!      P  R  L  L  I  Y  D  A  S  S  R  A  T  G  I
7607 ccc agg ctc ctc atc tat gAt gca tcc aAc agg gcc act ggc atc
!
!      P  A  R  F  S  G  S  G  P  G  T  D  F  T  L
45 7652 cca gCc agg ttc agt ggc agt ggg Cct ggg aca gac ttc act ctc
!
!      T  I  S  S  L  E  P  E  D  F  A  V  Y  Y  C
7697 acc atc agc agC ctA gag cct gaa gat ttt gca gtT tat tac tgt
!
50 !      Q  Q  R  S  W  H  P  W  T  F  G  Q  G  T  R
7742 cag cag CGt aAc tgg cat ccg tgg ACg TTC GGC CAA GGG ACC AAG
!
!      V  E  I  K  R  T  V  A  A  P  S  V  F  I  F
7787 gtg gaa atc aaa cga act gtg gCT GCA Cca tct gtc ttc atc ttc
55 !      BsgI....
!
!      P  P  S  D  E  Q  L  K  S  G  T  A  S  V  V
7832 ccg cca tct gat gag cag ttg aaa tct gga act gcc tct gtt gtg
!
60 !      C  L  L  N  N  F  Y  P  R  E  A  K  V  Q  W
7877 tgc ctg ctg aat aac ttc tat ccc aga gag gcc aaa gta cag tgg

```

- 207 -

```

!
!       K   V   D   N   A   L   Q   S   G   N   S   Q   E   S   V
7922    aag gtg gat aac gcc ctc caa tcg ggt aac tcc cag gag agt gtc
!
5 !       T   E   R   D   S   K   D   S   T   Y   S   L   S   S   T
7967    aca gag cgg gac agc aag gac agc acc tac agc ctc agc agc acc
!
!       L   T   L   S   K   A   D   Y   E   K   H   K   V   Y   A
8012    ctg acG CTG AGC aaa gca gac tac gag aaa cac aaa gtc tac gcc
10 !       EspI.....
!
!       C   E   V   T   H   Q   G   L   S   S   P   V   T   K   S
8057    tgc gaa gtc acc cat cag ggc ctG AGC TCg ccc gtc aca aag agc
15 !       SacI....
!
!       F   N   R   G   E   C   .   .
8102    ttc aac agg gga gag tgt taa taa
!
!       GGCGCG CCAattctat ttcaaGGAGA cagtcata
8126    AscI..... RBS2.
20 !
!       PelB signal sequence----- (22 codons)----->
!       1   2   3   4   5   6   7   8   9  10  11  12  13  14  15
!       M   K   Y   L   L   P   T   A   A   A   G   L   L   L   L
25 !       8160    atg aaa tac cta ttg cct acg gca gcc gct gga ttg tta tta ctc
!
!       ...PelB signal-----> Start VH, FR1----->
!       16  17  18  19  20  21  22  23  24  25  26  27  28  29  30
!       A   A   Q   P   A   M   A   E   V   Q   L   L   E   S   G
30 !       8205    gcG GCC cag ccG GCC atg gcc gaa gtt CAA TTG tta gag tct ggt
!       SfiI..... MfeI...
!
!                               NcoI....
!
!       31  32  33  34  35  36  37  38  39  40  41  42  43  44  45
!       G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A
35 !       8250    ggc ggt ctt gtt cag cct ggt ggt tct tta cgt ctt tct tgc gct
!
!       ...FR1-----> CDR1-----> FR2----->
!       46  47  48  49  50  51  52  53  54  55  56  57  58  59  60
!       A   S   G   F   T   F   S   T   Y   E   M   R   W   V   R
40 !       8295    gct TCC GGA ttc act ttc tct act tac gag atg cgt tgg gtt cgC
!       BspEI.. BstXI...
!
!       FR2-----> CDR2 ----->
!       61  62  63  64  65  66  67  68  69  70  71  72  73  74  75
!       Q   A   P   G   K   G   L   E   W   V   S   Y   I   A   P
45 !       8340    CAa gct ccT GGt aaa ggt ttg gag tgg gtt tct tat atc gct cct
!       BstXI.....
!
!       ...CDR2-----> FR3----->
!       76  77  78  79  80  81  82  83  84  85  86  87  88  89  90
!       S   G   G   D   T   A   Y   A   D   S   V   K   G   R   F
50 !       8385    tct ggt ggc gat act gct tat gct gac tcc gtt aaa ggt cgc ttc
!
!       91  92  93  94  95  96  97  98  99 100 101 102 103 104 105
!       T   I   S   R   D   N   S   K   N   T   L   Y   L   Q   M
55 !       8430    act atc TCT AGA gac aac tct aag aat act ctc tac ttg caa atg
!       XbaI...
!       Supplied by extender-----
60 !
!       -----FR3----->

```


- 208 -

```

!       106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
!       N   S   L   R   A   E   D   T   A   V   Y   Y   C   A   R
8475    aac agC TTA AGg gct gaq gac act qca qtc tac tat tgt gcg agg
!       AflIII...
5      from extender----->
!
!       CDR3-----> FR4-->
!       121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
!       R   L   D   G   Y   I   S   Y   Y   Y   G   M   D   V   W
10     8520  agg ctc gat ggc tat att tcc tac tac tac ggt atg GAC GTC tgg
!                                     AatII..
!
!       136 137 138 139 140 141 142 143 144 145
!       G   Q   G   T   T   V   T   V   S   S
15     8565  ggc caa ggg acc acG GTC ACC gtc tca agc
!                                     BstEII...
!
!       CH1 of IgG1----->
!       A   S   T   K   G   P   S   V   F   P   L   A   P   S   S
20     8595  gcc tcc acc aag ggc cca tcg gtc ttc ccc ctg gca ccc tcc tcc
!
!       K   S   T   S   G   G   T   A   A   L   G   C   L   V   K
!       8640  aag agc acc tct ggg ggc aca gcg gcc ctg ggc tgc ctg gtc aag
!
!       D   Y   F   P   E   P   V   T   V   S   W   N   S   G   A
25     8685  gac tac ttc ccc gaa ccg gtg acg gtg tcg tgg aac tca ggc gcc
!
!       L   T   S   G   V   H   T   F   P   A   V   L   Q   S   S
!       8730  ctg acc agc ggc gtc cac acc ttc ccg gct gtc cta cag tCC TCA
30                                     Bsu36I....
!
!       G   L   Y   S   L   S   S   V   V   T   V   P   S   S   S
!       8775  GGa ctc tac tcc ctc agc agc gta gtg acc gtg ccc tcc agc agc
35     Bsu36I....
!
!       L   G   T   Q   T   Y   I   C   N   V   N   H   K   P   S
!       8820  ttg ggc acc cag acc tac atc tgc aac gtg aat cac aag ccc agc
!
!       N   T   K   V   D   K   K   V   E   P   K   S   C   A   A
40     8865  aac acc aag gtg gac aag aaa gtt gag ccc aaa tct tgt GCG GCC
!                                     NotI.....
!
!       A   H   H   H   H   H   H   G   A   A   E   Q   K   L   I
!       8910  GCa cat cat cat cac cat cac ggg gcc gca gaa caa aaa ctc atc
45     ..NotI.... H6 tag..... Myc-Tag.....
!
!       S   E   E   D   L   N   G   A   A   q   A   S   S   A
!       8955  tca gaa gag gat ctg aat ggg gcc gca tag GCT AGC tct gct
!       Myc-Tag..... NheI...
50                                     Amber
!
!       III'stump
!
!       Domain 3 of III -----
55
!       S   G   D   F   D   Y   E   K   M   A   N   A   N   K   G   A
!       8997  agt ggc gac ttc gac tac gag aaa atg gct aat gcc aac aaa GGC GCC
!       tcc t t t t t a g a c t t g g t !W.T.
!                                     KasI...(2/4)
60
!       M   T   E   N   A   D   E   N   A   L   Q   S   D   A   K   G

```

- 209 -

```

9045 atG ACT GAG AAC GCT GAC GAG aat gct ttg caa agc gat gcc aag ggt
      c  a  t  c  t  a  c  g  c  a  g  t  c  t  c  t  a  c !W.T.
!
!
!
5 9093 aag tta gac agc gTC GCG Acc gac tat GGC GCC gcc ATC GAc ggc ttt
      a  c  t  t  t  c  t  t  t  c  t  t  t  t  t  t  t  c !W.T.
      NruI.... KasI...(3/4)
!
!
!
10 9141 atc ggc gat gtc agt ggt tTG GCC Aac ggc aac gga gcc acc gga gac
      t  t  c  t  t  c  c  t  t  t  t  t  t  t  t  t  t  t !W.T.
      MscI....(3/3)
!
!
!
15 9189 ttc GCA GGT tcG AAT TCt cag atg gcC CAG GTT GGA GAT GGg gac aac
      t  t  c  t  t  c  a  t  a  c  t  c  t  t  t  t  t !W.T.
      BspMI.. (2/2) XcmI.....
      EcoRI...
!
!
!
20 9237 agt ccg ctt atg aac aac ttt aga cag tac ctt ccg tct ctt ccg cag
      tca t t a  t  t  c  c  t  a  t  t  a  t  c  c  t  a !W.T.
!
!
!
25 9285 agt gtc gag tgc cgt cca ttc gtt ttc tct gcc ggc aag cct tac gag
      tcg t  a  t  c  t  t  c  t  agc t  t  a  a  t  a !W.T.
!
!
!
30 9333 ttc aGC Atc gac TGC gat aag atc aat ctt ttC CGC
      t  t  c  t  t  t  c  a  a  c  t  a  c  t  !W.T.
      BstAPI..... SacII...
      End Domain 3
!
!
!
35 9369 GGC gtt ttc gct ttc ttg cta tac gtc gct act ttc atg tac gtt ttc
      t  c  t  g  t  c  t  t  a  t  t  c  c  t  t  a  t  !W.T.
      start transmembrane segment
!
!
!
40 9417 aGC ACT TTC GCC AAT ATT TTA Cgc aac aaa gaa agc
      t  c  t  g  t  t  c  a  c  g  t  t  g  g  t  c  t !W.T.
      Intracellular anchor.
!
!
!
45 9453 tag tga tct CCT AGG
      AvrII..
!
!
!
50 9468 aag ccc gcc taa tga gcg ggc ttt ttt ttt ct ggt
      | Trp terminator |
!
!
!
55 9503 ATGCAT CCTGAGG ccgat actgtcgtcg tccctcaaa ctggcagatg
      NsiI.. Bsu36I.(3/3)
!
!
!
9551 caccgttacg atgcgcccac ctacaccaac gtgacctatc ccattacggt caatccgccc
9611 tttgttccca cggagaatcc gacgggttgt tactcgctca catttaatgt tgatgaaagc
9671 tggctacagg aaggccagac gcgaattatt ttgatggcg ttoctattgg ttaaaaaatg
9731 agctgattta acaaaaattt aaTgcgaatt ttaacaaaat attaacgttt acaATTATAA
      SwaI...
!
!
!
60 9791 Tatttgctta tacaattctc ctgttttttg ggctttttctg attatcaacc GGGGTAcac
9850 ATG att gac atg cta gtt tta cga tta ccg ttc atc gat tct ctt gtt tgc

```


- 210 -

```
!      Start gene II
! 9901 tcc aga ctc tca ggc aat gac ctg ata gcc ttt gtA GAT CTc tca aaa ata
!                                     BglII...
! 9952 gct acc ctc tcc ggc atT aat tta tca gct aga acg gtt gaa tat cat att
5 10003 gat ggt gat ttg act gtc tcc ggc ctt tct cac cct ttt gaa tet tta cct
10054 aca cat tac tca ggc att gca ttt aaa ata tat gag ggt tct aaa aat ttt
10105 tat cct tgc gtt gaa ata aag gct tct ccc gca aaa gta tta cag ggt cat
10156 aat gtt ttt ggt aca acc gat tta gct tta tgc tct gag gct tta ttg ctt
10207 aat ttt gct aat tct ttg cct tgc ctg tat gat tta ttg gat gtt !
10 ! gene II continues
!----- End of Table -----
```

- 211 -

! Table 37: DNA seq of w.t. M13 gene iii

```

!      1   2   3   4   5   6   7   8   9  10  11  12  13  14  15
!      fM   K   K   L   L   F   A   I   P   L   V   V   P   F   Y
5  1579  gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat
!      Signal sequence.....
!
!      16  17  18  19  20  21  22  23  24  25  26  27  28  29  30
!      S   H   S   A   E   T   V   E   S   C   L   A   K   P   H
10 1624  tct cac tcc gct gaa act gtt gaa agt tgt tta gca aaa ccc cat
!      Signal sequence> Domain 1-----
!
!      31  32  33  34  35  36  37  38  39  40  41  42  43  44  45
!      T   E   N   S   F   T   N   V   W   K   D   D   K   T   L
15 1669  aca gaa aat tca ttt act aac gtc tgg aaa gac gac aaa act tta
!      Domain 1-----
!
!      46  47  48  49  50  51  52  53  54  55  56  57  58  59  60
!      D   R   Y   A   N   Y   E   G   C   L   W   N   A   T   G
20 1714  gat cgt tac gct aac tat gag ggt tgt ctg tgG AAT GCt aca ggc
!                                     BsmI....
!      Domain 1-----
!
!      61  62  63  64  65  66  67  68  69  70  71  72  73  74  75
!      V   V   V   C   T   G   D   E   T   Q   C   Y   G   T   W
25 1759  gtt gta gtt tgt act ggt gac gaa act cag tgt tac ggt aca tgg
!      Domain 1-----
!
!      76  77  78  79  80  81  82  83  84  85  86  87  88  89  90
!      V   P   I   G   L   A   I   P   E   N   E   G   G   G   S
30 1804  gtt cct att ggg ctt gct atc cct gaa aat gag ggt ggt ggc tct
!      Domain 1-----> Linker 1-----
!
!      91  92  93  94  95  96  97  98  99 100 101 102 103 104 105
!      E   G   G   G   S   E   G   G   G   S   E   G   G   G   T
35 1849  gag ggt ggc ggt tct gag ggt ggc ggt tct gag ggt ggc ggt act
!      Linker 1----->
!
!      106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
!      K   P   P   E   Y   G   D   T   P   I   P   G   Y   T   Y
40 1894  aaa cct cct gag tac ggt gat aca cct att ccg ggc tat act tat
!      Domain 2-----
!
!      121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
!      I   N   P   L   D   G   T   Y   P   P   G   T   E   Q   N
45 1939  atc aac cct ctc gac ggc act taT CCG CCt ggt act gag caa aac
!                                     EciI....
!      Domain 2-----
!
!      136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
!      P   A   N   P   N   P   S   L   E   E   S   Q   P   L   N
50 1984  ccc gct aat cct aat cct tct ctt GAG GAG tct cag cct ctt aat
!                                     BseRI..
!      Domain 2-----
!
!      151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
!      T   F   M   F   Q   N   N   R   F   R   N   R   Q   G   A
55 2029  act ttc atg ttt cag aat aat agg ttc cga aat agg cag ggg gca
!      Domain 2-----
!
!      166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
!

```

- 212 -

```

!       L   T   V   Y   T   G   T   V   T   Q   G   T   D   P   V
2074 tta act gtt tat acg ggc act gtt act caa ggc act gac ccc gtt
!       Domain 2-----
5  !       181 182 183 184 185 186 187 188 189 190 191 192 193 194 195
!       K   T   Y   Y   Q   Y   T   P   V   S   S   K   A   M   Y
2119 aaa act tat tac cag tac act cct gta tca tca aaa gcc atg tat
!       Domain 2-----
10 !       196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
!       D   A   Y   W   N   G   K   F   R   D   C   A   F   H   S
2164 gac gct tac tgg aac ggt aaa ttC AGa gaC TGc gct ttc cat tct
!       AlwNI.....
!       Domain 2-----
15 !       211 212 213 214 215 216 217 218 219 220 221 222 223 224 225
!       G   F   N   E   D   P   F   V   C   E   Y   Q   G   Q   S
2209 ggc ttt aat gaG GAT CCa ttc gtt tgt gaa tat caa ggc caa tcg
!       BamHI...
20 !       Domain 2-----
!       226 227 228 229 230 231 232 233 234 235 236 237 238 239 240
!       S   D   L   P   Q   P   P   V   N   A   G   G   G   S   G
2254 tct gac ctg cct caa cct cct gtc aat gct ggc ggc ggc tct ggt
25 !       Domain 2-----> Linker 2-----
!       241 242 243 244 245 246 247 248 249 250 251 252 253 254 255
!       G   G   S   G   G   G   S   E   G   G   G   S   E   G   G
2299 ggt ggt tct ggt ggc ggc tct gag ggt ggt ggc tct gag ggt ggc
30 !       Linker 2-----
!       256 257 258 259 260 261 262 263 264 265 266 267 268 269 270
!       G   S   E   G   G   G   S   E   G   G   G   S   G   G   G
2344 ggt tct gag ggt ggc ggc tct gag gga ggc ggt tcc ggt ggt ggc
35 !       Linker 2-----
!       271 272 273 274 275 276 277 278 279 280 281 282 283 284 285
!       S   G   S   G   D   F   D   Y   E   K   M   A   N   A   N
2389 tct ggt tcc ggt gat ttt gat tat gaa aag atg gca aac gct aat
40 ! Linker 2> Domain 3-----
!       286 287 288 289 290 291 292 293 294 295 296 297 298 299 300
!       K   G   A   M   T   E   N   A   D   E   N   A   L   Q   S
2434 aag ggg gct atg acc gaa aat gcc gat gaa aac gcg cta cag tct
45 !       Domain 3-----
!       301 302 303 304 305 306 307 308 309 310 311 312 313 314 315
!       D   A   K   G   K   L   D   S   V   A   T   D   Y   G   A
2479 gac gct aaa ggc aaa ctt gat tct gtc gct act gat tac ggt gct
50 !       Domain 3-----
!       316 317 318 319 320 321 322 323 324 325 326 327 328 329 330
!       A   I   D   G   F   I   G   D   V   S   G   L   A   N   G
2524 gct atc gat ggt ttc att ggt gac gtt tcc ggc ctt gct aat ggt
55 !       Domain 3-----
!       331 332 333 334 335 336 337 338 339 340 341 342 343 344 345
!       N   G   A   T   G   D   F   A   G   S   N   S   Q   M   A
2569 aat ggt gct act ggt gat ttt gct ggc tct aat tcc caa atg gct
60 !       Domain 3-----

```

- 213 -

```

!      346 347 348 349 350 351 352 353 354 355 356 357 358 359 360
!      Q   V   G   D   G   D   N   S   P   L   M   N   N   F   R
2614  caa gtc ggt gac ggt gat aat tca cct tta atg aat aat ttc cgt
!      Domain 3-----
5  !
!      361 362 363 364 365 366 367 368 369 370 371 372 373 374 375
!      Q   Y   L   P   S   L   P   Q   S   V   E   C   R   P   F
2659  caa tat tta cct tcc ctc cct caa tcg gtt gaa tgt cgc cct ttt
!      Domain 3-----
10 !
!      376 377 378 379 380 381 382 383 384 385 386 387 388 389 390
!      V   F   S   A   G   K   P   Y   E   F   S   I   D   C   D
2704  gtc ttt agc gct ggt aaa cca tat gaa ttt tct att gat tgt gac
!      Domain 3-----
15 !
!      391 392 393 394 395 396 397 398 399 400 401 402 403 404 405
!      K   I   N   L   F   R   G   V   F   A   F   L   L   Y   V
2749  aaa ata aac tta ttc cgt ggt gtc ttt gcg ttt ctt tta tat gtt
!      Domain 3-----> Transmembrane segment-----
20 !
!      406 407 408 409 410 411 412 413 414 415 416 417 418 419 420
!      A   T   F   M   Y   V   F   S   T   F   A   N   I   L   R
2794  gcc acc ttt atg tat gta ttt tct acg ttt gct aac ata ctg cgt
!      Transmembrane segment-----> ICA---
25 !
!      421 422 423 424 425
!      N   K   E   S   .
2839  aat aag gag tct taa ! 2853
!      ICA-----> ICA = intracellular anchor
30 !
!----- End of Table -----

```

- 214 -

Table 38: Whole mature III anchor M13-III
derived anchor with recoded DNA

```

!
!       1   2   3
5  !       A   A   A
!       1   GCG gcc gca
!       NotI.....
!
!       4   5   6   7   8   9  10  11  12  13  14  15  16  17
10 !       H   H   H   H   H   H   G   A   A   E   Q   K   L   I
!       10   cat cat cat cac cat cac ggg gcc gca gaa caa aaa ctc atc
!
!       18  19  20  21  22  23  24  25  26  27  28  29
15 !       S   E   E   D   L   N   G   A   A   .   A   S
!       52   tca gaa gag gat ctg aat ggg gcc gca Tag GCT AGC
!                                     NheI...
!
!       30  31  32  33  34  35  36   37  38  39
!       D   I   N   D   D   R   M   A   S   T
20 !       88   GAT ATC aac gat gat cgt atg gct tct act
! (ON_G37bot) [RC] 5'-c aac gat gat cgt atg gcG CAT Gct gcc gag aca g-3'
!       EcoRV..
!       Enterokinase cleavage site.
!
25 ! Start mature III (recoded) Domain 1 ---->
!       40  41  42  43
!       A   E   T   V
!       118   |gcC|gaG|acA|gtC|
!               t   a   t   t ! W.T.
30 !
!       44  45  46  47  48  49  50  51  52  53  54  55  56  57  58
!       E   S   C   L   A   K   P   H   T   E   N   S   F   T   N
130 ! |gaa|TCC|tgC|CTG|GCC|AaG|ccT|caC|acT|gaG|aat|AGT|ttC|aCA|Aat|
!       agt t t a a a c t a a tca t t c ! W.T.
35 !       MscI....
!
!       59  60  61  62  63  64  65  66  67  68  69  70  71  72  73
!       V   W   K   D   D   K   T   L   D   R   Y   A   N   Y   E
175 ! |gtg|TGG|aaG|gaT|gaT|aaG|acC|CtT|gAT|CGA|TaT|gcC|aaT|taC|gaA|
40 !       c               a   c   c   a   t t a t c t c t g ! W.T.
!       BspDI...
!
!       74  75  76  77  78  79  80  81  82  83  84  85  86  87  88
!       G   C   L   W   N   A   T   G   V   V   V   C   T   G   D
45 ! 220 |ggC|tgC|TtA|tgG|aat|gcC|ACC|GGC|GtC|gtT|gtC|TGC|ACG|ggC|gaT|
!       t   t c g t a t a t t t t t c ! W.T.
!       SgrAI..... BsgI....
!
!       89  90  91  92  93  94  95  96  97  98  99  100 101 102 103
50 !       E   T   Q   C   Y   G   T   W   V   P   I   G   L   A   I
!       265 |gaG|acA|caA|tgC|taT|ggC|ACG|TGg|gtG|ccG|atA|gGC|TTA|GCC|atA|
!       a   t   g   t   c   t   a t t t g c t t c ! W.T.
!       PmlI..... BlpI.....
!
55 ! Domain 1-----> Linker 1----->
!       104 105 106 107 108 109 110 111 112 113 114 115 116 117 118
!       P   E   N   E   G   G   G   S   E   G   G   G   S   E   G
!       310 |ccG|gaG|aaC|gaA|ggC|ggC|ggT|AGC|gaA|ggC|ggT|ggC|AGC|gaA|ggC|
60 !       t   a   t   g   t   t   c t c t g t c t t c t g t ! W.T.
!
!       Linker 1-----> Domain 2----->

```

```

5 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133
   G G S E G G G T K P P E Y G D
355 |ggT|GGA|TCC|gaA|ggA|ggT|ggA|acC|aaG|ccG|ccG|gaA|taT|ggC|gaC|
   c t t g t c t t a t t g c t t ! W.T.
   BamHI..(2/2)

10 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148
   T P I P G Y T Y I N P L D G T
400 |acT|ccG|atA|CCT|GGT|taC|acC|taC|atT|aaT|ccG|TtA|gaT|ggA|acC|
   a t t g c t t t c c t c c c c t ! W.T.
   SexAI....

15 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163
   Y P P G T E Q N P A N P N P S
445 |taC|ccT|ccG|ggC|acC|gaA|caG|aaT|ccT|gcC|aaC|ccG|aaC|ccA|AGC|
   T G t t t g a c c t t t t t t t t t ! W.T.
   HindIII...

20 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178
   L E E S Q P L N T F M F Q N N
490 |TTA|gaA|gaA|AGC|caA|ccG|TtA|aaC|acC|ttT|atg|ttC|caA|aaC|aaC|
   c t G G t c t g t c t t t c t g t t ! W.T.
   HindIII.

25 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193
   R F R N R Q G A L T V Y T G T
535 |CgT|ttT|AgG|aaC|CgT|caA|gGT|GCT|CtT|acC|gTG|TAC|AcT|ggA|acC|
   a g c c a t a g g g a t a t t t g c t ! W.T.
   HgiAI... BsrGI...

30 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208
   V T Q G T D P V K T Y Y Q Y T
580 |gtC|acC|caG|GGT|ACC|gaT|ccT|gtC|aaG|acC|taC|taT|caA|taT|acC|
   t t a c t c c t a t t c g c t ! W.T.
   KpnI...

35 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223
   P V S S K A M Y D A Y W N G K
625 |ccG|gtC|TCG|AGT|aaG|gcT|atg|taC|gaT|gcC|taT|tgg|aaT|ggC|aaG|
   t a a t c a a c t c t c c t a ! W.T.
   BsaI....
   XhoI....

45 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238
   F R D C A F H S G F N E D P F
670 |ttT|CgT|gaT|tgT|gcC|ttT|caC|AGC|ggT|ttC|aaC|gaa|gac|CCt|ttT|
   C A a C c t c t t c t c t t G T a c ! W.T.

50 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253
   V C E Y Q G Q S S D L P Q P P
715 |gtC|tgC|gaG|taC|caG|ggT|caG|AGT|AGC|gaT|TtA|ccG|caG|ccA|CCG|
   t t a t a c a t c g t c t c c g t a t t ! W.T.
   DrdI.....
   AgeI.....

55 Domain 2-----> Linker 2----->
   254 255 256 257 258 259 260 261 262 263 264 265 266 267 268
   V N A G G G S G G S G G S
760 |GTT|AAC|gcG|ggT|ggT|ggT|AGC|ggC|ggA|ggC|AGC|ggC|ggT|ggT|AGC|
   c t t c c t c t t t t t t t t t ! W.T.
   AgeI.....
   HpaI....

```

- 216 -

```

!       HincII.
!
!       Linker 2-----> Domain 3-->
!       269 270 271 272 273 274 275 276 277 278 279 280 281 282 283
5      E   G   G   G   S   E   G   G   G   S   G   G   G   S   G
!      805 |gaA|ggC|ggA|ggT|AGC|gaA|ggA|ggT|ggC|AGC|ggA|ggC|ggT|AGC|ggC|
!           g   t   t   c tct   g   t   c   t tct   g   t   c tct   t ! W.T.
!
!       -----Domain 3----->
!       284 285 286 287 288 289 290 291 292 293 294 295 296 297 298
10     S   G   D   F   D   Y   E   K   M   A   N   A   N   K   G
!      850 |AGT|ggC|gac|ttc|gac|tac|gag|aaa|atg|gct|aat|gcc|aac|aaa|GGC|
!           tcc   t   t   t   t   t   a   g           a   c   t   t   g   g ! W.T.
!                                     KasI....
!
!       299 300 301 302 303 304 305 306 307 308 309 310 311 312 313
!       A   M   T   E   N   A   D   E   N   A   L   Q   S   D   A
!      895 |GCC|atg|act|gag|aac|gct|gac|gaG|AAT|GCA|ctg|caa|agt|gat|gCC|
!           t           c   a   t   c   t   a   c   g   a   g tct   c   t ! W.T.
20     KasI....           BsmI....           StyI...
!
!       314 315 316 317 318 319 320 321 322 323 324 325 326 327 328
!       K   G   K   L   D   S   V   A   T   D   Y   G   A   A   I
!      940 |AAG|GGT|aag|tta|gac|agc|gTC|GCc|Aca|gac|tat|ggT|Gct|gcc|atc|
!           a   c   a c t   t tct   t   t   t   c           t           ! W.T.
25     StyI.....           PflFI.....
!
!       329 330 331 332 333 334 335 336 337 338 339 340 341 342 343
!       D   G   F   I   G   D   V   S   G   L   A   N   G   N   G
!      985 |gac|ggc|ttt|atc|ggc|gat|gtc|agt|ggT|ctg|gct|aac|ggc|aac|gga|
!           t   t   c   t   t   c   t tcc   c c t           t   t   t   t ! W.T.
!
!       344 345 346 347 348 349 350 351 352 353
!       A   T   G   D   F   A   G   S   N   S
!     1030 |gcc|acc|gga|gac|ttc|GCA|GGT|tcG|AAT|Tct|
!           t   t   t   t   t   t   c   t           c ! W.T.
!                                     BstBI...
!                                     EcoRI...
!
!       BspMI..
!
!       354 355 356 357 358 359 360 361 362 363
!       Q   M   A   Q   V   G   D   G   D   N
!     1060 cag atg gcC CAG GTT GGA GAT GGg gac aac
!           a           t   a   c   t   c   t   t   t ! W.T.
45     XcmI.....
!
!       364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379
!       S   P   L   M   N   N   F   R   Q   Y   L   P   S   L   P   Q
!     1090 agt ccg ctt atg aac aac ttt aga cag tac ctt ccg tct ctt ccg cag
!           tca   t t a           t   t   c c t   a   t t a   t   c   c   t   a ! W.T.
!
!       380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395
!       S   V   E   C   R   P   F   V   F   S   A   G   K   P   Y   E
!     1138 agt gtc gag tgc cgt cca ttc gtt ttc tct gcc ggc aag cct tac gag
!           tcg   t   a   t   c   t   t   c   t   agc   t   t   a   a   t   a ! W.T.
!
!       Domain 3----->
!       396 397 398 399 400 401 402 403 404 405 406 407
!       F   S   I   D   C   D   K   I   N   L   F   R
!     1186 ttc aGC Atc gac TGC gat aag atc aat ctt ttC CGC
!           t tct   t   t   t   c   a   a   c t a           t

```

- 217 -

```

!           BstAPI.....                      SacII...
!
!   transmembrane segment----->
!   408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423
5 !   G   V   F   A   F   L   L   Y   V   A   T   F   M   Y   V   F
!   1222 GGC gtt ttc gct ttc ttg cta tac gtc gct act ttc atg tac gtt ttc
!       t   c   t   g   t   c   t   t   a   t   t   c   c   t       t   a   t ! W.T.
!
!   424 425 426 427 428 429 430   431 432 433 434 435
10 !   S   T   F   A   N   I   L       R   N   K   E   S
!   1270 aGC ACT TTC GCC AAT ATT TTA   Cgc aac aaa gaa agc
!       tct   g   t   t   c   a   c   g       t   t   g   g   tct ! W.T.
!                               Intracellular anchor.
!
!
15 !
!   1306           tag tga tct CCT AGG
!                               AvrII..
!
!   1321 aag ccc gcc taa tga gcg ggc ttt ttt ttt ct ggt
20 !       | Trp terminator |
!
! End Fab cassette
!----- End of Table -----

```


- 218 -

Table 39: ONs to make deletions in III

! ONs for use with *NheI*

!

N

5 (ON_G29bot) 5'-c gTT gAT ATc gCT Agc cTA-Tgc-3' !
 22 ! this is the reverse complement of 5'-gca tag gct agc gat atc aac g-3'
 ! *NheI*... scab.....
 (ON_G104top) 5'-g|ata|ggc|tta|gCT|aGC|ccg|gag|aac|gaa|gg-3' !
 10 30 ! Scab.....*NheI*... 104 105 106 107 108
 (ON_G236top) 5'-c|ttt|cac|agc|ggg|ttc|GCT|AGC|gac|cct|ttt|gtc|tgc-3' !
 37 !
 15 (ON_G236tCS) 5'-c|ttt|cac|agc|ggg|ttc|GCT|AGC|gac|cct|ttt|gtc|Agc-
 ! *NheI*... 236 237 238 239 240
 gag|tac|cag|ggg|c-3' !
 50

! ONs for use with *SphI* G CAT Gc

20 (ON_X37bot) 5'-gAc TgT cTc ggc Agc ATg cgc cAT Acg ATc ATc gTT g-3' !
 37 !
 ! N D D R M A H A
 ! (ON_X37bot)=[RC] 5'-c aac gat gat cgt atg gcG CAT Gct gcc gag aca gtc-3'
 ! *SphI*....Scab.....
 25 (ON_X104top) 5'-g|gtG ccg|ata|ggc|ttG|CAT|GCa|ccg|gag|aac|gaa|gg-3' !
 36 !
 ! Scab.....*SphI*... 104 105 106 107 108
 (ON_X236top) 5'-c|ttt|cac|agc|ggg|ttG|CaT|gCa|gac|cct|ttt|gtc|tgc-3' !
 37 !
 30 ! *SphI*... 236 237 238 239 240
 (ON_X236tCS) 5'-c|ttt|cac|agc|ggg|ttG|CaT|gCa|gac|cct|ttt|gtc|Agc-
 ! *NheI*... 236 237 238 239 240
 gag|tac|cag|ggg|c-3' !
 50

Table 40: Phage titers and enrichments of a
selections with a DY3F31-based human Fab library

	Input (total cfu)	Output (total cfu)	Output/input ratio
5 R1-ox selected on phOx-BSA	$4,5 \times 10^{12}$	$3,4 \times 10^5$	$7,5 \times 10^{-8}$
R2-Strep selected on Strep-beads	$9,2 \times 10^{12}$	3×10^8	$3,3 \times 10^{-5}$

Table 41: Frequency of ELISA positives in
DY3F31-based Fab libraries

	Anti-M13 HRP	9E10/RAM- HRP	Anti-CK/CL Gar-HRP
	R2-ox (with IPTG induction)	18/44	10/44
	R2-ox (without IPTG)	13/44	ND
5	R3-strep (with IPTG)	39/44	38/44
	R3-strep (without IPTG)	33/44	ND

- 221 -

We claim:

1. A method for cleaving single-stranded nucleic acid sequences at a desired location, the method comprising the steps of:

- 5 (i) contacting the nucleic acid with a single-stranded oligonucleotide, the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired and
10 including a sequence that with its complement in the nucleic acid forms a restriction endonuclease recognition site that on restriction results in cleavage of the nucleic acid at the desired location; and
15 (ii) cleaving the nucleic acid solely at the recognition site formed by the complementation of the nucleic acid and the oligonucleotide;

the contacting and the cleaving steps being performed
20 at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur
25 at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

2. A method for cleaving single-stranded nucleic acid sequences at a desired location, the
30 method comprising the steps of:

- 222 -

- (i) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired, and the double-stranded region of the oligonucleotide having a restriction endonuclease recognition site; and
- (ii) cleaving the nucleic acid solely at the restriction endonuclease recognition site formed by the complementation of the nucleic acid and the single-stranded region of the oligonucleotide;
- the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

3. In a method for displaying a member of a diverse family of peptides, polypeptides or proteins on the surface of a genetic package and collectively displaying at least a part of the diversity of the family, the improvement being characterized in that the displayed peptide, polypeptide or protein is encoded at least in part by a nucleic acid that has been cleaved

- 223 -

at a desired location by a method comprising the steps of:

- 5 (i) contacting the nucleic acid with a single-stranded oligonucleotide, the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired and including a sequence that with its complement in the nucleic acid forms a restriction
10 endonuclease recognition site that on restriction results in cleavage of the nucleic acid at the desired location; and
- 15 (ii) cleaving the nucleic acid solely at the recognition site formed by the complementation of the nucleic acid and the oligonucleotide;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the
20 oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction
25 endonuclease that is active at the chosen temperature.

4. In a method for displaying a member of a diverse family of peptides, polypeptides or proteins on the surface of a genetic package and collectively displaying at least a part of the diversity of the
30 family, the improvement being characterized in that the displayed peptide, polypeptide or protein is encoded by

- 224 -

a DNA sequence comprising a nucleic acid that has been cleaved at a desired location by

- 5 (i) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired, and the double-stranded region of the oligonucleotide having a restriction endonuclease recognition site; and
- 10 (ii) cleaving the nucleic acid solely at the restriction endonuclease recognition cleavage site formed by the complementation of the nucleic acid and the single-stranded region of the oligonucleotide;
- 15

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

20

25

5. A method for displaying a member of a diverse family of peptides, polypeptides or proteins on the surface of a genetic package and collectively displaying at least a part of the diversity of the family, the method comprising the steps of:

30

- 225 -

(i) preparing a collection of nucleic acids that code at least in part for members of the diverse family;

(ii) rendering the nucleic acids single-
5 stranded;

(iii) cleaving the single-stranded nucleic acids at a desired location by a method comprising the steps of:

(a) contacting the nucleic acid with a
10 single-stranded oligonucleotide, the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired and including a sequence that with its complement
15 in the nucleic acid forms a restriction endonuclease recognition site that on restriction results in cleavage of the nucleic acid at the desired location; and

(b) cleaving the nucleic acid solely at
20 the recognition site formed by the complementation of the nucleic acid and the oligonucleotide;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain
25 the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the
30 chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature; and

- 226 -

(iv) displaying a member of the family of peptides, polypeptides or proteins coded, at least in part, by the cleaved nucleic acids on the surface of the genetic package and collectively displaying at
5 least a portion of the diversity of the family.

6. A method for displaying a member of a diverse family of peptides, polypeptides or proteins on the surface of a genetic package and collectively displaying at least a portion of the diversity of the
10 family, the method comprising the steps of:

(i) preparing a collection of nucleic acids that code, at least in part, for members of the diverse family;

(ii) rendering the nucleic acids single-
15 stranded;

(iii) cleaving the single-stranded nucleic acids at a desired location by a method comprising the steps of:

(a) contacting the nucleic acid with a
20 partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired, and the
25 double-stranded region of the oligonucleotide having a restriction endonuclease recognition site; and

(b) cleaving the nucleic acid solely at the restriction endonuclease recognition
30 cleavage site formed by the complementation of the nucleic acid and the single-stranded region of the oligonucleotide;

- 227 -

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally
5 complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the restriction being carried out using a
10 cleavage endonuclease that is active at the chosen temperature; and

(iv) displaying a member of the family of peptides, polypeptides or proteins coded, at least in part, by the cleaved nucleic acids on the surface of
15 the genetic package and collectively displaying at least a portion of the diversity of the family.

7. In a method for expressing a member of a diverse family of peptides, polypeptides or proteins and collectively expressing at least a part of the
20 diversity of the family, the improvement being characterized in that the expressed peptide, polypeptide or protein is encoded at least in part by a nucleic acid that has been cleaved at a desired location by a method comprising the steps of:

25 (i) contacting the nucleic acid with a single-stranded oligonucleotide, the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired and
30 including a sequence that with its complement in the nucleic acid forms a restriction endonuclease recognition site that on

- 228 -

restriction results in cleavage of the
nucleic acid at the desired location; and

(ii) cleaving the nucleic acid solely at
the recognition site formed by the
5 complementation of the nucleic acid and the
 oligonucleotide;

the contacting and the cleaving steps being performed
at a temperature sufficient to maintain the nucleic
acid in substantially single-stranded form, the
10 oligonucleotide being functionally complementary to the
 nucleic acid over a large enough region to allow the
 two strands to associate such that cleavage may occur
 at the chosen temperature and at the desired location,
 and the cleavage being carried out using a restriction
15 endonuclease that is active at the chosen temperature.

8. In a method for expressing a member of a
diverse family of peptides, polypeptides or proteins
and collectively expressing at least a part of the
diversity of the family, the improvement being
20 characterized in that the expressed peptide,
 polypeptide or protein is encoded by a DNA sequence
 comprising a nucleic acid that has been cleaved at a
 desired location by

(i) contacting the nucleic acid with a
25 partially double-stranded oligonucleotide,
 the single-stranded region of the
 oligonucleotide being functionally
 complementary to the nucleic acid in the
 region in which cleavage is desired, and the
30 double-stranded region of the oligonucleotide

- 229 -

having a restriction endonuclease recognition site; and

- 5 (ii) cleaving the nucleic acid solely at the restriction endonuclease recognition cleavage site formed by the complementation of the nucleic acid and the single-stranded region of the oligonucleotide;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic
10 acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location,
15 and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

9. A method for expressing a member of a diverse family of peptides, polypeptides or proteins and collectively expressing at least a part of the
20 diversity of the family, the method comprising the steps of:

- (i) preparing a collection of nucleic acids that code at least in part for members of the diverse family;
- 25 (ii) rendering the nucleic acids single-stranded;
- (iii) cleaving the single-stranded nucleic acids at a desired location by a method comprising the steps of:
- 30 (a) contacting the nucleic acid with a single-stranded oligonucleotide, the

- 230 -

oligonucleotide being functionally
complementary to the nucleic acid in the
region in which cleavage is desired and
including a sequence that with its complement
5 in the nucleic acid forms a restriction
endonuclease recognition site that on
restriction results in cleavage of the
nucleic acid at the desired location; and
(b) cleaving the nucleic acid solely at
10 the recognition site formed by the
complementation of the nucleic acid and the
oligonucleotide;
the contacting and the cleaving steps being
performed at a temperature sufficient to maintain
15 the nucleic acid in substantially single-stranded
form, the oligonucleotide being functionally
complementary to the nucleic acid over a large
enough region to allow the two strands to
associate such that cleavage may occur at the
20 chosen temperature and at the desired location,
and the cleavage being carried out using a
restriction endonuclease that is active at the
chosen temperature; and
(iv) expressing a member of the family of
25 peptides, polypeptides or proteins coded, at least in
part, by the cleaved nucleic acids and collectively
expressing at least a portion of the diversity of the
family.

10. A method for expressing a member of a
30 diverse family of peptides, polypeptides or proteins
and collectively expressing at least a portion of the

- 231 -

diversity of the family, the method comprising the steps of:

(i) preparing a collection of nucleic acids that code, at least in part, for members of the diverse
5 family;

(ii) rendering the nucleic acids single-stranded;

(iii) cleaving the single-stranded nucleic acids at a desired location by a method comprising the
10 steps of:

(a) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally
15 complementary to the nucleic acid in the region in which cleavage is desired, and the double-stranded region of the oligonucleotide having a restriction endonuclease recognition site; and

20 (b) cleaving the nucleic acid solely at the restriction endonuclease recognition cleavage site formed by the complementation of the nucleic acid and the single-stranded region of the oligonucleotide;

25 the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large
30 enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the restriction being carried out using a

- 232 -

cleavage endonuclease that is active at the chosen temperature; and

(iv) expressing a member of the family of peptides, polypeptides or proteins coded, at least in part, by the cleaved nucleic acids and collectively expressing at least a portion of the diversity of the family.

11. A library comprising a collection of genetic packages that display a member of a diverse family of peptides, polypeptides or proteins and collectively display at least a portion of the diversity of the family, the library being produced using the methods of claims 3, 4, 5 or 6.

12. A library comprising a collection of genetic packages that display a member of a diverse family of peptides, polypeptides or proteins and that collectively display at least a portion of the family, the displayed peptides, polypeptides or proteins being encoded by DNA sequences comprising at least in part sequences produced by cleaving single-stranded nucleic acid sequences at a desired location by a method comprising the steps of:

(i) contacting the nucleic acid with a single-stranded oligonucleotide, the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired and including a sequence that with its complement in the nucleic acid forms a restriction endonuclease recognition site that on

- 233 -

restriction results in cleavage of the
nucleic acid at the desired location; and

(ii) cleaving the nucleic acid solely at
the recognition site formed by the
5 complementation of the nucleic acid and the
oligonucleotide;

the contacting and the cleaving steps being performed
at a temperature sufficient to maintain the nucleic
acid in substantially single-stranded form, the
10 oligonucleotide being functionally complementary to the
nucleic acid over a large enough region to allow the
two strands to associate such that cleavage may occur
at the chosen temperature and at the desired location,
and the cleavage being carried out using a restriction
15 endonuclease that is active at the chosen temperature.

13. A library comprising a collection of
genetic packages that display a member of a diverse
family of peptides, polypeptides or proteins and that
collectively display at least a portion of the
20 diversity of the family of the displayed peptides,
polypeptides or proteins being encoded by DNA sequences
comprising at least in part sequences produced by
cleaving single-stranded nucleic acid sequences at a
desired location by a method comprising the steps of:

25 (i) contacting the nucleic acid with a
partially double-stranded oligonucleotide,
the single-stranded region of the
oligonucleotide being functionally
complementary to the nucleic acid in the
30 region in which cleavage is desired, and the
double-stranded region of the oligonucleotide

- 234 -

having a restriction endonuclease recognition site; and

(ii) cleaving the nucleic acid solely at the restriction endonuclease recognition cleavage site formed by the complementation of the nucleic acid and the single-stranded region of the oligonucleotide;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

14. A library comprising a collection of members of a diverse family of peptides, polypeptides or proteins and collectively comprising at least a portion of the diversity of the family, the library being produced using the methods of claims 7, 8, 9 or 10.

15. A library comprising a collection of members of a diverse family of peptides, polypeptides or proteins and collectively comprising at least a portion of diversity of the family, the peptides, polypeptides or proteins being encoded by DNA sequences comprising at least in part sequences produced by cleaving single-stranded nucleic acid sequences at a desired location by a method comprising the steps of:

- 235 -

- (i) contacting the nucleic acid with a single-stranded oligonucleotide, the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired and including a sequence that with its complement in the nucleic acid forms a restriction endonuclease recognition site that on restriction results in cleavage of the nucleic acid at the desired location; and
- (ii) cleaving the nucleic acid solely at the recognition site formed by the complementation of the nucleic acid and the oligonucleotide;
- 15 the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the
- 20 two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.
16. A library comprising a collection of
- 25 members of a diverse family of peptides, polypeptides or proteins and collectively comprising at least a portion of the diversity of the family, the peptides, polypeptides or proteins being encoded by DNA sequences comprising at least in part sequences produced by
- 30 cleaving single-stranded nucleic acid sequences at a desired location by a method comprising the steps of:

- 236 -

- (i) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired, and the double-stranded region of the oligonucleotide having a restriction endonuclease recognition site; and
- (ii) cleaving the nucleic acid solely at the restriction endonuclease recognition cleavage site formed by the complementation of the nucleic acid and the single-stranded region of the oligonucleotide;
- the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

17. A library of claims 11, 12 or 13 wherein the genetic packages are selected from the group of phage, phagemid or yeast.

18. A library of claims 17 wherein the genetic packages are selected are phage or phagemid.

19. The methods or libraries according claims 2, 4, 6, 8, 10, 13 or 16 wherein in the

- 237 -

restriction endonuclease recognition site is for a Type II-S restriction endonuclease.

20. The methods or libraries according to claims 1 to 19, wherein the nucleic acid is cDNA.

5 21. The methods or libraries according to any one of claims 1 to 20, wherein the nucleic acids encode at least a portion of an immunoglobulin.

22. The methods or libraries according to claim 21, wherein the immunoglobulin comprises a Fab or
10 single chain Fv.

23. The methods or libraries according to claim 21 or 22, wherein the immunoglobulin comprises at least portion of a heavy chain.

24. The method or libraries according to
15 claim 23, wherein the heavy chain is IgM, IgG, IgA, IgE or IgD.

25. The methods or libraries according to claim 23 or 24, wherein at least a portion of the heavy chain is human.

20 26. The methods or libraries according to claim 21 or 22, wherein the immunoglobulin comprises at least a portion of FR1.

27. The methods or libraries according to claim 26, wherein at least a portion of the FR1 is
25 human..

- 238 -

28. The methods or libraries according to claim 21 or 22, wherein the immunoglobulin comprises at least a portion of a light chain.

5 29. The methods or libraries according to claim 28, wherein at least a portion of the light chain is human.

30. The methods or libraries according to any one of claims 1 to 16, wherein the nucleic acid
10 sequences are at least in part derived from patients suffering from at least one autoimmune disease and/or cancer.

31. The methods or libraries according to claim 30, wherein the autoimmune disease is selected
15 from the group comprising lupus, erythematosus, systemic sclerosis, rheumatoid arthritis, antiphospholipid syndrome or vasculitis.

32. The methods or libraries according to claim 30, wherein the nucleic acids are at least in
20 part isolated from the group comprising peripheral blood cells, bone marrow cells spleen cells or lymph node cells.

33. The methods according to claim 5, 6, 9 or 10 further comprising at least one nucleic acid
25 amplification step between one or more of steps (i) and (ii), steps (ii) and (iii) or between steps (iii) and (iv).

- 239 -

34. The method according to claim 33, wherein amplification primers for the amplification step are functionally complementary to a constant region of the nucleic acids.

5 35. The method according to claim 34, wherein the constant region is genetically constant in the nucleic acids.

36. The method according to claim 35, wherein the genetically constant region is a part of
10 the genome of immunoglobulin genes selected from the group of IgM, IgG, IgA, IgE or IgD.

37. The method according to claim 34, wherein the constant region is exogenous to the nucleic acids.

15 38. The methods according to claim 33, wherein the amplification step uses geneRACE™.

39. The methods or libraries according to any one of claims 1 to 16, wherein the chosen temperature is between 37°C and 75°C

20 40. The methods or libraries according to claim 39, wherein the chosen temperature is between 45°C and 75°C.

41. The methods or libraries according to claim 40, wherein the chosen temperature is between
25 50°C and 60°C.

- 240 -

42. The methods or libraries according to claim 41, wherein the chosen temperature is between 55°C and 60°C.

43. The methods or libraries according to
5 claim 1, 3, 5, 7, 9, 12 or 15, wherein the length of the single-stranded oligonucleotide is between 17 and 30 bases.

44. The methods or libraries according to
10 claim 43, wherein the length of the single-stranded oligonucleotide is between 18 and 24 bases.

45. The methods or libraries according to claim 1, 3, 5, 7, 9, 12 or 15, wherein the restriction endonuclease is selected from the group comprising
15 *MaeIII*, *Tsp45I*, *HphI*, *BsaJI*, *AluI*, *BlpI*, *DdeI*, *BglIII*, *MslI*, *BsiEI*, *EaeI*, *EagI*, *HaeIII*, *Bst4CI*, *HpyCH4III*, *HinfI*, *MlyI*, *PleI*, *MnlI*, *HpyCH4V*, *BsmAI*, *BpmI*, *XmnI*, or *SacI*.

46. The methods or libraries according to claim 45, wherein the restriction endonuclease is
20 selected from the group comprising *Bst4CI*, *TaaI*, *HpyCH4III*, *BlpI*, *HpyCH4V* or *MslI*.

47. The methods or libraries according to claim 2, 4, 6, 8, 10, 13 or 16, wherein the length of the single-stranded region of the partially double-
25 stranded oligonucleotide is between 14 and 22 bases.

48. The methods or libraries according to claim 47, wherein the length of the single-stranded

- 241 -

region of the partially double-stranded oligonucleotide is between 14 and 17 bases.

49. The methods or libraries according to claim 47, wherein the length of the single-stranded
5 region of the oligonucleotide is between 18 and 20 bases.

50. The methods or libraries according to claim 2, 4, 6, 8, 10, 13 or 16, wherein the length of the double-stranded region of the partially double-
10 stranded oligonucleotide is between 10 and 14 base pairs formed by a stem and its palindrome.

51. The methods or libraries according to claim 50 wherein, the partially double-stranded oligonucleotide comprises a loop of 3 to 8 bases
15 between the stem and the palindrome.

52. The methods or libraries according to claim 19 wherein the Type II-S restriction endonuclease is selected from the group comprising AarICAC, AceIII, Bbr7I, BbvI, BbvII, Bce83I, BceAI, BcefI, BciVI, BfiI, BlnI, BscAI, BseRI, BsmFI, BspMI, EciI, Eco57I, FauI, FokI, GsuI, HgaI, HphI, MboII, MlyI, MmeI, MnlI, PleI, RleAI, SfaNI, SspD5I, Sth132I, StsI, TaqII, Tth111II, or UbaPI.

53. The methods or libraries according to claim 52, wherein the Type II-S restriction
25 endonuclease is *FokI*.

- 242 -

54. A method for preparing single-stranded nucleic acids, the method comprising the steps-of:

5 (i) contacting a single-stranded nucleic acid sequence that has been cleaved with a restriction endonuclease with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acids in the region that remains after
10 cleavage, the double-stranded region of the oligonucleotide including any sequences necessary to return the sequences that remain after cleavage into proper and original reading frame for expression and containing a
15 restriction endonuclease recognition site 5' of those sequences; and

(ii) cleaving the partially double-stranded oligonucleotide sequence solely at
20 the restriction endonuclease recognition site contained within the double-stranded region of the partially double-stranded oligonucleotide.

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic
25 acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location,
30 and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

- 243 -

55. The method according to claim 54, wherein the length of the single-stranded portion of the partially double-stranded oligonucleotide is between 2 and 15 bases.

5 56. The method according to claim 55, wherein the length of the single-stranded portion of the partially double-stranded oligonucleotide is between 7 and 10 bases.

57. The method according to claim 54,
10 wherein the length of the double-stranded portion of the partially double-stranded oligonucleotide is between 12 and 100 base pairs.

58. The method according to claim 57,
15 wherein the length of the double-stranded portion of the partially double-stranded oligonucleotide is between 20 and 100 base pairs.

59. A method for preparing a library comprising a collection of genetic packages that display a member of a diverse family of peptides,
20 polypeptides or proteins and that collectively display at least a portion of the family comprising the steps:
(i) preparing a collection of nucleic acids that code at least in part for members of the diverse family;
25 (ii) rendering the nucleic acids single-stranded;
(iii) cleaving the single-stranded nucleic acids at a desired location by a method comprising the steps of:

- 244 -

- (a) contacting the nucleic acid with a single-stranded oligonucleotide, the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired and including a sequence that with its complement in the nucleic acid forms a restriction endonuclease recognition site that on restriction results in cleavage of the nucleic acid at the desired location; and
- (b) cleaving the nucleic acid solely at the recognition site formed by the complementation of the nucleic acid and the oligonucleotide;
- the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature;
- (iv) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acids in the region that remains after the cleavage in step (iii) has been effected, and the double-stranded region of the oligonucleotide including any sequences necessary to return the sequences that remain after cleavage into

- 245 -

proper and original reading frame for display and containing a restriction endonuclease recognition site 5' of those sequences that is different from the restriction site used in step (iii); and

- 5 (v) cleaving the nucleic acid solely at the restriction endonuclease recognition cleavage site contained within the double-stranded region of the partially double-stranded oligonucleotide;

10 the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to
15 associate such that cleavage may occur at the chosen temperature and at the desired location, and the restriction being carried out using a cleavage endonuclease that is active at the chosen temperature; and

- 20 (vi) displaying a member of the family of peptides, polypeptides or proteins coded, at least in part, by the cleaved nucleic acids on the surface of the genetic package and collectively displaying at least a portion of the diversity of the family.

25 60. A method for preparing a library comprising a collection of members of a diverse family of peptides, polypeptides or proteins and collectively comprising at least a portion of the family comprising the steps:

- 30 (i) preparing a collection of nucleic acids that code at least in part for members of the diverse family;

- 246 -

(ii) rendering the nucleic acids single-stranded;

(iii) cleaving the single-stranded nucleic acids at a desired location by a method comprising the 5 steps of:

(a) contacting the nucleic acid with a single-stranded oligonucleotide, the oligonucleotide being functionally complementary to the nucleic acid in the 10 region in which cleavage is desired and including a sequence that with its complement in the nucleic acid forms a restriction endonuclease recognition site that on restriction results in cleavage of the 15 nucleic acid at the desired location; and

(b) cleaving the nucleic acid solely at the recognition site formed by the complementation of the nucleic acid and the oligonucleotide;

20 the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large 25 enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the 30 chosen temperature;

(iv) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being

- 247 -

functionally complementary to the nucleic acids in the region that remains after the cleavage in step (iii) has been effected, and the double-stranded region of the oligonucleotide including any sequence necessary to
5 return the sequences that remain after cleavage into proper and original reading frame for expression and containing a restriction endonuclease recognition site 5' of those sequences that is different from the restriction site used in step (iii); and

10 (v) cleaving the nucleic acid solely at the restriction endonuclease recognition cleavage site contained within the double-stranded region of the partially double-stranded oligonucleotide;

the contacting and the cleaving steps being
15 performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to
20 associate such that cleavage may occur at the chosen temperature and at the desired location, and the restriction being carried out using a cleavage endonuclease that is active at the chosen temperature; and

25 (vi) expressing a member of the family of peptides, polypeptides or proteins coded, at least in part, by the cleaved nucleic acids and collectively expressing at least a portion of the diversity of the family.

30 61. The methods according to claim 59 or 60, further comprising at least one nucleic acid amplification step between one or more of steps (i) and

- 248 -

(ii), steps (ii) and (iii), steps (iii) and (iv) and steps (iv) and (v).

62. A library comprising a collection of genetic packages that display a member of a diverse
5 family of peptides, polypeptides or proteins and collectively display at least a portion of the diversity of the family, the library being produced using the methods of claims 59 or 61.

63. A library comprising a collection of
10 members of a diverse family of peptides, polypeptides or proteins and collectively comprise at least a portion of the diversity of the family, the library being produced using the methods of claims 60 or 61.

64. The methods and libraries according to
15 any one of claim 59 to 63, wherein the members of the library encode immunoglobulins.

65. The method and libraries according to claim 64, wherein the double-stranded region of the oligonucleotide encodes at least a part of a framework
20 sequence of an immunoglobulin.

66. The method and libraries according to claim 65, wherein the framework sequence comprises framework 1 of an antibody.

67. The method and libraries according to
25 claim 66, wherein the framework sequence comprises framework 1 of a variable domain of a light chain.

- 249 -

68. The method and libraries according to claim 66, wherein the framework sequence comprises framework 1 of a variable domain of a heavy chain.

69. The method and libraries according to
5 claim 65, wherein the framework sequence comprises framework 3 of an antibody.

70. The method and libraries according to claim 69, wherein the framework sequence comprises framework 3 of a variable domain of a light chain.

10 71. The method and libraries according to claim 69, wherein the framework sequence is framework 3 of a variable domain of a heavy chain.

72. The method and libraries according to claim 66, wherein the 5' primer is complementary to a
15 region outside framework 1.

73. The method according to claim 61, wherein amplification primers for the amplification step are functionally complementary to a constant region of the nucleic acids.

20 74. The method according to claim 73, wherein the constant region is genetically constant in the nucleic acids.

75. The method according to claim 74, wherein the genetically constant region is part of the
25 genome of immunoglobulin genes selected from the group of IgM, IgG, IgA, IgE or IgD.

- 250 -

76. The method according to claim 73,
wherein the constant region is exogenous to the nucleic
acids.

77. The methods according to claim 61,
5 wherein the amplification step uses geneRACE™.

78. A vector comprising:

- (i) a DNA sequence encoding an antibody
variable region linked to a version of PIII
anchor which does not mediate infection of
10 phage particles; and
(ii) wild-type gene III.

79. The vector according to claim 78,
wherein the DNA encodes a Fab.

80. The vector according to claim 78,
15 wherein the DNA encodes heavy chain VHCH1.

81. The vector according to claim 80,
wherein the heavy chain VHCH1 is linked to trpIII.

82. The vector according to claim 78,
wherein the DNA encodes light chain VLCL.

83. The vector according to claim 82,
20 wherein the light chain VLCL is linked to trpIII.

84. The vector according to claim 78,
wherein the DNA encodes scFv.

- 251 -

85. The vector according to claim 84,
wherein the scFv is VL-VH.

86. The vector according to claim 84,
wherein the scFv is VH-VL.

5 87. The vector according to claim 78,
wherein the DNA sequence encoding an antibody variable
region linked to a version of PIII anchor further
comprises an inducible promoter.

 88. The vector according to claim 87,
10 wherein the inducible promoter regulates expression of
the DNA sequence encoding an antibody variable region
linked to a version of PIII anchor.

 89. The vector according to claim 78,
wherein the DNA sequence encoding an antibody variable
15 region linked to a version of PIII anchor further
comprises an amber stop codon.

 90. The vector according to claim 89,
wherein the DNA encoding the amber stop codon is
located between the antibody variable region and the
20 version of pIII.

 91. The vector according to any one of
claims 78 to 90 wherein the vector is phage or
phagemid.

 92. A method for producing a population of
25 immunoglobulin genes that comprises steps of:

- 252 -

(i) introducing synthetic diversity into at least one of CDR1 or CDR2 of those genes; and

5 (ii) combining the diversity from step (i) with CDR3 diversity captured from B cells.

93. The method according to claim 92, wherein synthetic diversity is introduced into both CDR1 and CDR2.

10 94. A method for producing a library of immunoglobulin genes that comprises

(i) introducing synthetic diversity into at least one of CDR1 or CDR2 of those genes; and

15 (ii) combining the diversity from step (i) with CDR3 diversity captured from B cells.

95. The method according to claim 94, wherein synthetic diversity is introduced into both
20 CDR1 and CDR2.

96. A library of immunoglobulins that comprise members with at least one variable domain in which at least one of CDR1 and CDR2 contain synthetic diversity and CDR3 diversity is captured from B cells.

25 97. A library according to claim 96, where both CDR1 and CDR2 contain synthetic diversity.

- 253 -

98. The vector according to claim 78,
wherein the version of PIII anchor is characterized by
a wild type amino acid sequence and is encoded by a
non-wild type degenerate DNA sequence to a very high
5 extent.

99. In a method for displaying a member of a
diverse family of peptides, polypeptides or proteins on
the surface of a genetic package and collectively
displaying at least a part of the diversity of the
10 family, the improvement being characterized in that the
displayed peptide, polypeptide or protein is encoded by
a DNA sequence comprising a nucleic acid that has been
cleaved at a desired location by

(i) contacting the nucleic acid with a
15 partially double-stranded oligonucleotide,
the single-stranded region of the
oligonucleotide being functionally
complementary to the nucleic acid at its 5'
terminal and

(ii) cleaving the nucleic acid solely at
20 a restriction endonuclease cleavage site
located in the double-stranded region of the
oligonucleotide or amplifying the nucleic
acid using a primer at least in part
25 functionally complementary to at least a part
of the double-stranded region of the
oligonucleotide, the primer also introducing
on amplification an endonuclease cleavage
site and cleaving the amplified nucleic acid
30 sequence solely at that site;

- 254 -

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

10 100. A method for displaying a member of a diverse family of peptides, polypeptides or proteins on the surface of a genetic package and collectively displaying at least a portion of the diversity of the family, the method comprising the steps of:

15 (i) preparing a collection of nucleic acids that code, at least in part, for members of the diverse family;

 (ii) rendering the nucleic acids single-stranded;

20 (iii) cleaving the single-stranded nucleic acids at a desired location by a method comprising the steps of:

 (a) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acid at its 5' terminal region; and

25 (b) cleaving the nucleic acid solely at a restriction endonuclease cleavage site located in the double-stranded region of the oligonucleotide or amplifying the nucleic

30

- 255 -

acid using a primer at least in part
functionally complementary to at least a part
of the double-stranded region of the
oligonucleotide, the primer also introducing
5 on amplification an endonuclease cleavage
site and cleaving the amplified nucleic acid
sequence solely at that site;

the contacting and the cleaving steps being
performed at a temperature sufficient to maintain
10 the nucleic acid in substantially single-stranded
form, the oligonucleotide being functionally
complementary to the nucleic acid over a large
enough region to allow the two strands to
associate such that cleavage may occur at the
15 chosen temperature and at the desired location,
and the restriction being carried out using a
cleavage endonuclease that is active at the chosen
temperature; and

(iv) displaying a member of the family of
20 peptides, polypeptides or proteins coded, at least in
part, by the cleaved nucleic acids on the surface of
the genetic package and collectively displaying at
least a portion of the diversity of the family.

101. In a method for expressing a member of a
25 diverse family of peptides, polypeptides or proteins
and collectively expressing at least a part of the
diversity of the family, the improvement being
characterized in that the expressed peptide,
polypeptide or protein is encoded by a DNA sequence
30 comprising a nucleic acid that has been cleaved at a
desired location by

- 256 -

(i) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acid at its 5' terminal region; and

5

(ii) cleaving the nucleic acid solely at the restriction endonuclease cleavage site located in the double-stranded region of the oligonucleotide or amplifying the nucleic acid using a primer at least in part functionally complementary to at least a part of the double-stranded region of the oligonucleotide, the primer also introducing on amplification an endonuclease cleavage site and cleaving the amplified nucleic acid sequence solely at that site;

10

15

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

20

25

102. A method for expressing a member of a diverse family of peptides, polypeptides or proteins and collectively expressing at least a portion of the

- 257 -

diversity of the family, the method comprising the steps of:

(i) preparing a collection of nucleic acids that code, at least in part, for members of the diverse
5 family;

(ii) rendering the nucleic acids single-stranded;

(iii) cleaving the single-stranded nucleic acids at a desired location by a method comprising the
10 steps of:

(a) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the
15 oligonucleotide being functionally complementary to the nucleic acid at its 5' terminal region; and

(b) cleaving the nucleic acid solely at a restriction endonuclease cleavage site located in the double-stranded region of the
20 nucleotide; or amplifying the nucleic acid using a primer at least in part functionally complementary to at least a part of the double-stranded region of the
25 oligonucleotide, the primer also introducing on amplification an endonuclease cleavage site and cleaving the amplified nucleic acid sequence solely at that site;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain
30 the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large

- 258 -

enough region to allow the two strands to
associate such that cleavage may occur at the
chosen temperature and at the desired location,
and the restriction being carried out using a
5 cleavage endonuclease that is active at the chosen
temperature; and

(iv) expressing a member of the family of
peptides, polypeptides or proteins coded, at least in
part, by the cleaved nucleic acids and collectively
10 expressing at least a portion of the diversity of the
family.

103. A method for preparing a library
comprising a collection of genetic packages that
display a member of a diverse family of peptides,
15 polypeptides or proteins and that collectively display
at least a portion of the family comprising the steps:

(i) preparing a collection of nucleic acids
that code at least in part for members of the diverse
family;
20 (ii) rendering the nucleic acids single-
stranded;
(iii) cleaving the single-stranded nucleic
acids at a desired location by a method comprising the
steps of:

25 (a) contacting the nucleic acid with a
single-stranded oligonucleotide, the
oligonucleotide being functionally
complementary to the nucleic acid in the
region in which cleavage is desired and
30 including a sequence that with its complement
in the nucleic acid forms a restriction
endonuclease recognition site that on

- 259 -

restriction results in cleavage of the nucleic acid at the desired location; and

(b) cleaving the nucleic acid solely at the recognition site formed by the
5 complementation of the nucleic acid and the oligonucleotide;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded
10 form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location,
15 and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature;

(iv) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-
20 stranded region of the oligonucleotide being functionally complementary to the nucleic acids in the 5' terminal region that remains after the cleavage in step (iii) has been effected, and the double-stranded region of the oligonucleotide including any sequences
25 necessary to return the sequences that remain after cleavage into proper and original reading frame for display; and

(v) cleaving the nucleic acid solely at a restriction endonuclease cleavage site contained within
30 the double-stranded region of the partially double-stranded oligonucleotide, the site being different from that used in step (iii) or amplifying the nucleic acid using a primer at least in part functionally

- 260 -

complementary to at least a part of the double-stranded region of the oligonucleotide, the primer also introducing on amplification an endonuclease cleavage site and cleaving the amplified nucleic acid sequence

5 solely at that site;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally
10 complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the restriction being carried out using a
15 cleavage endonuclease that is active at the chosen temperature; and

(vi) displaying a member of the family of peptides, polypeptides or proteins coded, at least in part, by the cleaved nucleic acids on the surface of
20 the genetic package and collectively displaying at least a portion of the diversity of the family.

104. A method for preparing a library comprising a collection of members of a diverse family of peptides, polypeptides or proteins and collectively
25 comprising at least a portion of the family comprising the steps:

(i) preparing a collection of nucleic acids that code at least in part for members of the diverse family;

30 (ii) rendering the nucleic acids single-stranded;

- 261 -

(iii) cleaving the single-stranded nucleic acids at a desired location by a method comprising the steps of:

5 (a) contacting the nucleic acid with a single-stranded oligonucleotide, the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired and including a sequence that with its complement
10 in the nucleic acid forms a restriction endonuclease recognition site that on restriction results in cleavage of the nucleic acid at the desired location; and

15 (b) cleaving the nucleic acid solely at the recognition site formed by the complementation of the nucleic acid and the oligonucleotide;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain
20 the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the
25 chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature;

30 (iv) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acids in the 5' terminal region that remains after the cleavage in

- 262 -

step (iii) has been effected, and the double-stranded region of the oligonucleotide including any sequence necessary to return the sequences that remain after cleavage into proper and original reading frame for
5 expression; and

(v) cleaving the nucleic acid solely at a restriction endonuclease cleavage site contained within the double-stranded region of the partially double-stranded oligonucleotide, the site being different from
10 that used in step (iii) or amplifying the nucleic acid using a primer at least in part functionally complementary to at least a part of the double-stranded region of the oligonucleotide, the primer introducing on amplification an endonuclease cleavage site and
15 cleaving the amplified nucleic acid sequence solely at that site;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded
20 form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location,
25 and the restriction being carried out using a cleavage endonuclease that is active at the chosen temperature; and

(vi) expressing a member of the family of peptides, polypeptides or proteins coded, at least in
30 part, by the cleaved nucleic acids and collectively expressing at least a portion of the diversity of the family.

- 263 -

105. A library of immunoglobins comprising members having at least one variable domain in which one or both of the CDR 1 and CDR 2 have synthetic diversity and the CDR 3 has diversity captured from
5 B-Cells.

106. The library according to claim 104, wherein a first variable domain has synthetic diversity in CDR 1 and CDR 2 and has diversity in CDR 3 captured from B-cells and a second variable domain has diversity
10 captured from B-cells.

107. The library according to claim 104 or 105, wherein the variable domain is selected from the group of VH or VL.

108. A method for cleaving a nucleic acid
15 sequence at a desired location, the method comprising the steps of:

(i) contacting a single-stranded nucleic acid sequence with a partially double-stranded oligonucleotide, the single-stranded
20 region of the oligonucleotide being functionally complementary to the 5' terminal region of the nucleic acid sequence, the double-stranded region of the oligonucleotide including any sequences necessary to return
25 the sequence in the single-stranded nucleic acid sequence into proper and original reading frame for expression; and

(ii) cleaving the partially double-stranded oligonucleotide-single-stranded
30 nucleic acid combination solely at a

- 264 -

5 restriction endonuclease cleavage site
contained within the double-stranded
oligonucleotide or amplifying the combination
using a primer at least in part functionally
complementary to at least part of the double-
stranded region of the oligonucleotide, the
primer introducing during amplification an
endonuclease cleavage site and cleaving the
amplified sequence solely at the site.

10 109. The method according to claim 108,
wherein the length of the single-stranded portion of
the partially double-stranded oligonucleotide is
between 2 and 15 bases.

15 110. The method according to claim 109,
wherein the length of the single-stranded portion of
the partially double-stranded oligonucleotide is
between 7 and 10 bases.

20 111. The method according to claim 108,
wherein the length of the double-stranded portion of
the partially double-stranded oligonucleotide is
between 12 and 100 base pairs.

25 112. The method according to claim 111,
wherein the length of the double-stranded portion of
the partially double-stranded oligonucleotide is
between 20 and 100 base pairs.

113. The methods according to any one of
claims 99 to 104 and 108, further comprising at least

- 265 -

one nucleic acid amplification step between one or more of steps (i) and (ii), steps (ii) and (iii), steps (iii) and (iv) and steps (iv) and (v).

114. A library comprising a collection of
5 genetic packages that display a member of a diverse family of peptides, polypeptides or proteins and collectively display at least a portion of the diversity of the family, the library being produced using the methods of claims 99, 100, 103 or 113.

10 115. A library comprising a collection of members of a diverse family of peptides, polypeptides or proteins and collectively comprise at least a portion of the diversity of the family, the library being produced using the methods of claims 101, 102,
15 104 or 113.

116. The methods and libraries according to any one of claims 99 to 104 or 113, wherein the members of the library encode immunoglobulins.




FIG. 1

AMPLIFY VL GENES WITHOUT
USING VL SEQUENCES




FIG. 2

RACE non-biased antibody V-gene amplification






FIG. 3



**1, 2, 3 and 4 are
patient samples**

FIG. 4

1 2 3 4 5 6 7 8





Figure 5 - Gel analysis of PCR product from extender-kappa amplification
Approx. 75ng/5 μ l \rightarrow 15ng/ μ l

- 1 - 100bp
- 2 - LDM
- 3 - 50ng template
- 4 - 10ng template
- 5 - ssDNA unligated
- 6 - negative control
- 7 - LDM
- 8 - 100bp


FIG. 5



- Gel purified PCR product from extender-kappa amplification
Concentration : $\pm 35\text{ng}/\mu\text{l}$

1 - LDM
2 - 1µl purif.

FIG. 6



Gel-analysis of digested κ -ssDNA

1 μ l digested ssDNA \approx 8ng ssDNA

Total volume of 50 μ l = 400ng ssDNA

→ 400ng ssDNA available for ligation of the bridge-extenders

1 - 100bp

2 - LDM

3 - 1 μ l ssDNA pure

4 - 4 μ l beads after dig.

5 - 8 μ l beads after dig.

6 - LDM

7 - 100bp

FIG. 7



Gel analysis of extender – cleaved kappa ligation

20ng/5µl eluted material → 4ng/µl

- 1- 100bp
- 2 - LDM
- 3 - Ligationmix, 4µl
- 4 - Unligated ssDNA
- 5 - LDM

FIG. 8

Cleavage and ligation Kappa light chains




FIG. 9




FIG. 10




FIG. 11

Cleavage antibody light chain genes




FIG. 12A

Ligation of cleaved light chains




FIG. 12B

Figure 3: Cleavage and ligation lambda light chains




FIG. 13

CJ cleavage heavy chain




FIG.14A

Ligation heavy chain CDR3 diversity





FIG. 14B

Cleavage and ligation Heavy Chain

A) HpyCH4III cleavage


1 2 3 4



1 = Cleaved DNA eluted from PN column
2 = Beads after HpyCH4III digestion
3 = Supernatant after cleavage
4 = MspI digest of pBR322

B) PCR

1 2 3 4



1 = NEB 100bp ladder
2 = 5ul/100ul PCR product 20 cycles; sample A
3 = 5ul/100ul PCR product 20 cycles; sample B
4 = no template

FIG. 15




FIG. 16




FIG. 17

1. Annealing

3. PCR

2. Ligation

PCRpr.: 5' CCTCGACAGCGAAGTGCA CAG-3'

5' - XXX XXX XXX-VL..

Ext : 5' CCTCGACAGCGAAGTGCA CAG AGC GTC TTG-3'
 Bridge : 3' GGAGCTGTCGCTTCACGT GTC TCG CAG AAC TGA GTC GG-5'

-ApaLI-

AA-VL

Q S A L T Q P
 +1 +5 +7

FIG. 18


3. PCR

PCRpr.: 5' -CCTCTGTCACA GTGCA CAA GAC-3'

1. Annealing

5' -XXX-XXX X-VL..

2. Ligation



Ext : 5' -CCTCTGTCACA GTGCA CAA GAC ATC CAG ATG ACC CAG TCT CC
 Br1 : 3' -GG .. GGT AGG AGG G-5'

-ApalI-

AA-VL

Q D I Q M T Q S P S S
 +1 +8 +9 +10

FIG. 19

22/22

3. PCR

PCRpr.:

5' -GAC TGG GTG TAG TGA TCT AG-3'

+70


+92

(FR3)

V * * S R D N S Y Y C A K

1. Annealing

Bridge : 5' -G GTG TAG TGA TCT AGT GAC AAC TCT ... TAC TAT TGT GCG AAA-3'

Ext : 3' -C CAC ATC ACT AGA TCT CTG TTG AGA ... ATG ATA-5' 

-XbaI-

2. Ligation

3' -XXX XXX XXX-VH

FIG. 20

1

SEQUENCE LISTING

<110> LADNER, ROBERT C.
COHEN, EDWARD H.
NASTRI, HORACIO G.
ROOKEY, KRISTIN L.
HOET, RENE
HOOGENBOOM, HENDRICUS R. J. M.

<120> NOVEL METHODS OF CONSTRUCTING LIBRARIES COMPRISING
DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY
OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL
LIBRARIES

<130> DYAX/002 CIP2

<140> 10/045,674
<141> 2001-10-25

<150> 06/198,069
<151> 2000-04-17

<150> 09/837,306
<151> 2001-04-17

<160> 635

<170> PatentIn Ver. 2.1

<210> 1
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1
catgtgtatt actgtgc 17

<210> 2
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 2
cacatccgtg cttcttgac ggatgtggca cagtaataca catg 44

<210> 3
<211> 18

2

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 3

gtgtattaga ctgctgcc

18

<210> 4

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 4

ggcagcagtc taatacacca catccgtgtt cttcacggat gtg

43

<210> 5

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 5

cacatccgtg tttgttacac ggatgtggtg tcttacagtc cattctg

47

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 6

cagaatggac tgtaagacac

20

<210> 7

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 7
atcgagtctc actgagccac atccgtgggtt ttccacggat gtg 43

<210> 8
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 8
gctcagtgag actcgat 17

<210> 9
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified base
<222> (10)..(24)
<223> A, T, C, G, other or unknown

<400> 9
cacgaggagn nnnnnnnnnn nnnn 24

<210> 10
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 10
atgaccgaat tgctacaag 19

<210> 11
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 11
gactcctcag cttcttgctg aggagtcctt gtagcaattc ggtcat 46

<210> 12
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: 6 His tag

<400> 12
His His His His His His
1 5

<210> 13
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (6)..(10)
<223> A, T, C, G, other or unknown

<400> 13
gtctcnnnnn 10

<210> 14
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (1)..(6)
<223> A, T, C, G, other or unknown

<400> 14
nnnnnngaga c 11

<210> 15
<211> 24
<212> DNA
<213> Artificial Sequence

5

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (11)..(24)
<223> A, T, C, G, other or unknown

<400> 15
cacggatgtg nnnnnnnnnn nnnn

24

<210> 16
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (1)..(14)
<223> A, T, C, G, other or unknown

<400> 16
nnnnnnnnnn nnnncacatc cgtg

24

<210> 17
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 17
gtgtattact gtgc

14

<210> 18
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 18
cacatccgtg cacggatgtg gcacagtaat acac

34

6

<210> 19
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 19
gtgtattaga ctgc

14

<210> 20
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 20
gcagtcta acaccacatc cgtgcacgga tgtg

34

<210> 21
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 21
cacatccgtg cacggatgtg gtgtcttaca gtcc

34

<210> 22
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 22
ggactgtaag acac

14

<210> 23
<211> 34
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 23

gagtcctcact gagccacatc cgtgcacgga tgtg

34

<210> 24

<211> 14

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 24

gctcagtgag actc

14

<210> 25

<211> 14

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 25

gtgtattact gtgc

14

<210> 26

<211> 14

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 26

gtatattact gtgc

14

<210> 27

<211> 14

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 27

gtgtattact gtaa

14

<210> 28
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 28
gtgtattact gtac 14

<210> 29
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 29
ttgtattact gtgc 14

<210> 30
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 30
ttgtatcact gtgc 14

<210> 31
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 31
acatattact gtgc 14

<210> 32
<211> 14
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 32

acgtattact gtgc

14

<210> 33

<211> 14

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 33

atgtattact gtgc

14

<210> 34

<211> 101

<212> DNA

<213> Homo sapiens

<400> 34

agggtcacca tgaccaggga cacgtccatc agcacagcct acatgabcga gctgagcagg 60
ctgagatctg acgacacggc cgtgtattac tgtgcgagag a 101

<210> 35

<211> 98

<212> DNA

<213> Homo sapiens

<400> 35

agagtcacca ttaccaggga cacatccgcg agcacagcct acatggagct gagcagcctg 60
agatctgaag acacggctgt gtattactgt gcgagaga 98

<210> 36

<211> 98

<212> DNA

<213> Homo sapiens

<400> 36

agagtcacca tgaccaggaa cacctccata agcacagcct acatggagct gagcagcctg 60
agatctgagg acacggccgt gtattactgt gcgagagg 98

<210> 37

<211> 98

<212> DNA

<213> Homo sapiens

10

<400> 37
agagtcacca tgaccacaga cacatccacg agcacagcct acatggagct gaggagcctg 60
agatctgacg acacggccgt gtattactgt gcgagaga 98

<210> 38
<211> 98
<212> DNA
<213> Homo sapiens

<400> 38
agagtcacca tgaccgagga cacatctaca gacacagcct acatggagct gagcagcctg 60
agatctgagg acacggccgt gtattactgt gcaacaga 98

<210> 39
<211> 98
<212> DNA
<213> Homo sapiens

<400> 39
agagtcacca ttaccaggga caggtctatg agcacagcct acatggagct gagcagcctg 60
agatctgagg acacagccat gtattactgt gcaagata 98

<210> 40
<211> 98
<212> DNA
<213> Homo sapiens

<400> 40
agagtcacca tgaccaggga cacgtccacg agcacagtct acatggagct gagcagcctg 60
agatctgagg acacggccgt gtattactgt gcgagaga 98

<210> 41
<211> 98
<212> DNA
<213> Homo sapiens

<400> 41
agagtcacca ttaccaggga catgtccaca agcacagcct acatggagct gagcagcctg 60
agatccgagg acacggccgt gtattactgt gcggcaga 98

<210> 42
<211> 98
<212> DNA
<213> Homo sapiens

<400> 42
agagtcacga ttaccgcgga cgaatccacg agcacagcct acatggagct gagcagcctg 60
agatctgagg acacggccgt gtattactgt gcgagaga 98

<210> 43
<211> 98

<212> DNA
<213> Homo sapiens

<400> 43
agagtcacga ttaccgcgga caaatccacg agcacagcct acatggagct gagcagcctg 60
agatctgagg acacggccgt gtattactgt gcgagaga 98

<210> 44
<211> 98
<212> DNA
<213> Homo sapiens

<400> 44
agagtcacca taaccgcgga cacgtctaca gacacagcct acatggagct gagcagcctg 60
agatctgagg acacggccgt gtattactgt gcaacaga 98

<210> 45
<211> 100
<212> DNA
<213> Homo sapiens

<400> 45
aggctcacca tcaccaagga cacctccaaa aaccagggtgg tccttacaat gaccaacatg 60
gaccctgtgg acacagccac atattactgt gcacacagac 100

<210> 46
<211> 100
<212> DNA
<213> Homo sapiens

<400> 46
aggctcacca tctccaagga cacctccaaa agccagggtgg tccttaccat gaccaacatg 60
gaccctgtgg acacagccac atattactgt gcacggatac 100

<210> 47
<211> 100
<212> DNA
<213> Homo sapiens

<400> 47
aggctcacca tctccaagga cacctccaaa aaccagggtgg tccttacaat gaccaacatg 60
gaccctgtgg acacagccac gtattactgt gcacggatac 100

<210> 48
<211> 98
<212> DNA
<213> Homo sapiens

<400> 48
cgattcacca tctccagaga caacgccaaag aactcactgt atctgcaaat gaacagcctg 60
agagccgagg acacggctgt gtattactgt gcgagaga 98

12

<210> 49
<211> 100
<212> DNA
<213> Homo sapiens

<400> 49
cgattcacca tctccagaga caacgccaag aactccctgt atctgcaa at gaacagtctg 60
agagctgagg acacggcctt gtattactgt gcaaaagata 100

<210> 50
<211> 98
<212> DNA
<213> Homo sapiens

<400> 50
cgattcacca tctccaggga caacgccaag aactcactgt atctgcaa at gaacagcctg 60
agagccgagg acacggcctt gtattactgt gcgagaga 98

<210> 51
<211> 98
<212> DNA
<213> Homo sapiens

<400> 51
cgattcacca tctccagaga aaatgccaag aactccttgt atcttcaa at gaacagcctg 60
agagccgggg acacggctgt gtattactgt gcaagaga 98

<210> 52
<211> 98
<212> DNA
<213> Homo sapiens

<400> 52
agattcacca tctcaagaga tgattcaaaa aacacgctgt atctgcaa at gaacagcctg 60
aaaaccgagg acacagcctt gtattactgt accacaga 98

<210> 53
<211> 98
<212> DNA
<213> Homo sapiens

<400> 53
cgattcacca tctccagaga caacgccaag aactccctgt atctgcaa at gaacagtctg 60
agagccgagg acacggcctt gtatcactgt gcgagaga 98

<210> 54
<211> 98
<212> DNA
<213> Homo sapiens

<400> 54
cgattcacca tctccagaga caacgccaag aactcactgt atctgcaa at gaacagcctg 60
agagccgagg acacggctgt gtattactgt gcgagaga 98

<210> 55
<211> 98
<212> DNA
<213> Homo sapiens

<400> 55
cggttcacca tctccagaga caattccaag aacacgctgt atctgcaaat gaacagcctg 60
agagccgagg acacggcgtg atattactgt gcgaaaga 98

<210> 56
<211> 98
<212> DNA
<213> Homo sapiens

<400> 56
cgattcacca tctccagaga caattccaag aacacgctgt atctgcaaat gaacagcctg 60
agagctgagg acacggctgt gtattactgt gcgaaaga 98

<210> 57
<211> 98
<212> DNA
<213> Homo sapiens

<400> 57
cgattcacca tctccagaga caattccaag aacacgctgt atctgcaaat gaacagcctg 60
agagctgagg acacggctgt gtattactgt gcgagaga 98

<210> 58
<211> 98
<212> DNA
<213> Homo sapiens

<400> 58
cgattcacca tctccagaga caattccaag aacacgctgt atctgcaaat gaacagcctg 60
agagctgagg acacggctgt gtattactgt gcgaaaga 98

<210> 59
<211> 98
<212> DNA
<213> Homo sapiens

<400> 59
cgattcacca tctccagaga caattccaag aacacgctgt atctgcaaat gaacagcctg 60
agagccgagg acacggctgt gtattactgt gcgagaga 98

<210> 60
<211> 100
<212> DNA
<213> Homo sapiens

14

<400> 60
cgattcacca tctccagaga caacagcaaa aactccctgt atctgcaa at gaacagtctg 60
agaactgagg acaccgcctt gtattactgt gcaaaagata 100

<210> 61
<211> 98
<212> DNA
<213> Homo sapiens

<400> 61
cgattcacca tctccagaga caatgccaa aactcactgt atctgcaa at gaacagcctg 60
agagacgagg acacggctgt gtattactgt gcgagaga 98

<210> 62
<211> 98
<212> DNA
<213> Homo sapiens

<400> 62
agattcacca tctcaagaga tggttccaa agcatcgcct atctgcaa at gaacagcctg 60
aaaaccgagg acacggcgt gtattactgt actagaga 98

<210> 63
<211> 98
<212> DNA
<213> Homo sapiens

<400> 63
cgattcacca tctccagaga caattccaag aacacgctgt atcttcaa at gaacagcctg 60
agagccgagg acacggccgt gtattactgt gcgagaga 98

<210> 64
<211> 98
<212> DNA
<213> Homo sapiens

<400> 64
agattcacca tctccagaga caattccaag aacacgctgt atcttcaa at gggcagcctg 60
agagctgagg acatggctgt gtattactgt gcgagaga 98

<210> 65
<211> 98
<212> DNA
<213> Homo sapiens

<400> 65
agattcacca tctccagaga caattccaag aacacgctgt atcttcaa at gaacagcctg 60
agagctgagg acacggctgt gtattactgt gcgagaga 98

<210> 66
<211> 98

<212> DNA
<213> Homo sapiens

<400> 66
agattcacca tctcaagaga tgattcaaag aactcactgt atctgcaa at gaacagcctg 60
aaaaccgagg acacggccgt gtattactgt gctagaga 98

<210> 67
<211> 98
<212> DNA
<213> Homo sapiens

<400> 67
aggttcacca tctccagaga tgattcaaag aacacggcgt atctgcaa at gaacagcctg 60
aaaaccgagg acacggccgt gtattactgt actagaca 98

<210> 68
<211> 98
<212> DNA
<213> Homo sapiens

<400> 68
cgattcacca tctccagaga caacgccaaag aacacgctgt atctgcaa at gaacagctctg 60
agagccgagg acacggctgt gtattactgt gcaagaga 98

<210> 69
<211> 98
<212> DNA
<213> Homo sapiens

<400> 69
agattcacca tctccagaga caattccaag aacacgctgc atcttcaa at gaacagcctg 60
agagctgagg acacggctgt gtattactgt aagaaaga 98

<210> 70
<211> 98
<212> DNA
<213> Homo sapiens

<400> 70
cgagtcacca tatcagtaga caagtccaag aaccagttct ccctgaagct gagctctgtg 60
accgccgcgg acacggccgt gtattactgt gcgagaga 98

<210> 71
<211> 98
<212> DNA
<213> Homo sapiens

<400> 71
cgagtcacca tgtagtaga cacgtccaag aaccagttct ccctgaagct gagctctgtg 60
accgccgtgg acacggccgt gtattactgt gcgagaaa 98

16

<210> 72
<211> 98
<212> DNA
<213> Homo sapiens

<400> 72
cgagttacca tatcagtaga cacgtctaag aaccagttct ccctgaagct gagctctgtg 60
actgccgcgg acacggccgt gtattactgt gcgagaga 98

<210> 73
<211> 98
<212> DNA
<213> Homo sapiens

<400> 73
cgagtcacca tatcagtaga caggtccaag aaccagttct ccctgaagct gagctctgtg 60
accgccgcgg acacggccgt gtattactgt gccagaga 98

<210> 74
<211> 98
<212> DNA
<213> Homo sapiens

<400> 74
cgagttacca tatcagtaga cacgtccaag aaccagttct ccctgaagct gagctctgtg 60
actgccgcag acacggccgt gtattactgt gccagaga 98

<210> 75
<211> 98
<212> DNA
<213> Homo sapiens

<400> 75
cgagttacca tatcagtaga cacgtctaag aaccagttct ccctgaagct gagctctgtg 60
actgccgcgg acacggccgt gtattactgt gcgagaga 98

<210> 76
<211> 98
<212> DNA
<213> Homo sapiens

<400> 76
cgagtcacca tatcagtaga cacgtccaag aaccagttct ccctgaagct gagctctgtg 60
accgccgcgg acacggctgt gtattactgt gcgagaga 98

<210> 77
<211> 98
<212> DNA
<213> Homo sapiens

<400> 77
cgagtcacca tatccgtaga cacgtccaag aaccagttct ccctgaagct gagctctgtg 60
accgccgcag acacggctgt gtattactgt gcgagaca 98

<210> 78
<211> 98
<212> DNA
<213> Homo sapiens

<400> 78
cgagtcacca tatcagtaga cacgtccaag aaccagttct ccctgaagct gagctctgtg 60
accgctgcgg acacggccgt gtattactgt gcgagaga 98

<210> 79
<211> 98
<212> DNA
<213> Homo sapiens

<400> 79
cgagtcacca tatcagtaga cacgtccaag aaccagttct ccctgaagct gagctctgtg 60
accgctgcgg acacggccgt gtattactgt gcgagaga 98

<210> 80
<211> 98
<212> DNA
<213> Homo sapiens

<400> 80
cgagtcacca tatcagtaga cacgtccaag aaccagttct ccctgaagct gagctctgtg 60
accgccgcag acacggccgt gtattactgt gcgagaga 98

<210> 81
<211> 98
<212> DNA
<213> Homo sapiens

<400> 81
caggtcacca tctcagccga caagtccatc agcaccgcct acctgcagtg gagcagcctg 60
aaggcctcgg acaccgccat gtattactgt gcgagaca 98

<210> 82
<211> 96
<212> DNA
<213> Homo sapiens

<400> 82
cacgtcacca tctcagctga caagtccatc agcactgcct acctgcagtg gagcagcctg 60
aaggcctcgg acaccgccat gtattactgt gcgagaga 96

<210> 83
<211> 98
<212> DNA
<213> Homo sapiens

18

<400> 83
cgaataacca tcaaccaga cacatccaag aaccagttct ccctgcagct gaactctgtg 60
actcccagagg acacggctgt gtattactgt gcaagaga 98

<210> 84
<211> 98
<212> DNA
<213> Homo sapiens

<400> 84
cggtttgtct tctccttgga cacctctgtc agcacggcat atctgcagat ctgcagccta 60
aaggctgagg aactgccgt gtattactgt gcgagaga 98

<210> 85
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (3)..(9)
<223> A, T, C, G, other or unknown

<400> 85
gcnnnnnnng c 11

<210> 86
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(7)
<223> A, T, C, G, other or unknown

<400> 86
caynnnnrtg 10

<210> 87
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

19

oligonucleotide

<220>

<221> modified_base

<222> (6)..(11)

<223> A, T, C, G, other or unknown

<400> 87

gagtcnnnnn n

11

<210> 88

<211> 11

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (1)..(6)

<223> A, T, C, G, other or unknown

<400> 88

nnnnngaga c

11

<210> 89

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (4)..(7)

<223> A, T, C, G, other or unknown

<400> 89

gaannnttc

10

<210> 90

<211> 90

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic 3-23
FR3 nucleotide sequence

<220>
<221> CDS
<222> (1)..(90)

<220>
<221> modified_base
<222> (3)
<223> A, T, C or G

<220>
<221> modified_base
<222> (9)
<223> A, T, C or G

<220>
<221> modified_base
<222> (12)
<223> A, T, C or G

<220>
<221> modified_base
<222> (21)
<223> A, T, C or G

<220>
<221> modified_base
<222> (30)
<223> A, T, C or G

<220>
<221> modified_base
<222> (36)
<223> A, T, C or G

<220>
<221> modified_base
<222> (51)
<223> A, T, C or G

<220>
<221> modified_base
<222> (57)
<223> A, T, C or G

<220>
<221> modified_base
<222> (60)
<223> A, T, C or G

<220>
<221> modified_base
<222> (69)
<223> A, T, C or G

<220>
<221> modified_base
<222> (72)
<223> A, T, C or G

21

<220>
 <221> modified_base
 <222> (75)
 <223> A, T, C or G

<220>
 <221> modified_base
 <222> (78)
 <223> A, T, C or G

<220>
 <221> modified_base
 <222> (87)
 <223> A, T, C or G

<400> 90
 acn ath wsn mgn gay aay wsn aar aay acn ytn tay ttn car atg aay 48
 Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn
 1 5 10 15

wsn ttr mgn gcn gar gay acn gcn gtn tay tay tgy gcn aar 90
 Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys
 20 25 30

<210> 91
 <211> 30
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic 3-23
 FR3 protein sequence

<400> 91
 Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn
 1 5 10 15
 Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys
 20 25 30

<210> 92
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 probe

<400> 92
 agttctccct gcagctgaac tc

22

22

<210> 93
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 93
cactgtatct gcaaatgaac ag

22

<210> 94
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 94
ccctgtatct gcaaatgaac ag

22

<210> 95
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 95
ccgcctacct gcagtggagc ag

22

<210> 96
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 96
cgctgtatct gcaaatgaac ag

22

<210> 97
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

23

<223> Description of Artificial Sequence: Synthetic
probe

<400> 97

cggcataatct gcagatctgc ag

22

<210> 98

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
probe

<400> 98

cggcgtatct gcaaatgaac ag

22

<210> 99

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
probe

<400> 99

ctgcctacct gcagtggagc ag

22

<210> 100

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
probe

<400> 100

tcgcctatct gcaaatgaac ag

22

<210> 101

<211> 63

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 101

cgcttcacta agtctagaga caactctaag aatactctct acttgcagat gaacagctta 60
agg 63

<210> 102
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 102
caagtagaga gtattcttag agttgtctct agacttagtg aagcg 45

<210> 103
<211> 54
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 103
cgcttcacta agtctagaga caactctaag aatactctct acttgcaagt gaac 54

<210> 104
<211> 54
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 104
cgcttcacta agtctagaga caactctaag aatactctct acttgcaaat gaac 54

<210> 105
<211> 54
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 105
cgcttcacta agtctagaga caactctaag aatactctct acttgcaagt gagc 54

<210> 106
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 106

cgcttcacta agtctagaga c

21

<210> 107

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
probe

<400> 107

acatggagct gagcagcctg ag

22

<210> 108

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
probe

<400> 108

acatggagct gagcaggctg ag

22

<210> 109

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
probe

<400> 109

acatggagct gaggagcctg ag

22

<210> 110

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
probe

<400> 110

acctgcagtg gagcagcctg aa

22

<210> 111
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 111
atctgcaa at gaacagcctg aa 22

<210> 112
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 112
atctgcaa at gaacagcctg ag 22

<210> 113
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 113
atctgcaa at gaacagtctg ag 22

<210> 114
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 114
atctgcagat ctgcagccta aa 22

<210> 115
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 115
atcttcaa at gaacagcctg ag 22

<210> 116
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 116
atcttcaa at ggcagcctg ag 22

<210> 117
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 117
ccctgaagct gagctctgtg ac 22

<210> 118
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 118
ccctgcagct gaactctgtg ac 22

<210> 119
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

28

<400> 119
tccttacaat gaccaacatg ga 22

<210> 120
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 120
tccttaccat gaccaacatg ga 22

<210> 121
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 121
acatggagct gagcagcctg ag 22

<210> 122
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 122
ccctgaagct gagctctgtg ac 22

<210> 123
<211> 54
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 123
cgcttcacta agtctagaga caactctaag aatactctct acttgcagat gaac 54

<210> 124
<211> 60

29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 124

cgcttcactc agtctagaga taacagtaaa aatactttgt acttgcagct gagcagcctg 60

<210> 125

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 125

cgcttcactc agtctagaga taacagtaaa aatactttgt acttgcagct gagctctgtg 60

<210> 126

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 126

tcagctgcaa gtacaaagta tttttactgt tatctctaga ctgagtgaag cg 52

<210> 127

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 127

cgcttcactc agtctagaga taac 24

<210> 128

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 128
ccgtgtatta ctgtgcgaga ga 22

<210> 129
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 129
ctgtgtatta ctgtgcgaga ga 22

<210> 130
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 130
ccgtgtatta ctgtgcgaga gg 22

<210> 131
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 131
ccgtgtatta ctgtgcaaca ga 22

<210> 132
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 132
ccatgtatta ctgtgcaaga ta 22

31

<210> 133
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 133
ccgtgtatta ctgtgcggca ga 22

<210> 134
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 134
ccacatatta ctgtgcacac ag 22

<210> 135
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 135
ccacatatta ctgtgcacgg at 22

<210> 136
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 136
ccacgtatta ctgtgcacgg at 22

<210> 137
<211> 22
<212> DNA
<213> Artificial Sequence

32

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 137

ccttgtatta ctgtgcaaaa ga

22

<210> 138

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 138

ctgtgtatta ctgtgcaaga ga

22

<210> 139

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 139

ccgtgtatta ctgtaccaca ga

22

<210> 140

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 140

ccttgtatca ctgtgcgaga ga

22

<210> 141

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 141

ccgtatatta ctgtgcgaaa ga

22

<210> 142
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 142
ctgtgtatta ctgtgcgaaa ga 22

<210> 143
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 143
ccgtgtatta ctgtactaga ga 22

<210> 144
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 144
ccgtgtatta ctgtgctaga ga 22

<210> 145
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 145
ccgtgtatta ctgtactaga ca 22

<210> 146
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 146

ctgtgtatta ctgtaagaaa ga

22

<210> 147

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 147

ccgtgtatta ctgtgcgaga aa

22

<210> 148

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 148

ccgtgtatta ctgtgccaga ga

22

<210> 149

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 149

ctgtgtatta ctgtgcgaga ca

22

<210> 150

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

35

<400> 150
ccatgtatta ctgtgcgaga ca 22

<210> 151
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 151
ccatgtatta ctgtgcgaga 20

<210> 152
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 152
ccgtgtatta ctgtgcgaga g 21

<210> 153
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 153
ctgtgtatta ctgtgcgaga g 21

<210> 154
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 154
ccgtgtatta ctgtgcgaga g 21

<210> 155
<211> 21

36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 155

ccgtatatatta ctgtgcgaaa g

21

<210> 156

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 156

ctgtgtatta ctgtgcgaaa g

21

<210> 157

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 157

ctgtgtatta ctgtgcgaga c

21

<210> 158

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 158

ccatgtatta ctgtgcgaga c

21

<210> 159

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 159
ccatgtatta ctgtgcgaga

20

<210> 160
<211> 94
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 160
ggtgtagtga tctagtgcaca actctaagaa tactctctac ttgcagatga acagctttag 60
ggctgaggac actgcagtct actattgtgc gaga 94

<210> 161
<211> 94
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 161
ggtgtagtga tctagtgcaca actctaagaa tactctctac ttgcagatga acagctttag 60
ggctgaggac actgcagtct actattgtgc gaaa 94

<210> 162
<211> 85
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 162
atagtagact gcagtgtcct cagcccttaa gctgttcac tgcaagtaga gattattctt 60
agagttgtct ctatgcact acacc 85

<210> 163
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 163
ggtgtagtga tctagagaca ac

22

<210> 164
<211> 55
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 164
gggtgtagtga aacagcttta gggctgagga cactgcagtc tactattgtg cgaga 55

<210> 165
<211> 55
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 165
gggtgtagtga aacagcttta gggctgagga cactgcagtc tactattgtg cgaaa 55

<210> 166
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 166
atagtagact gcagtgtcct cagcccttaa gctgtttcac tacacc 46

<210> 167
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 167
gggtgtagtga aacagcttaa gggctgagga cactgcagtc tactat 46

<210> 168
<211> 26
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 168

ggtgtagtga aacagcttaa gggctg

26

<210> 169

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
probe

<400> 169

agttctccct gcagctgaac tc

22

<210> 170

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
probe

<400> 170

cactgtatct gcaaatgaac ag

22

<210> 171

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
probe

<400> 171

ccctgtatct gcaaatgaac ag

22

<210> 172

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
probe

40

<400> 172
ccgcctacct gcagtggagc ag 22

<210> 173
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 173
cgctgtatct gcaaatgaac ag 22

<210> 174
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 174
cggcatatct gcagatctgc ag 22

<210> 175
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 175
cggcgatatct gcaaatgaac ag 22

<210> 176
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 176
ctgcctacct gcagtggagc ag 22

<210> 177
<211> 22

41

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
probe

<400> 177
tcgcctatct gcaaatgaac ag 22

<210> 178
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 178
acatggagct gagcagcctg ag 22

<210> 179
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 179
acatggagct gagcaggctg ag 22

<210> 180
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 180
acatggagct gaggagcctg ag 22

<210> 181
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 181
acctgcagtg gagcagcctg aa 22

<210> 182
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 182
atctgcaa at gaacagcctg aa 22

<210> 183
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 183
atctgcaa at gaacagcctg ag 22

<210> 184
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 184
atctgcaa at gaacagtctg ag 22

<210> 185
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 185
atctgcagat ctgcagccta aa 22

43

<210> 186
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 186
atcttcaa at gaacagcctg ag

22

<210> 187
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 187
atcttcaa at ggcagcctg ag

22

<210> 188
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 188
ccctgaagct gagctctgtg ac

22

<210> 189
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 189
ccctgcagct gaactctgtg ac

22

<210> 190
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 190

tccttacaat gaccaacatg ga

22

<210> 191

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 191

tccttaccat gaccaacatg ga

22

<210> 192

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 192

ccgtgtatta ctgtgcgaga ga

22

<210> 193

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 193

ctgtgtatta ctgtgcgaga ga

22

<210> 194

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 194

ccgtgtatta ctgtgcgaga gg

22

<210> 195
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 195
ccgtgtatta ctgtgcaaca ga 22

<210> 196
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 196
ccatgtatta ctgtgcaaga ta 22

<210> 197
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 197
ccgtgtatta ctgtgcggca ga 22

<210> 198
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 198
ccacatatta ctgtgcacac ag 22

<210> 199
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 199

ccacatatta ctgtgcacgg at

22

<210> 200

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 200

ccacgtatta ctgtgcacgg at

22

<210> 201

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 201

ccttgtatta ctgtgcaaaa ga

22

<210> 202

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 202

ctgtgtatta ctgtgcaaga ga

22

<210> 203

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

47

<400> 203
ccgtgtatta ctgtaccaca ga 22

<210> 204
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 204
ccttgatatca ctgtgcgaga ga 22

<210> 205
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 205
ccgtatatatta ctgtgcgaaa ga 22

<210> 206
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 206
ctgtgtatta ctgtgcgaaa ga 22

<210> 207
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 207
ccgtgtatta ctgtactaga ga 22

<210> 208
<211> 22

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 208
ccgtgtatta ctgtgctaga ga 22

<210> 209
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 209
ccgtgtatta ctgtactaga ca 22

<210> 210
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 210
ctgtgtatta ctgtaagaaa ga 22

<210> 211
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 211
ccgtgtatta ctgtgcgaga aa 22

<210> 212
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 212
ccgtgtatta ctgtgccaga ga 22

<210> 213
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 213
ctgtgtatta ctgtgcgaga ca 22

<210> 214
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 214
ccatgtatta ctgtgcgaga ca 22

<210> 215
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 215
ccatgtatta ctgtgcgaga aa 22

<210> 216
<211> 90
<212> DNA
<213> Homo sapiens

<400> 216
cagggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggata caccttcacc 90

<210> 217
<211> 90
<212> DNA
<213> Homo sapiens

<400> 217
caggtccagc ttgtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaagggtt 60
tcctgcaagg cttctggata caccttcact 90

<210> 218
<211> 90
<212> DNA
<213> Homo sapiens

<400> 218
caggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaagggtc 60
tcctgcaagg cttctggata caccttcacc 90

<210> 219
<211> 90
<212> DNA
<213> Homo sapiens

<400> 219
caggttcagc tgggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaagggtc 60
tcctgcaagg cttctggata cacctttacc 90

<210> 220
<211> 90
<212> DNA
<213> Homo sapiens

<400> 220
caggtccagc tgggtacagtc tggggctgag gtgaagaagc ctggggcctc agtgaagggtc 60
tcctgcaagg tttccggata caccctcact 90

<210> 221
<211> 90
<212> DNA
<213> Homo sapiens

<400> 221
cagatgcagc tgggtgcagtc tggggctgag gtgaagaaga ctgggtcctc agtgaagggtt 60
tcctgcaagg cttccggata caccttcacc 90

<210> 222
<211> 90
<212> DNA
<213> Homo sapiens

<400> 222
caggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaagggtt 60
tcctgcaagg catctggata caccttcacc 90

<210> 223
<211> 90

51

<212> DNA
<213> Homo sapiens

<400> 223
caaatgcagc tgggtgcagtc tgggcctgag gtgaagaagc ctgggacctc agtgaaggtc 60
tcctgcaagg cttctggatt cacctttact 90

<210> 224
<211> 90
<212> DNA
<213> Homo sapiens

<400> 224
cagggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60
tcctgcaagg cttctggagg caccttcagc 90

<210> 225
<211> 90
<212> DNA
<213> Homo sapiens

<400> 225
cagggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60
tcctgcaagg cttctggagg caccttcagc 90

<210> 226
<211> 90
<212> DNA
<213> Homo sapiens

<400> 226
gagggtccagc tgggtacagtc tggggctgag gtgaagaagc ctggggctac agtgaaaaac 60
tcctgcaagg tttctggata caccttcacc 90

<210> 227
<211> 90
<212> DNA
<213> Homo sapiens

<400> 227
cagatcacct tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg 60
acctgcacct tctctgggtt ctacttcagc 90

<210> 228
<211> 90
<212> DNA
<213> Homo sapiens

<400> 228
cagggtcacct tgaaggagtc tggtcctgtg ctggtgaaac ccacagagac cctcacgctg 60
acctgcaccg tctctgggtt ctacttcagc 90

52

<210> 229
<211> 90
<212> DNA
<213> Homo sapiens

<400> 229
caggtcacct tgaaggagtc tggtcctgcg ctggtgaaac ccacacagac cctcacactg 60
acctgcacct tctctgggtt ctcaactcagc 90

<210> 230
<211> 90
<212> DNA
<213> Homo sapiens

<400> 230
gaggtgcagc tgggtggagtc tgggggaggc ttggtccagc ctgggggggc cctgagactc 60
tcctgtgcag cctctggatt cacctttagt 90

<210> 231
<211> 90
<212> DNA
<213> Homo sapiens

<400> 231
gaagtgcagc tgggtggagtc tgggggaggc ttggtacagc ctggcaggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttagt 90

<210> 232
<211> 90
<212> DNA
<213> Homo sapiens

<400> 232
caggtgcagc tgggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

<210> 233
<211> 90
<212> DNA
<213> Homo sapiens

<400> 233
gaggtgcagc tgggtggagtc tgggggaggc ttggtacagc ctgggggggc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

<210> 234
<211> 90
<212> DNA
<213> Homo sapiens

<400> 234
gaggtgcagc tgggtggagtc tgggggaggc ttggtaaagc ctgggggggc ccttagactc 60
tcctgtgcag cctctggatt cactttcagt 90

<210> 235
<211> 90
<212> DNA
<213> Homo sapiens

<400> 235
gaggtgcagc tgggtggagtc tgggggaggt gtggtacggc ctgggggggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttgat 90

<210> 236
<211> 90
<212> DNA
<213> Homo sapiens

<400> 236
gaggtgcagc tgggtggagtc tgggggaggt ctggtcaagc ctgggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

<210> 237
<211> 90
<212> DNA
<213> Homo sapiens

<400> 237
gaggtgcagc tgttggagtc tgggggaggt ttggtacagc ctgggggggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttcagt 90

<210> 238
<211> 90
<212> DNA
<213> Homo sapiens

<400> 238
caggtgcagc tgggtggagtc tgggggaggt gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

<210> 239
<211> 90
<212> DNA
<213> Homo sapiens

<400> 239
caggtgcagc tgggtggagtc tgggggaggt gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

<210> 240
<211> 90
<212> DNA
<213> Homo sapiens

54

<400> 240
caggtgcagc tgggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

<210> 241
<211> 90
<212> DNA
<213> Homo sapiens

<400> 241
caggtgcagc tgggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt 90

<210> 242
<211> 90
<212> DNA
<213> Homo sapiens

<400> 242
gaagtgcagc tgggtggagtc tgggggagtc gtggtacagc ctgggggggc cctgagactc 60
tcctgtgcag cctctggatt cacctttgat 90

<210> 243
<211> 90
<212> DNA
<213> Homo sapiens

<400> 243
gaggtgcagc tgggtggagtc tgggggaggc ttggtacagc ctgggggggc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

<210> 244
<211> 90
<212> DNA
<213> Homo sapiens

<400> 244
gaggtgcagc tgggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc 60
tcctgtacag cttctggatt cacctttggt 90

<210> 245
<211> 90
<212> DNA
<213> Homo sapiens

<400> 245
gaggtgcagc tgggtggagac tggaggaggc ttgatccagc ctgggggggc cctgagactc 60
tcctgtgcag cctctgggtt caccgtcagt 90

<210> 246
<211> 90
<212> DNA

55

<213> Homo sapiens

<400> 246

gaggtgcagc tgggtggagtc tgggggaggc ttggtccagc ctgggggggc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

<210> 247

<211> 90

<212> DNA

<213> Homo sapiens

<400> 247

gaggtgcagc tgggtggagtc tgggggaggc ttggtccagc ctgggggggc cctgagactc 60
tcctgtgcag cctctggatt caccgtcagt 90

<210> 248

<211> 90

<212> DNA

<213> Homo sapiens

<400> 248

gaggtgcagc tgggtggagtc tgggggaggc ttggtccagc ctggagggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

<210> 249

<211> 90

<212> DNA

<213> Homo sapiens

<400> 249

gaggtgcagc tgggtggagtc tgggggaggc ttggtccagc ctgggggggc cctgaaactc 60
tcctgtgcag cctctgggtt caccttcagt 90

<210> 250

<211> 90

<212> DNA

<213> Homo sapiens

<400> 250

gaggtgcagc tgggtggagtc cgggggaggc ttagttcagc ctgggggggc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt 90

<210> 251

<211> 90

<212> DNA

<213> Homo sapiens

<400> 251

gaggtgcagc tgggtggagtc tcggggagtc ttggtacagc ctgggggggc cctgagactc 60
tcctgtgcag cctctggatt caccgtcagt 90

56

<210> 252
<211> 90
<212> DNA
<213> Homo sapiens

<400> 252
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggggac cctgtccctc 60
acctgcgctg tctctggtgg ctccatcagc 90

<210> 253
<211> 90
<212> DNA
<213> Homo sapiens

<400> 253
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcgctg tctctggtta ctccatcagc 90

<210> 254
<211> 90
<212> DNA
<213> Homo sapiens

<400> 254
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcacagac cctgtccctc 60
acctgcactg tctctggtgg ctccatcagc 90

<210> 255
<211> 90
<212> DNA
<213> Homo sapiens

<400> 255
caggtgcagc tgcaggagtc cggctcagga ctggtgaagc cttcacagac cctgtccctc 60
acctgcgctg tctctggtgg ctccatcagc 90

<210> 256
<211> 90
<212> DNA
<213> Homo sapiens

<400> 256
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcacagac cctgtccctc 60
acctgcactg tctctggtgg ctccatcagc 90

<210> 257
<211> 90
<212> DNA
<213> Homo sapiens

<400> 257
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcacagac cctgtccctc 60
acctgcactg tctctggtgg ctccatcagc 90

<210> 258
<211> 90
<212> DNA
<213> Homo sapiens

<400> 258
caggtgcagc tacagcagtg gggcgcagga ctgttgaagc cttcggagac cctgtccctc 60
acctgcgctg tctatggtgg gtccttcagt 90

<210> 259
<211> 90
<212> DNA
<213> Homo sapiens

<400> 259
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctggtgg ctccatcagc 90

<210> 260
<211> 90
<212> DNA
<213> Homo sapiens

<400> 260
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctggtgg ctccatcagc 90

<210> 261
<211> 90
<212> DNA
<213> Homo sapiens

<400> 261
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctggtgg ctccgtcagc 90

<210> 262
<211> 90
<212> DNA
<213> Homo sapiens

<400> 262
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcgctg tctctggtta ctccatcagc 90

<210> 263
<211> 90
<212> DNA
<213> Homo sapiens

58

<400> 263

gaggtgcagc tgggtgcagtc tggagcagag gtgaaaaagc ccggggagtc tctgaagatc 60
tcctgtaagg gttctggata cagctttacc 90

<210> 264

<211> 90

<212> DNA

<213> Homo sapiens

<400> 264

gaagtgcagc tgggtgcagtc tggagcagag gtgaaaaagc ccggggagtc tctgaggatc 60
tcctgtaagg gttctggata cagctttacc 90

<210> 265

<211> 90

<212> DNA

<213> Homo sapiens

<400> 265

caggtacagc tgcagcagtc aggtccagga ctggtgaagc cctcgcagac cctctcactc 60
acctgtgcca tctccggga cagtgtctc 90

<210> 266

<211> 90

<212> DNA

<213> Homo sapiens

<400> 266

caggtgcagc tgggtgcaatc tgggtctgag ttgaagaagc ctggggcctc agtgaagggt 60
tcctgcaagg cttctggata caccttcact 90

<210> 267

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 267

ccgtgtatta ctgtgcgaga ga 22

<210> 268

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

59

<400> 268
ctgtgtatta ctgtgcgaga ga 22

<210> 269
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 269
ccgtgtatta ctgtgcgaga gg 22

<210> 270
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 270
ccgtatatta ctgtgcgaaa ga 22

<210> 271
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 271
ctgtgtatta ctgtgcgaaa ga 22

<210> 272
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 272
ctgtgtatta ctgtgcgaga ca 22

<210> 273
<211> 22

60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 273

ccatgtatta ctgtgcgaga ca

22

<210> 274

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 274

ccatgtatta ctgtgcgaga aa

22

<210> 275

<211> 69

<212> DNA

<213> Homo sapiens

<400> 275

gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

<210> 276

<211> 69

<212> DNA

<213> Homo sapiens

<400> 276

gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

<210> 277

<211> 69

<212> DNA

<213> Homo sapiens

<400> 277

gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

<210> 278

<211> 69

<212> DNA

<213> Homo sapiens

<400> 278
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

<210> 279
<211> 69
<212> DNA
<213> Homo sapiens

<400> 279
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

<210> 280
<211> 69
<212> DNA
<213> Homo sapiens

<400> 280
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

<210> 281
<211> 69
<212> DNA
<213> Homo sapiens

<400> 281
aacatccaga tgacccagtc tccatctgcc atgtctgcat ctgtaggaga cagagtcacc 60
atcacttgt 69

<210> 282
<211> 69
<212> DNA
<213> Homo sapiens

<400> 282
gacatccaga tgacccagtc tccatcctca ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgt 69

<210> 283
<211> 69
<212> DNA
<213> Homo sapiens

<400> 283
gacatccaga tgacccagtc tccatcctca ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgt 69

<210> 284
<211> 69

62

<212> DNA

<213> Homo sapiens

<400> 284

gccatccagt tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

<210> 285

<211> 69

<212> DNA

<213> Homo sapiens

<400> 285

gccatccagt tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

<210> 286

<211> 69

<212> DNA

<213> Homo sapiens

<400> 286

gacatccaga tgaccagtc tccatcttcc gtgtctgcat ctgtaggaga cagagtcacc 60
atcacttgt 69

<210> 287

<211> 69

<212> DNA

<213> Homo sapiens

<400> 287

gacatccaga tgaccagtc tccatcttct gtgtctgcat ctgtaggaga cagagtcacc 60
atcacttgt 69

<210> 288

<211> 69

<212> DNA

<213> Homo sapiens

<400> 288

gacatccagt tgaccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

<210> 289

<211> 69

<212> DNA

<213> Homo sapiens

<400> 289

gccatccgga tgaccagtc tccattctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

63

<210> 290
<211> 69
<212> DNA
<213> Homo sapiens

<400> 290
gccatccgga tgaccagtc tccatcctca ttctctgcat ctacaggaga cagagtcacc 60
atcacttgt 69

<210> 291
<211> 69
<212> DNA
<213> Homo sapiens

<400> 291
gtcatctgga tgaccagtc tccatcctta ctctctgcat ctacaggaga cagagtcacc 60
atcagttgt 69

<210> 292
<211> 69
<212> DNA
<213> Homo sapiens

<400> 292
gccatccaga tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

<210> 293
<211> 69
<212> DNA
<213> Homo sapiens

<400> 293
gacatccaga tgaccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgc 69

<210> 294
<211> 69
<212> DNA
<213> Homo sapiens

<400> 294
gatattgtga tgaccagac tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgc 69

<210> 295
<211> 69
<212> DNA
<213> Homo sapiens

<400> 295
gatattgtga tgaccagac tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgc 69

<210> 296
<211> 69
<212> DNA
<213> Homo sapiens

<400> 296
gatgttgtga tgactcagtc tccactctcc ctgcccgta cccttgga gccggcctcc 60
atctcctgc 69

<210> 297
<211> 69
<212> DNA
<213> Homo sapiens

<400> 297
gatgttgtga tgactcagtc tccactctcc ctgcccgta cccttgga gccggcctcc 60
atctcctgc 69

<210> 298
<211> 69
<212> DNA
<213> Homo sapiens

<400> 298
gatattgtga tgaccagac tccactctct ctgtccgta cccttgga gccggcctcc 60
atctcctgc 69

<210> 299
<211> 69
<212> DNA
<213> Homo sapiens

<400> 299
gatattgtga tgaccagac tccactctct ctgtccgta cccttgga gccggcctcc 60
atctcctgc 69

<210> 300
<211> 69
<212> DNA
<213> Homo sapiens

<400> 300
gatattgtga tgactcagtc tccactctcc ctgcccgta cccttgga gccggcctcc 60
atctcctgc 69

<210> 301
<211> 69
<212> DNA
<213> Homo sapiens

65

<400> 301
gatattgtga tgactcagtc tccactctcc ctgcccgta cccctggaga gccggcctcc 60
atctcctgc 69

<210> 302
<211> 69
<212> DNA
<213> Homo sapiens

<400> 302
gatattgtga tgacccagac tccactctcc tcacctgtca cccttggaca gccggcctcc 60
atctcctgc 69

<210> 303
<211> 69
<212> DNA
<213> Homo sapiens

<400> 303
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgc 69

<210> 304
<211> 69
<212> DNA
<213> Homo sapiens

<400> 304
gaaattgtgt tgacgcagtc tccagccacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgc 69

<210> 305
<211> 69
<212> DNA
<213> Homo sapiens

<400> 305
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgc 69

<210> 306
<211> 69
<212> DNA
<213> Homo sapiens

<400> 306
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgc 69

<210> 307
<211> 69

<212> DNA
<213> Homo sapiens

<400> 307
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgc 69

<210> 308
<211> 69
<212> DNA
<213> Homo sapiens

<400> 308
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgc 69

<210> 309
<211> 69
<212> DNA
<213> Homo sapiens

<400> 309
gaaattgtaa tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgc 69

<210> 310
<211> 69
<212> DNA
<213> Homo sapiens

<400> 310
gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctggggga gagggccacc 60
atcaactgc 69

<210> 311
<211> 69
<212> DNA
<213> Homo sapiens

<400> 311
gaaacgacac tcacgcagtc tccagcattc atgtcagcga ctccaggaga caaagtcaac 60
atctcctgc 69

<210> 312
<211> 69
<212> DNA
<213> Homo sapiens

<400> 312
gaaattgtgc tgactcagtc tccagacttt cagtctgtga ctccaaagga gaaagtcacc 60
atcacctgc 69

67

<210> 313
<211> 69
<212> DNA
<213> Homo sapiens

<400> 313
gaaattgtgc tgactcagtc tccagacttt cagtctgtga ctccaaagga gaaagtcacc 60
atcacctgc 69

<210> 314
<211> 69
<212> DNA
<213> Homo sapiens

<400> 314
gatgttgtga tgacacagtc tccagctttc ctctctgtga ctccaggga gaaagtcacc 60
atcacctgc 69

<210> 315
<211> 66
<212> DNA
<213> Homo sapiens

<400> 315
cagtctgtgc tgactcagcc accctcgggtg tctgaagccc ccaggcagag ggtcaccatc 60
tcctgt 66

<210> 316
<211> 66
<212> DNA
<213> Homo sapiens

<400> 316
cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc 60
tcctgc 66

<210> 317
<211> 66
<212> DNA
<213> Homo sapiens

<400> 317
cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag ggtcaccatc 60
tcttgc 66

<210> 318
<211> 66
<212> DNA
<213> Homo sapiens

<400> 318
cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag ggtcaccatc 60
tcttgc 66

<210> 319
<211> 66
<212> DNA
<213> Homo sapiens

<400> 319
cagtctgtgt tgacgcagcc gccctcagtg tctgcccgc caggacagaa ggtcaccatc 60
tcctgc 66

<210> 320
<211> 66
<212> DNA
<213> Homo sapiens

<400> 320
cagtctgccc tgactcagcc tccctccgtg tccgggtctc ctggacagtc agtcaccatc 60
tcctgc 66

<210> 321
<211> 66
<212> DNA
<213> Homo sapiens

<400> 321
cagtctgccc tgactcagcc tcgctcagtg tccgggtctc ctggacagtc agtcaccatc 60
tcctgc 66

<210> 322
<211> 66
<212> DNA
<213> Homo sapiens

<400> 322
cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc 60
tcctgc 66

<210> 323
<211> 66
<212> DNA
<213> Homo sapiens

<400> 323
cagtctgccc tgactcagcc tccctccgtg tccgggtctc ctggacagtc agtcaccatc 60
tcctgc 66

<210> 324
<211> 66
<212> DNA
<213> Homo sapiens

<400> 324

69

cagtctgccc tgactcagcc tgacctcgtg tctgggtctc ctggacagtc gatcaccatc 60
tcctgc 66

<210> 325
<211> 66
<212> DNA
<213> Homo sapiens

<400> 325
tcctatgagc tgactcagcc accctcagtg tccgtgtccc caggacagac agccagcatc 60
acctgc 66

<210> 326
<211> 66
<212> DNA
<213> Homo sapiens

<400> 326
tcctatgagc tgactcagcc actctcagtg tcagtggccc tgggacagac ggccaggatt 60
acctgt 66

<210> 327
<211> 66
<212> DNA
<213> Homo sapiens

<400> 327
tcctatgagc tgacacagcc accctcgggtg tcagtgtccc caggacaaac ggccaggatc 60
acctgc 66

<210> 328
<211> 66
<212> DNA
<213> Homo sapiens

<400> 328
tcctatgagc tgacacagcc accctcgggtg tcagtgtccc taggacagat ggccaggatc 60
acctgc 66

<210> 329
<211> 66
<212> DNA
<213> Homo sapiens

<400> 329
tcttctgagc tgactcagga cctctgctgtg tctgtggcct tgggacagac agtcaggatc 60
acatgc 66

<210> 330
<211> 66
<212> DNA
<213> Homo sapiens

<400> 330
tcctatgtgc tgactcagcc accctcagtg tcagtggccc caggaaagac ggccaggatt 60
acctgt 66

<210> 331
<211> 66
<212> DNA
<213> Homo sapiens

<400> 331
tcctatgagc tgacacagct accctcgggtg tcagtgtccc caggacagac agccaggatc 60
acctgc 66

<210> 332
<211> 66
<212> DNA
<213> Homo sapiens

<400> 332
tcctatgagc tgatgcagcc accctcgggtg tcagtgtccc caggacagac ggccaggatc 60
acctgc 66

<210> 333
<211> 66
<212> DNA
<213> Homo sapiens

<400> 333
tcctatgagc tgacacagcc atcctcagtg tcagtgtctc cgggacagac agccaggatc 60
acctgc 66

<210> 334
<211> 66
<212> DNA
<213> Homo sapiens

<400> 334
ctgcctgtgc tgactcagcc cccgtctgca tctgccttgc tgggagcctc gatcaagctc 60
acctgc 66

<210> 335
<211> 66
<212> DNA
<213> Homo sapiens

<400> 335
cagcctgtgc tgactcaatc atcctctgcc tctgcttccc tgggatactc ggtcaagctc 60
acctgc 66

<210> 336
<211> 66

71

<212> DNA

<213> Homo sapiens

<400> 336

cagcttgtgc tgactcaatc gccctctgcc tctgcctccc tgggagcctc ggtaagctc 60
acctgc 66

<210> 337

<211> 66

<212> DNA

<213> Homo sapiens

<400> 337

cagcctgtgc tgactcagcc accttctccc tccgcatctc ctggagaatc cgccagactc 60
acctgc 66

<210> 338

<211> 66

<212> DNA

<213> Homo sapiens

<400> 338

caggctgtgc tgactcagcc ggcttccctc tctgcatctc ctggagcatc agccagtctc 60
acctgc 66

<210> 339

<211> 66

<212> DNA

<213> Homo sapiens

<400> 339

cagcctgtgc tgactcagcc atcttcccat tctgcatctt ctggagcatc agtcagactc 60
acctgc 66

<210> 340

<211> 66

<212> DNA

<213> Homo sapiens

<400> 340

aattttatgc tgactcagcc ccactctgtg tcggagtctc cggggaagac ggtaaccatc 60
tcctgc 66

<210> 341

<211> 66

<212> DNA

<213> Homo sapiens

<400> 341

cagactgtgg tgactcagga gccctcactg actgtgtccc caggagggac agtcactctc 60
acctgt 66

72

<210> 342
<211> 66
<212> DNA
<213> Homo sapiens

<400> 342
caggctgtgg tgactcagga gccctcactg actgtgtccc caggaggac agtcactctc 60
acctgt 66

<210> 343
<211> 66
<212> DNA
<213> Homo sapiens

<400> 343
cagactgtgg tgaccagga gccatcggtc tcagtgtccc ctggaggac agtcacactc 60
acttgt 66

<210> 344
<211> 66
<212> DNA
<213> Homo sapiens

<400> 344
cagcctgtgc tgactcagcc accttctgca tcagcctccc tgggagcctc ggtcacactc 60
acctgc 66

<210> 345
<211> 66
<212> DNA
<213> Homo sapiens

<400> 345
caggcagggc tgactcagcc accctcggtg tccaagggct tgagacagac cgccacactc 60
acctgc 66

<210> 346
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (1)..(6)
<223> A, T, C, G, other or unknown

<400> 346
nnnnnngact c

11

73

<210> 347
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (6)..(11)
<223> A, T, C, G, other or unknown

<400> 347
gagtcnnnnn n

11

<210> 348
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (3)..(9)
<223> A, T, C, G, other or unknown

<400> 348
gcnnnnnnng c

11

<210> 349
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(11)
<223> A, T, C, G, other or unknown

<400> 349
acctgcnnnn n

11

<210> 350
<211> 25
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 350

cacatccgtg ttgttcacgg atgtg

25

<210> 351

<211> 88

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 351

aatagtagac tgcagtgtcc tcagccctta agctgttcat ctgcaagtag agagtattct 60
tagagttgtc tctagactta gtgaagcg 88

<210> 352

<211> 88

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 352

cgcttcacta agtctagaga caactctaag aatactctct acttgcagat gaacagctta 60
agggctgagg aactgcagt ctactatt 88

<210> 353

<211> 95

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 353

cgcttcacta agtctagaga caactctaag aatactctct acttgcagat gaacagctta 60
agggctgagg aactgcagt ctactattgt gcgag 95

<210> 354

<211> 95

<212> DNA

<213> Artificial Sequence

75

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 354

cgcttcacta agtctagaga caactctaag aatactctct acttgagat gaacagctta 60
agggctgagg acactgcagt ctactattgt acgag 95

<210> 355

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 355

cgcttcacta agtctagaga caac 24

<210> 356

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (8)..(15)

<223> A, T, C, G, other or unknown

<400> 356

cacctgcnnn nnnnn 15

<210> 357

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (7)..(17)

<223> A, T, C, G, other or unknown

<400> 357

cagctcnnnn nnnnnnn 17

76

<210> 358
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(17)
<223> A, T, C, G, other or unknown

<400> 358
gaagacnnnn nnnnnnn

17

<210> 359
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (6)..(17)
<223> A, T, C, G, other or unknown

<400> 359
gcagcnnnnn nnnnnnn

17

<210> 360
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(12)
<223> A, T, C, G, other or unknown

<400> 360
gaagacnnnn nn

12

<210> 361
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(22)
<223> A, T, C, G, other or unknown

<400> 361
cttgagnnnn nnnnnnnnnn nn

22

<210> 362
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (6)..(19)
<223> A, T, C, G, other or unknown

<400> 362
acggcnnnnn nnnnnnnnn

19

<210> 363
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (6)..(18)
<223> A, T, C, G, other or unknown

<400> 363
acggcnnnnn nnnnnnnnn

18

<210> 364
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(12)
<223> A, T, C, G, other or unknown

<400> 364
gtatccnnnn nn

12

<210> 365
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(11)
<223> A, T, C, G, other or unknown

<400> 365
actgggnnnn n

11

<210> 366
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (6)..(10)
<223> A, T, C, G, other or unknown

<400> 366
ggatcnnnnn

10

<210> 367
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (6)..(11)

79

<223> A, T, C, G, other or unknown

<400> 367

gcacncccc n

11

<210> 368

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (7)..(16)

<223> A, T, C, G, other or unknown

<400> 368

gaggagcccc ccccc

16

<210> 369

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (6)..(19)

<223> A, T, C, G, other or unknown

<400> 369

gggaccccc ccccccccc

19

<210> 370

<211> 14

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (7)..(14)

<223> A, T, C, G, other or unknown

<400> 370

acctgcccc cccc

14

80

<210> 371
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(17)
<223> A, T, C, G, other or unknown

<400> 371
ggcggannnn nnnnnnn

17

<210> 372
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(22)
<223> A, T, C, G, other or unknown

<400> 372
ctgaagnnnn nnnnnnnnnn nn

22

<210> 373
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified base
<222> (6)..(11)
<223> A, T, C, G, other or unknown

<400> 373
cccgcnnnnn n

11

<210> 374
<211> 18

81

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (6)..(18)
<223> A, T, C, G, other or unknown

<400> 374
ggatgnnnnn nnnnnnnn

18

<210> 375
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(22)
<223> A, T, C, G, other or unknown

<400> 375
ctggagnnnn nnnnnnnnnn nn

22

<210> 376
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (6)..(15)
<223> A, T, C, G, other or unknown

<400> 376
gacgcnnnnn nnnnn

15

<210> 377
<211> 13
<212> DNA
<213> Artificial Sequence

<220>

82

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (6)..(13)

<223> A, T, C, G, other or unknown

<400> 377

ggtgannnnn nnn

13

<210> 378

<211> 13

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (6)..(13)

<223> A, T, C, G, other or unknown

<400> 378

gaagannnnn nnn

13

<210> 379

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (6)..(10)

<223> A, T, C, G, other or unknown

<400> 379

gagtcnnnnn

10

<210> 380

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

83

<220>
<221> modified_base
<222> (7)..(26)
<223> A, T, C, G, other or unknown

<400> 380
tccracnnnn nnnnnnnnnn nnnnnn

26

<210> 381
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (5)..(11)
<223> A, T, C, G, other or unknown

<400> 381
cctcnnnnnn n

11

<210> 382
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (6)..(10)
<223> A, T, C, G, other or unknown

<400> 382
gagtcnnnnn

10

<210> 383
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(18)
<223> A, T, C, G, other or unknown

<400> 383
cccacannnn nnnnnnnn 18

<210> 384
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (6)..(14)
<223> A, T, C, G, other or unknown

<400> 384
gcatacnnnnn nnnn 14

<210> 385
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (6)..(13)
<223> A, T, C, G, other or unknown

<400> 385
ggtgannnnn nnn 13

<210> 386
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (5)..(12)
<223> A, T, C, G, other or unknown

<400> 386
cccgnnnnnn nn 12

85

<210> 387
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (6)..(19)
<223> A, T, C, G, other or unknown

<400> 387
ggatgnnnnn nnnnnnnnn

19

<210> 388
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(17)
<223> A, T, C, G, other or unknown

<400> 388
gaccgannnn nnnnnnn

17

<210> 389
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(17)
<223> A, T, C, G, other or unknown

<400> 389
cacccannnn nnnnnnn

17

<210> 390
<211> 17
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>

<221> modified_base

<222> (7)..(17)

<223> A, T, C, G, other or unknown

<400> 390

caarcannnn nnnnnnn

17

<210> 391

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 391

gctgtgtatt actgtgcgag

20

<210> 392

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 392

gccgtgtatt actgtgcgag

20

<210> 393

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 393

gccgtatatt actgtgcgag

20

<210> 394

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 394

gccgtgtatt actgtacgag

20

<210> 395

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 395

gccatgtatt actgtgcgag

20

<210> 396

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 396

cacatccgtg ttgttcacgg atgtg

25

<210> 397

<211> 88

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 397

aatagtagac tgcagtgtcc tcagccctta agctgttcat ctgcaagtag agagtattct 60
tagagttgtc tctagactta gtgaagcg 88

<210> 398

<211> 95

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

88

<400> 398
cgcttcacta agtctagaga caactctaag aatactctct acttgcagat gaacagctta 60
agggtgagg acactgcagt ctactattgt gcgag 95

<210> 399
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 399
cgcttcacta agtctagaga caac 24

<210> 400
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 400
cacatccgtg ttgttcacgg atgtgggagg atggagactg ggtc 44

<210> 401
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 401
cacatccgtg ttgttcacgg atgtgggaga gtggagactg agtc 44

<210> 402
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 402
cacatccgtg ttgttcacgg atgtgggtgc ctggagactg cgtc 44

<210> 403

89

<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 403
cacatccgtg ttgttcacgg atgtgggtgg ctggagactg cgtc 44

<210> 404
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 404
cctctactct tgtcacagtg cacaagacat ccag 34

<210> 405
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 405
cctctactct tgtcacagtg 20

<210> 406
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 406
ggaggatgga ctggatgtct tgtgcactgt gacaagagta gagg 44

<210> 407
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 407
ggagagtgga ctggatgtct tgtgcactgt gacaagagta gagg 44

<210> 408
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 408
ggtgcctgga ctggatgtct tgtgcactgt gacaagagta gagg 44

<210> 409
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 409
ggtggctgga ctggatgtct tgtgcactgt gacaagagta gagg 44

<210> 410
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 410
cacatccgtg ttgttcacgg atgtggatcg actgtccagg agac 44

<210> 411
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 411
cacatccgtg ttgttcacgg atgtggactg tctgtcccaa ggcc 44

91

<210> 412
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 412
cacatccgtg ttgttcacgg atgtggactg actgtccagg agac 44

<210> 413
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 413
cacatccgtg ttgttcacgg atgtggaccc tctgccctgg ggcc 44

<210> 414
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 414
cctctgactg agtgcacaga gtgctttaac ccaaccggct agtgtagcg gttccccgg 59

<210> 415
<211> 69
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 415
cctctgactg agtgcacaga gtgctttaac ccaaccggct agtgtagcg gttccccggg 60
acagtcgat 69

<210> 416
<211> 69
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 416

cctctgactg agtgcacaga gtgctttaac ccaaccggct agtgtagcg gttccccggg 60
acagacagt 69

<210> 417

<211> 69

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 417

cctctgactg agtgcacaga gtgctttaac ccaaccggct agtgtagcg gttccccggg 60
acagtcagt 69

<210> 418

<211> 70

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 418

cctctgactg agtgcacaga gtgctttaac ccaaccggct agtgtagcg gtstccccgg 60
ggcagagggt 70

<210> 419

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 419

cctctgactg agtgcacaga gtgc 24

<210> 420

<211> 13

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (5)..(9)
<223> A, T, C, G, other or unknown

<400> 420
ggcnnnnng gcc

13

<210> 421
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(12)
<223> A, T, C, G, other or unknown

<400> 421
ccannnnnnn nntgg

15

<210> 422
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(9)
<223> A, T, C, G, other or unknown

<400> 422
cgannnnnt gc

12

<210> 423
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(8)

94

<223> A, T, C, G, other or unknown

<400> 423

gccnnnnngg c

11

<210> 424

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (4)..(7)

<223> A, T, C, G, other or unknown

<400> 424

gatnnnnatc

10

<210> 425

<211> 11

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (4)..(8)

<223> A, T, C, G, other or unknown

<400> 425

gacnnnnngt c

11

<210> 426

<211> 11

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (4)..(8)

<223> A, T, C, G, other or unknown

<400> 426

gcannnnntg c

11

<210> 427
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(12)
<223> A, T, C, G, other or unknown

<400> 427
gtatccnnnn nn

12

<210> 428
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(9)
<223> A, T, C, G, other or unknown

<400> 428
gacnnnnnnng tc

12

<210> 429
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(8)
<223> A, T, C, G, other or unknown

<400> 429
ccannnnntg g

11

<210> 430
<211> 12

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (1)..(6)
<223> A, T, C, G, other or unknown

<400> 430
nnnnnngaga cg

12

<210> 431
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(9)
<223> A, T, C, G, other or unknown

<400> 431
ccannnnntt gg

12

<210> 432
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(7)
<223> A, T, C, G, other or unknown

<400> 432
gaannnttc

10

<210> 433
<211> 11
<212> DNA
<213> Artificial Sequence

<220>

97

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (7)..(11)

<223> A, T, C, G, other or unknown

<400> 433

ggtctcnnnn n

11

<210> 434

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (1)..(10)

<223> A, T, C, G, other or unknown

<400> 434

nnnnnnnnnn ctcctc

16

<210> 435

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (1)..(9)

<223> A, T, C, G, other or unknown

<400> 435

nnnnnnnnnt ccgcc

15

<210> 436

<211> 13

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

98

<221> modified_base
<222> (5)..(9)
<223> A, T, C, G, other or unknown

<400> 436
ggccnnnnng gcc

13

<210> 437
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(9)
<223> A, T, C, G, other or unknown

<400> 437
ccannnnnnt gg

12

<210> 438
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(9)
<223> A, T, C, G, other or unknown

<400> 438
gacnnnnnng tc

12

<210> 439
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(9)
<223> A, T, C, G, other or unknown

99

<400> 439
cgannnnnt gc

12

<210> 440
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(8)
<223> A, T, C, G, other or unknown

<400> 440
gcannnnntg c

11

<210> 441
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(8)
<223> A, T, C, G, other or unknown

<400> 441
ccannnnntg g

11

<210> 442
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(7)
<223> A, T, C, G, other or unknown

<400> 442
gaannnttc

10

100

<210> 443
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (1)..(6)
<223> A, T, C, G, other or unknown

<400> 443
nnnnnngaga cg

12

<210> 444
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(12)
<223> A, T, C, G, other or unknown

<400> 444
gtatccnnnn nn

12

<210> 445
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(8)
<223> A, T, C, G, other or unknown

<400> 445
gacnnnnngt c

11

<210> 446
<211> 11
<212> DNA
<213> Artificial Sequence

101

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(11)
<223> A, T, C, G, other or unknown

<400> 446
ggtctcnnnn n 11

<210> 447
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(8)
<223> A, T, C, G, other or unknown

<400> 447
gccnnnnngg c 11

<210> 448
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(12)
<223> A, T, C, G, other or unknown

<400> 448
ccannnnnnn nntgg 15

<210> 449
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

102

<220>
<221> modified_base
<222> (1)..(10)
<223> A, T, C, G, other or unknown

<400> 449
nnnnnnnnnn ctcctc

16

<210> 450
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (1)..(9)
<223> A, T, C, G, other or unknown

<400> 450
nnnnnnnnnt ccgcc

15

<210> 451
<211> 9532
<212> DNA
<213> Unknown Organism

<220>
<223> Description of Unknown Organism: MALIA3 nucleotide
sequence

<220>
<221> CDS
<222> (1579)..(1638)

<220>
<221> CDS
<222> (2343)..(3443)

<220>
<221> CDS
<222> (3945)..(4400)

<220>
<221> CDS
<222> (4406)..(4450)

<220>
<221> CDS
<222> (4746)..(5789)

<400> 451

103

```

aatgctacta ctattagtag aattgatgcc accttttcag ctcgcgcccc aaatgaaaat 60
atagctaaac aggttattga ccatttgcca aatgtatcta atgggtcaaac taaatctact 120
cgttcgcaga attgggaatc aactgttaca tggaatgaaa cttccagaca ccgtacttta 180
gttgcatatt taaaacatgt tgagctacag caccagattc agcaattaag ctctaagcca 240
tccgcaaaaa tgacctctta tcaaaaggag caattaaagg tactctctaa tcttgacctg 300
ttggagtttg cttccggtct ggttcgcttt gaagctcgaa ttaaaacgcg atatttgaag 360
tctttcgggc ttctctctaa tctttttgat gcaatccgct ttgcttctga ctataatagt 420
cagggttaaag acctgatttt tgatttatgg tcattctcgt tttctgaact gtttaaagca 480
tttgaggggg attcaatgaa tatttatgac gattccgcag tattggacgc tatccagtct 540
aaacatttta ctattacccc ctctggcaaa acttcttttg caaaagcctc tcgctatttt 600
ggtttttata gtcgtctggt aaacgagggt tatgatagtg ttgctcttac tatgcctcgt 660
aattcctttt ggcgttatgt atctgcatta gttgaatgtg gtattcctaa atctcaactg 720
atgaatcttt ctacctgtaa taatgttggt ccggttagtc gttttattaa cgtagatttt 780
tcttccaac gtctgactg gtataatgag ccagttctta aaatcgata aggtaattca 840
caatgattaa agttgaaatt aaaccatctc aagcccaatt tactactcgt tctggtgttt 900
ctcgtcaggg caagccttat tcaactgaatg agcagctttg ttacgttgat ttgggtaatg 960
aatatccggt tcttgtcaag attactcttg atgaaggta gccagcctat gcgcctggtc 1020
tgtacaccgt tcactgtgcc tctttcaaag ttggtcagtt cggttcctt atgattgacc 1080
gtctgcgcct cgttccggct aagtaacatg gagcaggtcg cggatttcga cacaatttat 1140
caggcgatga taaaaatctc cggtgtactt tgtttcgcg cttgtataat cgctgggggt 1200
caaagatgag tgttttagtg tattctttcg cctctttcgt tttaggttg tgccttcgta 1260
gtggcattac gtattttacc cgtttaatgg aaacttcctc atgaaaaagt ctttagtcct 1320
caaagcctct gtagccgttg ctaccctcgt tccgatgctg tctttcgctg ctgaggggtga 1380
cgatcccga aaagcggcct ttaactccct gcaagcctca gcgaccgaat atatcggtta 1440
tgcgtagggc atggttggtg tcattgtcgg cgcaactatc ggtatcaagc tgtttaagaa 1500
attcacctcg aaagcaagct gataaaccga tacaattaaa ggctcctttt ggagcctttt 1560

tttttggaga ttttcaac gtg aaa aaa tta tta ttc gca att cct tta gtt 1611
Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val
1 5 10

gtt cct ttc tat tct cac agt gca cag tctgtcgtga cgcagccgcc 1658
Val Pro Phe Tyr Ser His Ser Ala Gln

```

20

25

49

60

75

90

105

12.

140

Me

															105			
					145						150						155	
gtc	acc	gtc	tct	agt	gcc	tcc	acc	aag	ggc	cca	tcg	gtc	ttc	ccc	ctg	2801		
Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu			
					160						165						170	
gca	ccc	tcc	tcc	aag	agc	acc	tct	ggg	ggc	aca	gcg	gcc	ctg	ggc	tgc	2849		
Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys			
					175						180						185	
ctg	gtc	aag	gac	tac	ttc	ccc	gaa	ccg	gtg	acg	gtg	tcg	tgg	aac	tca	2897		
Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser			
					190						195						200	205
ggc	gcc	ctg	acc	agc	ggc	gtc	cac	acc	ttc	ccg	gct	gtc	cta	cag	tct	2945		
Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser			
					210						215						220	
agc	gga	ctc	tac	tcc	ctc	agc	agc	gta	gtg	acc	gtg	ccc	tct	tct	agc	2993		
Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser			
					225						230						235	
ttg	ggc	acc	cag	acc	tac	atc	tgc	aac	gtg	aat	cac	aag	ccc	agc	aac	3041		
Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn			
					240						245						250	
acc	aag	gtg	gac	aag	aaa	gtt	gag	ccc	aaa	tct	tgt	gcg	gcc	gct	cat	3089		
Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Ala	Ala	Ala	His			
					255						260						265	
cac	cac	cat	cat	cac	tct	gct	gaa	caa	aaa	ctc	atc	tca	gaa	gag	gat	3137		
His	His	His	His	His	Ser	Ala	Glu	Gln	Lys	Leu	Ile	Ser	Glu	Glu	Asp			
					270						275						280	285
ctg	aat	ggt	gcc	gca	gat	atc	aac	gat	gat	cgt	atg	gct	ggc	gcc	gct	3185		
Leu	Asn	Gly	Ala	Ala	Asp	Ile	Asn	Asp	Asp	Arg	Met	Ala	Gly	Ala	Ala			
					290						295						300	
gaa	act	gtt	gaa	agt	tgt	tta	gca	aaa	ccc	cat	aca	gaa	aat	tca	ttt	3233		
Glu	Thr	Val	Glu	Ser	Cys	Leu	Ala	Lys	Pro	His	Thr	Glu	Asn	Ser	Phe			
					305						310						315	
act	aac	gtc	tgg	aaa	gac	gac	aaa	act	tta	gat	cgt	tac	gct	aac	tat	3281		
Thr	Asn	Val	Trp	Lys	Asp	Asp	Lys	Thr	Leu	Asp	Arg	Tyr	Ala	Asn	Tyr			
					320						325						330	
gag	ggt	tgt	ctg	tgg	aat	gct	aca	ggc	gtt	gta	gtt	tgt	act	ggt	gac	3329		
Glu	Gly	Cys	Leu	Trp	Asn	Ala	Thr	Gly	Val	Val	Val	Cys	Thr	Gly	Asp			
					335						340						345	
gaa	act	cag	tgt	tac	ggt	aca	tgg	gtt	cct	att	ggg	ctt	gct	atc	cct	3377		
Glu	Thr	Gln	Cys	Tyr	Gly	Thr	Trp	Val	Pro	Ile	Gly	Leu	Ala	Ile	Pro			
					350						355						360	365
gaa	aat	gag	ggt	ggt	ggc	tct	gag	ggt	ggc	ggt	tct	gag	ggt	ggc	ggt	3425		
Glu	Asn	Glu	Gly	Gly	Gly	Ser	Glu	Gly	Gly	Gly	Ser	Glu	Gly	Gly	Gly			
					370						375						380	

106

tct gag ggt ggc ggt act aaacctctg agtacggtga tacacctatt 3473
 Ser Glu Gly Gly Gly Thr
 385

ccgggctata cttatatcaa ccctctcgac ggcacttata cgcttggtag tgagcaaaac 3533
 cccgctaata ctaatccttc tcttgaggag tctcagcctc ttaatacttt catgtttcag 3593
 aataataggt tccgaaatag gcagggggca ttaactgttt atacgggcac tgttactcaa 3653
 ggcactgacc ccgttaaaac ttattaccag tacactcctg tatcatcaaa agccatgtat 3713
 gacgcttact ggaacggtaa attcagagac tgcgctttcc attctggctt taatgaagat 3773
 ccattcgttt gtgaatatca aggccaatcg tctgacctgc ctcaacctcc tgtcaatgct 3833
 ggcggcggct ctggtggtgg ttctggtggc ggctctgagg gtggtggctc tgagggtggc 3893
 ggttctgagg gtggcggctc tgagggaggc ggttccggtg gtggctctgg t tcc ggt 3950
 Ser Gly

gat ttt gat tat gaa aag atg gca aac gct aat aag ggg gct atg acc 3998
 Asp Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly Ala Met Thr
 390 395 400 405

gaa aat gcc gat gaa aac gcg cta cag tct gac gct aaa ggc aaa ctt 4046
 Glu Asn Ala Asp Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly Lys Leu
 410 415 420

gat tct gtc gct act gat tac ggt gct gct atc gat ggt ttc att ggt 4094
 Asp Ser Val Ala Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe Ile Gly
 425 430 435

gac gtt tcc ggc ctt gct aat ggt aat ggt gct act ggt gat ttt gct 4142
 Asp Val Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp Phe Ala
 440 445 450

ggc tct aat tcc caa atg gct caa gtc ggt gac ggt gat aat tca cct 4190
 Gly Ser Asn Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn Ser Pro
 455 460 465

tta atg aat aat ttc cgt caa tat tta cct tcc ctc cct caa tcg gtt 4238
 Leu Met Asn Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln Ser Val
 470 475 480 485

gaa tgt cgc cct ttt gtc ttt agc gct ggt aaa cca tat gaa ttt tct 4286
 Glu Cys Arg Pro Phe Val Phe Ser Ala Gly Lys Pro Tyr Glu Phe Ser
 490 495 500

att gat tgt gac aaa ata aac tta ttc cgt ggt gtc ttt gcg ttt ctt 4334
 Ile Asp Cys Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala Phe Leu
 505 510 515

tta tat gtt gcc acc ttt atg tat gta ttt tct acg ttt gct aac ata 4382
 Leu Tyr Val Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala Asn Ile
 520 525 530

ctg cgt aat aag gag tct taatc atg cca gtt ctt ttg ggt att ccg tta 4432

Leu	Arg	Asn	Lys	Glu	Ser	Met	Pro	Val	Leu	Leu	Gly	Ile	Pro	Leu	
535						540							545		
tta	ttg	cgt	ttc	ctc	ggt	ttccttctg	taactttgtt	cggctatctg							4480
Leu	Leu	Arg	Phe	Leu	Gly										
550															
cttacttttc	ttaaaaagg	g	cttcggtaag	atagctattg	ctatttcatt	gtttcttgct									4540
cttattattg	ggcttaactc	aattcttg	ggttatctct	ctgatattag	cgctcaatta										4600
ccctctgact	ttgttcagg	g	tggtcagtta	attctcccg	ctaagcgct	tcctgtttt									4660
tatgttattc	tctctgtaa	ggctgctatt	ttcattttt	acgttaaaca	aaaaatcg										4720
tcttatttgg	attgggataa	ataat	atg	gct	g	t	t	t	t	g	a	a	g	a	4772
			Met	Ala	Val	Tyr	Phe	Val	Thr	Gly	Lys				
			555												
tta	ggc	tct	gga	aag	acg	ctc	g	t	g	g	a	a	c	a	4820
Leu	Gly	Ser	Gly	Lys	Thr	Leu	Val	Ser	Val	Gly	Lys	Ile	Gln	Asp	Lys
565						570					575				
att	g	t	g	g	t	a	a	a	a	c	a	a	a	a	4868
Ile	Val	Ala	Gly	Cys	Lys	Ile	Ala	Thr	Asn	Leu	Asp	Leu	Arg	Leu	Gln
580					585					590					595
aac	ctc	ccg	caa	gtc	ggg	agg	ttc	gct	aaa	acg	cct	cgc	g	tt	aga
Asn	Leu	Pro	Gln	Val	Gly	Arg	Phe	Ala	Lys	Thr	Pro	Arg	Val	Leu	Arg
				600					605					610	
ata	ccg	gat	aag	cct	tct	ata	tct	gat	ttg	ctt	gct	att	ggg	cgc	ggt
Ile	Pro	Asp	Lys	Pro	Ser	Ile	Ser	Asp	Leu	Leu	Ala	Ile	Gly	Arg	Gly
			615					620					625		
aat	gat	tcc	tac	gat	gaa	aat	aaa	aac	ggc	ttg	ctt	g	ctc	gat	gag
Asn	Asp	Ser	Tyr	Asp	Glu	Asn	Lys	Asn	Gly	Leu	Leu	Val	Leu	Asp	Glu
			630				635						640		
tgc	ggt	act	tgg	ttt	aat	acc	cgt	tct	tgg	aat	gat	aag	gaa	aga	cag
Cys	Gly	Thr	Trp	Phe	Asn	Thr	Arg	Ser	Trp	Asn	Asp	Lys	Glu	Arg	Gln
645						650					655				
ccg	att	att	gat	tgg	ttt	cta	cat	gct	cgt	aaa	tta	gga	tgg	gat	att
Pro	Ile	Ile	Asp	Trp	Phe	Leu	His	Ala	Arg	Lys	Leu	Gly	Trp	Asp	Ile
660					665					670					675
att	ttt	ctt	gtt	cag	gac	tta	tct	att	gtt	gat	aaa	cag	g	cgt	tct
Ile	Phe	Leu	Val	Gln	Asp	Leu	Ser	Ile	Val	Asp	Lys	Gln	Ala	Arg	Ser
				680					685					690	
gca	tta	gct	gaa	cat	gtt	gtt	tat	tgt	cgt	cgt	ctg	gac	aga	att	act
Ala	Leu	Ala	Glu	His	Val	Val	Tyr	Cys	Arg	Arg	Leu	Asp	Arg	Ile	Thr
			695					700					705		
tta	cct	ttt	gtc	ggt	act	tta	tat	tct	ctt	att	act	ggc	tcg	aaa	atg
Leu	Pro	Phe	Val	Gly	Thr	Leu	Tyr	Ser	Leu	Ile	Thr	Gly	Ser	Lys	Met
			710				715								

108

cct ctg cct aaa tta cat gtt ggc gtt gtt aaa tat ggc gat tct caa 5300
 Pro Leu Pro Lys Leu His Val Gly Val Val Lys Tyr Gly Asp Ser Gln
 725 730 735

tta agc cct act gtt gag cgt tgg ctt tat act ggt aag aat ttg tat 5348
 Leu Ser Pro Thr Val Glu Arg Trp Leu Tyr Thr Gly Lys Asn Leu Tyr
 740 745 750 755

aac gca tat gat act aaa cag gct ttt tct agt aat tat gat tcc ggt 5396
 Asn Ala Tyr Asp Thr Lys Gln Ala Phe Ser Ser Asn Tyr Asp Ser Gly
 760 765 770

gtt tat tct tat tta acg cct tat tta tca cac ggt cgg tat ttc aaa 5444
 Val Tyr Ser Tyr Leu Thr Pro Tyr Leu Ser His Gly Arg Tyr Phe Lys
 775 780 785

cca tta aat tta ggt cag aag atg aaa tta act aaa ata tat ttg aaa 5492
 Pro Leu Asn Leu Gly Gln Lys Met Lys Leu Thr Lys Ile Tyr Leu Lys
 790 795 800

aag ttt tct cgc gtt ctt tgt ctt gcg att gga ttt gca tca gca ttt 5540
 Lys Phe Ser Arg Val Leu Cys Leu Ala Ile Gly Phe Ala Ser Ala Phe
 805 810 815

aca tat agt tat ata acc caa cct aag ccg gag gtt aaa aag gta gtc 5588
 Thr Tyr Ser Tyr Ile Thr Gln Pro Lys Pro Glu Val Lys Lys Val Val
 820 825 830 835

tct cag acc tat gat ttt gat aaa ttc act att gac tct tct cag cgt 5636
 Ser Gln Thr Tyr Asp Phe Asp Lys Phe Thr Ile Asp Ser Ser Gln Arg
 840 845 850

ctt aat cta agc tat cgc tat gtt ttc aag gat tct aag gga aaa tta 5684
 Leu Asn Leu Ser Tyr Arg Tyr Val Phe Lys Asp Ser Lys Gly Lys Leu
 855 860 865

att aat agc gac gat tta cag aag caa ggt tat tca ctc aca tat att 5732
 Ile Asn Ser Asp Asp Leu Gln Lys Gln Gly Tyr Ser Leu Thr Tyr Ile
 870 875 880

gat tta tgt act gtt tcc att aaa aaa ggt aat tca aat gaa att gtt 5780
 Asp Leu Cys Thr Val Ser Ile Lys Lys Gly Asn Ser Asn Glu Ile Val
 885 890 895

aaa tgt aat taattttgtt ttcttgatgt ttgtttcatc atcttctttt 5829
 Lys Cys Asn
 900

gctcaggtaa ttgaaatgaa taattcgcct ctgcgcgatt ttgtaacttg gtattcaaag 5889

caatcaggcg aatccgttat tgtttctccc gatgtaaaag gtactgttac tgtatatcca 5949

tctgacgtta aacctgaaaa tctacgcaat ttctttattt ctgttttacg tgctaataat 6009

tttgatatgg ttggttcaat tccttcata attcagaagt ataatccaaa caatcaggat 6069

tatattgatg aattgccatc atctgataat caggaatatg atgataattc cgctccttct 6129

ggtggtttct ttgttccgca aaatgataat gttactcaaa cttttaaaat taataacggt 6189
cgggcaaagg atttaatacg agttgtcgaa ttgtttgtaa agtctaatac ttctaaatcc 6249
tcaaagtgtat tatctattga cggctctaata ctattagttg tttctgcacc taaagatatt 6309
ttagataacc ttctcaatt ctttctact gttgatttgc caactgacca gatattgatt 6369
gagggtttga tatttgaggt tcagcaaggt gatgcttag atttttcatt tgctgctggc 6429
tctcagcgtg gcactgttgc aggcggtgtt aatactgacc gcctcacctc tgttttatct 6489
tctgctggtg gttcgttcgg tatttttaat ggcgatgtt tagggctatc agttcgcgca 6549
ttaaagacta atagccattc aaaaatattg tctgtgccac gtattcttac gctttcaggt 6609
cagaagggtt ctatctctgt tggccagaat gtccctttta ttactggtcg tgtgactggt 6669
gaatctgcc aatgaaataa tccatttcag acgattgagc gtcaaatgt aggtatttcc 6729
atgagcggtt ttctgttgc aatggctggc ggtaatattg ttctggatat taccagcaag 6789
gccgatagtt tgagtcttc tactcaggca agtgatgtta ttactaatca aagaagtatt 6849
gctacaacgg ttaatttgc tgatggacag actcttttac tcggtggcct cactgattat 6909
aaaaacactt ctcaagattc tggcgtaccg ttctgtcta aaatccctt aatcggcctc 6969
ctgttttagt cccgtctga ttccaacgag gaaagcacgt tatacgtgct cgtcaaagca 7029
accatagtac gcgccctgta gcggcgcat aagcgcgcg ggtgtggtg ttacgcgcag 7089
cgtgaccgct acacttgcca gcgccctagc gcccgctcct ttcgctttct tcccttcctt 7149
tctcgccacg ttcccggtt tccccgtca agctctaaat cgggggctcc ctttagggtt 7209
ccgatttagt gctttacggc acctcgacc caaaaaactt gatttgggtg atggttcacg 7269
tagtgggcca tcgccctgat agacggttt tcgcccttg acgttgaggt ccacgttctt 7329
taatagtga ctctgttcc aaactggaac aacactcaac cctatctcgg gctattcttt 7389
tgatttataa gggattttgc cgatttcgga accaccatca aacaggattt tcgcctgctg 7449
gggcaaacca gcgtggaccg cttgctgcaa ctctctcagg gccaggcggg gaagggaat 7509
cagctgttgc ccgtctcact ggtgaaaaga aaaaccaccc tggatccaag cttgcaggtg 7569
gcacttttcg gggaaatgtg cgcggaaccc ctatttgtt atttttctaa atacattcaa 7629
atatgtatcc gctcatgaga caataaccct gataaatgct tcaataatat tgaaaaagga 7689
agagtatgag tattcaacat ttccgtgtcg cccttattcc cttttttgcg gcattttgcc 7749
ttctgtttt tgctcaccga gaaacgctg tgaaagtaaa agatgctgaa gatcagttgg 7809
gcgcacgagt gggttacatc gaactggatc tcaacagcgg taagatcctt gagagttttc 7869

gccccgaaga acgtttttcca atgatgagca ctttttaaagt tctgctatgt catacactat 7929
tatcccgat tgacgccggg caagagcaac tcggtcgccg ggccggtat tctcagaatg 7989
acttggttga gtactcacca gtcacagaaa agcatcttac ggatggcatg acagtaagag 8049
aattatgcag tgctgccata accatgagtg ataacactgc ggccaactta cttctgacaa 8109
cgatcggagg accgaaggag ctaaccgctt ttttgacaa catgggggat catgtaactc 8169
gccttgatcg ttggaaccg gagctgaatg aagccatacc aaacgacgag cgtgacacca 8229
cgatgcctgt agcaatgcc acaacgttgc gcaaactatt aactggcgaa ctacttactc 8289
tagcttccc gcaacaatta atagactgga tggaggcgga taaagttgca ggaccacttc 8349
tgcgctcggc ccttcgggt ggctggttta ttgctgataa atctggagcc ggtgagcgtg 8409
ggtctcgcg tatcattgca gcaactgggc cagatggtaa gccctccgt atcgtagtta 8469
tctacacgac ggggagtcag gcaactatgg atgaacgaaa tagacagatc gctgagatag 8529
gtgcctcact gattaagcat tggtaactgt cagaccaagt ttactcatat atactttaga 8589
ttgatttaaa acttcatttt taatttaaaa ggatctaggt gaagatcctt tttgataatc 8649
tcatgaccaa aatcccttaa cgtgagtttt cgttccactg tacgtaagac ccccaagctt 8709
gtcgactgaa tggcgaatgg cgctttgcct ggtttccggc accagaagcg gtgccgga 8769
gctggctgga gtgcgatctt cctgaggccg atactgtcgt cgtccctca aactggcaga 8829
tgacgggta cgatgcgcc atctacacca acgtaacct tccattacg gtcaatccgc 8889
cgtttggtcc caggagaat ccgacgggtt gttactcgct cacatttaat gttgatgaaa 8949
gctggctaca ggaaggccag acgcaatta tttttgatgg cgttcctatt ggtaaaaaa 9009
tgagctgatt taacaaaaat ttaacgcgaa ttttaacaaa atattaacgt ttacaattta 9069
aatatttgc tacaatct tcctgttttt ggggcttttc tgattatcaa ccgggtaca 9129
tatgattgac atgctagttt tacgattacc gttcatcgat tctctgttt gctccagact 9189
ctcaggcaat gacctgatag cctttgtaga tctctcaaaa atagctaccc tctccggcat 9249
gaatttatca gctagaacgg ttgaatatca tattgatggg gatttgactg tctccggcct 9309
ttctcacct tttgaatctt tacctacaca ttactcaggc attgcattta aaatatatga 9369
gggttctaaa aatttttatc cttgcgttga aataaaggct tctccgcaa aagtattaca 9429
gggtcataat gtttttgta caaccgattt agctttatgc tctgaggctt tattgcttaa 9489
ttttgcta tctttgcctt gcctgtatga tttattggat gtt 9532

111

<210> 452
 <211> 20
 <212> PRT
 <213> Unknown Organism

<220>
 <223> Description of Unknown Organism: MALIA3 peptide
 sequence

<400> 452
 Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ser
 1 5 10 15
 His Ser Ala Gln
 20

<210> 453
 <211> 367
 <212> PRT
 <213> Unknown Organism

<220>
 <223> Description of Unknown Organism: MALIA3 protein
 sequence

<400> 453
 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Ala
 1 5 10 15
 Ala Gln Pro Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly
 20 25 30
 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
 35 40 45
 Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly
 50 55 60
 Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr
 65 70 75 80
 Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
 85 90 95
 Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
 100 105 110
 Thr Ala Val Tyr Tyr Cys Ala Lys Asp Tyr Glu Gly Thr Gly Tyr Ala
 115 120 125
 Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser
 130 135 140
 Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr
 145 150 155 160
 Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro

112

165 170 175

Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val
180 185 190

His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser
195 200 205

Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile
210 215 220

Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val
225 230 235 240

Glu Pro Lys Ser Cys Ala Ala Ala His His His His His His Ser Ala
245 250 255

Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala Asp Ile
260 265 270

Asn Asp Asp Arg Met Ala Gly Ala Ala Glu Thr Val Glu Ser Cys Leu
275 280 285

Ala Lys Pro His Thr Glu Asn Ser Phe Thr Asn Val Trp Lys Asp Asp
290 295 300

Lys Thr Leu Asp Arg Tyr Ala Asn Tyr Glu Gly Cys Leu Trp Asn Ala
305 310 315 320

Thr Gly Val Val Val Cys Thr Gly Asp Glu Thr Gln Cys Tyr Gly Thr
325 330 335

Trp Val Pro Ile Gly Leu Ala Ile Pro Glu Asn Glu Gly Gly Gly Ser
340 345 350

Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Thr
355 360 365

<210> 454

<211> 152

<212> PRT

<213> Unknown Organism

<220>

<223> Description of Unknown Organism: MALIA3 protein
sequence

<400> 454

Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly Ala
1 5 10 15

Met Thr Glu Asn Ala Asp Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly
20 25 30

Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe
35 40 45

113

Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp
 50 55 60

Phe Ala Gly Ser Asn Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn
 65 70 75 80

Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln
 85 90 95

Ser Val Glu Cys Arg Pro Phe Val Phe Ser Ala Gly Lys Pro Tyr Glu
 100 105 110

Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala
 115 120 125

Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala
 130 135 140

Asn Ile Leu Arg Asn Lys Glu Ser
 145 150

<210> 455

<211> 15

<212> PRT

<213> Unknown Organism

<220>

<223> Description of Unknown Organism: MALIA3 peptide sequence

<400> 455

Met Pro Val Leu Leu Gly Ile Pro Leu Leu Leu Arg Phe Leu Gly
 1 5 10 15

<210> 456

<211> 348

<212> PRT

<213> Unknown Organism

<220>

<223> Description of Unknown Organism: MALIA3 protein sequence

<400> 456

Met Ala Val Tyr Phe Val Thr Gly Lys Leu Gly Ser Gly Lys Thr Leu
 1 5 10 15

Val Ser Val Gly Lys Ile Gln Asp Lys Ile Val Ala Gly Cys Lys Ile
 20 25 30

Ala Thr Asn Leu Asp Leu Arg Leu Gln Asn Leu Pro Gln Val Gly Arg
 35 40 45

Phe Ala Lys Thr Pro Arg Val Leu Arg Ile Pro Asp Lys Pro Ser Ile
 50 55 60

114

Ser Asp Leu Leu Ala Ile Gly Arg Gly Asn Asp Ser Tyr Asp Glu Asn
 65 70 75 80
 Lys Asn Gly Leu Leu Val Leu Asp Glu Cys Gly Thr Trp Phe Asn Thr
 85 90 95
 Arg Ser Trp Asn Asp Lys Glu Arg Gln Pro Ile Ile Asp Trp Phe Leu
 100 105 110
 His Ala Arg Lys Leu Gly Trp Asp Ile Ile Phe Leu Val Gln Asp Leu
 115 120 125
 Ser Ile Val Asp Lys Gln Ala Arg Ser Ala Leu Ala Glu His Val Val
 130 135 140
 Tyr Cys Arg Arg Leu Asp Arg Ile Thr Leu Pro Phe Val Gly Thr Leu
 145 150 155 160
 Tyr Ser Leu Ile Thr Gly Ser Lys Met Pro Leu Pro Lys Leu His Val
 165 170 175
 Gly Val Val Lys Tyr Gly Asp Ser Gln Leu Ser Pro Thr Val Glu Arg
 180 185 190
 Trp Leu Tyr Thr Gly Lys Asn Leu Tyr Asn Ala Tyr Asp Thr Lys Gln
 195 200 205
 Ala Phe Ser Ser Asn Tyr Asp Ser Gly Val Tyr Ser Tyr Leu Thr Pro
 210 215 220
 Tyr Leu Ser His Gly Arg Tyr Phe Lys Pro Leu Asn Leu Gly Gln Lys
 225 230 235 240
 Met Lys Leu Thr Lys Ile Tyr Leu Lys Lys Phe Ser Arg Val Leu Cys
 245 250 255
 Leu Ala Ile Gly Phe Ala Ser Ala Phe Thr Tyr Ser Tyr Ile Thr Gln
 260 265 270
 Pro Lys Pro Glu Val Lys Lys Val Val Ser Gln Thr Tyr Asp Phe Asp
 275 280 285
 Lys Phe Thr Ile Asp Ser Ser Gln Arg Leu Asn Leu Ser Tyr Arg Tyr
 290 295 300
 Val Phe Lys Asp Ser Lys Gly Lys Leu Ile Asn Ser Asp Asp Leu Gln
 305 310 315 320
 Lys Gln Gly Tyr Ser Leu Thr Tyr Ile Asp Leu Cys Thr Val Ser Ile
 325 330 335
 Lys Lys Gly Asn Ser Asn Glu Ile Val Lys Cys Asn
 340 345

<210> 457

<211> 24

<212> DNA

115

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 457

tggaagaggc acgttctttt cttt

24

<210> 458

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 458

cttttctttg ttgccgttg ggtg

24

<210> 459

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 459

acactctccc ctgttgaagc tctt

24

<210> 460

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 460

accgcctcca ccgggcgcgc cttattaaca ctctcccctg ttgaagctct t

51

<210> 461

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 461

tgaacattct gtaggggcca ctg

23

<210> 462

116

<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 462
agagcattct gcaggggcca ctg 23

<210> 463
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 463
accgcctcca ccgggcgcgc cttattatga acattctgta ggggccactg 50

<210> 464
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 464
accgcctcca ccgggcgcgc cttattaaga gcattctgca ggggccactg 50

<210> 465
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 465
cgactggagc acgaggacac tga 23

<210> 466
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 466
ggacactgac atggactgaa ggagta 26

<210> 467
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 467
gggaggatgg agactgggtc 20

<210> 468
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 468
gggaagatgg agactgggtc 20

<210> 469
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 469
gggagagtgg agactgagtc 20

<210> 470
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 470
gggtgcctgg agactgcgtc 20

<210> 471
<211> 20
<212> DNA
<213> Artificial Sequence

118

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 471

gggtggctgg agactgcgtc

20

<210> 472

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 472

gggaggatgg agactgggtc atctggatgt cttgtgcact gtgacagagg

50

<210> 473

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 473

gggaagatgg agactgggtc atctggatgt cttgtgcact gtgacagagg

50

<210> 474

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 474

gggagagtgg agactgggtc atctggatgt cttgtgcact gtgacagagg

50

<210> 475

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 475

gggtgcctgg agactgggtc atctggatgt cttgtgcact gtgacagagg

50

<210> 476
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 476
gggtggctgg agactgggtc atctggatgt cttgtgcact gtgacagagg 50

<210> 477
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 477
gggagtctgg agactgggtc atctggatgt cttgtgcact gtgacagagg 50

<210> 478
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 478
cctctgtcac agtgcacaag acatccagat gacccagtct cc 42

<210> 479
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 479
cctctgtcac agtgcacaag ac 22

<210> 480
<211> 24
<212> DNA
<213> Artificial Sequence

120

<220>

<223> Description of Artificial Sequence: Primer

<400> 480

acactctccc ctgttgaagc tctt

24

<210> 481

<211> 668

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(668)

<400> 481

agt gca caa gac atc cag atg acc cag tct cca gcc acc ctg tct gtg	48
Ser Ala Gln Asp Ile Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val	
1 5 10 15	
tct cca ggg gaa agg gcc acc ctc tcc tgc agg gcc agt cag agt gtt	96
Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val	
20 25 30	
agt aac aac tta gcc tgg tac cag cag aaa cct ggc cag gtt ccc agg	144
Ser Asn Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Val Pro Arg	
35 40 45	
ctc ctc atc tat ggt gca tcc acc agg gcc act gat atc cca gcc agg	192
Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Asp Ile Pro Ala Arg	
50 55 60	
ttc agt ggc agt ggg tct ggg aca gac ttc act ctc acc atc agc aga	240
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg	
65 70 75 80	
ctg gag cct gaa gat ttt gca gtg tat tac tgt cag cgg tat ggt agc	288
Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Arg Tyr Gly Ser	
85 90 95	
tca ccg ggg tgg acg ttc ggc caa ggg acc aag gtg gaa atc aaa cga	336
Ser Pro Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg	
100 105 110	
act gtg gct gca cca tct gtc ttc atc ttc ccg cca tct gat gag cag	384
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln	
115 120 125	
ttg aaa tct gga act gcc tct gtt gtg tgc ctg ctg aat aac ttc tat	432
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr	
130 135 140	
ccc aga gag gcc aaa gta cag tgg aag gtg gat aac gcc ctc caa tcg	480
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser	
145 150 155 160	
ggt aac tcc cag gag agt gtc aca gag cag gac agc aag gac agc acc	528

121

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175
 tac agc ctc agc agc acc ctg acg ctg agc aaa gca gac tac gag aaa 576
 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190
 cac aaa gtc tac gcc tgc gaa gtc acc cat cag ggc ctg agc tcg cct 624
 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205
 gtc aca aag agc ttc aac aaa gga gag tgt aag ggc gaa ttc gc 668
 Val Thr Lys Ser Phe Asn Lys Gly Glu Cys Lys Gly Glu Phe Ala
 210 215 220

<210> 482
 <211> 223
 <212> PRT
 <213> Homo sapiens

<400> 482
 Ser Ala Gln Asp Ile Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val
 1 5 10 15
 Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val
 20 25 30
 Ser Asn Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Val Pro Arg
 35 40 45
 Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Asp Ile Pro Ala Arg
 50 55 60
 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg
 65 70 75 80
 Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Arg Tyr Gly Ser
 85 90 95
 Ser Pro Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 100 105 110
 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 115 120 125
 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140
 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160
 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175
 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190

122

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205

Val Thr Lys Ser Phe Asn Lys Gly Glu Cys Lys Gly Glu Phe Ala
 210 215 220

<210> 483

<211> 13

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 483

agccaccctg tct

13

<210> 484

<211> 700

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(699)

<400> 484

agt gca caa gac atc cag atg acc cag tct cct gcc acc ctg tct gtg 48
 Ser Ala Gln Asp Ile Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val
 1 5 10 15

tct cca ggt gaa aga gcc acc ctc tcc tgc agg gcc agt cag gtg tct 96
 Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ser
 20 25 30

cca ggg gaa aga gcc acc ctc tcc tgc aat ctt ctc agc aac tta gcc 144
 Pro Gly Glu Arg Ala Thr Leu Ser Cys Asn Leu Leu Ser Asn Leu Ala
 35 40 45

tgg tac cag cag aaa cct ggc cag gct ccc agg ctc ctc atc tat ggt 192
 Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly
 50 55 60

gct tcc acc ggg gcc att ggt atc cca gcc agg ttc agt ggc agt ggg 240
 Ala Ser Thr Gly Ala Ile Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly
 65 70 75 80

tct ggg aca gag ttc act ctc acc atc agc agc ctg cag tct gaa gat 288
 Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp
 85 90 95

ttt gca gtg tat ttc tgt cag cag tat ggt acc tca ccg ccc act ttc 336
 Phe Ala Val Tyr Phe Cys Gln Gln Tyr Gly Thr Ser Pro Pro Thr Phe
 100 105 110

123

ggc gga ggg acc aag gtg gag atc aaa cga act gtg gct gca cca tct 384
 Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser
 115 120 125

gtc ttc atc ttc ccg cca tct gat gag cag ttg aaa tct gga act gcc 432
 Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala
 130 135 140

tct gtt gtg tgc ccg ctg aat aac ttc tat ccc aga gag gcc aaa gta 480
 Ser Val Val Cys Pro Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val
 145 150 155 160

cag tgg aag gtg gat aac gcc ctc caa tcg ggt aac tcc cag gag agt 528
 Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser
 165 170 175

gtc aca gag cag gac aac aag gac agc acc tac agc ctc agc agc acc 576
 Val Thr Glu Gln Asp Asn Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr
 180 185 190

ctg acg ctg agc aaa gta gac tac gag aaa cac gaa gtc tac gcc tgc 624
 Leu Thr Leu Ser Lys Val Asp Tyr Glu Lys His Glu Val Tyr Ala Cys
 195 200 205

gaa gtc acc cat cag ggc ctt agc tcg ccc gtc acg aag agc ttc aac 672
 Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn
 210 215 220

agg gga gag tgt aag aaa gaa ttc gtt t 700
 Arg Gly Glu Cys Lys Lys Glu Phe Val
 225 230

<210> 485

<211> 233

<212> PRT

<213> Homo sapiens

<400> 485

Ser Ala Gln Asp Ile Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val
 1 5 10 15

Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Val Ser
 20 25 30

Pro Gly Glu Arg Ala Thr Leu Ser Cys Asn Leu Leu Ser Asn Leu Ala
 35 40 45

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly
 50 55 60

Ala Ser Thr Gly Ala Ile Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly
 65 70 75 80

Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp
 85 90 95

Phe Ala Val Tyr Phe Cys Gln Gln Tyr Gly Thr Ser Pro Pro Thr Phe

124

100	105	110
Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser		
115	120	125
Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala		
130	135	140
Ser Val Val Cys Pro Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val		
145	150	155
Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser		
165	170	175
Val Thr Glu Gln Asp Asn Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr		
180	185	190
Leu Thr Leu Ser Lys Val Asp Tyr Glu Lys His Glu Val Tyr Ala Cys		
195	200	205
Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn		
210	215	220
Arg Gly Glu Cys Lys Lys Glu Phe Val		
225	230	

<210> 486

<211> 419

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic 3-23
VH nucleotide sequence

<220>

<221> CDS

<222> (12)..(419)

<400> 486

ctgtctgaac g gcc cag ccg gcc atg gcc gaa gtt caa ttg tta gag tct 50

Ala Gln Pro Ala Met Ala Glu Val Gln Leu Leu Glu Ser

1

5

10

ggc ggc ggt ctt gtt cag cct ggt ggt tct tta cgt ctt tct tgc gct 98

Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala

15

20

25

gct tcc gga ttc act ttc tct tcg tac gct atg tct tgg gtt cgc caa 146

Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln

30

35

40

45

gct cct ggt aaa ggt ttg gag tgg gtt tct gct atc tct ggt tct ggt 194

Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly

50

55

60

ggc	agt	act	tac	tat	gct	gac	tcc	gtt	aaa	ggt	cgc	ttc	act	atc	tct	242
Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	
			65					70					75			
aga	gac	aac	tct	aag	aat	act	ctc	tac	ttg	cag	atg	aac	agc	tta	agg	290
Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	
			80				85					90				
gct	gag	gac	act	gca	gtc	tac	tat	tgc	gct	aaa	gac	tat	gaa	ggt	act	338
Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala	Lys	Asp	Tyr	Glu	Gly	Thr	
			95			100					105					
ggt	tat	gct	ttc	gac	ata	tgg	ggt	caa	ggt	act	atg	gtc	acc	gtc	tct	386
Gly	Tyr	Ala	Phe	Asp	Ile	Trp	Gly	Gln	Gly	Thr	Met	Val	Thr	Val	Ser	
110					115					120					125	
agt	gcc	tcc	acc	aag	ggc	cca	tcg	gtc	ttc	ccc						419
Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro						
				130					135							

```
<210> 487
<211> 136
<212> PRT
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: Synthetic 3-23
VH protein sequence

```

<400> 487
Ala Gln Pro Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly
  1          5          10          15
Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
          20          25          30
Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly
          35          40          45
Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr
          50          55          60
Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
          65          70          75          80
Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
          85          90          95
Thr Ala Val Tyr Tyr Cys Ala Lys Asp Tyr Glu Gly Thr Gly Tyr Ala
          100          105          110
Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser
          115          120          125
Thr Lys Gly Pro Ser Val Phe Pro
          130          135

```

<210> 488
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 488
ctgtctgaac ggcccagccg 20

<210> 489
<211> 83
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 489
ctgtctgaac ggcccagccg gcatggccg aagttcaatt gtagagtct ggtggcggtc 60
ttgttcagcc tgggtgttct tta 83

<210> 490
<211> 54
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 490
gaaagtgaat ccggaagcag cgcaagaaaag acgtaaagaa ccaccaggct gaac 54

<210> 491
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 491
agaaacccac tccaaacctt taccaggagc ttggcgaacc ca 42

<210> 492
<211> 94
<212> DNA
<213> Artificial Sequence

127

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 492

agtgtcctca gcccttaagc tgttcacatctg caagtagaga gtattccttag agttgtctct 60
agagatagtg aagcgacctt taacggagtc agca 94

<210> 493

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 493

gcttaagggc tgaggacact gcagttctact attgcgctaa agactatgaa ggtactgggt 60
atgctttcga catatggggt c 81

<210> 494

<211> 72

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 494

ggggaagacc gatgggccct tggaggaggc actagagacg gtgaccatag taccttgacc 60
tatgtcgaaa gc 72

<210> 495

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 495

ggggaagacc gatgggccct tgg 23

<210> 496

<211> 56

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

128

<220>
<221> modified_base
<222> (22)..(24)
<223> A, T, C, G, other or unknown

<220>
<221> modified_base
<222> (28)..(30)
<223> A, T, C, G, other or unknown

<220>
<221> modified_base
<222> (34)..(36)
<223> A, T, C, G, other or unknown

<220>
<223> nnn codes for any amino acid but Cys

<400> 496
gcttccggat tcactttctc tnnntacnnn atgnnntggg ttcgccaagc tcctgg 56

<210> 497
<211> 68
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (19)..(21)
<223> A, T, C or G

<220>
<221> modified_base
<222> (25)..(30)
<223> A, T, C or G

<220>
<221> modified_base
<222> (40)..(42)
<223> A, T, C or G

<220>
<221> modified_base
<222> (46)..(48)
<223> A, T, C or G

<400> 497
gggttgaggat gggtttctnn nactnnnnnn tctggtggcn nnactnnnta tgctgactcc 60
gttaaagg 68

<210> 498

129

<211> 912
 <212> DNA
 <213> Escherichia coli

<400> 498
 tccggagctt cagatctgtt tgcctttttg tggggtggtg cagatcgcgt tacggagatc 60
 gaccgactgc ttgagcaaaa gccacgctta actgctgatac aggcattgga tgttattcgc 120
 caaaccagtc gtcaggatct taacctgagg ctttttttac ctactctgca agcagcgaca 180
 tctggtttga cacagagcga tccgcgtcgt cagttggtag aaacattaac acgttgggat 240
 ggcatacaatt tgcttaataa tgatggtaaa acctggcagc agccaggctc tgccatcctg 300
 aacgtttggc tgaccagtat gttgaagcgt accgtagtgg ctgccgtacc tatgccattt 360
 gataagtggg acagcgccag tggctacgaa acaacccagg acggcccaac tggttcgtcg 420
 aatataagtg ttggagcaaa aattttgtat gaggcggtgc agggagacaa atcaccaatc 480
 ccacaggcgg ttgatctgtt tgctgggaaa ccacagcagg aggttgtgtt ggctgcgtcg 540
 gaagatacct gggagactct ttccaaacgc tatggcaata atgtgagtaa ctggaaaaca 600
 cctgcaatgg ccttaacggt cggggcaaat aatttctttg gtgtaccgca ggccgcagcg 660
 gaagaaacgc gtcatacaggc ggagtatcaa aaccgtggaa cagaaaacga tatgattgtt 720
 ttctcaccac cgacaagcga tcgtcctgtg cttgcctggg atgtggtcgc acccggtcag 780
 agtgggttta ttgctcccga tggaacagtt gataagcact atgaagatca gctgaaaatg 840
 tacgaaaatt ttggccgtaa gtcgctctgg ttaacgaagc aggatgtgga ggcgcataag 900
 gagtcgtcta ga 912

<210> 499
 <211> 10
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<220>
 <221> modified_base
 <222> (4)..(7)
 <223> A, T, C, G, other or unknown

<400> 499
 gatnnnnatc 10

<210> 500
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<220>
 <221> modified_base
 <222> (1)..(15)
 <223> A, T, C, G, other or unknown

<400> 500
 nnnnnnnnnn nnnnngtccc 20

130

<210> 501
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(8)
<223> A, T, C, G, other or unknown

<400> 501
gcannnnntg c

11

<210> 502
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(7)
<223> A, T, C, G, other or unknown

<400> 502
gacnnnnngtc

10

<210> 503
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (1)..(7)
<223> A, T, C, G, other or unknown

<400> 503
nnnnnnngcg gg

12

<210> 504
<211> 12
<212> DNA

131

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (7)..(12)

<223> A, T, C, G, other or unknown

<400> 504

gtatccnnnn nn

12

<210> 505

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (4)..(9)

<223> A, T, C, G, other or unknown

<400> 505

gcannnnnnt cg

12

<210> 506

<211> 11

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (4)..(8)

<223> A, T, C, G, other or unknown

<400> 506

gccnnnnngg c

11

<210> 507

<211> 11

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

132

oligonucleotide

<220>
<221> modified_base
<222> (7)..(11)
<223> A, T, C, G, other or unknown

<400> 507
ggtctcnnnn n

11

<210> 508
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(11)
<223> A, T, C, G, other or unknown

<400> 508
gacnnnnngt c

11

<210> 509
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(8)
<223> A, T, C, G, other or unknown

<400> 509
gacnnnnngt c

11

<210> 510
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base

133

<222> (4)..(9)

<223> A, T, C, G, other or unknown

<400> 510

gacnnnnnng tc

12

<210> 511

<211> 11

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (4)..(8)

<223> A, T, C, G, other or unknown

<400> 511

ccannnnntg g

11

<210> 512

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (1)..(9)

<223> A, T, C, G, other or unknown

<400> 512

nnnnnnnnng caggt

15

<210> 513

<211> 11

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (7)..(11)

<223> A, T, C, G, other or unknown

<400> 513

134

acctgcnnnn n

11

<210> 514

<211> 13

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (5)..(9)

<223> A, T, C, G, other or unknown

<400> 514

ggccnnnnng gcc

13

<210> 515

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (4)..(12)

<223> A, T, C, G, other or unknown

<400> 515

ccannnnnnn nntgg

15

<210> 516

<211> 11

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (7)..(11)

<223> A, T, C, G, other or unknown

<400> 516

cgtctcnnnn n

11

<210> 517

135

<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (1)..(6)
<223> A, T, C, G, other or unknown

<400> 517
nnnnnngaga cg

12

<210> 518
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (1)..(10)
<223> A, T, C, G, other or unknown

<400> 518
nnnnnnnnnn ctctctc

16

<210> 519
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(16)
<223> A, T, C, G, other or unknown

<400> 519
gaggagnnnn nnnnnn

16

<210> 520
<211> 11
<212> DNA
<213> Artificial Sequence

136

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(8)
<223> A, T, C, G, other or unknown

<400> 520
cctnnnnnag g

11

<210> 521
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(9)
<223> A, T, C, G, other or unknown

<400> 521
ccannnnnnt gg

12

<210> 522
<211> 6680
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Vector pCES5
nucleotide sequence

<220>
<221> CDS
<222> (201)..(1058)

<220>
<221> CDS
<222> (2269)..(2682)

<220>
<221> CDS
<222> (2723)..(2866)

<220>
<221> CDS
<222> (3767)..(3850)

<220>
<221> CDS

137

<222> (4198)..(5799)

<400> 522

gacgaaaggg cctcgtgata cgcctatttt tataggttaa tgtcatgata ataatggttt 60

cttagacgtc aggtggcact ttccggggaa atgtgcgcgg aaccctatt tgtttatttt 120

tctaaatata ttcaaatacg taccgctca tgagacaata accctgataa atgcttcaat 180

aatattgaaa aaggaagagt atg agt att caa cat ttc cgt gtc gcc ctt att 233

Met Ser Ile Gln His Phe Arg Val Ala Leu Ile
1 5 10

ccc ttt ttt gcg gca ttt tgc ctt cct gtt ttt gct cac cca gaa acg 281

Pro Phe Phe Ala Ala Phe Cys Leu Pro Val Phe Ala His Pro Glu Thr
15 20 25

ctg gtg aaa gta aaa gat gct gaa gat cag ttg ggt gcc cga gtg ggt 329

Leu Val Lys Val Lys Asp Ala Glu Asp Gln Leu Gly Ala Arg Val Gly
30 35 40

tac atc gaa ctg gat ctc aac agc ggt aag atc ctt gag agt ttt cgc 377

Tyr Ile Glu Leu Asp Leu Asn Ser Gly Lys Ile Leu Glu Ser Phe Arg
45 50 55

ccc gaa gaa cgt ttt cca atg atg agc act ttt aaa gtt ctg cta tgt 425

Pro Glu Glu Arg Phe Pro Met Met Ser Thr Phe Lys Val Leu Leu Cys
60 65 70 75

ggc gcg gta tta tcc cgt att gac gcc ggg caa gag caa ctc ggt cgc 473

Gly Ala Val Leu Ser Arg Ile Asp Ala Gly Gln Glu Gln Leu Gly Arg
80 85 90

cgc ata cac tat tct cag aat gac ttg gtt gag tac tca cca gtc aca 521

Arg Ile His Tyr Ser Gln Asn Asp Leu Val Glu Tyr Ser Pro Val Thr
95 100 105

gaa aag cat ctt acg gat ggc atg aca gta aga gaa tta tgc agt gct 569

Glu Lys His Leu Thr Asp Gly Met Thr Val Arg Glu Leu Cys Ser Ala
110 115 120

gcc ata acc atg agt gat aac act gcg gcc aac tta ctt ctg aca acg 617

Ala Ile Thr Met Ser Asp Asn Thr Ala Ala Asn Leu Leu Leu Thr Thr
125 130 135

atc gga gga ccg aag gag cta acc gct ttt ttg cac aac atg ggg gat 665

Ile Gly Gly Pro Lys Glu Leu Thr Ala Phe Leu His Asn Met Gly Asp
140 145 150 155

cat gta act cgc ctt gat cgt tgg gaa ccg gag ctg aat gaa gcc ata 713

His Val Thr Arg Leu Asp Arg Trp Glu Pro Glu Leu Asn Glu Ala Ile
160 165 170

cca aac gac gag cgt gac acc acg atg cct gta gca atg gca aca acg 761

Pro Asn Asp Glu Arg Asp Thr Thr Met Pro Val Ala Met Ala Thr Thr
175 180 185

ttg cgc aaa cta tta act ggc gaa cta ctt act cta gct tcc cgg caa 809

138

Leu Arg Lys Leu Leu Thr Gly Glu Leu Leu Thr Leu Ala Ser Arg Gln
 190 195 200
 caa tta ata gac tgg atg gag gcg gat aaa gtt gca gga cca ctt ctg 857
 Gln Leu Ile Asp Trp Met Glu Ala Asp Lys Val Ala Gly Pro Leu Leu
 205 210 215
 cgc tcg gcc ctt ccg gct ggc tgg ttt att gct gat aaa tct gga gcc 905
 Arg Ser Ala Leu Pro Ala Gly Trp Phe Ile Ala Asp Lys Ser Gly Ala
 220 225 230 235
 ggt gag cgt ggg tct cgc ggt atc att gca gca ctg ggg cca gat ggt 953
 Gly Glu Arg Gly Ser Arg Gly Ile Ile Ala Ala Leu Gly Pro Asp Gly
 240 245 250
 aag ccc tcc cgt atc gta gtt atc tac acg acg ggg agt cag gca act 1001
 Lys Pro Ser Arg Ile Val Val Ile Tyr Thr Thr Gly Ser Gln Ala Thr
 255 260 265
 atg gat gaa cga aat aga cag atc gct gag ata ggt gcc tca ctg att 1049
 Met Asp Glu Arg Asn Arg Gln Ile Ala Glu Ile Gly Ala Ser Leu Ile
 270 275 280
 aag cat tgg taactgtcag accaagttaa ctcatatata ctttagattg 1098
 Lys His Trp
 285
 atttaaaact tcatttttaa tttaaaagga tctaggtgaa gatccttttt gataatctca 1158
 tgacaaaaat cccttaacgt gagttttcgt tccactgagc gtcagacccc gtagaaaaga 1218
 tcaaaggatc ttcttgagat cctttttttc tgcgcgtaat ctgctgcttg caaacaaaaa 1278
 aaccaccgct accagcgtg gtttggttgc cggatcaaga gctaccaact ctttttccga 1338
 aggtaactgg cttcagcaga gcgcagatac caaatactgt ccttctagtg tagccgtagt 1398
 taggccacca cttcaagaac tctgtagcac cgctacata cctcgctctg ctaatcctgt 1458
 taccagtggc tgctgccagt ggcgataagt cgtgtcttac cgggttgac tcaagacgat 1518
 agttaccgga taaggcgag cggtcgggct gaacggggg ttcgtgcata cagcccagct 1578
 tggagcgaac gacctacacc gaactgagat acctacagcg tgagcattga gaaagcgcca 1638
 cgcttcccga agggagaaaag gcggacaggt atccggtaag cggcaggggc ggaacaggag 1698
 agcgcacgag ggagcttcca ggggaaaacg cctggatatc ttatagtcct gtcgggtttc 1758
 gccacctctg acttgagcgt cgatttttgt gatgctcgtc aggggggcgg agcctatgga 1818
 aaaacgccag caacgcggcc tttttacggt tcctggcctt ttgctggcct tttgctcaca 1878
 tgttctttcc tgcgttatcc cctgattctg tggataaccg tattaccgcc tttgagttag 1938
 ctgataccgc tcgccgagc cgaacgaccg agcgcagcga gtcagtgagc gaggaagcgg 1998
 aagagcgccc aatacgcaaa ccgcctctcc ccgcgcgttg gccgattcat taatgcagct 2058

ggcacgacag gtttcccgac tggaaagcgg gcagtgagcg caacgcaatt aatgtgagtt	2118
agctcactca ttaggcacccc caggcttttac actttatgct tccggctcgt atgttggtgtg	2178
gaattgtgag cggataacaa tttcacacag gaaacagcta tgaccatgat tacgccaaagc	2238
tttgagagcct tttttttgga gatttttcaac gtg aaa aaa tta tta ttc gca att	2292
Met Lys Lys Leu Leu Phe Ala Ile	290
cct tta gtt gtt cct ttc tat tct cac agt gca cag gtc caa ctg cag	2340
Pro Leu Val Val Pro Phe Tyr Ser His Ser Ala Gln Val Gln Leu Gln	295 300 305 310
gtc gac ctc gag atc aaa cgt gga act gtg gct gca cca tct gtc ttc	2388
Val Asp Leu Glu Ile Lys Arg Gly Thr Val Ala Ala Pro Ser Val Phe	315 320 325
atc ttc ccg cca tct gat gag cag ttg aaa tct gga act gcc tct gtt	2436
Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val	330 335 340
gtg tgc ctg ctg aat aac ttc tat ccc aga gag gcc aaa gta cag tgg	2484
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp	345 350 355
aag gtg gat aac gcc ctc caa tcg ggt aac tcc cag gag agt gtc aca	2532
Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr	360 365 370
gag cag gac agc aag gac agc acc tac agc ctc agc agc acc ctg acg	2580
Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr	375 380 385 390
ctg agc aaa gca gac tac gag aaa cac aaa gtc tac gcc tgc gaa gtc	2628
Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val	395 400 405
acc cat cag ggc ctg agt tca ccg gtg aca aag agc ttc aac agg gga	2676
Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly	410 415 420
gag tgt taataaggcg cgccaattct atttcaagga gacagtcata atg aaa tac	2731
Glu Cys Met Lys Tyr	425
cta ttg cct acg gca gcc gct gga ttg tta tta ctc gcg gcc cag ccg	2779
Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala Ala Gln Pro	430 435 440
gcc atg gcc gaa gtt caa ttg tta gag tct ggt ggc ggt ctt gtt cag	2827
Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln	445 450 455
cct ggt ggt tct tta cgt ctt tct tgc gct gct tcc gga gcttcagatc	2876
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly	460 465 470

tgtttgcctt tttgtgggt ggtgcagatc gcgttacgga gatcgaccga ctgcttgagc 2936
 aaaagccacg cttaactgct gatcaggcat gggatgttat tcgcaaacc agtcgtcagg 2996
 atcttaacct gaggcttttt ttacctactc tgcaagcagc gacatctggt ttgacacagā 3056
 gcgatccgcg tcgtcagttg gtagaacat taacacgttg ggatggcatc aatttgctta 3116
 atgatgatgg taaaacctgg cagcagccag gctctgccat cctgaacgtt tggctgacca 3176
 gtatgttgaa gcgtaccgta gtggctgccg tacctatgcc atttgataag tggtagacg 3236
 ccagtggcta cgaaacaacc caggacggcc caactggctc gctgaatata agtgttggag 3296
 caaaaatttt gtatgaggcg gtgcaggag acaatcacc aatcccacag gcggttgatc 3356
 tgtttgctgg gaaaccacag caggagggtt tgttggctgc gctggaagat acctgggaga 3416
 ctctttccaa acgctatggc aataatgtga gtaactggaa aacacctgca atggccttaa 3476
 cgttccgggc aaataatttc tttggtgtac cgcaggccgc agcggaagaa acgctcatc 3536
 aggcggagta tcaaaaccgt ggaacagaaa acgatatgat tgttttctca ccaacgaaa 3596
 gcgatcgctc tgtgcttgcc tgggatgtgg tcgcaccggt tcagagtggg tttattgctc 3656
 ccgatggaac agttgataag cactatgaag atcagctgaa aatgtacgaa aattttggcc 3716
 gtaagtcgct ctggttaacg aagcaggatg tggaggcgca taaggagtcg tct aga 3772
 Ser Arg
 gac aac tct aag aat act ctc tac ttg cag atg aac agc tta agt ctg 3820
 Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Ser Leu
 475 480 485 490
 agc att cgg tcc ggg caa cat tct cca aac tgaccagacg acacaaacgg 3870
 Ser Ile Arg Ser Gly Gln His Ser Pro Asn
 495 500
 cttacgctaa atcccgcgca tgggatggta aagagtggtc gtctttgctg gcctggactc 3930
 atcagatgaa ggcaaaaat tggcaggagt ggacacagca ggcagcgaaa caagcactga 3990
 ccatcaactg gtactatgct gatgtaaacg gcaatattgg ttatgttcat actggtgctt 4050
 atccagatcg tcaatcaggc catgatccgc gattaccggt tcctggtacg ggaaaatggg 4110
 actggaaagg gctattgcct ttgaaatga accctaaggt gtataacccc cagaagctag 4170
 cctgcggctt cggtcaccgt ctcaagc gcc tcc acc aag ggc cca tcg gtc ttc 4224
 Ala Ser Thr Lys Gly Pro Ser Val Phe
 505
 ccc ctg gca ccc tcc tcc aag agc acc tct ggg ggc aca gcg gcc ctg 4272
 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
 510 515 520 525

141

ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg gtg acg gtg tgc tgg	4320
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp	
530 535 540	
aac tca ggc gcc ctg acc agc ggc gtc cac acc ttc ccg gct gtc cta	4368
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu	
545 550 555	
cag tcc tca gga ctc tac tcc ctc agc agc gta gtg acc gtg ccc tcc	4416
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser	
560 565 570	
agc agc ttg ggc acc cag acc tac atc tgc aac gtg aat cac aag ccc	4464
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro	
575 580 585	
agc aac acc aag gtg gac aag aaa gtt gag ccc aaa tct tgt gcg gcc	4512
Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Ala Ala	
590 595 600 605	
gca cat cat cat cac cat cac ggg gcc gca gaa caa aaa ctc atc tca	4560
Ala His His His His His His Gly Ala Glu Gln Lys Leu Ile Ser	
610 615 620	
gaa gag gat ctg aat ggg gcc gca tag act gtt gaa agt tgt tta gca	4608
Glu Glu Asp Leu Asn Gly Ala Ala Thr Val Glu Ser Cys Leu Ala	
625 630 635	
aaa cct cat aca gaa aat tca ttt act aac gtc tgg aaa gac gac aaa	4656
Lys Pro His Thr Glu Asn Ser Phe Thr Asn Val Trp Lys Asp Asp Lys	
640 645 650	
act tta gat cgt tac gct aac tat gag ggc tgt ctg tgg aat gct aca	4704
Thr Leu Asp Arg Tyr Ala Asn Tyr Glu Gly Cys Leu Trp Asn Ala Thr	
655 660 665	
ggc gtt gtg gtt tgt act ggt gac gaa act cag tgt tac ggt aca tgg	4752
Gly Val Val Val Cys Thr Gly Asp Glu Thr Gln Cys Tyr Gly Thr Trp	
670 675 680	
gtt cct att ggg ctt gct atc cct gaa aat gag ggt ggt gcc tct gag	4800
Val Pro Ile Gly Leu Ala Ile Pro Glu Asn Glu Gly Gly Gly Ser Glu	
685 690 695 700	
ggt ggc ggt tct gag ggt ggc ggt tct gag ggt ggc ggt act aaa cct	4848
Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Thr Lys Pro	
705 710 715	
cct gag tac ggt gat aca cct att ccg ggc tat act tat atc aac cct	4896
Pro Glu Tyr Gly Asp Thr Pro Ile Pro Gly Tyr Thr Tyr Ile Asn Pro	
720 725 730	
ctc gac ggc act tat ccg cct ggt act gag caa aac ccc gct aat cct	4944
Leu Asp Gly Thr Tyr Pro Pro Gly Thr Glu Gln Asn Pro Ala Asn Pro	
735 740 745	
aat cct tct ctt gag gag tct cag cct ctt aat act ttc atg ttt cag	4992
Asn Pro Ser Leu Glu Glu Ser Gln Pro Leu Asn Thr Phe Met Phe Gln	

142

750	755	760	
aat aat agg ttc cga aat agg cag ggt gca tta act gtt tat acg ggc	5040		
Asn Asn Arg Phe Arg Asn Arg Gln Gly Ala Leu Thr Val Tyr Thr Gly			
765	770	775	780
act gtt act caa ggc act gac ccc gtt aaa act tat tac cag tac act	5088		
Thr Val Thr Gln Gly Thr Asp Pro Val Lys Thr Tyr Tyr Gln Tyr Thr			
785	790	795	
cct gta tca tca aaa gcc atg tat gac gct tac tgg aac ggt aaa ttc	5136		
Pro Val Ser Ser Lys Ala Met Tyr Asp Ala Tyr Trp Asn Gly Lys Phe			
800	805	810	
aga gac tgc gct ttc cat tct ggc ttt aat gag gat cca ttc gtt tgt	5184		
Arg Asp Cys Ala Phe His Ser Gly Phe Asn Glu Asp Pro Phe Val Cys			
815	820	825	
gaa tat caa ggc caa tcg tct gac ctg cct caa cct cct gtc aat gct	5232		
Glu Tyr Gln Gly Gln Ser Ser Asp Leu Pro Gln Pro Pro Val Asn Ala			
830	835	840	
ggc ggc ggc tct ggt ggt ggt tct ggt ggc ggc tct gag ggt ggc ggc	5280		
Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly			
845	850	855	860
tct gag ggt ggc ggt tct gag ggt ggc ggc tct gag ggt ggc ggt tcc	5328		
Ser Glu Gly Gly Gly Ser Glu Gly Gly Ser Glu Gly Gly Gly Ser			
865	870	875	
ggt ggc ggc tcc ggt tcc ggt gat ttt gat tat gaa aaa atg gca aac	5376		
Gly Gly Gly Ser Gly Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala Asn			
880	885	890	
gct aat aag ggg gct atg acc gaa aat gcc gat gaa aac gcg cta cag	5424		
Ala Asn Lys Gly Ala Met Thr Glu Asn Ala Asp Glu Asn Ala Leu Gln			
895	900	905	
tct gac gct aaa ggc aaa ctt gat tct gtc gct act gat tac ggt gct	5472		
Ser Asp Ala Lys Gly Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly Ala			
910	915	920	
gct atc gat ggt ttc att ggt gac gtt tcc ggc ctt gct aat ggt aat	5520		
Ala Ile Asp Gly Phe Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn			
925	930	935	940
ggt gct act ggt gat ttt gct ggc tct aat tcc caa atg gct caa gtc	5568		
Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn Ser Gln Met Ala Gln Val			
945	950	955	
ggt gac ggt gat aat tca cct tta atg aat aat ttc cgt caa tat tta	5616		
Gly Asp Gly Asp Asn Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr Leu			
960	965	970	
cct tct ttg cct cag tcg gtt gaa tgt cgc cct tat gtc ttt ggc gct	5664		
Pro Ser Leu Pro Gln Ser Val Glu Cys Arg Pro Tyr Val Phe Gly Ala			
975	980	985	

143

ggt aaa cca tat gaa ttt tct att gat tgt gac aaa ata aac tta ttc 5712
 Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu Phe
 990 995 1000

cgt ggt gtc ttt gcg ttt ctt tta tat gtt gcc acc ttt atg tat gta 5760
 Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val
 1005 1010 1015 1020

ttt tcg acg ttt gct aac ata ctg cgt aat aag gag tct taataagaat 5809
 Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys Glu Ser
 1025 1030

tcactggccg tcgtttttaca acgtcgtgac tgggaaaacc ctggcggttac ccaacttaat 5869
 cgccttgacag cacatcccc tttcgccagc tggcgtaata gcgaagaggc ccgcaccgat 5929
 cgcccttccc aacagttgag cagcctgaat ggcgaaatggc gcctgatgag gtattttctc 5989
 cttacgcacg tgtgcggtat ttcacaccgc atataaattg taaacgttaa tattttgtta 6049
 aaattcgagc taaatttttg ttaaatacagc tcatttttta accaataggc cgaaatcggc 6109
 aaaaaccctt ataaatcaaa agaataagccc gagatagggt tgagtgttgt tccagtttgg 6169
 aacaagagtc cactattaaa gaacgtggac tccaacgtca aagggcgaaa aaccgtctat 6229
 cagggcgatg gccactacg tgaacatca cccaaatcaa gttttttggg gtcgaggtgc 6289
 cgtaaagcac taaatcgaa ccctaaaggg agccccgat ttagagcttg acggggaaaag 6349
 ccggcgaaag tggcgagaaa ggaagggaag aaagcgaaag gagcgggcgc tagggcgctg 6409
 gcaagtgtag cggtcacgct gcgcgtaacc accacacccg ccgcgcttaa tgcgccgcta 6469
 cagggcgagc actatggttg ctttgacggg tgcagtctca gtacaatctg ctctgatgcc 6529
 gcatagttaa gccagccccg acacccgcca acacccgctg acgcgccctg acgggcttgt 6589
 ctgctcccg catccgctta cagacaagct gtgaccgtct ccgggagctg catgtgtcag 6649
 aggtttttcac cgtcatcacc gaaacgcgcg a 6680

<210> 523

<211> 286

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Vector pCES5
 protein sequence

<400> 523

Met Ser Ile Gln His Phe Arg Val Ala Leu Ile Pro Phe Phe Ala Ala
 1 5 10 15

Phe Cys Leu Pro Val Phe Ala His Pro Glu Thr Leu Val Lys Val Lys
 20 25 30

144

Asp Ala Glu Asp Gln Leu Gly Ala Arg Val Gly Tyr Ile Glu Leu Asp
 35 40 45
 Leu Asn Ser Gly Lys Ile Leu Glu Ser Phe Arg Pro Glu Glu Arg Phe
 50 55 60
 Pro Met Met Ser Thr Phe Lys Val Leu Leu Cys Gly Ala Val Leu Ser
 65 70 75 80
 Arg Ile Asp Ala Gly Gln Glu Gln Leu Gly Arg Arg Ile His Tyr Ser
 85 90 95
 Gln Asn Asp Leu Val Glu Tyr Ser Pro Val Thr Glu Lys His Leu Thr
 100 105 110
 Asp Gly Met Thr Val Arg Glu Leu Cys Ser Ala Ala Ile Thr Met Ser
 115 120 125
 Asp Asn Thr Ala Ala Asn Leu Leu Thr Thr Ile Gly Gly Pro Lys
 130 135 140
 Glu Leu Thr Ala Phe Leu His Asn Met Gly Asp His Val Thr Arg Leu
 145 150 155 160
 Asp Arg Trp Glu Pro Glu Leu Asn Glu Ala Ile Pro Asn Asp Glu Arg
 165 170 175
 Asp Thr Thr Met Pro Val Ala Met Ala Thr Thr Leu Arg Lys Leu Leu
 180 185 190
 Thr Gly Glu Leu Leu Thr Leu Ala Ser Arg Gln Gln Leu Ile Asp Trp
 195 200 205
 Met Glu Ala Asp Lys Val Ala Gly Pro Leu Leu Arg Ser Ala Leu Pro
 210 215 220
 Ala Gly Trp Phe Ile Ala Asp Lys Ser Gly Ala Gly Glu Arg Gly Ser
 225 230 235 240
 Arg Gly Ile Ile Ala Ala Leu Gly Pro Asp Gly Lys Pro Ser Arg Ile
 245 250 255
 Val Val Ile Tyr Thr Thr Gly Ser Gln Ala Thr Met Asp Glu Arg Asn
 260 265 270
 Arg Gln Ile Ala Glu Ile Gly Ala Ser Leu Ile Lys His Trp
 275 280 285

<210> 524

<211> 138

<212> PRT

<213> Artificial Sequence

<220>

 <223> Description of Artificial Sequence: Vector pCES5
 protein sequence

145

<400> 524

```

Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ser
 1           5           10           15

His Ser Ala Gln Val Gln Leu Gln Val Asp Leu Glu Ile Lys Arg Gly
 20           25           30

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 35           40           45

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 50           55           60

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 65           70           75           80

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 85           90           95

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
100           105           110

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
115           120           125

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
130           135

```

<210> 525

<211> 48

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Vector pCES5
protein sequence

<400> 525

```

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Ala
 1           5           10           15

Ala Gln Pro Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly
 20           25           30

Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
 35           40           45

```

<210> 526

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Vector pCES5

146

protein sequence

<400> 526

Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu
 1 5 10 15

Ser Leu Ser Ile Arg Ser Gly Gln His Ser Pro Asn
 20 25

<210> 527

<211> 533

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Vector pCES5
 protein sequence

<400> 527

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Lys Val Glu Pro Lys Ser Cys Ala Ala Ala His His His His His His
 100 105 110

Gly Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala
 115 120 125

Ala Thr Val Glu Ser Cys Leu Ala Lys Pro His Thr Glu Asn Ser Phe
 130 135 140

Thr Asn Val Trp Lys Asp Asp Lys Thr Leu Asp Arg Tyr Ala Asn Tyr
 145 150 155 160

Glu Gly Cys Leu Trp Asn Ala Thr Gly Val Val Val Cys Thr Gly Asp
 165 170 175

Glu Thr Gln Cys Tyr Gly Thr Trp Val Pro Ile Gly Leu Ala Ile Pro
 180 185 190

Glu Asn Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly
 195 200 205

147

Ser Glu Gly Gly Gly Thr Lys Pro Pro Glu Tyr Gly Asp Thr Pro Ile
 210 215 220
 Pro Gly Tyr Thr Tyr Ile Asn Pro Leu Asp Gly Thr Tyr Pro Pro Gly
 225 230 235 240
 Thr Glu Gln Asn Pro Ala Asn Pro Asn Pro Ser Leu Glu Glu Ser Gln
 245 250 255
 Pro Leu Asn Thr Phe Met Phe Gln Asn Asn Arg Phe Arg Asn Arg Gln
 260 265 270
 Gly Ala Leu Thr Val Tyr Thr Gly Thr Val Thr Gln Gly Thr Asp Pro
 275 280 285
 Val Lys Thr Tyr Tyr Gln Tyr Thr Pro Val Ser Ser Lys Ala Met Tyr
 290 295 300
 Asp Ala Tyr Trp Asn Gly Lys Phe Arg Asp Cys Ala Phe His Ser Gly
 305 310 315 320
 Phe Asn Glu Asp Pro Phe Val Cys Glu Tyr Gln Gly Gln Ser Ser Asp
 325 330 335
 Leu Pro Gln Pro Pro Val Asn Ala Gly Gly Gly Ser Gly Gly Gly Ser
 340 345 350
 Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly
 355 360 365
 Gly Gly Ser Glu Gly Gly Gly Ser Gly Gly Gly Ser Gly Ser Gly Asp
 370 375 380
 Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly Ala Met Thr Glu
 385 390 395 400
 Asn Ala Asp Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly Lys Leu Asp
 405 410 415
 Ser Val Ala Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe Ile Gly Asp
 420 425 430
 Val Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp Phe Ala Gly
 435 440 445
 Ser Asn Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn Ser Pro Leu
 450 455 460
 Met Asn Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln Ser Val Glu
 465 470 475 480
 Cys Arg Pro Tyr Val Phe Gly Ala Gly Lys Pro Tyr Glu Phe Ser Ile
 485 490 495
 Asp Cys Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala Phe Leu Leu
 500 505 510

148

Tyr Val Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala Asn Ile Leu
515 520 525

Arg Asn Lys Glu Ser
530

<210> 528
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 528
acctcactgg cttccgatt cactttctct 30

<210> 529
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 529
agaaaccac tccaaacctt taccaggagc ttggcgaacc ca 42

<210> 530
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 530
ggaaggcagt gatctagaga tagtgaagcg acctttaacg gagtcagcat a 51

<210> 531
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 531
ggaaggcagt gatctagaga tag 23

<210> 532
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 532
gtgctgactc agccaccctc 20

<210> 533
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 533
gccctgactc agcctgcctc 20

<210> 534
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 534
gagctgactc aggaccctgc 20

<210> 535
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 535
gagctgactc agccaccctc 20

<210> 536
<211> 38
<212> DNA
<213> Artificial Sequence

150

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 536

cctcgacagc gaagtcaca gagcgtcttg actcagcc

38

<210> 537

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 537

cctcgacagc gaagtcaca gagcgtcttg

30

<210> 538

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 538

cctcgacagc gaagtcaca gagcgctttg actcagcc

38

<210> 539

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 539

cctcgacagc gaagtcaca gagcgctttg

30

<210> 540

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 540

cctcgacagc taagtcaca gagcgctttg actcagcc

38

151

<210> 541
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 541
cctcgacagc gaagtcaca gagcgctttg 30

<210> 542
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 542
cctcgacagc gaagtcaca gagcgaattg actcagcc 38

<210> 543
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 543
cctcgacagc gaagtcaca gagcgaattg 30

<210> 544
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 544
cctcgacagc gaagtcaca gtacgaattg actcagcc 38

<210> 545
<211> 30
<212> DNA
<213> Artificial Sequence

152

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 545

cctcgacagc gaagtgcaca gtacgaattg

30

<210> 546

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 546

cctcgacagc gaagtgcaca g

21

<210> 547

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 547

ccgtgtatta ctgtgcgaga g

21

<210> 548

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 548

ctgtgtatta ctgtgcgaga g

21

<210> 549

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 549

153

ccgtatatatta ctgtgcgaaa g

21

<210> 550

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 550

ctgtgtatta ctgtgcgaaa g

21

<210> 551

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 551

ctgtgtatta ctgtgcgaga c

21

<210> 552

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 552

ccatgtatta ctgtgcgaga c

21

<210> 553

<211> 94

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 553

gggtgtagtga tctagtgcaca actctaagaa tactctctac ttgcagatga acagctttag 60
ggctgaggac actgcagtct actattgtgc gaga 94

<210> 554

<211> 94

154

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 554

gggtgtagtga tctagtgaca actctaagaa tactctctac ttgcagatga acagctttag 60
ggctgaggac actgcagtct actattgtgc gaaa 94

<210> 555

<211> 85

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 555

atagtagact gcagtgctct cagcccttaa gctgttcac tgcaagtaga gagtattctt 60
agagttgtct ctatgacact acacc 85

<210> 556

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 556

gactgggtgt agtgatctag 20

<210> 557

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 557

cttttctttg ttgccgttgg ggtg 24

<210> 558

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

155

<220>
<221> modified_base
<222> (1)..(9)
<223> A, T, C, G, other or unknown

<400> 558
nnnnnnnnng caggt

15

<210> 559
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(11)
<223> A, T, C, G, other or unknown

<400> 559
acctgcnnnn n

11

<210> 560
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(7)
<223> A, T, C, G, other or unknown

<400> 560
gatnnnnatc

10

<210> 561
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(16)

156

<223> A, T, C, G, other or unknown

<400> 561

gaggagnnnnn nnnnnn

16

<210> 562

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (1)..(10)

<223> A, T, C, G, other or unknown

<400> 562

nnnnnnnnnn ctcctc

16

<210> 563

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (7)..(10)

<223> A, T, C, G, other or unknown

<400> 563

ctcttcnnnn

10

<210> 564

<211> 11

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (1)..(5)

<223> A, T, C, G, other or unknown

<400> 564

nnnnngaaga g

11

157

<210> 565
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (1)..(15)
<223> A, T, C, G, other or unknown

<400> 565
nnnnnnnnnn nnnnngtccc

20

<210> 566
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(9)
<223> A, T, C, G, other or unknown

<400> 566
gacnnnnnng tc

12

<210> 567
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(11)
<223> A, T, C, G, other or unknown

<400> 567
cgtctcnnnn n

11

<210> 568
<211> 12

158

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (7)..(12)
<223> A, T, C, G, other or unknown

<400> 568
gtatccnnnn nn

12

<210> 569
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(9)
<223> A, T, C, G, other or unknown

<400> 569
gcannnnnnt cg

12

<210> 570
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(8)
<223> A, T, C, G, other or unknown

<400> 570
gccnnnnngg c

11

<210> 571
<211> 11
<212> DNA
<213> Artificial Sequence

<220>

159

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (7)..(11)

<223> A, T, C, G, other or unknown

<400> 571

ggtctcnnnn n

11

<210> 572

<211> 11

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (4)..(8)

<223> A, T, C, G, other or unknown

<400> 572

gacnnnnngt c

11

<210> 573

<211> 11

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (4)..(8)

<223> A, T, C, G, other or unknown

<400> 573

gacnnnnngt c

11

<210> 574

<211> 11

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

160

<221> modified_base
<222> (4)..(8)
<223> A, T, C, G, other or unknown

<400> 574
ccannnnntg g

11

<210> 575
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(12)
<223> A, T, C, G, other or unknown

<400> 575
ccannnnnnn nntgg

15

<210> 576
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (5)..(9)
<223> A, T, C, G, other or unknown

<400> 576
ggccnnnnng gcc

13

<210> 577
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(9)
<223> A, T, C, G, other or unknown

161

<400> 577
ccannnnnnt gg

12

<210> 578
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(8)
<223> A, T, C, G, other or unknown

<400> 578
cctnnnnnag g

11

<210> 579
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(7)
<223> A, T, C, G, other or unknown

<400> 579
gacnnnngtc

10

<210> 580
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(12)
<223> A, T, C, G, other or unknown

<400> 580
ccannnnnnn nntgg

15

162

<210> 581
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (4)..(8)
<223> A, T, C, G, other or unknown

<400> 581
gcannnnntg c

11

<210> 582
<211> 10251
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CJRA05
nucleotide sequence

<220>
<221> CDS
<222> (1578)..(1916)

<220>
<221> CDS
<222> (2388)..(2843)

<220>
<221> CDS
<222> (2849)..(2893)

<220>
<221> CDS
<222> (3189)..(4232)

<220>
<221> CDS
<222> (7418)..(8119)

<220>
<221> CDS
<222> (8160)..(9452)

<400> 582
aatgctacta ctattagtag aattgatgcc accttttcag ctgcgcgcc aaatgaaaat 60
atagctaaac aggttattga ccatttgcga aatgtatcta atggtcaaac taaatctact 120
cgttcgcaga attgggaatc aactgttata tggaatgaaa cttccagaca ccgtacttta 180

163

```

gttgcatatt taaaacatgt tgagctacag cattatattc agcaattaag ctctaagcca 240
tccgcaaaaa tgacctctta tcaaaaggag caattaaagg tactctctaa tcttgacctg 300
ttggagtttg cttccggtct gggtcgcttt gaagctcgaa ttaaacgcg atatttgaag 360
tctttcgggc ttcctcttaa tctttttgat gcaatccgct ttgcttctga ctataatagt 420
cagggtaaag acctgatttt tgatttatgg tcattctcgt tttctgaact gtttaaagca 480
tttgaggggg attcaatgaa tatttatgac gattccgcag tattggacgc tatccagtct 540
aaacatttta ctattacccc ctctggcaaa acttcttttg caaaagcctc tcgctatttt 600
ggtttttatt gtcgtctggt aaacgagggt tatgatagtg ttgctcttac tatgcctcgt 660
aattcccttt ggcgttatgt atctgcatta gttgaatgtg gtattcctaa atctcaactg 720
atgaatcttt ctacctgtaa taatgttggt ccgttagttc gttttattaa cgtagatttt 780
tcttccaac gtcctgactg gtataatgag ccagttctta aaatcgcata aggtaattca 840
caatgattaa agttgaaatt aaaccatctc aagcccaatt tactactcgt tctgggtgtt 900
ctcgtcaggg caagccttat tcaactgaat agcagctttg ttacgttgat ttgggtaatg 960
aatatccggt tcttgtcaag attactcttg atgaaggta gccagcctat ggcctggtc 1020
tgtacaccgt tcactgtcc tctttcaaag ttggtcagtt cggttccctt atgattgacc 1080
gtctgcgcct cgttccggct aagtaacatg gagcaggtcg cggatttcga cacaatttat 1140
caggcgatga tacaatctc cgttgactt tgtttcgcgc ttggtataat cgctgggggt 1200
caaagatgag tgtttttagtg tattcttttg cctctttcgt ttaggttg tgcttcgta 1260
gtggcattac gtattttacc cgtttaatgg aaacttcctc atgaaaaagt ctttagtctt 1320
caaagcctct gtagccgttg ctaccctcgt tccgatgctg tctttcgtg ctgaggggtga 1380
cgatcccgca aaagcggcct ttaactcct gcaagcctca gcgaccgaat atatcggtta 1440
tgcgtgggag atggttggtg tcattgtcgg cgcaactatc ggtatcaagc tgtttaagaa 1500
attcacctcg aaagcaagct gataaaccga tacaattaaa ggctcctttt ggagcctttt 1560

ttttggagat tttcaac gtg aaa aaa tta tta ttc gca att cct tta gtt 1610
          Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val
              1              5              10

gtt cct ttc tat tct ggc gcg gcc gaa tca cat cta gac ggc gcc gct 1658
Val Pro Phe Tyr Ser Gly Ala Ala Glu Ser His Leu Asp Gly Ala Ala
          15              20              25

gaa act gtt gaa agt tgt tta gca aaa tcc cat aca gaa aat tca ttt 1706
Glu Thr Val Glu Ser Cys Leu Ala Lys Ser His Thr Glu Asn Ser Phe
          30              35              40

```

164

act aac gtc tgg aaa gac gac aaa act tta gat cgt tac gct aac tat 1754
 Thr Asn Val Trp Lys Asp Asp Lys Thr Leu Asp Arg Tyr Ala Asn Tyr
 45 50 55

gag ggc tgt ctg tgg aat gct aca ggc gtt gta gtt tgt act ggt gac 1802
 Glu Gly Cys Leu Trp Asn Ala Thr Gly Val Val Val Cys Thr Gly Asp
 60 65 70 75

gaa act cag tgt tac ggt aca tgg gtt cct att ggg ctt gct atc cct 1850
 Glu Thr Gln Cys Tyr Gly Thr Trp Val Pro Ile Gly Leu Ala Ile Pro
 80 85 90

gaa aat gag ggt ggt ggc tct gag ggt ggc ggt tct gag ggt ggc ggt 1898
 Glu Asn Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly
 95 100 105

tct gag ggt ggc ggt act aaacctcctg agtacggtga tacacctatt 1946
 Ser Glu Gly Gly Gly Thr
 110

ccgggctata cttatatcaa ccctctcgac ggcacttata cgcttggtac tgagcaaaac 2006
 cccgctaata ctaatccttc tcttgaggag tctcagcctc ttaatacttt catgtttcag 2066
 aataataggt tccgaaatag gcagggggca ttaactgttt atacgggcac tgttactcaa 2126
 ggcactgacc ccgttaaaac ttattaccag tacactcctg tatcatcaaa agccatgtat 2186
 gagcgttact ggaacggtaa attcagagac tgcgctttcc attctggctt taatgaggat 2246
 ttatttgttt gtgaatatca aggccaatcg tctgacctgc ctcaacctcc tgtcaatgct 2306
 ggcgggcggt ctggtggtgg ttctggtggc ggctctgagg gtggtggctc tgagggaggc 2366
 ggttccgggt gtggtctctg t tcc ggt gat ttt gat tat gaa aag atg gca 2417
 Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala
 115 120

aac gct aat aag ggg gct atg acc gaa aat gcc gat gaa aac gcg cta 2465
 Asn Ala Asn Lys Gly Ala Met Thr Glu Asn Ala Asp Glu Asn Ala Leu
 125 130 135

cag tct gac gct aaa ggc aaa ctt gat tct gtc gct act gat tac ggt 2513
 Gln Ser Asp Ala Lys Gly Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly
 140 145 150 155

gct gct atc gat ggt ttc att ggt gac gtt tcc ggc ctt gct aat ggt 2561
 Ala Ala Ile Asp Gly Phe Ile Gly Asp Val Ser Gly Leu Ala Asn Gly
 160 165 170

aat ggt gct act ggt gat ttt gct ggc tct aat tcc caa atg gct caa 2609
 Asn Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn Ser Gln Met Ala Gln
 175 180 185

gtc ggt gac ggt gat aat tca cct tta atg aat aat ttc cgt caa tat 2657
 Val Gly Asp Gly Asp Asn Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr
 190 195 200

165

tta cct tcc ctc cct caa tcg gtt gaa tgt cgc cct ttt gtc ttt ggc 2705
 Leu Pro Ser Leu Pro Gln Ser Val Glu Cys Arg Pro Phe Val Phe Gly
 205 210 215

gct ggt aaa cca tat gaa ttt tct att gat tgt gac aaa ata aac tta 2753
 Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu
 220 225 230 235

ttc cgt ggt gtc ttt gcg ttt ctt tta tat gtt gcc acc ttt atg tat 2801
 Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr
 240 245 250

gta ttt tct acg ttt gct aac ata ctg cgt aat aag gag tct taatc atg 2851
 Val Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys Glu Ser Met
 255 260 265

cca gtt ctt ttg ggt att ccg tta tta ttg cgt ttc ctc ggt 2893
 Pro Val Leu Leu Gly Ile Pro Leu Leu Leu Arg Phe Leu Gly
 270 275 280

ttccttctgg taactttgtt cggctatctg cttacttttc ttaaaaaggg cttcggttaa 2953
 atagctattg ctatttcatt gtttcttgct cttattattg ggcttaactc aattcttggtg 3013
 gggtatctct ctgatattag cgctcaatta ccctctgact ttgttcaggg tggtcagtta 3073
 attctcccgct ctaatgcgct tccctgtttt tatgttattc tctctgtaaa ggctgctatt 3133
 ttcatttttg acgttaaaca aaaaatcggt tcttatttggt attgggataa ataat atg 3191
 Met

gct gtt tat ttt gta act ggc aaa tta ggc tct gga aag acg ctc gtt 3239
 Ala Val Tyr Phe Val Thr Gly Lys Leu Gly Ser Gly Lys Thr Leu Val
 285 290 295

agc gtt ggt aag att cag gat aaa att gta gct ggg tgc aaa ata gca 3287
 Ser Val Gly Lys Ile Gln Asp Lys Ile Val Ala Gly Cys Lys Ile Ala
 300 305 310

act aat ctt gat tta agg ctt caa aac ctc ccg caa gtc ggg agg ttc 3335
 Thr Asn Leu Asp Leu Arg Leu Gln Asn Leu Pro Gln Val Gly Arg Phe
 315 320 325

gct aaa acg cct cgc gtt ctt aga ata ccg gat aag cct tct ata tct 3383
 Ala Lys Thr Pro Arg Val Leu Arg Ile Pro Asp Lys Pro Ser Ile Ser
 330 335 340 345

gat ttg ctt gct att ggg cgc ggt aat gat tcc tac gat gaa aat aaa 3431
 Asp Leu Leu Ala Ile Gly Arg Gly Asn Asp Ser Tyr Asp Glu Asn Lys
 350 355 360

aac ggc ttg ctt gtt ctc gat gag tgc ggt act tgg ttt aat acc cgt 3479
 Asn Gly Leu Leu Val Leu Asp Glu Cys Gly Thr Trp Phe Asn Thr Arg
 365 370 375

tct tgg aat gat aag gaa aga cag ccg att att gat tgg ttt cta cat 3527
 Ser Trp Asn Asp Lys Glu Arg Gln Pro Ile Ile Asp Trp Phe Leu His
 380 385 390

166

gct cgt aaa tta gga tgg gat att att ttt ctt gtt cag gac tta tct 3575
 Ala Arg Lys Leu Gly Trp Asp Ile Ile Phe Leu Val Gln Asp Leu Ser
 395 400 405

att gtt gat aaa cag gcg cgt tct gca tta gct gaa cat gtt gtt tat 3623
 Ile Val Asp Lys Gln Ala Arg Ser Ala Leu Ala Glu His Val Val Tyr
 410 415 420 425

tgt cgt cgt ctg gac aga att act tta cct ttt gtc ggt act tta tat 3671
 Cys Arg Arg Leu Asp Arg Ile Thr Leu Pro Phe Val Gly Thr Leu Tyr
 430 435 440

tct ctt att act ggc tcg aaa atg cct ctg cct aaa tta cat gtt ggc 3719
 Ser Leu Ile Thr Gly Ser Lys Met Pro Leu Pro Lys Leu His Val Gly
 445 450 455

gtt gtt aaa tat ggc gat tct caa tta agc cct act gtt gag cgt tgg 3767
 Val Val Lys Tyr Gly Asp Ser Gln Leu Ser Pro Thr Val Glu Arg Trp
 460 465 470

ctt tat act ggt aag aat ttg tat aac gca tat gat act aaa cag gct 3815
 Leu Tyr Thr Gly Lys Asn Leu Tyr Asn Ala Tyr Asp Thr Lys Gln Ala
 475 480 485

ttt tct agt aat tat gat tcc ggt gtt tat tct tat tta acg cct tat 3863
 Phe Ser Ser Asn Tyr Asp Ser Gly Val Tyr Ser Tyr Leu Thr Pro Tyr
 490 495 500 505

tta tca cac ggt cgg tat ttc aaa cca tta aat tta ggt cag aag atg 3911
 Leu Ser His Gly Arg Tyr Phe Lys Pro Leu Asn Leu Gly Gln Lys Met
 510 515 520

aaa tta act aaa ata tat ttg aaa aag ttt tct cgc gtt ctt tgt ctt 3959
 Lys Leu Thr Lys Ile Tyr Leu Lys Lys Phe Ser Arg Val Leu Cys Leu
 525 530 535

gcg att gga ttt gca tca gca ttt aca tat agt tat ata acc caa cct 4007
 Ala Ile Gly Phe Ala Ser Ala Phe Thr Tyr Ser Tyr Ile Thr Gln Pro
 540 545 550

aag ccg gag gtt aaa aag gta gtc tct cag acc tat gat ttt gat aaa 4055
 Lys Pro Glu Val Lys Lys Val Val Ser Gln Thr Tyr Asp Phe Asp Lys
 555 560 565

ttc act att gac tct tct cag cgt ctt aat cta agc tat cgc tat gtt 4103
 Phe Thr Ile Asp Ser Ser Gln Arg Leu Asn Leu Ser Tyr Arg Tyr Val
 570 575 580 585

ttc aag gat tct aag gga aaa tta att aat agc gac gat tta cag aag 4151
 Phe Lys Asp Ser Lys Gly Lys Leu Ile Asn Ser Asp Asp Leu Gln Lys
 590 595 600

caa ggt tat tca ctc aca tat att gat tta tgt act gtt tcc att aaa 4199
 Gln Gly Tyr Ser Leu Thr Tyr Ile Asp Leu Cys Thr Val Ser Ile Lys
 605 610 615

aaa ggt aat tca aat gaa att gtt aaa tgt aat taattttgtt ttcttgatgt 4252

167

Lys Gly Asn Ser Asn Glu Ile Val Lys Cys Asn
620 625

ttgtttcatc atcttctttt gctcaggtaa ttgaaatgaa taattcgctt ctgcgcgatt 4312
ttgtaacttg gtattcaaag caatcaggcg aatccgttat tgtttctccc gatgtaaaag 4372
gtactgttac tgtatattca tctgacgtta aacctgaaaa tctacgcaat ttctttattt 4432
ctgttttacg tgcaataaat tttgatatgg taggttctaa cccttccatt attcagaagt 4492
ataatccaaa caatcaggat tatattgatg aattgccatc atctgataat caggaatatg 4552
atgataattc cgctccttct ggtggtttct ttgttccgca aaatgataat gttactcaaa 4612
cttttaaaat taataacgtt cgggcaaagg atttaatacg agttgtcgaa ttgtttgtaa 4672
agtctaatac ttctaaatcc tcaaagtat tatctattga cggctctaatt ctattagtgtg 4732
ttagtgctcc taaagatatt ttagataacc ttctcaatt cctttcaact gttgatttgc 4792
caactgacca gatattgatt gagggtttga tatttgaggt tcagcaaggt gatgcttag 4852
atttttcatt tgctgtggc tctcagcgtg gcaactgttg aggcggtgtt aatactgacc 4912
gcctcacctc tgttttatct tctgctggtg gttcggtcgg tatttttaat ggcgatgttt 4972
tagggctatc agttcgcgca ttaaagacta atagccattc aaaaatattg tctgtgccac 5032
gtattcttac gctttcaggt cagaagggtt ctatctctgt tggccagaat gtccctttta 5092
ttactggtcg tgtgactggt gaatctgcca atgtaaataa tccatttcag acgattgagc 5152
gtcaaaatgt aggtatttcc atgagcgttt ttctgttgc aatggctggc ggtaatattg 5212
ttctggatat taccagcaag gccgatagtt tgagttcttc tactcaggca agtgatgtta 5272
ttactaatca aagaagtatt gctacaacgg ttaatttgcg tgatggacag actcttttac 5332
tcggtggcct cactgattat aaaaacactt ctcaggattc tggcgtaccg ttctgtcta 5392
aaatcccttt aatcggcctc ctgttttagct cccgctctga ttctaacgag gaaagcacgt 5452
tatacgtgct cgtcaaagca accatagtac gcgccctgta gcggcgcat aagcgcggcg 5512
ggtgtggtgg ttacgcgcag cgtgaccgtt acacttgcca gcgccctagc gccgctcct 5572
ttcgctttct tcccttctt tctcgccacg ttcccggtt ttccccgta agctctaaat 5632
cgggggctcc ctttaggggt ccgatttagt gctttacggc acctcgaccc caaaaaactt 5692
gatttgggtg atggttcacg tagtgggcca tcgccctgat agacggtttt tcgccctttg 5752
acgttggagt ccacgttctt taatagtgga ctctgttcc aaactggaac aacactcaac 5812
cctatctcgg gctattcttt tgatttataa gggattttgc cgatttcgga accaccatca 5872
aacaggattt tcgcctgctg gggcaaacca gcgtggaccg cttgctgcaa ctctctcagg 5932

gccaggcggg gaagggcaat cagctgttgc cgtctcact ggtgaaaaga aaaaccaccc 5992
 tggatccaag cttgcagggtg gcacttttcg gggaaatgtg cgcggaaccc ctatttgttt 6052
 atttttctaa atacattcaa atatgtatcc gctcatgaga caataaccct gataaatgct 6112
 tcaataatat tgaaaaagga agagtatgag tattcaacat ttccgtgtcg cccttattcc 6172
 cttttttgcg gcattttgcc ttcctgtttt tgctcaccca gaaacgctgg tgaaagtaaa 6232
 agatgctgaa gatcagttgg gcgcactagt gggttacatc gaactggatc tcaacagcgg 6292
 taagatcctt gagagttttc gccccgaaga acgtttttcca atgatgagca cttttaaagt 6352
 tctgctatgt ggcgcgggtat tatcccgat tgacgccggg caagagcaac tcggtcgccg 6412
 catacactat tctcagaatg acttggttga gtactcacca gtcacagaaa agcatcttac 6472
 ggatggcatg acagtaagag aattatgcag tgctgccata accatgagtg ataacactgc 6532
 ggccaactta cttctgacaa cgatcggagg accgaaggag ctaaccgctt ttttgacaa 6592
 catgggggat catgtaactc gccttgatcg ttgggaaccg gagctgaatg aagccatacc 6652
 aaacgacgag cgtgacacca cgatgcctgt agcaatggca acaacgttgc gcaaactatt 6712
 aactggcgaa ctacttactc tagcttcccg gcaacaatta atagactgga tggaggcgga 6772
 taaagttgca ggaccacttc tgcgctcggc ccttcgggt ggctggttta ttgctgataa 6832
 atctggagcc ggtgagcgtg ggtctcggg tatcattgca gcactggggc cagatggtaa 6892
 gccctcccg atcgtagtta tctacacgac ggggagtcag gcaactatgg atgaacgaaa 6952
 tagacagatc gctgagatag gtgcctcact gattaagcat tggtactgt cagaccaagt 7012
 ttactcatat atactttaga ttgatttaaa acttcatttt taatttaaaa ggatctaggt 7072
 gaagatcctt tttgataatc tcatgaccaa aatcccttaa cgtgagtttt cgttccactg 7132
 tacgtaagac cccaagctt gtcgactgaa tggcgaatgg cgctttgcct gggttccggc 7192
 accagaagcg gtgccgaaa gctggctgga gtgcgatctt cctgacgctc gagcgcaacg 7252
 caattaatgt gagttagctc actcattagg caccacaggc tttacacttt atgcttccgg 7312
 ctcgtatggt gtgtggaatt gtgagcggat aacaatttca cacaggaaac agctatgacc 7372
 atgattacgc caagctttgg agcctttttt ttggagattt tcaac gtg aaa aaa tta 7429
 Met Lys Lys Leu
 630
 tta ttc gca att cct tta gtt gtt cct ttc tat tct cac agt gca caa 7477
 Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ser His Ser Ala Gln
 635 640 645
 gac atc cag atg acc cag tct cca gcc acc ctg tct ttg tct cca ggg 7525

169

Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ala	Thr	Leu	Ser	Leu	Ser	Pro	Gly		
650						655					660						
gaa	aga	gcc	acc	ctc	tcc	tgc	agg	gcc	agt	cag	ggt	gtt	agc	agc	tac	7573	
Glu	Arg	Ala	Thr	Leu	Ser	Cys	Arg	Ala	Ser	Gln	Gly	Val	Ser	Ser	Tyr		
665					670					675					680		
tta	gcc	tgg	tac	cag	cag	aaa	cct	ggc	cag	gct	ccc	agg	ctc	ctc	atc	7621	
Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Leu	Leu	Ile		
				685					690					695			
tat	gat	gca	tcc	aac	agg	gcc	act	ggc	atc	cca	gcc	agg	ttc	agt	ggc	7669	
Tyr	Asp	Ala	Ser	Asn	Arg	Ala	Thr	Gly	Ile	Pro	Ala	Arg	Phe	Ser	Gly		
			700					705					710				
agt	ggg	cct	ggg	aca	gac	ttc	act	ctc	acc	atc	agc	agc	cta	gag	cct	7717	
Ser	Gly	Pro	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Glu	Pro		
		715					720					725					
gaa	gat	ttt	gca	gtt	tat	tac	tgt	cag	cag	cgt	aac	tgg	cat	ccg	tgg	7765	
Glu	Asp	Phe	Ala	Val	Tyr	Tyr	Cys	Gln	Gln	Arg	Asn	Trp	His	Pro	Trp		
	730					735					740						
acg	ttc	ggc	caa	ggg	acc	aag	gtg	gaa	atc	aaa	cga	act	gtg	gct	gca	7813	
Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala		
745					750					755					760		
cca	tct	gtc	ttc	atc	ttc	ccg	cca	tct	gat	gag	cag	ttg	aaa	tct	gga	7861	
Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly		
			765						770					775			
act	gcc	tct	gtt	gtg	tgc	ctg	ctg	aat	aac	ttc	tat	ccc	aga	gag	gcc	7909	
Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala		
			780					785					790				
aaa	gta	cag	tgg	aag	gtg	gat	aac	gcc	ctc	caa	tcg	ggt	aac	tcc	cag	7957	
Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln		
		795					800					805					
gag	agt	gtc	aca	gag	cgg	gac	agc	aag	gac	agc	acc	tac	agc	ctc	agc	8005	
Glu	Ser	Val	Thr	Glu	Arg	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser		
		810				815					820						
agc	acc	ctg	acg	ctg	agc	aaa	gca	gac	tac	gag	aaa	cac	aaa	gtc	tac	8053	
Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr		
825					830					835					840		
gcc	tgc	gaa	gtc	acc	cat	cag	ggc	ctg	agc	tcg	ccc	gtc	aca	aag	agc	8101	
Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser		
				845					850					855			
ttc	aac	agg	gga	gag	tgt	taataaggcg	cgccaattct	atttcaagga								8149	
Phe	Asn	Arg	Gly	Glu	Cys												
			860														
gacagtcata	atg	aaa	tac	cta	ttg	cct	acg	gca	gcc	gct	gga	ttg	tta			8198	
	Met	Lys	Tyr	Leu	Leu	Pro	Thr	Ala	Ala	Ala	Gly	Leu	Leu				
			865					870					875				

170

tta ctc gcg gcc cag ccg gcc atg gcc gaa gtt caa ttg tta gag tct	8246
Leu Leu Ala Ala Gln Pro Ala Met Ala Glu Val Gln Leu Leu Glu Ser	
880 885 890	
ggt ggc ggt ctt gtt cag cct ggt ggt tct tta cgt ctt tct tgc gct	8294
Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala	
895 900 905	
gct tcc gga ttc act ttc tct act tac gag atg cgt tgg gtt cgc caa	8342
Ala Ser Phe Thr Phe Ser Thr Tyr Glu Met Arg Trp Val Arg Gln	
910 915 920	
gct cct ggt aaa ggt ttg gag tgg gtt tct tat atc gct cct tct ggt	8390
Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ala Pro Ser Gly	
925 930 935	
ggc gat act gct tat gct gac tcc gtt aaa ggt cgc ttc act atc tct	8438
Gly Asp Thr Ala Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser	
940 945 950 955	
aga gac aac tct aag aat act ctc tac ttg cag atg aac agc tta agg	8486
Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg	
960 965 970	
gct gag gac act gca gtc tac tat tgt gcg agg agg ctc gat ggc tat	8534
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Arg Leu Asp Gly Tyr	
975 980 985	
att tcc tac tac tac ggt atg gac gtc tgg ggc caa ggg acc acg gtc	8582
Ile Ser Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val	
990 995 1000	
acc gtc tca agc gcc tcc acc aag ggc cca tcg gtc ttc ccc ctg gca	8630
Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala	
1005 1010 1015	
ccc tcc tcc aag agc acc tct ggg ggc aca gcg gcc ctg ggc tgc ctg	8678
Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu	
1020 1025 1030 1035	
gtc aag gac tac ttc ccc gaa ccg gtg acg gtg tcg tgg aac tca ggc	8726
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly	
1040 1045 1050	
gcc ctg acc agc ggc gtc cac acc ttc ccg gct gtc cta cag tcc tca	8774
Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser	
1055 1060 1065	
gga ctc tac tcc ctc agc agc gta gtg acc gtg ccc tcc agc agc ttg	8822
Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu	
1070 1075 1080	
ggc acc cag acc tac atc tgc aac gtg aat cac aag ccc agc aac acc	8870
Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr	
1085 1090 1095	
aag gtg gac aag aaa gtt gag ccc aaa tct tgt gcg gcc gca cat cat	8918

171

Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Ala Ala Ala His His
 1100 1105 1110 1115
 cat cac cat cac ggg gcc gca gaa caa aaa ctc atc tca gaa gag gat 8966
 His His His His Gly Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp
 1120 1125 1130
 ctg aat ggg gcc gca tag gct agc tct gct wsy ggy gay tty gay tay 9014
 Leu Asn Gly Ala Ala Gln Ala Ser Ser Ala Ser Gly Asp Phe Asp Tyr
 1135 1140 1145
 gar aar atg gct aaw gcy aay aar ggs gcy atg acy gar aay gcy gay 9062
 Glu Lys Met Ala Asn Ala Asn Lys Gly Ala Met Thr Glu Asn Ala Asp
 1150 1155 1160
 gar aay gck ytr car wsy gay gcy aar ggy aar ytw gay wsy gtc gck 9110
 Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly Lys Leu Asp Ser Val Ala
 1165 1170 1175
 acy gay tay ggy gcy gcc atc gay ggy tty aty ggy gay gtc wsy ggy 9158
 Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe Ile Gly Asp Val Ser Gly
 1180 1185 1190 1195
 ytk gcy aay ggy aay ggy gcy acy ggy gay tty gcw ggy tck aat tcy 9206
 Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn Ser
 1200 1205 1210
 car atg gcy car gty ggy gay gck gay aay wsw cck ytw atg aay aay 9254
 Gln Met Ala Gln Val Gly Asp Gly Asp Asn Ser Pro Leu Met Asn Asn
 1215 1220 1225
 tty mgw car tay ytw cck tcy cty cck car wsk gty gar tgy cgy ccw 9302
 Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln Ser Val Glu Cys Arg Pro
 1230 1235 1240
 tty gty tty wsy gcy ggy aar ccw tay gar tty wsy aty gay tgy gay 9350
 Phe Val Phe Ser Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp
 1245 1250 1255
 aar atm aay ytw tty cgy ggy gty tty gck tty ytk yta tay gty gcy 9398
 Lys Ile Asn Leu Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala
 1260 1265 1270 1275
 acy tty atg tay gtw tty wsy ack tty gcy aay atw ytr cgy aay aar 9446
 Thr Phe Met Tyr Val Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys
 1280 1285 1290
 gar wsy tagtgatctc ctaggaagcc cgcctaata gcgggctttt tttttctggt 9502
 Glu Ser
 atgcatcctg aggcggatac tgctgctgct cctcaaaact ggcagatgca cggttacgat 9562
 gcgcccattct acaccaacgt gacctatccc attacggtca atccgccggtt tgttccacg 9622
 gagaatccga cgggttggtta ctcgctcaca tttaatgttg atgaaagctg gctacaggaa 9682
 ggccagacgc gaattatttt tgatggcggt cctattggtt aaaaaatgag ctgatttaac 9742

172

aaaaatttaa tgcgaatttt aacaaaatat taacgtttac aatttaaata tttgcttata 9802
 caatcttcct gtttttgggg cttttctgat tatcaaccgg ggtacatatg attgacatgc 9862
 tagttttacg attaccgttc atcgattctc ttgtttgctc cagactctca ggcaatgacc 9922
 tgatagcctt tgtagatctc tcaaaaatag ctaccctctc cggcattaat ttatcagcta 9982
 gaacggttga atatcatatt gatggtgatt tgactgtctc cggcctttct cacccttttg 10042
 aatctttacc tacacattac tcaggcattg catttaaaat atatgagggt tctaaaaatt 10102
 tttatccttg cgttgaaata aaggcttctc ccgcaaaagt attacagggt cataatgttt 10162
 ttggtacaac cgatttagct ttatgctctg aggcctttatt gcttaatttt gctaattctt 10222
 tgccttgccct gtatgattta ttgatgtt 10251

<210> 583

<211> 113

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CJRA05
 protein sequence

<400> 583

Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ser
 1 5 10 15

Gly Ala Ala Glu Ser His Leu Asp Gly Ala Ala Glu Thr Val Glu Ser
 20 25 30

Cys Leu Ala Lys Ser His Thr Glu Asn Ser Phe Thr Asn Val Trp Lys
 35 40 45

Asp Asp Lys Thr Leu Asp Arg Tyr Ala Asn Tyr Glu Gly Cys Leu Trp
 50 55 60

Asn Ala Thr Gly Val Val Val Cys Thr Gly Asp Glu Thr Gln Cys Tyr
 65 70 75 80

Gly Thr Trp Val Pro Ile Gly Leu Ala Ile Pro Glu Asn Glu Gly Gly
 85 90 95

Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly
 100 105 110

Thr

<210> 584

<211> 152

<212> PRT

<213> Artificial Sequence

173

<220>

<223> Description of Artificial Sequence: CJRA05
protein sequence

<400> 584

```

Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly Ala
 1           5           10           15
Met Thr Glu Asn Ala Asp Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly
          20           25           30
Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe
          35           40           45
Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp
          50           55           60
Phe Ala Gly Ser Asn Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn
          65           70           75           80
Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln
          85           90           95
Ser Val Glu Cys Arg Pro Phe Val Phe Gly Ala Gly Lys Pro Tyr Glu
          100          105          110
Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala
          115          120          125
Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala
          130          135          140
Asn Ile Leu Arg Asn Lys Glu Ser
          145          150

```

<210> 585

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CJRA05
peptide sequence

<400> 585

```

Met Pro Val Leu Leu Gly Ile Pro Leu Leu Leu Arg Phe Leu Gly
 1           5           10           15

```

<210> 586

<211> 348

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CJRA05

174

protein sequence

<400> 586

```

Met Ala Val Tyr Phe Val Thr Gly Lys Leu Gly Ser Gly Lys Thr Leu
  1           5           10           15
Val Ser Val Gly Lys Ile Gln Asp Lys Ile Val Ala Gly Cys Lys Ile
          20           25           30
Ala Thr Asn Leu Asp Leu Arg Leu Gln Asn Leu Pro Gln Val Gly Arg
          35           40           45
Phe Ala Lys Thr Pro Arg Val Leu Arg Ile Pro Asp Lys Pro Ser Ile
          50           55           60
Ser Asp Leu Leu Ala Ile Gly Arg Gly Asn Asp Ser Tyr Asp Glu Asn
          65           70           75           80
Lys Asn Gly Leu Leu Val Leu Asp Glu Cys Gly Thr Trp Phe Asn Thr
          85           90           95
Arg Ser Trp Asn Asp Lys Glu Arg Gln Pro Ile Ile Asp Trp Phe Leu
          100          105          110
His Ala Arg Lys Leu Gly Trp Asp Ile Ile Phe Leu Val Gln Asp Leu
          115          120          125
Ser Ile Val Asp Lys Gln Ala Arg Ser Ala Leu Ala Glu His Val Val
          130          135          140
Tyr Cys Arg Arg Leu Asp Arg Ile Thr Leu Pro Phe Val Gly Thr Leu
          145          150          155          160
Tyr Ser Leu Ile Thr Gly Ser Lys Met Pro Leu Pro Lys Leu His Val
          165          170          175
Gly Val Val Lys Tyr Gly Asp Ser Gln Leu Ser Pro Thr Val Glu Arg
          180          185          190
Trp Leu Tyr Thr Gly Lys Asn Leu Tyr Asn Ala Tyr Asp Thr Lys Gln
          195          200          205
Ala Phe Ser Ser Asn Tyr Asp Ser Gly Val Tyr Ser Tyr Leu Thr Pro
          210          215          220
Tyr Leu Ser His Gly Arg Tyr Phe Lys Pro Leu Asn Leu Gly Gln Lys
          225          230          235          240
Met Lys Leu Thr Lys Ile Tyr Leu Lys Lys Phe Ser Arg Val Leu Cys
          245          250          255
Leu Ala Ile Gly Phe Ala Ser Ala Phe Thr Tyr Ser Tyr Ile Thr Gln
          260          265          270
Pro Lys Pro Glu Val Lys Lys Val Val Ser Gln Thr Tyr Asp Phe Asp
          275          280          285
Lys Phe Thr Ile Asp Ser Ser Gln Arg Leu Asn Leu Ser Tyr Arg Tyr

```

175

290

295

300

Val Phe Lys Asp Ser Lys Gly Lys Leu Ile Asn Ser Asp Asp Leu Gln
 305 310 315 320

Lys Gln Gly Tyr Ser Leu Thr Tyr Ile Asp Leu Cys Thr Val Ser Ile
 325 330 335

Lys Lys Gly Asn Ser Asn Glu Ile Val Lys Cys Asn
 340 345

<210> 587

<211> 234

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CJRA05
 protein sequence

<400> 587

Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ser
 1 5 10 15

His Ser Ala Gln Asp Ile Gln Met Thr Gln Ser Pro Ala Thr Leu Ser
 20 25 30

Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Gly
 35 40 45

Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
 50 55 60

Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala
 65 70 75 80

Arg Phe Ser Gly Ser Gly Pro Gly Thr Asp Phe Thr Leu Thr Ile Ser
 85 90 95

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Asn
 100 105 110

Trp His Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 115 120 125

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
 130 135 140

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 145 150 155 160

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 165 170 175

Gly Asn Ser Gln Glu Ser Val Thr Glu Arg Asp Ser Lys Asp Ser Thr
 180 185 190

176

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
195 200 205

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
210 215 220

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230

<210> 588

<211> 431

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CJRA05
protein sequence

<400> 588

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
1 5 10 15

Ala Gln Pro Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly
20 25 30

Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
35 40 45

Phe Thr Phe Ser Thr Tyr Glu Met Arg Trp Val Arg Gln Ala Pro Gly
50 55 60

Lys Gly Leu Glu Trp Val Ser Tyr Ile Ala Pro Ser Gly Gly Asp Thr
65 70 75 80

Ala Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
85 90 95

Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
100 105 110

Thr Ala Val Tyr Tyr Cys Ala Arg Arg Leu Asp Gly Tyr Ile Ser Tyr
115 120 125

Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser
130 135 140

Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
145 150 155 160

Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp
165 170 175

Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
180 185 190

Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr
195 200 205

177

Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
 210 215 220
 Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp
 225 230 235 240
 Lys Lys Val Glu Pro Lys Ser Cys Ala Ala Ala His His His His His
 245 250 255
 His Gly Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly
 260 265 270
 Ala Ala Gln Ala Ser Ser Ala Ser Gly Asp Phe Asp Tyr Glu Lys Met
 275 280 285
 Ala Asn Ala Asn Lys Gly Ala Met Thr Glu Asn Ala Asp Glu Asn Ala
 290 295 300
 Leu Gln Ser Asp Ala Lys Gly Lys Leu Asp Ser Val Ala Thr Asp Tyr
 305 310 315 320
 Gly Ala Ala Ile Asp Gly Phe Ile Gly Asp Val Ser Gly Leu Ala Asn
 325 330 335
 Gly Asn Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn Ser Gln Met Ala
 340 345 350
 Gln Val Gly Asp Gly Asp Asn Ser Pro Leu Met Asn Asn Phe Arg Gln
 355 360 365
 Tyr Leu Pro Ser Leu Pro Gln Ser Val Glu Cys Arg Pro Phe Val Phe
 370 375 380
 Ser Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp Lys Ile Asn
 385 390 395 400
 Leu Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala Thr Phe Met
 405 410 415
 Tyr Val Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys Glu Ser
 420 425 430

<210> 589

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Illustrative peptide

<400> 589

Glu Gly Gly Gly Ser
 1 5

178

<210> 590
 <211> 1275
 <212> DNA
 <213> Unknown Organism

<220>
 <221> CDS
 <222> (1)..(1272)

<220>
 <223> Description of Unknown Organism: M13 nucleotide
 sequence

<400> 590
 gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat tct 48
 Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ser
 1 5 10 15
 cac tcc gct gaa act gtt gaa agt tgt tta gca aaa ccc cat aca gaa 96
 His Ser Ala Glu Thr Val Glu Ser Cys Leu Ala Lys Pro His Thr Glu
 20 25 30
 aat tca ttt act aac gtc tgg aaa gac gac aaa act tta gat cgt tac 144
 Asn Ser Phe Thr Asn Val Trp Lys Asp Asp Lys Thr Leu Asp Arg Tyr
 35 40 45
 gct aac tat gag ggt tgt ctg tgg aat gct aca ggc gtt gta gtt tgt 192
 Ala Asn Tyr Glu Gly Cys Leu Trp Asn Ala Thr Gly Val Val Val Cys
 50 55 60
 act ggt gac gaa act cag tgt tac ggt aca tgg gtt cct att ggg ctt 240
 Thr Gly Asp Glu Thr Gln Cys Tyr Gly Thr Val Pro Ile Gly Leu
 65 70 75 80
 gct atc cct gaa aat gag ggt ggt ggc tct gag ggt ggc ggt tct gag 288
 Ala Ile Pro Glu Asn Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu
 85 90 95
 ggt ggc ggt tct gag ggt ggc ggt act aaa cct cct gag tac ggt gat 336
 Gly Gly Gly Ser Glu Gly Gly Gly Thr Lys Pro Pro Glu Tyr Gly Asp
 100 105 110
 aca cct att ccg ggc tat act tat atc aac cct ctc gac ggc act tat 384
 Thr Pro Ile Pro Gly Tyr Thr Tyr Ile Asn Pro Leu Asp Gly Thr Tyr
 115 120 125
 ccg cct ggt act gag caa aac ccc gct aat cct aat cct tct ctt gag 432
 Pro Pro Gly Thr Glu Gln Asn Pro Ala Asn Pro Asn Pro Ser Leu Glu
 130 135 140
 gag tct cag cct ctt aat act ttc atg ttt cag aat aat agg ttc cga 480
 Glu Ser Gln Pro Leu Asn Thr Phe Met Phe Gln Asn Asn Arg Phe Arg
 145 150 155 160
 aat agg cag ggg gca tta act gtt tat acg ggc act gtt act caa ggc 528
 Asn Arg Gln Gly Ala Leu Thr Val Tyr Thr Gly Thr Val Thr Gln Gly
 165 170 175

179

act gac ccc gtt aaa act tat tac cag tac act cct gta tca tca aaa	576
Thr Asp Pro Val Lys Thr Tyr Tyr Gln Tyr Thr Pro Val Ser Ser Lys	
180 185 190	
gcc atg tat gac gct tac tgg aac ggt aaa ttc aga gac tgc gct ttc	624
Ala Met Tyr Asp Ala Tyr Trp Asn Gly Lys Phe Arg Asp Cys Ala Phe	
195 200 205	
cat tct ggc ttt aat gag gat cca ttc gtt tgt gaa tat caa ggc caa	672
His Ser Gly Phe Asn Glu Asp Pro Phe Val Cys Glu Tyr Gln Gly Gln	
210 215 220	
tcg tct gac ctg cct caa cct cct gtc aat gct ggc ggc ggc tct ggt	720
Ser Ser Asp Leu Pro Gln Pro Pro Val Asn Ala Gly Gly Gly Ser Gly	
225 230 235 240	
ggg ggt tct ggt ggc ggc tct gag ggt ggt ggc tct gag ggt ggc ggt	768
Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Ser Glu Gly Gly Gly	
245 250 255	
tct gag ggt ggc ggc tct gag gga ggc ggt tcc ggt ggt ggc tct ggt	816
Ser Glu Gly Gly Gly Ser Glu Gly Gly Ser Gly Gly Gly Ser Gly	
260 265 270	
tcc ggt gat ttt gat tat gaa aag atg gca aac gct aat aag ggg gct	864
Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly Ala	
275 280 285	
atg acc gaa aat gcc gat gaa aac gcg cta cag tct gac gct aaa ggc	912
Met Thr Glu Asn Ala Asp Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly	
290 295 300	
aaa ctt gat tct gtc gct act gat tac ggt gct gct atc gat ggt ttc	960
Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe	
305 310 315 320	
att ggt gac gtt tcc ggc ctt gct aat ggt aat ggt gct act ggt gat	1008
Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp	
325 330 335	
ttt gct ggc tct aat tcc caa atg gct caa gtc ggt gac ggt gat aat	1056
Phe Ala Gly Ser Asn Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn	
340 345 350	
tca cct tta atg aat aat ttc cgt caa tat tta cct tcc ctc cct caa	1104
Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln	
355 360 365	
tcg gtt gaa tgt cgc cct ttt gtc ttt agc gct ggt aaa cca tat gaa	1152
Ser Val Glu Cys Arg Pro Phe Val Phe Ser Ala Gly Lys Pro Tyr Glu	
370 375 380	
ttt tct att gat tgt gac aaa ata aac tta ttc cgt ggt gtc ttt gcg	1200
Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala	
385 390 395 400	
ttt ctt tta tat gtt gcc acc ttt atg tat gta ttt tct acg ttt gct	1248
Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala	

180

405

410

415

aac ata ctg cgt aat aag gag tct taa
 Asn Ile Leu Arg Asn Lys Glu Ser
 420

1275

<210> 591

<211> 424

<212> PRT

<213> Unknown Organism

<220>

<223> Description of Unknown Organism: M13 protein
 sequence

<400> 591

Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ser
 1 5 10 15
 His Ser Ala Glu Thr Val Glu Ser Cys Leu Ala Lys Pro His Thr Glu
 20 25 30
 Asn Ser Phe Thr Asn Val Trp Lys Asp Asp Lys Thr Leu Asp Arg Tyr
 35 40 45
 Ala Asn Tyr Glu Gly Cys Leu Trp Asn Ala Thr Gly Val Val Val Cys
 50 55 60
 Thr Gly Asp Glu Thr Gln Cys Tyr Gly Thr Trp Val Pro Ile Gly Leu
 65 70 75 80
 Ala Ile Pro Glu Asn Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu
 85 90 95
 Gly Gly Gly Ser Glu Gly Gly Gly Thr Lys Pro Pro Glu Tyr Gly Asp
 100 105 110
 Thr Pro Ile Pro Gly Tyr Thr Tyr Ile Asn Pro Leu Asp Gly Thr Tyr
 115 120 125
 Pro Pro Gly Thr Glu Gln Asn Pro Ala Asn Pro Asn Pro Ser Leu Glu
 130 135 140
 Glu Ser Gln Pro Leu Asn Thr Phe Met Phe Gln Asn Asn Arg Phe Arg
 145 150 155 160
 Asn Arg Gln Gly Ala Leu Thr Val Tyr Thr Gly Thr Val Thr Gln Gly
 165 170 175
 Thr Asp Pro Val Lys Thr Tyr Tyr Gln Tyr Thr Pro Val Ser Ser Lys
 180 185 190
 Ala Met Tyr Asp Ala Tyr Trp Asn Gly Lys Phe Arg Asp Cys Ala Phe
 195 200 205
 His Ser Gly Phe Asn Glu Asp Pro Phe Val Cys Glu Tyr Gln Gly Gln
 210 215 220

181

Ser Ser Asp Leu Pro Gln Pro Pro Val Asn Ala Gly Gly Gly Ser Gly
 225 230 235 240
 Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly
 245 250 255
 Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Gly Gly Gly Ser Gly
 260 265 270
 Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly Ala
 275 280 285
 Met Thr Glu Asn Ala Asp Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly
 290 295 300
 Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe
 305 310 315 320
 Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp
 325 330 335
 Phe Ala Gly Ser Asn Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn
 340 345 350
 Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln
 355 360 365
 Ser Val Glu Cys Arg Pro Phe Val Phe Ser Ala Gly Lys Pro Tyr Glu
 370 375 380
 Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala
 385 390 395 400
 Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala
 405 410 415
 Asn Ile Leu Arg Asn Lys Glu Ser
 420

<210> 592

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 592

caacgatgat cgtatggcgc atgctgccga gacag

35

<210> 593

<211> 1355

<212> DNA

<213> Artificial Sequence

182

<220>

<223> Description of Artificial Sequence: M13-III
nucleotide sequence

<220>

<221> CDS

<222> (1)..(1305)

<400> 593

```

gcg gcc gca cat cat cat cac cat cac ggg gcc gca gaa caa aaa ctc 48
Ala Ala Ala His His His His His His Gly Ala Ala Glu Gln Lys Leu
  1             5             10             15

atc tca gaa gag gat ctg aat ggg gcc gca tag gct agc gat atc aac 96
Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala Ala Ser Asp Ile Asn
      20             25             30

gat gat cgt atg gct tct act gcy gar acw gty gaa wsy tgy ytr gcm 144
Asp Asp Arg Met Ala Ser Thr Ala Glu Thr Val Glu Ser Cys Leu Ala
      35             40             45

aar ccy cay acw gar aat wsw tty acw aay gts tgg aar gay gay aar 192
Lys Pro His Thr Glu Asn Ser Phe Thr Asn Val Trp Lys Asp Asp Lys
      50             55             60

acy ytw gat cgw tay gcy aay tay gar ggy tgy ytr tgg aat gcy acm 240
Thr Leu Asp Arg Tyr Ala Asn Tyr Glu Gly Cys Leu Trp Asn Ala Thr
      65             70             75

ggc gty gtw gty tgy ack ggy gay gar acw car tgy tay ggy acr tgg 288
Gly Val Val Val Cys Thr Gly Asp Glu Thr Gln Cys Tyr Gly Thr Trp
      80             85             90             95

gtk cck atw ggs ytw gcy atm cck gar aay gar ggy ggy ggy wsy gar 336
Val Pro Ile Gly Leu Ala Ile Pro Glu Asn Glu Gly Gly Gly Ser Glu
      100            105            110

ggy ggy ggy wsy gar ggy ggy ggw tcy gar ggw ggy ggw acy aar cck 384
Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Thr Lys Pro
      115            120            125

cck gar tay ggy gay acw cck atw cck ggy tay acy tay aty aay cck 432
Pro Glu Tyr Gly Asp Thr Pro Ile Pro Gly Tyr Thr Tyr Ile Asn Pro
      130            135            140

ytm gay ggm acy tay cck cck ggy acy gar car aay ccy gcy aay cck 480
Leu Asp Gly Thr Tyr Pro Pro Gly Thr Glu Gln Asn Pro Ala Asn Pro
      145            150            155

aay ccw wsy ytw gar gar wsy car cck ytw aay acy tty atg tty car 528
Asn Pro Ser Leu Glu Glu Ser Gln Pro Leu Asn Thr Phe Met Phe Gln
      160            165            170            175

aay aay mgk tty mgr aay mgk car ggk gcw ytw acy gtk tay ack ggm 576
Asn Asn Arg Phe Arg Asn Arg Gln Gly Ala Leu Thr Val Tyr Thr Gly
      180            185            190

```

183

acy gty acy car ggy acy gay ccy gty aar acy tay tay car tay acy	624
Thr Val Thr Gln Gly Thr Asp Pro Val Lys Thr Tyr Tyr Gln Tyr Thr	
195 200 205	
cck gtm tcr wsw aar gcy atg tay gay gcy tay tgg aay ggy aar tty	672
Pro Val Ser Ser Lys Ala Met Tyr Asp Ala Tyr Trp Asn Gly Lys Phe	
210 215 220	
mgw gay tgy gcy tty cay wsy ggy tty aay gar gay ccw tty gty tgy	720
Arg Asp Cys Ala Phe His Ser Gly Phe Asn Glu Asp Pro Phe Val Cys	
225 230 235	
gar tay car ggy car wsk wsy gay ytr cck car ccw cck gty aay gck	768
Glu Tyr Gln Gly Gln Ser Ser Asp Leu Pro Gln Pro Pro Val Asn Ala	
240 245 250 255	
ggy ggy ggy wsy ggy ggy ggy wsy ggy ggy ggy wsy gar ggy ggy ggy	816
Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly	
260 265 270	
wsy gar ggy ggy wsy ggy ggy wsy ggy wsy ggy gay tty gay	864
Ser Glu Gly Gly Ser Gly Gly Gly Ser Gly Ser Gly Asp Phe Asp	
275 280 285	
tay gar aar atg gcw aay gcy aay aar ggs gcy atg acy gar aay gcy	912
Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly Ala Met Thr Glu Asn Ala	
290 295 300	
gay gar aay gcr ctr car wst gay gcy aar ggy aar ytw gay wsy gtc	960
Asp Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly Lys Leu Asp Ser Val	
305 310 315	
gcy acw gay tay ggt gct gcy atc gay ggy tty aty ggy gay gty wsy	1008
Ala Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe Ile Gly Asp Val Ser	
320 325 330 335	
ggy ctk gct aay ggy aay ggy gcy acy ggy gay tty gcw ggy tck aat	1056
Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn	
340 345 350	
tcy car atg gcy car gty ggy gay gky gay aay wsw cck ytw atg aay	1104
Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn Ser Pro Leu Met Asn	
355 360 365	
aay tty mgw car tay ytw cck tcy cty cck car wsk gty gar tgy cgy	1152
Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln Ser Val Glu Cys Arg	
370 375 380	
ccw tty gty tty wsy gcy ggy aar ccw tay gar tty wsy aty gay tgy	1200
Pro Phe Val Phe Ser Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys	
385 390 395	
gay aar atm aay ytw ttc cgy ggy gty tty gck tty ytk yta tay gty	1248
Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr Val	
400 405 410 415	
gcy acy tty atg tay gtw tty wsy ack tty gcy aay atw ytr cgy aay	1296
Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn	

184

420

425

430

aar gar wsy tagtgatctc ctaggaagcc cgcctaataga gcgggctttt
Lys Glu Ser

1345

tttttctggt

1355

<210> 594

<211> 434

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: M13-III
protein sequence

<400> 594

Ala Ala Ala His His His His His His Gly Ala Ala Glu Gln Lys Leu
1 5 10 15

Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala Ala Ser Asp Ile Asn Asp
20 25 30

Asp Arg Met Ala Ser Thr Ala Glu Thr Val Glu Ser Cys Leu Ala Lys
35 40 45

Pro His Thr Glu Asn Ser Phe Thr Asn Val Trp Lys Asp Asp Lys Thr
50 55 60

Leu Asp Arg Tyr Ala Asn Tyr Glu Gly Cys Leu Trp Asn Ala Thr Gly
65 70 75 80

Val Val Val Cys Thr Gly Asp Glu Thr Gln Cys Tyr Gly Thr Trp Val
85 90 95

Pro Ile Gly Leu Ala Ile Pro Glu Asn Glu Gly Gly Gly Ser Glu Gly
100 105 110

Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Thr Lys Pro Pro
115 120 125

Glu Tyr Gly Asp Thr Pro Ile Pro Gly Tyr Thr Tyr Ile Asn Pro Leu
130 135 140

Asp Gly Thr Tyr Pro Pro Gly Thr Glu Gln Asn Pro Ala Asn Pro Asn
145 150 155 160

Pro Ser Leu Glu Glu Ser Gln Pro Leu Asn Thr Phe Met Phe Gln Asn
165 170 175

Asn Arg Phe Arg Asn Arg Gln Gly Ala Leu Thr Val Tyr Thr Gly Thr
180 185 190

Val Thr Gln Gly Thr Asp Pro Val Lys Thr Tyr Tyr Gln Tyr Thr Pro
195 200 205

185

Val Ser Ser Lys Ala Met Tyr Asp Ala Tyr Trp Asn Gly Lys Phe Arg
 210 215 220
 Asp Cys Ala Phe His Ser Gly Phe Asn Glu Asp Pro Phe Val Cys Glu
 225 230 235 240
 Tyr Gln Gly Gln Ser Asp Leu Pro Gln Pro Pro Val Asn Ala Gly
 245 250 255
 Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly Ser
 260 265 270
 Glu Gly Gly Gly Ser Gly Gly Gly Ser Gly Ser Gly Asp Phe Asp Tyr
 275 280 285
 Glu Lys Met Ala Asn Ala Asn Lys Gly Ala Met Thr Glu Asn Ala Asp
 290 295 300
 Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly Lys Leu Asp Ser Val Ala
 305 310 315 320
 Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe Ile Gly Asp Val Ser Gly
 325 330 335
 Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn Ser
 340 345 350
 Gln Met Ala Gln Val Gly Asp Gly Asp Asn Ser Pro Leu Met Asn Asn
 355 360 365
 Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln Ser Val Glu Cys Arg Pro
 370 375 380
 Phe Val Phe Ser Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp
 385 390 395 400
 Lys Ile Asn Leu Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala
 405 410 415
 Thr Phe Met Tyr Val Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys
 420 425 430
 Glu Ser

<210> 595

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 595

cgttgatatc gctagcctat gc

186

<210> 596
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 596
gataggctta gctagcccgg agaacgaagg

30

<210> 597
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 597
ctttcacagc ggtttcgcta gcgacccttt tgtctgc

37

<210> 598
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 598
ctttcacagc ggtttcgcta gcgacccttt tgcagcgag taccagggtc

50

<210> 599
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 599
gactgtctcg gcagcatgcg ccatacgatc atcggtg

37

<210> 600
<211> 37
<212> DNA
<213> Artificial Sequence

<220>

187

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> CDS

<222> (2)..(25)

<400> 600

c aac gat gat cgt atg gcg cat gct gccgagacag tc
Asn Asp Asp Arg Met Ala His Ala
1 5

37

<210> 601

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 601

Asn Asp Asp Arg Met Ala His Ala
1 5

<210> 602

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 602

ctttcacagc ggtttgcatg cagacccttt tgtctgc

37

<210> 603

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 603

ctttcacagc ggtttgcatg cagacccttt tgtcagcgag taccagggtc

50

<210> 604

<211> 7

<212> PRT

<213> Artificial Sequence

188

<220>

<223> Description of Artificial Sequence: Illustrative peptide

<400> 604

Tyr Ala Asp Ser Val Lys Gly
1 5

<210> 605

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 605

cctcgacagc gaagtgcaca g

21

<210> 606

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 606

ggctgagtca agacgctctg tgcacttcgc tgtcgagg

38

<210> 607

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Illustrative peptide

<400> 607

Gln Ser Ala Leu Thr Gln Pro
1 5

<210> 608

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 608

cctctgtcac agtcacaag ac

22

<210> 609
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 609
cctctgtcac agtcacaaag acatccagat gaccagctct cc 42

<210> 610
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 610
gggaggatgg agactgggtc gtctggatgt cttgtgcact gtgacagagg 50

<210> 611
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Illustrative
peptide

<400> 611
Gln Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
1 5 10

<210> 612
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 612
gactgggtgt agtgatctag 20

<210> 613
<211> 28
<212> DNA
<213> Artificial Sequence

190

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 613

ggtgtagtga tcttctagtg acaactct

28

<210> 614

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 614

Val Ser Ser Arg Asp Asn
1 5

<210> 615

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> CDS

<222> (1)..(15)

<400> 615

tac tat tgt gcg aaa
Tyr Tyr Cys Ala Lys
1 5

15

<210> 616

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 616

Tyr Tyr Cys Ala Lys
1 5

<210> 617

<211> 36

191

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 617

ggtgccgata ggcttgcata caccggagaa cgaagg

36

<210> 618

<211> 95

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 618

cgcttcacta agtctagaga caactctaag aatactctct acttgcatat gaacagctta 60
agggtctgagg acactgcagt ctactattgt acgag 95

<210> 619

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> modified_base

<222> (4)..(7)

<223> A, T, C, G, other or unknown

<400> 619

gatnnnnatc

10

<210> 620

<211> 10

<212> PRT

<213> Unknown Organism

<220>

<223> Description of Unknown Organism: MALIA3-derived
peptide

<400> 620

Met Lys Leu Leu Asn Val Ile Asn Phe Val
1 5 10

<210> 621

192

<211> 29
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: CJRA05-derived peptide

<400> 621
 Met Ser Val Leu Val Tyr Ser Phe Ala Ser Phe Val Leu Gly Trp Cys
 1 5 10 15
 Leu Arg Ser Gly Ile Thr Tyr Phe Thr Arg Leu Met Glu
 20 25

<210> 622
 <211> 15
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Illustrative nucleotide sequence

<400> 622
 tttttttttt ttttt 15

<210> 623
 <211> 87
 <212> PRT
 <213> Unknown Organism

<220>
 <223> Description of Unknown Organism: MALIA3-derived peptide

<400> 623
 Met Ile Lys Val Glu Ile Lys Pro Ser Gln Ala Gln Phe Thr Thr Arg
 1 5 10 15
 Ser Gly Val Ser Arg Gln Gly Lys Pro Tyr Ser Leu Asn Glu Gln Leu
 20 25 30
 Cys Tyr Val Asp Leu Gly Asn Glu Tyr Pro Val Leu Val Lys Ile Thr
 35 40 45
 Leu Asp Glu Gly Gln Pro Ala Tyr Ala Pro Gly Leu Tyr Thr Val His
 50 55 60
 Leu Ser Ser Phe Lys Val Gly Gln Phe Gly Ser Leu Met Ile Asp Arg
 65 70 75 80
 Leu Arg Leu Val Pro Ala Lys
 85

193

<210> 624
 <211> 29
 <212> PRT
 <213> Unknown Organism

<220>
 <223> Description of Unknown Organism: MALIA3-derived peptide

<400> 624
 Met Ser Val Leu Val Tyr Ser Phe Ala Ser Phe Val Leu Gly Trp Cys
 1 5 10 15
 Leu Arg Ser Gly Ile Thr Tyr Phe Thr Arg Leu Met Glu
 20 25

<210> 625
 <211> 10
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic oligonucleotide

<220>
 <221> modified_base
 <222> (7)..(10)
 <223> A, T, C, G, other or unknown

<400> 625
 ctcttcnnnn

10

<210> 626
 <211> 87
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: CJRA05-derived peptide

<400> 626
 Met Ile Lys Val Glu Ile Lys Pro Ser Gln Ala Gln Phe Thr Thr Arg
 1 5 10 15
 Ser Gly Val Ser Arg Gln Gly Lys Pro Tyr Ser Leu Asn Glu Gln Leu
 20 25 30
 Cys Tyr Val Asp Leu Gly Asn Glu Tyr Pro Val Leu Val Lys Ile Thr
 35 40 45
 Leu Asp Glu Gly Gln Pro Ala Tyr Ala Pro Gly Leu Tyr Thr Val His
 50 55 60
 Leu Ser Ser Phe Lys Val Gly Gln Phe Gly Ser Leu Met Ile Asp Arg

194

65

70

75

80

Leu Arg Leu Val Pro Ala Lys
85

<210> 627

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CJRA05-derived peptide

<400> 627

Met Lys Leu Leu Asn Val Ile Asn Phe Val
1 5 10

<210> 628

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 628

gacccagtct ccatacctcc

19

<210> 629

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 629

gactcagtct ccactctcc

19

<210> 630

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 630

gacgcagtct ccaggcacc

19

195

<210> 631
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 631
gacgcagtct ccagccacc

19

<210> 632
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 632
gtctcctgga cagtcgac

19

<210> 633
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 633
ggccttgga cagacagtc

19

<210> 634
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 634
gtctcctgga cagtcagtc

19

<210> 635
<211> 19
<212> DNA
<213> Artificial Sequence

196

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 635

ggccccaggg cagagggtc

19

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)